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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and
Allergies (NDA) derived dietary reference values (DRVs) for vitamin D. The Panel considers that serum
25(OH)D concentration, which reﬂects the amount of vitamin D attained from both cutaneous synthesis
and dietary sources, can be used as a biomarker of vitamin D status in adult and children populations.
The Panel notes that the evidence on the relationship between serum 25(OH)D concentration and
musculoskeletal health outcomes in adults, infants and children, and adverse pregnancy-related health
outcomes, is widely variable. The Panel considers that Average Requirements and Population Reference
Intakes for vitamin D cannot be derived, and therefore deﬁnes adequate intakes (AIs), for all population
groups. Taking into account the overall evidence and uncertainties, the Panel considers that a serum 25
(OH)D concentration of 50 nmol/L is a suitable target value for all population groups, in view of setting
the AIs. For adults, an AI for vitamin D is set at 15 lg/day, based on a meta-regression analysis and
considering that, at this intake, the majority of the population will achieve a serum 25(OH)D
concentration near or above the target of 50 nmol/L. For children aged 1–17 years, an AI for vitamin D
is set at 15 lg/day, based on the meta-regression analysis. For infants aged 7–11 months, an AI for
vitamin D is set at 10 lg/day, based on trials in infants. For pregnant and lactating women, the
Panel sets the same AI as for non-pregnant non-lactating women, i.e. 15 lg/day. The Panel underlines
that the meta-regression was done on data collected under conditions of assumed minimal cutaneous
vitamin D synthesis. In the presence of cutaneous vitamin D synthesis, the requirement for dietary
vitamin D is lower or may even be zero.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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Keywords: vitamin D, 25(OH)D, UV-B irradiation, musculoskeletal health outcomes, meta-regression,
adequate intake, dietary reference value
Requestor: European Commission
Question number: EFSA-Q-2011-01230
Correspondence: nda@efsa.europa.eu
EFSA Journal 2016;14(10):4547www.efsa.europa.eu/efsajournal
Panel members: Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina
Heinonen, Karen-Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry McArdle, Androniki Naska, Monika
Neuh€auser-Berthold, Gra_zyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sj€odin,
Martin Stern, Daniel Tome, Dominique Turck, Henk Van Loveren, Marco Vinceti and Peter Willatts. In
line with EFSA’s policy on declarations of interest, Panel member Harry McArdle did not participate in
the development and adoption of this scientiﬁc opinion.
Acknowledgements: The Panel wishes to thank the members of the Working Group on dietary
reference values for vitamins: Christel Lamberg-Allardt, Monika Neuh€auser-Berthold, Gra _zyna Nowicka,
Kristina Pentieva, Hildegard Przyrembel, Inge Tetens, Daniel Tome and Dominique Turck for the
preparatory work on this scientiﬁc opinion and EFSA staff members: Laura Ciccolallo, Celine Dumas,
Lucia Fabiani and Laura Martino for the support provided to this scientiﬁc opinion.
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies),
2016. Scientiﬁc opinion on dietary reference values for vitamin D. EFSA Journal 2016;14(10):4547,
145 pp. doi:10.2903/j.efsa.2016.4547
ISSN: 1831-4732
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2016;14(10):4547
Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a Scientiﬁc Opinion on dietary reference values (DRV) for the
European population, including vitamin D.
Vitamin D is the generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which
are formed from their respective provitamins, ergosterol and 7-dehydrocholesterol, following a two
step-reaction involving ultraviolet-B (UV-B) irradiation and subsequent thermal isomerisation. Vitamin
D2 and vitamin D3 are fat-soluble and present in foods and dietary supplements. Vitamin D3 is also
synthesised endogenously in the skin following exposure to UV-B irradiation.
During summer months, or following exposure to artiﬁcial UV-B irradiation, the synthesis of vitamin
D3 in the skin may be the main source of vitamin D. Dietary intake of vitamin D is essential in case
endogenous synthesis, due to insufﬁcient UV-B exposure, is lacking or insufﬁcient. Factors affecting the
synthesis of vitamin D3 in the skin include latitude, season, ozone layer and clouds (absorbing UV-B
irradiation), surface characteristics (reﬂecting UV-B irradiation), time spent outdoors, use of sunscreen,
clothing, skin colour and age. The Panel notes that sun exposure may contribute a considerable and
varying amount of vitamin D available to the body and therefore considers that the association
between vitamin D intake and status, for the purpose of deriving DRVs for vitamin D, should be
assessed under conditions of minimal endogenous vitamin D synthesis. Vitamin D from dietary sources
is absorbed throughout the small intestine. The Panel considers that the average vitamin D absorption
from a usual diet is about 80% and limited data are available on the effect of the food or supplement
matrix on absorption of vitamin D (vitamin D2 or vitamin D3).
In the body, within hours of ingestion or synthesis in the skin, vitamin D is either converted into its
biologically active metabolite 1,25(OH)2D or delivered to the storage tissues (as either vitamin D or its
metabolites). The ﬁrst step of the conversion occurs in the liver, where vitamin D is hydroxylated to 25
(OH)D, while the second step occurs primarily in the kidneys, where 25(OH)D is hydroxylated to 1,25
(OH)2D. Vitamin D, 1,25(OH)2D and 25(OH)D are transported in the blood bound mainly to the vitamin
D-binding protein (DBP). Of the two metabolites of vitamin D, 25(OH)D is the major circulating form,
with a longer mean half-life, of about 13–15 days. 25(OH)D is taken up from the blood into many
tissues, including in the adipose tissue, muscle and liver for storage.
After its release from DBP to tissues, 1,25(OH)2D exerts, in association with the intracellular vitamin
D receptor (VDR), important biological functions throughout the body. In the intestine, it binds to VDR
to facilitate calcium and phosphorus absorption. In the kidney, it stimulates the parathyroid hormone
(PTH)-dependent tubular reabsorption of calcium. In the bone, PTH and 1,25(OH)2D interact to
activate the osteoclasts responsible for bone resorption. In addition, 1,25(OH)2D suppresses the PTH
gene expression, inhibits proliferation of parathyroid cells, and is involved in cell differentiation and
antiproliferative actions in various cell types. Both 25(OH)D and 1,25(OH)2D are catabolised before
elimination and the main route of excretion is via the faeces.
Vitamin D deﬁciency leads to impaired mineralisation of bone due to an inefﬁcient absorption of
dietary calcium and phosphorus, and is associated with an increase in PTH serum concentration.
Clinical symptoms of vitamin D deﬁciency manifest as rickets in children, and osteomalacia in adults.
The Panel reviewed possible biomarkers of vitamin D intake and/or status, namely serum
concentration of 25(OH)D, free 25(OH)D, 1,25(OH)2D and PTH concentration, markers of bone
formation and bone turnover. In spite of the high variability in 25(OH)D measurements obtained with
different analytical methods, the Panel concludes that serum 25(OH)D concentration, which reﬂects
the amount of vitamin D attained from both cutaneous synthesis and dietary sources, can be used as
a biomarker of vitamin D status in adult and children populations. Serum 25(OH)D concentration can
also be used as a biomarker of vitamin D intake in a population with low exposure to UV-B irradiation.
In consideration of the various biological functions of 1,25(OH)2D, the Panel assessed the available
evidence on the relationship between serum 25(OH)D concentration and several health outcomes, to
evaluate whether they might inform the setting of DRVs for vitamin D. The Panel ﬁrst considered the
available evidence on serum 25(OH)D concentration and musculoskeletal health outcomes, i.e. bone
mineral density (BMD)/bone mineral content (BMC) and calcium absorption in adults and infants/
children, risk of osteomalacia, fracture risk, risk of falls/falling, muscle strength/muscle function/
physical performance in adults, and risk of rickets in infants/children. The Panel then reviewed data on
the relationship between maternal serum 25(OH)D concentration and health outcomes in pregnancy
(risk of pre-eclampsia, of small for gestational age and of preterm birth, and indicators of bone health
in infants) and lactation. The Panel took as a starting point the results of the literature search and the
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conclusions from the most recent report on DRVs for vitamin D by the Institute of Medicine (IOM) that
was based on two systematic reviews. The Panel also considered an update of one of these two
systematic reviews, as well as two recent reports from DRV-setting bodies. The Panel undertook a
separate literature search to identify primary intervention and prospective observational studies in
healthy subjects (infants, children and adults, including free-living older adults) that were published
after the IOM report until March 2015. As a second step, the Panel considered available evidence on
several other non-musculoskeletal health outcomes (e.g. cancer or cardiovascular diseases), based on
the reports and reviews mentioned above without undertaking a speciﬁc literature search of primary
studies. The Panel considers that the available evidence on serum 25(OH)D concentration and
musculoskeletal health outcomes and pregnancy-related health outcomes is suitable to set DRVs for
vitamin D for (healthy) adults, infants, children, and pregnant women, respectively. However, the
Panel considers that there is no evidence for a relationship between serum 25(OH)D concentration and
health outcomes of lactating women that may be used to set a DRV for vitamin D, and that the
available evidence on non-musculoskeletal health outcomes is insufﬁcient to be used as criterion for
setting DRVs for vitamin D.
The Panel notes that data on the relationship between serum 25(OH)D concentration and adverse
musculoskeletal or pregnancy-related health outcomes are widely variable. However, taking into
account the overall evidence and uncertainties, the Panel considers that, for adults, infants and
children, there is evidence for an increased risk of adverse musculoskeletal health outcomes at serum
25(OH)D concentrations below 50 nmol/L. The Panel also considers that there is evidence for an
increased risk of adverse pregnancy-related health outcomes at serum 25(OH)D concentrations below
50 nmol/L.
The Panel assessed the available evidence on the relationship between vitamin D intake and
musculoskeletal health outcomes to evaluate whether they might inform the setting of DRVs for
vitamin D. The Panel notes that these studies usually do not provide information on the habitual
dietary intake of vitamin D, and the extent to which cutaneous vitamin D synthesis has contributed to
the vitamin D supply (and thus may have confounded the relationship between vitamin D intake and
the reported health outcomes) is not known. The Panel therefore concludes that these studies are not
useful as such for setting DRVs for vitamin D, and may only be used to support the outcome of the
characterisation of the vitamin D intake-status relationship undertaken by the Panel under conditions
of assumed minimal endogenous vitamin D synthesis.
The Panel concludes that a serum 25(OH)D concentration of 50 nmol/L is a suitable target value to
set the DRVs for vitamin D, for all age and sex groups (healthy adults, infants, children, pregnant and
lactating women). For setting DRVs for vitamin D, the Panel considers the dietary intake of vitamin D
necessary to achieve this serum 25(OH)D concentration. As for other nutrients, DRVs for vitamin D are
set assuming that intakes of interacting nutrients, such as calcium, are adequate.
EFSA undertook a meta-regression analysis of the relationship between serum 25(OH)D
concentration and total vitamin D intake (habitual diet, and fortiﬁed foods or supplements using
vitamin D3). Randomised trials conducted in a period of assumed minimal endogenous vitamin D
synthesis were identiﬁed through a comprehensive literature search and a review undertaken for EFSA
by an external contractor (Brouwer-Brolsma et al., 2016). The analysis was performed using summary
data from 83 trial arms (35 studies), of which nine were on children (four trials, age range:
2–17 years) and the other arms were on adults (mean age between 22 and 86 years, excluding
pregnant or lactating women). Data were extracted for each arm of the individual trials. The meta-
regression analysis resulted in two predictive equations of achieved serum 25(OH)D concentrations:
one derived from an unadjusted model (including only the natural log of the total intake) and one
derived from a model including the natural log of the total intake and adjusted for a number of
relevant factors (baseline serum 25(OH)D concentration, latitude, study start year, type of analytical
method applied to assess serum 25(OH)D, assessment of compliance) set at their mean values.
The Panel considers that the available evidence does not allow the setting of average requirements
(ARs) and population reference intakes (PRIs), and therefore deﬁnes adequate intakes (AIs) instead,
for all population groups.
For adults, the Panel sets an AI for vitamin D at 15 lg/day. This is based on the adjusted model of
the meta-regression analysis, and considering that, at this intake, the majority of the adult population
will achieve a serum 25(OH)D concentration near or above the target of 50 nmol/L.
For children aged 1–17 years, the Panel sets an AI for vitamin D for all children at 15 lg/day. This
is based on the adjusted model of the meta-regression analysis on all trials (adults and children) as
well as on a stratiﬁed analysis by age group (adults versus children).
Dietary reference values for vitamin D
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For infants aged 7–11 months, the Panel sets an AI for vitamin D at 10 lg/day, considering four
recent trials on the effect of vitamin D supplementation on serum 25(OH)D concentration in (mostly)
breastfed infants.
For pregnant and lactating women, the Panel considers that the AI is the same as for non-pregnant
non-lactating women, i.e. 15 lg/day.
The Panel underlines that the meta-regression analysis on adults and children was done on data
collected under conditions of assumed minimal cutaneous vitamin D synthesis. In the presence of
cutaneous vitamin D synthesis, the requirement for dietary vitamin D is lower or may even be zero.
Dietary reference values for vitamin D
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Background as provided by the European Commission
The scientiﬁc advice on nutrient intakes is important as the basis of Community action in the ﬁeld
of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The
Scientiﬁc Committee for Food (SCF) report on nutrient and energy intakes for the European
Community dates from 1993. There is a need to review and if necessary to update these earlier
recommendations to ensure that the Community action in the area of nutrition is underpinned by the
latest scientiﬁc advice.
In 1993, the SCF adopted an opinion on nutrient and energy intakes for the European Community.1
The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it
did not include certain substances of physiological importance, for example dietary ﬁbre.
Since then new scientiﬁc data have become available for some of the nutrients, and scientiﬁc
advisory bodies in many European Union (EU) Member States and in the United States have reported
on recommended dietary intakes. For a number of nutrients, these newly established (national)
recommendations differ from the reference intakes in the SCF (1993) report. Although there is
considerable consensus between these newly derived (national) recommendations, differing opinions
remain on some of the recommendations. Therefore, there is a need to review the existing EU
Reference Intakes in the light of new scientiﬁc evidence, and taking into account the more recently
reported national recommendations. There is also a need to include dietary components that were not
covered in the SCF opinion of 1993, such as dietary ﬁbre, and to consider whether it might be
appropriate to establish reference intakes for other (essential) substances with a physiological effect.
In this context, the European Food Safety Authority (EFSA) is requested to consider the existing
population reference intakes for energy, micro- and macronutrients and certain other dietary
components, to review and complete the SCF recommendations, in the light of new evidence, and in
addition advise on a population reference intake for dietary ﬁbre.
For communication of nutrition and healthy eating messages to the public, it is generally more
appropriate to express recommendations for the intake of individual nutrients or substances in food-
based terms. In this context, EFSA is asked to provide assistance on the translation of nutrient based
recommendations for a healthy diet into food based recommendations intended for the population as a
whole.
Terms of Reference as provided by the European Commission
In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/20022, the
Commission requests EFSA to review the existing advice of the Scientiﬁc Committee for Food on
population reference intakes for energy, nutrients and other substances with a nutritional or
physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle,
contribute to good health through optimal nutrition.
In the ﬁrst instance, EFSA is asked to provide advice on energy, macronutrients and dietary ﬁbre.
Speciﬁcally advice is requested on the following dietary components:
• carbohydrates, including sugars;
• fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty
acids, trans-fatty acids;
• protein;
• dietary ﬁbre.
Following on from the ﬁrst part of the task, EFSA is asked to advise on population reference intakes
of micronutrients in the diet and, if considered appropriate, other essential substances with a
nutritional or physiological effect in the context of a balanced diet which, when part of an overall
healthy lifestyle, contribute to good health through optimal nutrition.
Finally, EFSA is asked to provide guidance on the translation of nutrient-based dietary advice into
guidance, intended for the European population as a whole, on the contribution of different foods or
categories of foods to an overall diet that would help to maintain good health through optimal
nutrition (food-based dietary guidelines).
1 Scientiﬁc Committee for Food, 1993. Nutrient and energy intakes for the European Community. Reports of the Scientiﬁc
Committee for Food, 31st series. Food – Science and Technique, European Commission, Luxembourg, 248 pp.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(10):4547
Assessment
1. Introduction
In 1993, the Scientiﬁc Committee for Food (SCF) adopted an opinion on nutrient and energy
intakes for the European Community and derived for vitamin D acceptable ranges of intakes for adults
aged 18–64 years according to the amount of endogenous synthesis of vitamin D while one single
value was set for adults aged ≥ 65 years (SCF, 1993). Acceptable ranges of intakes were also set for
infants aged 6–11 months, and children aged 4–10 and 11–17 years, according to the amount of
endogenous vitamin D synthesis, while a single reference value for the age range 1–3 years was
selected. The same reference value was proposed for pregnancy and for lactation.
In the present Opinion, vitamin D intake is expressed in lg and concentrations in blood are
expressed in nmol/L.3
2. Deﬁnition/category
2.1. Chemistry
Vitamin D is the generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which
are formed from their respective provitamins ergosterol and 7-dehydrocholesterol (7-DHC) involving
ultraviolet-B (UV-B) irradiation that opens the B-ring of the molecules, and subsequent thermal
isomerisation (Figure 1). Vitamin D2 differs from vitamin D3 in the side chain where it has a double
bond between C22 and C23 and an additional methyl group on C24 (Binkley and Lensmeyer, 2010).
The molecular masses of ergocalciferol and cholecalciferol are 396.65 and 384.64 g/mol, respectively.
In this assessment, the term vitamin D refers to both vitamin D3 and vitamin D2 unless the speciﬁc
form is indicated. Analytical methods for the quantiﬁcation of vitamin D in serum are discussed in
Section 2.4.1.
HO
CH3
CH3
CH3H3C
H3C
CH3
CH3
CH3
CH2
H3C
CH3
HO
Vitamin D2
or
ergocalciferol
CH3
Ergosterol
(pro-vitamin D2)
UV-B irradiation and thermal isomerisation
CH2
CH3
HO
H3C CH3
CH3
HO
CH3
CH3
7-Dehydrocholesterol
(pro-vitamin D3)
Vitamin D3
or 
cholecalciferol
H3C CH3
CH3
UV-B irradiation and thermal isomerisation
Figure 1: Vitamins D2 (ergocalciferol) and D3 (cholecalciferol) with their respective provitamins. Based
on data from Norman (2012)
3 For conversion between µg and International Units (IU) of vitamin D intake: 1 µg = 40 IU and 0.025 µg = 1 IU. For conversion
between nmol/L and ng/mL for serum 25(OH)D concentration: 2.5 nmol/L = 1 ng/mL.
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2.2. Function of vitamin D
2.2.1. Biochemical functions
In the body, vitamin D2 and D3 are converted to the main circulating form, 25-hydroxyvitamin D
(25(OH)D2 or 25(OH)D3 termed calcidiols). It can be transformed into the biologically active
metabolites 1,25-dihydroxy-ergocalciferol (1,25(OH)2D2) or 1,25-dihydroxy-cholecalciferol (1,25
(OH)2D3) called calcitriols (Section 2.3.6 and Figure 2). The term 25(OH)D refers to both 25(OH)D2
and 25(OH)D3 and 1,25(OH)2D refers to both 1,25(OH)2D3 and 1,25(OH)2D2 unless the speciﬁc form is
indicated.
The principal function of the biologically active metabolite 1,25(OH)2D is to maintain calcium and
phosphorus homeostasis in the circulation, together with parathyroid hormone (PTH) and ﬁbroblast
growth factor (FGF-23) (EFSA NDA Panel, 2012a; Jones, 2013). If the serum ionised calcium
concentration falls below a normal concentration of about 1.1–1.4 mmol/L, a cascade of events occurs
to restore and maintain it within the range required for normal cellular and tissue functions (Mundy
and Guise, 1999; Weaver and Heaney, 2006; Ajibade et al., 2010; EFSA NDA Panel, 2015b). The main
target tissues of 1,25(OH)2D are the intestine, the kidneys and the bone (Figure 2, Section 2.3.6). In
the intestine, 1,25(OH)2D binds to the vitamin D receptor (VDR) to facilitate calcium and phosphorus
absorption by active transport. In the kidneys, 1,25(OH)2D stimulates the tubular reabsorption of
calcium dependent on PTH that increases the production of 1,25(OH)2D from 25(OH)D in the proximal
tubule (Holt and Wysolmerski, 2011). 1,25(OH)2D also downregulates the activity of the enzyme
1a-hydroxylase (CYP27B1), which is responsible for the conversion of 25(OH)D to 1,25(OH)2D in the
kidney. In the bone, PTH and 1,25(OH)2D interact to activate the osteoclasts responsible for bone
resorption. Osteoclasts then release hydrochloric acid and hydrolytic enzymes to dissolve the bone
matrix and thereby release calcium and phosphorus into the circulation (Holick, 2006, 2007).
The metabolite 1,25(OH)2D is also important in other tissues (Bouillon et al., 2008; EFSA NDA
Panel, 2012a; Jones, 2014) that have VDRs as well as the 1a-hydroxylase to convert 25(OH)D into
1,25(OH)2D (Holick, 2007). For example, the parathyroid cells express the VDR and the 1a-
hydroxylase, which allows the local formation of 1,25(OH)2D. 1,25(OH)2D suppresses the expression of
the gene encoding PTH and among other actions, inhibits proliferation of parathyroid cells (Bienaime
et al., 2011) (Figure 2).
Other functions of 1,25(OH)2D include cell differentiation and antiproliferative actions in various cell
types, such as bone marrow (osteoclast precursors and lymphocytes), cells belonging to the immune
system, skin, breast and prostate epithelial cells, muscle and intestine (Norman, 2008, 2012; Jones,
2014).
2.2.2. Health consequences of deﬁciency and excess
2.2.2.1. Deﬁciency
Clinical symptoms of vitamin D deﬁciency manifest as rickets in children and osteomalacia in adults
(Sections 5.1.1, 5.1.2.1.2, 5.1.2.2.2). Both are caused by the impaired mineralisation of bone due to
an inefﬁcient absorption of dietary calcium and phosphorus, and both are associated with an increase
in serum PTH concentration to prevent hypocalcaemia (Holick, 2006; Holick et al., 2012).
Rickets is characterised by a triad of clinical symptoms: skeletal changes (with deformities,
craniotabes, growth retardation), radiologic changes (widening of the metaphyseal plates, decreased
mineralisation, deformities) and increases in bone alkaline phosphatase (ALP) activity in serum
(Wharton and Bishop, 2003). Depending on the severity and duration of vitamin D deﬁciency, initial
hypocalcaemia progresses to normocalcaemia and hypophosphatemia, because of increased PTH
secretion and, ﬁnally to combined hypocalcaemia and hypophosphatemia when calcium can no longer
be released from bone. Osteomalacia is characterised by increased bone resorption and suppression
of new bone mineralisation (Lips, 2006), and serum calcium concentration is often normal
(2.25–2.6 mmol/L) despite the undermineralisation of bone. The clinical symptoms of vitamin D
deﬁciency in adults are less pronounced than in children, and may include diffuse pain in muscles and
bone and speciﬁc fractures. Muscle pain and weakness (myopathy) that accompany the skeletal
symptoms in older adults may contribute to poor physical performance, increased risk of falls/falling
and a higher risk of bone fractures.
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Prolonged vitamin D insufﬁciency may lead to low bone mineral density (BMD) and may dispose
older subjects, particularly post-menopausal women, for osteoporosis, a situation characterised by a
reduction in bone mass, reduced bone quality and an increased risk of bone fracture, predominantly in
the forearm, vertebrae, and hip (Heaney et al., 2000; Gaugris et al., 2005; Holick, 2007; Avenell et al.,
2014).
2.2.2.2. Excess
Following ingestion of pharmacological doses (e.g. 125–1,000 lg/day) of vitamin D over a period of
at least 1 month, the concentration of serum 25(OH)D increases, while that of 1,25(OH)2D is
unchanged or even reduced (EFSA NDA Panel, 2012a; Jones, 2014). High serum 25(OH)D
concentrations (> 220 nmol/L) may lead to hypercalcaemia, which may eventually lead to soft tissue
calciﬁcation and resultant renal and cardiovascular damage (Vieth, 1999; Zittermann and Koerfer,
2008).
In revising the tolerable upper intake Levels (ULs) for vitamin D (EFSA NDA Panel, 2012a), data on
possible associations between vitamin D intake or serum 25(OH)D concentration and adverse long-
term health outcomes were considered. However, no studies reported on associations between vitamin
D intake and increased risk for adverse long-term health outcomes. Studies reporting on an association
between serum 25(OH)D concentration and all-cause mortality or cancer were inconsistent. For adults,
hypercalcaemia was selected as the indicator of hypervitaminosis D or vitamin D toxicity (EFSA NDA
Panel, 2012a). Two studies administered doses between 234 and 275 lg/day vitamin D3 in men
without reported hypercalcaemia (Barger-Lux et al., 1998; Heaney et al., 2003b), and a No Observed
Adverse Effect Level (NOAEL) of 250 lg/day was established (Hathcock et al., 2007). Taking into
account uncertainties associated with these two studies, the UL for adults was set at 100 lg/day. Two
studies in pregnant and lactating women, both using doses of vitamin D2 and D3 up to 100 lg/day for
several weeks to months, did not report adverse effects for either mothers or their offspring (Hollis
and Wagner, 2004a; Hollis et al., 2011). Thus, the UL of 100 lg/day applies to all adults, including
pregnant and lactating women (EFSA NDA Panel, 2012a).
There is a paucity of data on high vitamin D intakes in children and adolescents. Considering
phases of rapid bone formation and growth and the unlikelihood that this age group has a lower
tolerance for vitamin D compared to adults, the UL was set at 100 lg/day for ages 11–17 years (EFSA
NDA Panel, 2012a). The same consideration applied also to children aged 1–10 years, but taking into
account their smaller body size, a UL of 50 lg/day was selected (EFSA NDA Panel, 2012a).
For infants, data relating high vitamin D intakes to impaired growth and hypercalcaemia (Jeans and
Stearns, 1938; Fomon et al., 1966; Ala-Houhala, 1985; Vervel et al., 1997; Hypp€onen et al., 2011)
were used as indicators as in the previous risk assessment by the SCF to set the UL at 25 lg/day (SCF,
2002a). The Panel retained the UL of 25 lg/day and noted that no long-term studies on
hypercalcaemia were available (EFSA NDA Panel, 2012a).
The Panel notes that two randomised controlled trials (RCTs) have been published after the
assessment of the UL by the EFSA NDA Panel (2012a). In both RCTs, infants received vitamin D3
supplementation doses ranging between 10 and 40 lg/day, from age 2 weeks to age 3 months
(Holmlund-Suila et al., 2012) or from age 1 month to age 12 months (Gallo et al., 2013), with
concomitant increases in mean serum 25(OH)D concentrations (Section 5.1.2.2.1). In the shorter term
study (Holmlund-Suila et al., 2012), hypercalcaemia or hypercalciuria did not occur at any dose of
vitamin D3 supplemented. In the longer term study (Gallo et al., 2013), the dose of 40 lg/day was
discontinued prematurely because of elevated serum 25(OH)D concentrations above 250 nmol/L, a
criterion a priori chosen by the authors to indicate hypervitaminosis D.
2.3. Physiology and metabolism
2.3.1. Cutaneous synthesis of vitamin D
Vitamin D3 is synthesised in the skin from 7-DHC following exposure to UV-B irradiation, which, by
opening the B-ring, leads to the formation of previtamin D3 in the upper layers of the skin that,
immediately after its formation, thermally isomerises to vitamin D3 in the lower layers of the skin
(Figure 1) (Engelsen et al., 2005; EFSA NDA Panel, 2012a). The synthesis of vitamin D3 in the skin is a
function of the amount of UV-B irradiation reaching the dermis, the availability of 7-DHC and heat
(body temperature). During summer months or following exposure to artiﬁcial UV-B irradiation, the
synthesis of vitamin D3 in the skin may be the main source of vitamin D. Dietary intake of vitamin D is
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essential in case endogenous synthesis, due to insufﬁcient UV-B exposure, is lacking or insufﬁcient.
With increasing latitude, both the qualitative and quantitative properties of sunlight are not sufﬁcient in
parts of the year for vitamin D3 synthesis in the skin to take place, leading to the so-called vitamin D
winter (Engelsen et al., 2005). For example, in Rome, Italy (41.9°N), the vitamin D winter was
reported to be from November through February; in Berlin, Germany (52.5°N) or Amsterdam, the
Netherlands (52.4°N), it was reported to be between October and April (Tsiaras and Weinstock, 2011);
and in Tromsø, Norway (69.4°N), it was reported to be between beginning of October through mid-
March (Engelsen et al., 2005); this is based on different models and assuming a cloudless day/clear
atmosphere.
Besides considering latitude and season, a UV-index can be used to estimate vitamin D3 synthesis
in the skin (Brouwer-Brolsma et al., 2016) (Section 5.3.2.1), assuming that sun exposure with a UV-
index < 3 does not supply the body with sufﬁcient vitamin D (Webb and Engelsen, 2006; McKenzie
et al., 2009). The categorisation of studies where subjects are exposed to a UV-index < 3 and ≥ 3 can
be done using data from the World Health Organization (WHO) (Section 5.3.2.1).4 However, it has
been found that, even when the UV-index is < 3, there may be endogenous vitamin D synthesis
(Seckmeyer et al., 2013). Another approach to estimate vitamin D3 synthesis in the skin is to use a
simulation model that implies a number of assumptions for the calculations (Webb, 2006; Webb and
Engelsen, 2006). This simulation model estimates for example that the exposure to UV-B irradiation at
45°N at any time of the year in the middle of the day may result in vitamin D synthesis in the skin,
while at 50°N, it estimates that there is no appreciable vitamin D synthesis from mid-November till
February (Brouwer-Brolsma et al., 2016) (Section 5.3.2.1).
In addition to latitude and season, the vitamin D synthesis in the skin of humans is affected by
several other external factors. The ozone layer effectively absorbs UV-B irradiation. Clouds, when
completely overcast, can attenuate the UV-B irradiation by as much as 99%. Surface, especially snow,
can however reﬂect up to 95% of the UV-B irradiation. Time spent outdoors, the use of sunscreen,
and clothing also affect the sun-induced vitamin D synthesis in the skin (Engelsen, 2010).
After adjustment for potential confounders, individuals with initially lower serum 25(OH)D
concentration (below 37.5 nmol/L) responded more quickly to UV-B exposure (and thus synthesised
vitamin D in the skin) than individuals with higher concentrations (Brustad et al., 2007). The sun-
induced vitamin D synthesis was reported to be higher in subjects with light skin compared to people
with dark skin, because of the higher content of melanin in the skin of the latter group (Webb and
Engelsen, 2006; Brouwer-Brolsma et al., 2016). The ability to vitamin D synthesis in the skin decreases
with age (Lamberg-Allardt, 1984; MacLaughlin and Holick, 1985).
UV-B irradiation regulates total synthesis of vitamin D3 in the skin, as both previtamin D3 and
vitamin D3 present in the skin are photodegraded to biologically inert isomers following UV-B exposure
(Webb et al., 1989). This downregulation of vitamin D synthesis in the skin prevents vitamin D toxicity
due to prolonged sun exposure (Holick, 1994). Vitamin D intoxication by UV-B irradiation has not been
reported.
The Panel notes that sun exposure may contribute a considerable and varying amount of vitamin D
available to the body. The Panel considers that the association between vitamin D intake and status for
the purpose of deriving dietary reference values (DRVs) for vitamin D should be assessed under
conditions of minimal endogenous vitamin D synthesis (Section 5.3.2).
2.3.2. Intestinal absorption
Vitamin D from foods is absorbed throughout the small intestine, mostly in the distal small
intestine. Studies using radiolabelled compounds indicate that the absorption efﬁciency of vitamin D
varies between 55% and 99% (mean 78%) in humans, with no discrimination between vitamin D2
and D3 (Thompson et al., 1966; Lo et al., 1985; Jones, 2014; Borel et al., 2015; Reboul, 2015).
Due to the fat soluble characteristics of vitamin D, the absorption process is more efﬁcient in the
presence of biliary salts and when dietary fat is present in the lumen of the small intestine. A
systematic review on a limited number of studies (generally reporting not statistically signiﬁcant
results) suggests that an oil vehicle improves the absorption of vitamin D, as shown by a greater
serum 25(OH)D response, compared with a powder or an ethanol vehicle (Grossmann and Tangpricha,
2010). However, few data on the effect of the food matrix on vitamin D absorption (vitamin D2 or
vitamin D3) have been published and the effect of the supplement matrix is not clear, as reviewed by
4 http://www.who.int/uv/intersunprogramme/activities/uv_index/en/index3.html
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Borel et al. (2015). A recent study reports that vitamin D2 when given as supplement was more
effective in increasing serum 25(OH)D2 than vitamin D2-fortiﬁed bread (Itkonen et al., 2016). Data
suggest that age per se has no effect on vitamin D absorption efﬁciency (Borel et al., 2015). The
vitamin D absorbed from the intestine is incorporated into chylomicrons that reach the systemic
circulation through the lymphatic system (Jones, 2013).
The Panel considers that the average absorption of vitamin D from a usual diet is about 80%, that
limited data are available on the effect of the food or supplement matrix on absorption of vitamin D
(vitamin D2 or D3), and that age per se has no effect on vitamin D absorption efﬁciency.
2.3.3. Transport in blood
Transport of vitamin D from skin to storage tissue or to the liver is carried out by a speciﬁc plasma
protein called vitamin D-binding protein (DBP). Transport of vitamin D2 or D3 from the diet to storage
depots or liver is on chylomicrons, although some evidence indicates that transfer from chylomicrons
to DBP occurs (Jones, 2014).
After hydroxylation of vitamin D in the liver (Section 2.3.6), serum 25(OH)D concentrations in the
blood reﬂect the amount of vitamin D attained from both cutaneous synthesis (Section 2.3.1) and
dietary sources (Section 2.3.2). In the blood, 85–90% of 25(OH)D is transported bound to DBP,
10–15% is bound to albumin, and < 1% is free (Bikle et al., 1985; Powe et al., 2013; Chun et al., 2014;
Yousefzadeh et al., 2014). In a second hydroxylation step, which takes place mainly in the kidney, but
also in other tissues, 1,25(OH)2D may be formed (Section 2.3.6). In the blood, 1,25(OH)2D is primarily
transported bound to DBP and albumin (Bikle et al., 1986; Jones et al., 1998; Powe et al., 2013).
The serum concentration of 25(OH)D is approximately 1,000 times higher than that of 1,25(OH)2D.
An overview of reported 25(OH)D concentrations from studies in 17 European countries (Spiro and
Buttriss, 2014) and other recent European data ((Thiering et al., 2015) in Germany) show that mean/
median concentrations (Section 2.4.1) range from about 20 to 95 nmol/L in adults or children.
While serum 25(OH)D has a mean half-life of approximately 13–15 days (Jones KS et al., 2014)
(Section 2.4.1) due to its strong afﬁnity for DBP, serum 1,25(OH)2D has a half-life measured in hours
(Jones et al., 1998; IOM, 2011).
2.3.4. Distribution to tissues
Within hours of ingestion (Section 2.3.2) or synthesis in the skin (Section 2.3.1), vitamin D is
distributed to the liver for conversion (hydroxylation, Section 2.3.6, Figure 2) or delivered as either
vitamin D or its metabolites to the storage tissues (Section 2.3.5) (Jones, 2013). The vitamin D from
dietary sources is released from the chylomicrons by action of the enzyme lipoprotein lipase upon
arrival in the tissues. Serum 25(OH)D and 1,25(OH)2D are released from DBP to various tissues such
as bone, intestine, kidney, pancreas, brain and skin. Upon release from DBP, 1,25(OH)2D is bound
intracellularly to VDR (Section 2.3.6) (Gropper et al., 2009). 25(OH)D is taken up from the blood into
tissues, probably by protein-binding (Mawer et al., 1972).
2.3.5. Storage
The long-term storage sites of vitamin D include mainly the adipose tissue, muscle, liver and other
tissues (Heaney et al., 2009; Whiting et al., 2013).
Adipose tissue is a major repository in the body for vitamin D (Blum et al., 2008) and, in subjects
with no vitamin D2 supplementation, vitamin D was found in adipocyte lipid droplets as both vitamin
D3 and its metabolites (25(OH)D3 and 1,25(OH)2D3) (Malmberg et al., 2014).
Studies have reported an inverse relationship between body mass index (BMI)/body fat and serum
25(OH)D concentrations (for reviews: Saneei et al., 2013; Vanlint, 2013). The mechanisms for this
relationship are not fully understood. They have been suggested, among others, to include a
‘trapping’/sequestration of vitamin D in the body tissues, particularly in adipose tissue in overweight
and obese individuals (Wortsman et al., 2000; Parikh et al., 2004; Blum et al., 2008; Jungert et al.,
2012), a volumetric dilution of the vitamin D in obese subjects (Drincic et al., 2012), and altered
behaviour of obese subjects resulting in less cutaneous vitamin D synthesis in the skin (Vanlint, 2013).
2.3.6. Metabolism
Activation of vitamin D involves two steps. The ﬁrst occurs after vitamin D is released from DBP to
the liver, where it undergoes 25-hydroxylation to 25(OH)D (IOM, 2011; Jones, 2014) (Figure 2). Both a
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mitochondrial enzyme (CYP27A1) and several microsomal enzymes (including CYP2R1, CYP3A4 and
CYP2J3) are able to carry out the 25-hydroxylation of vitamin D2 or vitamin D3 (Jones G et al., 2014).
The 25-hydroxylation is more efﬁcient with ‘low’ serum 1,25(OH)2D concentrations than with ‘normal’
serum 1,25(OH)2D concentrations (Gropper et al., 2009). The product of the 25-hydroxylation step, 25
(OH)D, is bound to DBP (Section 2.3.3) and transported to the kidneys.
The second step is the 1a-hydroxylation of 25(OH)D primarily in the kidneys (Jones, 2014). Apart
from the kidneys, 1,25(OH)2D is also produced in an autocrine way in other organs such as bone cells
and parathyroid cells. The placenta is one of the extrarenal sites for production of 1,25(OH)2D by the
1a-hydroxylase. This local production supports the calcium demand of the fetus and does not
contribute to the circulating concentration of 1,25(OH)2D of the mother (Jones, 2014).
The activity of the 1a-hydroxylase (Section 2.2.1) is regulated by calcium, phosphate, and their
regulating hormones (Figure 2). Any interruption of this conversion process, due to, for example, liver or
kidney disease, may lead to vitamin D deﬁciency (Section 2.2.2.1) (Holick, 2007). After its production,
1,25(OH)2D is transported bound to DBP in the blood (Section 2.3.3) to the target tissues (Section 2.2.1).
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Figure 2: Metabolism of vitamin D. Based on data from Holick (2006)
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The metabolite 1,25(OH)2D is fairly unstable (Section 2.3.3) without the attachment to carrier
proteins (Norman, 2008; Lehmann and Meurer, 2010). Once at the target cells, 1,25(OH)2D must be
released from the DBP and current evidence suggests that it is the unbound fraction that has access to
the target cells (Section 2.4). Free 1,25(OH)2D taken up by target cells is either rapidly metabolised or
bound to VDRs (Lehmann and Meurer, 2010). VDRs are involved in various regulatory processes that
stand beyond classical homeostasis of calcium and phosphate. VDRs have been identiﬁed in the
cardiovascular system and most cell types in the immune system, and also in other tissues like
pancreas, skeletal muscle, lung, central nervous system, and reproductive system (Holick, 2004;
Bischoff-Ferrari, 2010). Thus, 1,25(OH)2D in association with VDR has a biological function not limited
to bone, intestine, kidneys and parathyroid glands, but throughout the body, regulating many
functions.
Upon binding of 1,25(OH)2D, the VDR undergoes conformational changes that will allow interaction
with several other transcriptional factors within the nucleus in the target cells (Bouillon et al., 2008). To
interact with transcriptional factors and affect gene transcription, the active VDR must form a
heterodimer with the retinoid receptor, and this heterodimer can then bind to selector or promoter
sites of the target cell DNA. This new complex recruits various activators and co-depressors that affect
gene expression. This can include protein synthesis and secretion, cellular proliferation or
differentiation. Several factors determine the overall cellular responses, including cell type and cell
number, availability of VDR and the afﬁnity of the 1,25(OH)2D to this receptor (Jones et al., 1998).
According to the review by Jones (2013), although vitamin D2 and D3 present structural differences
(Figure 1, Section 2.1), qualitatively, they trigger an identical set of biological responses in the body
(Figure 2), primarily by the regulation of gene expression mediated by the same VDR. None of the
steps in the speciﬁc vitamin D signal transduction cascade appears to discriminate between vitamin D2
and vitamin D3 at the molecular level (Jones, 2013). Vitamins D2 and D3 are considered biologically
equivalent in terms of their ability to cure rickets (Jones, 2013).
Potential differences in the biological potencies of vitamin D2 and D3 have been addressed in
studies that measured increases in plasma 25(OH)D concentrations (Section 2.4.1) as a surrogate non-
functional marker of biological activity after supplemental vitamin D2 or D3 (Jones, 2013; Lehmann
et al., 2013; Itkonen et al., 2016). These studies have consistently shown that administration of
vitamin D2 supplements decreases the percentage contribution of vitamin D3 to the total pool of
vitamin D undergoing 25-hydroxylation, and that this decrease is accompanied by a fall in absolute
serum 25(OH)D3 concentrations. Data suggest that vitamin D3 may be the preferred substrate for
hepatic 25-hydroxylation (conversion to 25(OH)D) (Holmberg et al., 1986; Tripkovic et al., 2012), while
data from toxicity and repletion studies suggest some preferential non-speciﬁc catabolism of vitamin
D2 (compared to vitamin D3), accelerating its degradation (Jones, 2013). A meta-analysis comparing
supplementation studies with vitamin D2 and D3 concluded that, even though bolus doses of vitamin
D3 (> 125 lg/day) were more efﬁcacious for raising total serum 25(OH)D concentration compared with
vitamin D2 doses, the differences between the two forms of vitamin D supplements disappeared when
given as lower daily doses (Tripkovic et al., 2012).
The catabolism of 25(OH)D and 1,25(OH)2D in the body involves inactivation by 24-hydroxylation,
which gives rise initially to 24,25(OH)2D (preventing the conversion of 25(OH)D to 1,25(OH)2D (Jones
et al., 2012; Biancuzzo et al., 2013)) and to 1,24,25(OH)3D (i.e. 1,24,25-trihydroxyvitamin D, then
leading to calcitroic acid) (Section 2.3.7). Following vitamin D supplementation, 24-hydroxylase
(CYP27A1) is upregulated with a lag of several weeks (Wagner et al., 2011).
There is some evidence that certain products of the degradation pathway are functional. For
example, the 24,25(OH)2D3 is of importance in bone mineralisation and PTH suppression (Jones,
2014). Others have indicated that the 24-hydroxylated metabolites are important in fracture repair,
although the vast majority of the evidence points towards 24-hydroxylation being a step in the
pathway of inactivation (Jones, 2014).
The Panel notes that 1,25(OH)2D in association with VDR has a biological function not limited to
the bone, intestine, kidneys and parathyroid glands, but throughout the body, regulating many
functions. The Panel also notes the conﬂicting results regarding the potential differences in the
biological potencies and catabolism of vitamin D2 and D3. The Panel thus considers that the association
between vitamin D intake and status for the purpose of deriving DRVs for vitamin D, may need to be
investigated considering vitamin D2 and D3 separately (Section 5.3.2).
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2.3.7. Elimination
There are two main pathways of degradation, the C23 lactone pathway, and the C24 oxidation
pathway (Section 2.3.6 and Figure 2) (Holick, 1999; Jones, 2014). Vitamin D metabolites in the body are
degraded in an oxidative pathway involving stepwise side-chain modiﬁcations by the actions of CYP24A1
(24-hydroxylase). 1,25(OH)2D is a strong controller of its own degradation by stimulating the
24-hydroxylase (IOM, 2011). After several steps, one of the ﬁnal products of the C24 oxidation pathway,
i.e. calcitroic acid, is excreted, mainly in the bile and thus in the faeces. Human CYP24A1 also catalyses,
although to a lesser extent, the 23-hydroxylation of both 25(OH)D and 1,25(OH)2D leading, in sequential
steps, to 25(OH)D-26,23-lactone and 1,25(OH)2D-26,23-lactone, respectively (Jones G et al., 2014). 1,25
(OH)2D can also be epimerised by the conversion of the conﬁguration of the hydroxyl-group at the C-3 of
the A ring to 3-epi-1a,25(OH)2D. Other vitamin D metabolites can be epimerised as well and are then less
biologically active. 3-epi-1a,25(OH)2D showed some transcriptional activity towards target genes and
induction of antiproliferative/differentiation activity in human leukaemia cells (Kamao et al., 2004).
2.3.7.1. Faeces and urine
The majority (around 70%) of the metabolites of the vitamin D pathways of degradation are
excreted in the bile (Jones, 2014). Due to active renal reuptake, the urinary excretion of vitamin D
metabolites is low.
The Panel notes that the main route of excretion of vitamin D metabolites is via the faeces.
2.3.7.2. Breast milk
Breast milk accounts for a small part of the vitamin D elimination in lactating women (Taylor et al.,
2013). The concentration of vitamin D in breast milk is higher than that of 25(OH)D (and of 1,25
(OH)2D), and vitamin D passes more readily from the circulation into the breast milk than 25(OH)D
(Makin et al., 1983; Hollis et al., 1986). In general, mean vitamin D concentrations in breast milk of
healthy lactating women, unsupplemented or supplemented with vitamin D below the UL, are low and
in the range of 0.25–2.0 lg/L (Dawodu and Tsang, 2012; EFSA NDA Panel, 2013). There is a general
agreement that human milk does not contain sufﬁcient vitamin D to prevent rickets in the breast-fed
infant (Olafsdottir et al., 2001).
The amount of vitamin D in human milk modestly correlates with maternal vitamin D intake up to
about 18 lg/day, with evidence for a lower response in African-American compared to Caucasian
women (who had mean maternal serum 25(OH)D concentration of about 67 and 112 nmol/L,
respectively) (Specker et al., 1985; EFSA NDA Panel, 2012a).
Vitamin D supplementation starting in late pregnancy (i.e. after 27 weeks of gestation) (Wall et al.,
2016) or early lactation (Ala-Houhala et al., 1988a; Hollis and Wagner, 2004a) may increase the
vitamin D concentration of breast milk, although only modestly unless high supplemental doses are
used. For example, Hollis and Wagner (2004a) supplemented 18 lactating mothers within 1 month
after birth with 10 lg vitamin D3 and with either 40 lg or 90 lg vitamin D2 daily for 3 months. Mean
serum total 25(OH)D concentration increased compared to baseline in both groups (from about 69 to
about 90 nmol/L, and from about 82 to about 111 nmol/L, respectively). Mean milk antirachitic
activity5 increased from 35.5 to 69.7 IU/L in the group receiving 50 lg vitamin D/day and from 40.4 to
134.6 IU/L in the group receiving 100 lg vitamin D/day. This was attributable to increases in milk
concentrations of both vitamin D and 25(OH)D.
Considering a mean milk transfer of 0.8 L/day during the ﬁrst 6 months of lactation in exclusively
breastfeeding women (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009), and a
concentration of vitamin D in mature human milk of 1.1 lg/L (mid-point of the range of means of
0.25–2.0 lg/L), the secretion of vitamin D into milk during lactation is around 0.9 lg/day.
The Panel considers that secretion of vitamin D into breast milk during the ﬁrst 6 months of
exclusive breastfeeding is about 0.9 lg/day.
2.3.8. Metabolic links with other nutrients
Vitamin D interacts with other nutrients from the diet. There is interaction between 1,25(OH)2D,
calcium and phosphorus that affects mineral and vitamin D metabolism (EFSA NDA Panel, 2015b,c).
5 Vitamin D antirachitic activity in milk was assessed through measurement of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3
concentrations in the milk and conversion of ﬁndings into biological activity values with reference data from biological activity
assays.
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Administration of potassium salts may alter renal synthesis of 1,25(OH)2-vitamin D (Sebastian et al.,
1990; Lemann et al., 1991). Vitamin A has been suggested to interfere with the action of vitamin D.
The active metabolite of vitamin A, i.e. retinoic acid, and 1,25(OH)2D regulate gene expression
through nuclear receptors (Section 2.3.6). Data on interactions between vitamin A and vitamin D have
been reviewed (SCF, 2002b; EFSA NDA Panel, 2015a). Both 1,25(OH)2D and vitamin K are needed for
the synthesis of osteocalcin in the osteoblasts and 1,25(OH)2D regulates the expression of osteocalcin.
2.4. Biomarkers
2.4.1. Plasma/serum concentration of 25(OH)D
Plasma or serum concentration of 25(OH)D represents total vitamin D from exposure to both UV
irradiation (cutaneous synthesis) and dietary sources (Section 2.3.3) and can be used as a biomarker
of vitamin D intake in people with low exposure to UV-B irradiation from sunlight (EFSA NDA Panel,
2012a). Serum 25(OH)D has a long mean half-life of approximately 13–15 days (IOM, 2011; Jones KS
et al., 2014) (Section 2.3.3) and is considered a useful marker of vitamin D status (both D2 and D3)
(Seamans and Cashman, 2009; EFSA NDA Panel, 2012a).
Plasma/serum 25(OH)D2 is of dietary origin only, while plasma/serum 25(OH)D3 may be of dietary
or dermal origin (Sections 2.3.1 and 3). Body composition has an impact on serum 25(OH)D
concentration and an inverse correlation between serum 25(OH)D concentrations and BMI has been
observed (Section 2.3.5). Increasing oral vitamin D intake increases 25(OH)D concentration until a
plateau is reached after about 6 weeks, which indicates an equilibrium between the production and
degradation of serum 25(OH)D (Vieth, 1999; Viljakainen et al., 2006b).
A linear relationship was reported between vitamin D intake and serum 25(OH)D concentrations up
to a total vitamin D intake of 35 lg/day (Cashman et al., 2011b) and 50 lg/day (Cranney et al.,
2007). The US Institute of Medicine (IOM, 2011) found a steeper rise in the serum 25(OH)D
concentrations with vitamin D intakes up to 25 lg/day and a slower, more ﬂattened response when
25 lg/day or more were consumed (Section 5.3.2).
During pregnancy, maternal 25(OH)D concentration is generally unaffected, according to most of
(but not all) the studies reviewed by IOM (2011) for this aspect (Section 4, Appendix B). The
contradictory results in the literature are also discussed by others (Zhang et al., 2014). In this
longitudinal analysis of a random sample (not seasonally balanced) of 30 women between 15 weeks of
gestation and 2 months post partum, mean serum total 25(OH)D concentration signiﬁcantly decreased
between 20 and 36 weeks of gestation (from 51.0 to 37.4 nmol/L).
There is an ongoing debate about the optimal range of serum 25(OH)D concentration and the cut-
off values for deﬁning deﬁciency, insufﬁciency and sufﬁciency (Jones, 2014) (Section 4). A serum 25
(OH)D concentration of 25–30 nmol/L has been proposed as a value below which the risk of rickets
and osteomalacia increases (Cashman et al., 2011a). Other health outcomes may also be considered
(Sections 4 and 5.1).
There are numerous methods for the measurement of 25(OH)D in serum (Wallace et al., 2010;
Carter, 2011) including high-performance liquid chromatography with UV-detection (HPLC/UV), liquid
chromatography-tandem mass spectrometry (LC–MS/MS), and immunoassays (radioimmunoassays
RIA, competitive protein binding assays CPBA, enzyme-linked immunosorbent assays ELISA) that are
either manual or automated. LC–MS/MS and HPLC methods are considered the gold standard methods
(Wallace et al., 2010; Carter, 2011). These methods have the advantage that they can measure 25
(OH)D3 and 25(OH)D2 separately, which is needed in speciﬁc situations (Tai et al., 2010; Carter, 2011).
Also, some methods allow detection of other vitamin D metabolites, such as 24,25(OH)2D (Wallace
et al., 2010; Carter, 2012).
Formerly, all methods suffered from the lack of an international common standard, this lack
contributing to the variability of results of serum 25(OH)D measurements (Section 5.1.2.1.7). The
Vitamin D External Quality Assessment Scheme (DEQAS)6 has revealed considerable differences
between methods (both within and between laboratories), raising concerns about the comparability
and accuracy of different assays and laboratories (Snellman et al., 2010; Carter, 2011; Farrell et al.,
2012; Heijboer et al., 2012). The introduction of a standard reference material for vitamin D in human
serum by the US National Institute of Standards and Technology (NIST)7 has been a step forward in
6 http://www.deqas.org/
7 http://www.nist.gov/mml/csd/organic/vitamindinserum.cfm
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providing a reference measurement procedure (RMP) against which assays could be standardised
(Carter, 2012). The Vitamin D Standardization Program (VDSP)8 has developed protocols for
standardising procedures of 25(OH)D measurement in national health/nutrition surveys to promote 25
(OH)D measurements that are accurate and comparable over time, location, and laboratory to improve
public health practice (Cashman et al., 2013). The VDSP RMP has been joined by a number of
commercial methods and laboratories and thus, their results are comparable to LC–MS/MS as regards
25(OH)D concentrations. In the VDSP, LC–MS/MS is the reference method. According to a reanalysis of
serum 25(OH)D concentrations using the VDSP protocol, the range of mean concentrations
(Section 2.3.3) in 14 European studies in children and adult populations (including one study in
migrants in Finland) was 38.3–65 nmol/L (versus 44.8–69 nmol/L in the originally analysed serum 25
(OH)D data) (Cashman et al., 2016).
Thus, there is a range of methodologies available for the measurement of 25(OH)D, and each
method has its advantages and limitations (Wallace et al., 2010). Given the lack of consensus on the
optimal range of serum 25(OH)D concentration and on the cut-off values for deﬁning deﬁciency,
insufﬁciency and sufﬁciency mentioned above, the Panel considered relevant studies on the
relationship between serum 25(OH)D concentration and health outcomes (Section 5.1), and this
review was undertaken irrespective of the analytical method applied to measure serum 25(OH)D
concentration. However, analytical methods are considered by the Panel in a sensitivity analysis for the
assessment of the relationship between total vitamin D intake and serum 25(OH)D concentration
(Section 5.3.2, Appendices C and D).
The Panel considers that serum 25(OH)D concentration can be used as a biomarker of vitamin D
intake in a population with low exposure to UV-B irradiation (from sunlight, Section 2.3.1), and of
vitamin D status at population level.
2.4.2. Free serum 25(OH)D concentration
Free serum 25(OH)D is the fraction of serum 25(OH)D that circulates without being bound to DBP
and albumin (Section 2.3.3). This free form accounts for less than 1% of total 25(OH)D in the body,
but has been hypothesised to be a potential marker of vitamin D status, because this free fraction is
readily available to target cells (Powe et al., 2013; Chun et al., 2014; Johnsen et al., 2014).
The Panel considers that, at present, free serum 25(OH)D concentration cannot be used as a
biomarker of vitamin D intake and status and that more research is needed to establish the potential
of free serum 25(OH)D concentration as a biomarker of vitamin D status.
2.4.3. Plasma/serum 1,25(OH)2D concentration
The biologically active 1,25(OH)2D has a half-life measured in hours (Section 2.3.3) and is closely
linked with blood calcium, PTH, and phosphate concentrations (Sections 2.2.1 and 2.3.6, Figure 2).
During pregnancy, maternal 1,25(OH)2D synthesis increases (IOM, 2011) (Section 2.4.1).
Zerwekh (2008) considered that plasma/serum 1,25(OH)2D concentration cannot be used to assess
vitamin D status, in view of its short half-life and the tight regulation of its concentration. Serum 1,25
(OH)2D concentrations do not change according to month of the year (apart in October compared to
April) within serum 25(OH)D3 concentrations of 40 nmol/L and 78 nmol/L in healthy children and
adults (18 months–35 years) (Chesney et al., 1981). In a cross-sectional study of post-menopausal
women, serum 1,25(OH)2D concentration was found to be negatively correlated with serum 25(OH)D
concentration at 25(OH)D concentrations ≤ 40 nmol/L and positively at concentrations > 40 nmol/L,
illustrating a non-linear association between concentrations of serum 25(OH)D and of the active
metabolite 1,25(OH)2D (Need et al., 2000). In this study, at serum 25(OH)D concentrations ≤ 40 nmol/L
(compared to higher concentrations), 1,25(OH)2D concentration was found to be closely related to PTH
concentration.
In another study of vitamin D metabolites and calcium absorption in older patients with 25(OH)D
concentration < 40 nmol/L (Need et al., 2008) (Section 5.1.2.1.6 and Appendix B), serum 1,25(OH)2D
concentrations were signiﬁcantly decreased concurrent with increases in serum PTH, ALP, and urine
hydroxyproline in subjects with serum 25(OH)D < 10 nmol/L. This suggests that this level of substrate is
insufﬁcient tomaintain serum 1,25(OH)2D concentration, despite secondary hyperparathyroidism.
8 https://ods.od.nih.gov/Research/vdsp.aspx
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The Panel considers that, because of the tight homeostatic regulation of 1,25(OH)2D concentration
in blood, this marker cannot be used as a biomarker of vitamin D status, but rather reﬂects vitamin D
function.
2.4.4. Serum parathyroid hormone (PTH) concentration
Serum PTH concentration and its relationship with 25(OH)D concentration (via its relationship with
1,25(OH)2D, Sections 2.2.1, 2.3.6 and 2.4.3, and Figure 2) has been suggested as a possible
biomarker or functional endpoint of vitamin D status. Sai et al. (2011) reviewed 70 studies undertaken
in children or adults and showed that it was not possible to set a cut-off value for 25(OH)D
concentration using PTH as a reference, due to the low consistency in the cut-off value observed in
these studies. A systematic review and meta-analysis of 36 RCTs and four before–after studies that
investigated vitamin D supplementation in healthy subjects and the response of 25(OH)D, PTH, BMD,
bone markers and calcium absorption, revealed large heterogeneity across the results when comparing
18 RCTs using PTH as a biomarker of vitamin D status (Seamans and Cashman, 2009). In this
publication, subgrouping by addition of calcium supplementation or no calcium supplementation
suggested an effect of vitamin D supplementation on circulating PTH in the absence of calcium,
without important heterogeneity, but not in the presence of calcium supplementation, with strong
heterogeneity.
The Panel considers that serum PTH concentration is not a biomarker of vitamin D intake, as serum
PTH is also inﬂuenced by, e.g. serum calcium and phosphate concentrations and other factors. The
Panel also considers that serum PTH concentration in healthy subjects is not a useful biomarker for
vitamin D status as assessed by serum 25(OH)D concentration.
2.4.5. Other biomarkers
Since vitamin D is a well-established nutrient in relation to bone, markers of bone formation and
turnover (osteocalcin, bone speciﬁc ALP and urine N-telopeptide crosslinks) have been considered as
markers of long-term status of vitamin D (Bonjour et al., 2014). Low urinary calcium excretion and an
increased bone speciﬁc ALP activity have been used as biomarkers in the diagnosis of vitamin D
deﬁciency (Section 2.2.2.1).
Serum concentrations of calcium and inorganic phosphorus that may be low and high PTH serum
concentration can help in the diagnosis of rickets or osteomalacia (Section 2.2.2.1). Structural bone
markers (low BMD, rickets or osteoporosis) have also been used as biomarkers of vitamin D status, but
have the disadvantage of a slow reaction time, which means that when the condition is diagnosed,
bone health may be irreversibly damaged.
The Panel considers that more research is needed to establish the relationship between responses
of bone markers (e.g. osteocalcin, bone ALP and urine N-telopeptide crosslinks) to changes in vitamin
D status.
2.4.6. Conclusions on biomarkers
The Panel considers that serum 25(OH)D concentration can be used as a biomarker of vitamin D
intake in a population with low exposure to UV-B irradiation (from sunlight, Section 2.3.1), and of
vitamin D status at population level. The Panel notes that, due to the high variability in 25(OH)D
measurements obtained with different analytical methods (Section 2.4.1), comparison of results from
different studies as well as to reference range values has to be done with caution.
2.5. Effects of genotypes
Some polymorphisms of genes encoding proteins involved in vitamin D synthesis, transport and
metabolism inﬂuence serum 25(OH)D concentration (Berry and Hypp€onen, 2011). Two genome-wide
association studies (Ahn et al., 2010; Wang et al., 2010), conducted as meta-analyses of data from
subjects of European ancestry, identiﬁed variants in the genes DHCR7, CYP2R1, GC (group speciﬁc
component gene) and CYP24A1, expressing 7-dehydrocholesterol reductase (DHCR7), 25-hydroxylase,
DBP and 24-hydroxylase, respectively.
Mutations in DHCR7, going along with an impaired activity of the gene, are seen in the rare Smith–
Lemli–Opitz syndrome and result in an accumulation of 7-DHC (Figure 1, Sections 2.1 and 2.3.1), the
substrate for the 25(OH)D synthesis in the skin (Berry and Hypp€onen, 2011). It has been reported that
DHCR7 mutations are related to a higher vitamin D status and that allele frequencies of DHCR7 single
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nucleotide polymorphisms (SNPs) are high at Northern latitudes (0.72 in Europe, 0.41 in Northeast
Asia) (Kuan et al., 2013). CYP2R1 encodes the enzyme primarily responsible for the hydroxylation of
vitamin D to 25(OH)D in the liver (Section 2.3.6) and GC encodes the DBP that is the major carrier
protein for vitamin D and its metabolites (Section 2.3.3). Variants in both genes have been associated
with lower 25(OH)D serum concentrations in carriers as compared to non-carriers (Nissen et al., 2014).
However, genetic variations in the GC gene were also associated with enhanced albumin-bound and
free, and therefore readily bioavailable, serum 25(OH)D concentrations (Sections 2.3.3 and 2.4.2)
(Powe et al., 2013; Chun et al., 2014; Johnsen et al., 2014). Season, dietary and supplemental intake
may modify the effects on serum 25(OH)D concentration of the variants in the genes GC and CYP2R1
(Engelman et al., 2013; Waterhouse et al., 2014).
CYP24A1 catalyses the conversion of both 25(OH)D3 and 1,25(OH)2D3 into 24-hydroxylated
products to be excreted (Sections 2.3.6 and 2.3.7). The reaction is important in the regulation of the
concentration of the active 1,25(OH)2D in the kidney and in other tissues (Jones et al., 2012).
Inactivating mutations in the gene encoding this enzyme can cause idiopathic infantile hypercalcaemia
(Dinour et al., 2013) and have been linked to other hypercalcaemic conditions causing nephrolithiasis
and nephrocalcinosis (Jones et al., 2012). The possibility that increased expression of CYP24A1 may be
an underlying cause of vitamin D deﬁciency and progression of disease states has been discussed
(Jones et al., 2012). Associations of the CYP27B1 genotypes, that code for 1a-hydroxylase
(Sections 2.2.1 and 2.3.6), with 25(OH)D concentrations have also been reported (Hypponen et al.,
2009; Signorello et al., 2011) but were not found signiﬁcant in other studies (Berry and Hypp€onen,
2011). With regard to variants of the gene encoding VDR, there is no consistent ﬁnding on their
relationship with serum 25(OH)D concentrations; in particular in some studies investigating the Fok-1
polymorphism of VDR, it is not clear how this SNP inﬂuences 25(OH)D concentrations (McGrath et al.,
2010; Nieves et al., 2012).
The Panel considers that data on the effect of genotype on vitamin D synthesis, transport and
metabolism are insufﬁcient for use in deriving the requirements for vitamin D according to genotype
variants.
3. Dietary sources and intake data
Vitamin D2 and D3 are fat-soluble. The major food sources for naturally occurring vitamin D3
include animal foods such as fatty ﬁsh, offal (particularly liver), meat and meat products, and egg
yolks (Anses/CIQUAL, 2012; Schmid and Walther, 2013).
Fish (and especially fatty ﬁsh and ﬁsh liver) have the highest natural content of vitamin D (Schmid
and Walther, 2013), presumably derived from an accumulation in the food chain originating from
microalgae that contain both vitamin D3 and provitamin D3 (J€apelt and Jakobsen, 2013). Egg yolk also
has a high vitamin D3 content (Schmid and Walther, 2013), which strongly correlates with the content
of vitamin D3 of the hen’s feed (Mattila et al., 1993, 1999). Animal studies showed that vitamin D3 and
25(OH)D3 were effectively transferred from the hen to the egg yolk, depending on the hen’s diet
(Mattila et al., 2011) and UV-B exposure (Kuhn et al., 2015). The content of vitamin D of meat products
varies and depends, among other things, on the contents of vitamin D in the fodder, the fat content of
the meat product, and latitude where the animals have grazed (Mattila et al., 2011; Liu et al., 2013).
The vitamin D metabolite 25(OH)D is present in some foods of animal origin in varying amounts
(Mattila et al., 1993, 1995, 1999; Clausen et al., 2003; Ovesen et al., 2003; Jakobsen and Saxholt,
2009; Cashman, 2012). Due to the suggested higher biological activity of 25(OH)D in foods compared
with the native vitamin D, a conversion factor of 5 has been used for 25(OH)D3 in the calculation of
total vitamin D3 in some food composition tables, including those in the UK, Denmark and Switzerland
(Cashman, 2012; Cashman et al., 2012).
Some higher fungi, such as mushrooms, are a natural source of vitamin D2. Vitamin D2 is produced
in fungi and yeasts by UV-B exposure of provitamin D2 and the content depends on the amount of
UV-B light exposure and time of exposure (Kristensen et al., 2012; Tangpricha, 2012).
Further sources of dietary vitamin D are fortiﬁed foods (most often milk, margarine and/or butter,
and breakfast cereals) and dietary supplements. Currently, cholecalciferol (vitamin D3) and
ergocalciferol (vitamin D2) may be added to both foods
9 and food supplements.10 The vitamin D
9 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26.
10 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51.
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content of infant and follow-on formulae and of processed cereal-based foods and baby foods for
infants and children is regulated.11
The stability of vitamin D3 and 25(OH)D3 and vitamin D2 in foodstuffs during cooking has been
shown to vary widely with heating process and foodstuffs, with reported retentions in eggs, margarine
and bread after boiling, frying and baking of between 40% and 88% (Jakobsen and Knuthsen, 2014).
Published dietary intake data (mean/median and high percentiles) have been collected for adults in
14 European countries and for infants and children in 11 European countries (EFSA NDA Panel,
2012a). Mean intakes of vitamin D in European countries varied according to sex, age and
supplementation habits. A direct comparison between countries was difﬁcult as there was a large
diversity in the methodology used for dietary assessment, age classiﬁcation was not uniform, and data
from food composition tables used for nutrient intake estimation were different. In the data collected
from the different surveys/studies considered, mean/median intake of vitamin D from foods varied
from 1.1 to 8.2 lg/day in adults. It varied from 1.7 to 5.6 lg/day in children aged about 1–5 years
old, from 1.4 to 2.7 lg/day in children aged about 4–13 years old, and from 1.6 to 4.0 lg/day in
children aged about 11–18 years old. When foods and supplements were considered together, mean
vitamin D intake varied from 3.1 to 23.5 lg/day in adults. It varied from 8.9 to 12.5 lg/day in infants,
from 2.3 lg/day to 9.0 lg/day in children aged about 1.5–3 years old, and from 1.8 lg/day to 6.6 lg/day
in children aged about 4–11 years old. In high consumers (95th percentile) in adults, intake was up to
16 lg/day from foods and up to about 24 lg/day from foods and supplements. In high consumers
(90th or 95th percentile according to surveys) in infants, children and adolescents, intake from foods
and supplements was, respectively, up to 19 lg/day, 15 lg/day and 8 lg/day (EFSA NDA Panel,
2012a).
4. Overview of dietary reference values and recommendations
4.1. Adults
The German-speaking countries (D-A-CH, 2015) considered a review (Linseisen et al., 2011)
following the guidelines of the German Nutrition Society on evidence-based nutrition. A serum 25(OH)
D concentration of at least 50 nmol/L was considered advisable for bone health in younger adults
(aged less than 65 years), as well as in older adults (65 years and over) (Dawson-Hughes et al., 2005;
Linseisen et al., 2011). For younger adults, D-A-CH reported on IOM (2011) and an Irish study
undertaken in winter at latitudes comparable with those of Germany (Cashman et al., 2008), that
showed that 10 or 20 lg/day of supplemental vitamin D allowed, respectively, 50% or 90–95% of the
population to reach a serum 25(OH)D concentration above 50 nmol/L. For older adults, the main focus
was the minimisation of the age-related loss of bone mass, the risk of bone fractures, skeletal muscle
function and the related risks of loss of strength/mobility/balance, of falls and of fractures (Pfeifer
et al., 2000, 2009; Bischoff-Ferrari et al., 2003; Dawson-Hughes et al., 2010; EFSA NDA Panel, 2011;
IOM, 2011; Linseisen et al., 2011). D-A-CH considered that studies in older adults supported a
protective effect of 10–20 lg/day supplemental vitamin D on loss of the ability to move, on falls,
fractures and premature death (Autier and Gandini, 2007; Bischoff-Ferrari et al., 2009a,b; LaCroix
et al., 2009; Bjelakovic et al., 2011; Linseisen et al., 2011). With 50 lg/day vitamin D, about 90–95%
of older adults had a serum 25(OH)D concentration above 50 nmol/L and 50% had a concentration of
75 nmol/L (Cashman et al., 2009). D-A-CH set the adequate intake (AI) for all adults at 20 lg/day
in situations in which endogenous vitamin D synthesis is absent. D-A-CH considered vitamin D
supplements and/or endogenous synthesis to cover the difference between the ‘usual’ intake (2–4 lg/day)
and this value.
The Nordic Council of Ministers (2014)12 considered a systematic literature review on vitamin D
intake/status and health (Lamberg-Allardt et al., 2013) (Section 5.1), based on which a serum 25(OH)
D concentration of 50 nmol/L was considered as indicative of a sufﬁcient vitamin D status in adults.
They also reported on a systematic review of intervention studies on vitamin D supplementation
(Cashman et al., 2011a), from which ﬁve studies (Ala-Houhala et al., 1988b; Barnes et al., 2006;
Cashman et al., 2008, 2011b; Viljakainen et al., 2009) were used for speciﬁc meta-regression analyses
(Section 5.3.1). Based on two meta-regression analyses in different age groups (Section 5.3.1), the
11 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC. OJ L 401, 30.12.2006, p. 1. and Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-
based foods and baby foods for infants and young children. OJ L 339, 06.12.2006, p. 16.
12 Further abbreviated into NCM in tables.
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average requirement (AR) for all adults and the Recommended Intake (RI) for adults aged less than
75 years were set at 7.5 and 10 lg/day, respectively, assuming some contribution of endogenous
synthesis of vitamin D during outdoor activities in summer. An RI was set at 20 lg/day for people with
little or no sun exposure during the summer as well as for adults aged 75 years and over, to account
for their more limited endogenous synthesis and in consideration of the available data on total
mortality, bone health, fractures and falls. A lower intake level of 2.5 lg/day was also set.
The Health Council of the Netherlands (2012) considered that diet provides one-third of the vitamin
D requirement and sufﬁcient sun exposure provides the remainder. It was roughly estimated that
sunlight exposure in the Netherlands leads to the production, on average over the whole year, of
6–7 lg/day vitamin D, with signiﬁcantly higher amounts during summer and a decline to nearly zero
during winter (Signaleringscommissie Kanker van KWF Kankerbestrijding, 2010). The Council
considered that an intake of 11–15 lg/day (Cashman et al., 2008, 2009, 2011b) would be sufﬁcient
for adults aged < 70 years to reach a serum 25(OH)D concentration > 30 nmol/L that was derived
from data on prevention of rickets in young children. As there was no sign that vitamin D
supplementation is required in this group, the Council rounded the AI down to 10 lg/day. Adults with
fair skin and insufﬁcient sun exposure, or with dark skin, or women aged 50–70 years regardless of
skin colour and amount of time spent outdoors, were advised to take a vitamin D supplement of
10 lg/day. In older adults (≥ 70 years), an intake of 20–25 lg/day was considered sufﬁcient to reach
a serum 25(OH)D concentration of 50 nmol/L, which was considered advisable for protection against
bone fractures (Health Council of the Netherlands, 2000; Cranney et al., 2007; Chung et al., 2009;
IOM, 2011). Considering age-related physiological changes (IOM, 2011), for older adults (70 years and
over), an estimated average requirement (EAR) and a recommended dietary allowance (RDA) of 10
and 20 lg/day were set. As sun exposure and dietary intake of vitamin D vary in this age group, all
older adults were advised to take a vitamin D supplement of 20 lg/day. All these reference values
apply in case of insufﬁcient exposure to sunlight.
IOM (2011) (Appendix B) underlined the interactions between calcium and vitamin D with regard to
bone health and the lack of a dose–response relationship between vitamin D intake and bone health.
However, based on systematic reviews (Cranney et al., 2007; Chung et al., 2009) and other data
published after them, IOM considered that total vitamin D intake can be related to change in serum 25
(OH)D concentrations under minimal sun exposure and that a dose–response curve for serum 25(OH)D
and bone health outcomes can be established. It was considered that serum 25(OH)D concentrations
below 30 nmol/L were associated with an increased risk of rickets, impaired fractional calcium
absorption and decreased bone mineral content (BMC), in children and adolescents. Concentrations
below 30 nmol/L were also associated with an increased risk of osteomalacia and impaired fetal
skeletal outcomes, impaired fractional calcium absorption and increased risk of osteomalacia in young
and middle-aged adults, and impaired fractional calcium absorption and fracture risk in older adults
(IOM, 2011). The IOM considered serum 25(OH)D concentrations > 50 nmol/L as adequate for good
bone health for practically all individuals. From the dose–response curve for serum 25(OH)D and bone
health outcomes, assuming a normal distribution of requirements, the IOM selected serum 25(OH)D
concentrations of 50 nmol/L, 40 nmol/L and 30 nmol/L as, respectively, the ‘RDA-type’ and ‘EAR-type’
reference values, and the ‘lower end of the requirement range’. The IOM undertook speciﬁc meta-
regression analyses (Section 5.3.1). From the lack of effect of age in these analyses, the IOM
concluded that the intake to achieve the EAR-type value of 40 nmol/L was the same across all
populations considered. From these analyses, an intake of 10 and 15 lg/day vitamin D would predict a
mean serum 25(OH)D concentration higher than the EAR and RDA-type values in children and adults,
but given the uncertainties of the analyses, these intakes were selected for the EAR (all adults) and
the RDA (until the age of 70 years). For ages 51–70 years, the IOM found no basis to set a speciﬁc
RDA, as women of this age may have some degree of bone loss but a lower fracture risk than later in
life, and as there was generally no effect of vitamin D alone on bone health in this age group. Given
the diversity of physiological/health status of adults older than 70 years, and uncertainties and
variabilities in the physiology of ageing, IOM set the RDA at 20 lg/day, considering the reported
signiﬁcant effect of 2.5 mg of vitamin D every 4 months (equivalent to 20 lg/day) on the relative risk
of fracture in (mainly) men (without calcium supplementation) (Trivedi et al., 2003).
WHO/FAO (2004) considered that a serum 25(OH)D concentration above 27 nmol/L ensures normal
bone health. WHO/FAO (2004) reported on the previous approach of IOM (1997) and calculated the
recommended nutrient intakes by doubling the vitamin D dietary intake (rounded to the nearest 1.25
lg) required to maintain 25(OH)D concentrations above 27 nmol/L, in order to cover the needs of all
individuals irrespective of sunlight exposure. Between 42°N and 42°S, the most efﬁcient way to acquire
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vitamin D was considered to usually be the endogenous synthesis in the skin. About 30 min of daily
sun exposure of the arms and face without sunscreen could usually provide the daily vitamin D needs
(Holick, 1994). Subjects not synthesising vitamin D because of factors such as latitude, season
(particularly winter at latitudes higher than 42°), ageing, skin pigmentation, clothing, or sunscreen use,
were recommended to consume the recommended nutrient intake. WHO/FAO mentioned the age-
related decline in the rate of vitamin D synthesis in the skin, in the rate of vitamin D hydroxylation and
in the response of target tissues such as bone (Holick, 1994; Shearer, 1997). WHO/FAO also
mentioned studies in older adults, including institutionalised subjects or inpatients with low sun
exposure, reporting on ‘low’ 25(OH)D and elevated PTH or ALP concentrations in plasma, decline in
bone mass and increase in the incidence of hip fractures (Chapuy and Meunier, 1997; Dawson-Hughes
et al., 1997). The recommended nutrient intakes for adults were set at 5 lg/day (19–50 years), 10 lg/day
(51–65 years) and 15 lg/day (> 65 years).
The French food safety agency (Afssa, 2001) estimated vitamin D requirements to be 10–15 lg/day
from the minimal amounts needed to prevent or correct deﬁciency (Holick, 1994, 1998; Glerup et al.,
2000), and estimated endogenous production to cover 50–70% of these requirements in case of
‘normal’ sun exposure (i.e. about 5–7 lg/day), thus the reference value was set at 5 lg/day for adults
aged < 75 years. For older adults, sun exposure was reported to be frequently insufﬁcient (particularly
in women in summer), intestinal absorption to be reduced and endogenous production to be less
efﬁcient (Dawson-Hughes, 1996). Considering seasonal changes in serum 25(OH)D and serum PTH
concentrations and bone health in older adults (Dawson-Hughes, 1996; Cynober et al., 2000), the
reference value was set at 10–15 lg/day. This was higher than the spontaneous intake observed at
that time in France (ESVITAF, 1986; Hercberg et al., 1994), therefore the consumption of supplements
under medical supervision or of fortiﬁed foods was discussed. The importance of calcium intake was
also stressed.
SCF (1993) considered serum 25(OH)D concentration ranges of 25–100 nmol/L (whole population)
and 25–50 nmol/L (older and institutionalised people) as advisable. The dietary vitamin D intake
needed to attain serum 25(OH)D concentration of 25–100 nmol/L was considered to depend on, e.g.
latitude, climate, air pollution, social and ethnic groups in Europe, and considered this intake not to be
essential for healthy adults with appropriate calcium and phosphate intake and sun exposure
(Markestad and Elzouki, 1991). The SCF lacked data on the effect of dietary vitamin D on serum 25
(OH)D concentration of non-pregnant young adults. Based on studies on older adults (65 years and
over) (MacLennan and Hamilton, 1977; Toss et al., 1983), an intake of 10 lg/day was considered to
maintain 25(OH)D concentrations of 25–100 nmol/L, even in case of minimal endogenous synthesis.
For adults aged 18–64 years, the acceptable range of intake was 0–10 lg/day (the highest value being
set in case of minimal endogenous vitamin D synthesis). Because of lack of sun exposure and the
decline with age of endogenous vitamin D synthesis, the SCF considered older adults (65 years and
over) and institutionalised people to require 10 lg/day of vitamin D to maintain 25(OH)D
concentrations of 25–50 nmol/L (MacLennan and Hamilton, 1977; Toss et al., 1983).
The UK has revised the DRVs for vitamin D (DH, 1991), reviewing available data on vitamin D
intake/serum 25(OH)D concentration and musculoskeletal health outcomes, i.e. rickets in infants and
children (Section 4.2); osteomalacia in adults; ‘bone health indices’ (BMD, BMC, biochemical markers of
bone turnover), muscle strength and function for different life stages; stress fractures in younger adults
(< 50 years); fracture prevention and risk of falls in adults aged more than 50 years; as well as
non-musculoskeletal health outcomes (SACN, 2016). Based on this review, the Scientiﬁc Advisory
Committee on Nutrition (SACN) considered that the risk of poor musculoskeletal health is increased at
serum 25(OH)D concentrations below about 20–30 nmol/L and retained the concentration of 25 nmol/L
as set by DH (1998). This concentration of 25 nmol/L was considered to ‘represent a ‘population
protective level’; i.e. the concentration that individuals in the UK should be above, throughout the year,
in terms of protecting musculoskeletal health’. A Reference Nutrient Intake (RNI) of 10 lg/day,13
applicable throughout the year, was set for the UK population aged 4 years and over (Cashman et al.,
2008, 2009, 2011b). This was considered as ‘the average amount needed to achieve a serum 25(OH)D
concentration ≥ 25 nmol/L during winter in 97.5% of the population’. It also applies to ‘population
groups at increased risk of having a serum 25(OH)D concentration < 25 nmol/L’, e.g. minority ethnic
groups with darker skin.
An overview of DRVs for vitamin D for adults is presented in Table 1.
13 No EAR or lower RNI were set.
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4.2. Infants and children
D-A-CH (2015) considered that infants reach a serum 25(OH)D concentration of at least 50 nmol/L
with an intake of 10 lg/day (Wagner et al., 2006, 2010), which was set as the AI, achieved through
supplementation, independent of vitamin D endogenous synthesis and intake through consumption of
breast milk or formulas. For older children, a serum 25(OH)D concentration of at least 50 nmol/L was
considered to be achieved with an intake of 5–10 lg/day (Viljakainen et al., 2006b). However, a higher
value of 20 lg/day was set as the AI for all children after 1 year given the lack of sun exposure
(Cashman et al., 2011b) and vitamin D supplementation was recommended in winter time for children
aged up to 2 years (Wabitsch et al., 2011).
The Nordic Council of Ministers (2014) set a RI of 10 lg/day up to the age of 2 years, based on
rickets prevention (Markestad, 1983; Ala-Houhala, 1985; Specker et al., 1992) and the low sun
exposure in Nordic countries. For older children, the vitamin D intake required for serum 25(OH)D
concentration above 50 nmol/L in Danish adolescent girls throughout winter was shown to be partly
dependent on the status in early autumn (Andersen et al., 2013). A meta-regression analysis on data
on children and young adults (Section 5.3.1) was used to set the RI at 10 lg/day, assuming some
vitamin D endogenous synthesis during summer outdoor activities.
The Health Council of the Netherlands (2012) used data on the effect of 7.5–10 lg/day
supplemental vitamin D for rickets prevention (Lerch and Meissner, 2007) and assumed a sufﬁcient
calcium intake to set an AI of 10 lg/day for children aged up to 4 years. As most young children do
not consume sufﬁcient vitamin D and they should be protected against the sun, the Council advised all
young children to take a 10 lg/day vitamin D supplement. Above 4 years, an AI of 10 lg/day was also
set, and fair-skinned children sufﬁciently exposed to sunlight and with a varied diet (including low-fat
margarine, cooking fats and oils) were not considered to require supplemental vitamin D.
IOM (2011) (Appendix B) considered that data were insufﬁcient to establish an EAR for infants and
that the low breast milk vitamin D concentration could not be used to set requirements. In infants, an
intake of 10 lg/day was associated with no clinical deﬁciency and a serum 25(OH)D concentration
generally above 50 nmol/L (Greer et al., 1982; Rothberg et al., 1982; Ala-Houhala, 1985; Ala-Houhala
et al., 1988b; Greer and Marshall, 1989; Hollis and Wagner, 2004a). Thus, 10 lg/day was chosen as
the AI for the ﬁrst year of life, assuming an early supplementation of breast-fed infants and a gradual
increase in formula intake in the other infants. For the age 1–18 years, IOM assumed a normal
distribution of requirements and minimal sun exposure to set the same EAR and RDA as for adults
aged less than 70 years (i.e. 10 and 15 lg/day, respectively).
WHO/FAO (2004) considered infants to be at risk for vitamin D deﬁciency because of their high
skeletal growth, particularly breast-fed infants because of the low vitamin D concentration in breast
milk (Specker et al., 1985) and low sun exposure. Sporadic cases of rickets in Northern cities, almost
always in breast-fed infants (Binet and Kooh, 1996; Brunvand and Nordshus, 1996; Gessner et al., 1997;
Table 1: Overview of dietary reference values for vitamin D for adults
SACN
(2016)
D-A-CH
(2015)
NCM
(2014)
NL
(2012)(i)
IOM
(2011)
WHO/FAO
(2004)(a)
Afssa
(2001)
SCF
(1993)
DH
(1991)(b)
Age (years) ≥ 18 ≥ 19 18–74 18–69 19–70 19–50 20–74 18–64 19–64
DRV (lg/day) 10(c) 20(d) 10(e) 10(d) 15(f) 5 5(g) 0–10(h) 0
Age (years) 51–65
DRV (lg/day) 10
Age (years) ≥ 75 ≥ 70 ≥ 71 ≥ 66 ≥ 75 ≥ 65 ≥ 65
DRV (lg/day) 20(c) 20(c) 20(f) 15 10–15 10 10
(a): PRI in case of no endogenous vitamin D synthesis.
(b): DRVs revised by SACN (2016).
(c): PRI.
(d): AI in case of lack of endogenous synthesis.
(e): PRI assuming some endogenous vitamin D synthesis. PRI of 20 lg/day in case of little or no sun exposure during the
summer season.
(f): PRI considering minimal sun exposure.
(g): Populations with ‘normal’ sun exposure.
(h): Acceptable range of intake. Zero in case of adequate endogenous synthesis, 10 lg/day for younger adults in case of minimal
endogenous synthesis.
(i): NL, Health Council of the Netherlands
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Pettifor and Daniels, 1997), and the increased need for 1,25(OH)2D at puberty (Aksnes and Aarskog,
1982) were mentioned. Adolescents were considered to usually have sufﬁcient sun exposure to
synthesise vitamin D, and vitamin D produced in summer and early autumn to be stored mainly in
adipose tissue (Mawer et al., 1972), thus available for winter time. However, ‘low’ vitamin D stores
during adolescence may occur (Gultekin et al., 1987). WHO/FAO set a recommended nutrient intake of
5 lg/day for infants and children with insufﬁcient vitamin D synthesis (e.g. during winter at latitudes
higher than 42°).
Afssa (2001) set the reference value at 20–25 lg/day for infants, taking into account the frequency
of rickets in some French regions and of ‘low’ 25(OH)D concentrations at the end of winter. The
reference values for children were set at 10 lg/day (1–3 years), and then at 5 lg/day (4–19 years)
based on the same considerations as for adults. Supplementation of breast-fed and formula-fed infants
(10–20 lg/day), of children aged 18 months to 5 years during winter (10–20 lg/day), and of
adolescents during winter and with low sun exposure (Zeghoud et al., 1995) was advised.
SCF (1993) considered the incidence of rickets in unsupplemented infants and serum 25(OH)D
concentrations in supplemented and unsupplemented infants (Poskitt et al., 1979; Garabedian et al.,
1991). The SCF considered that infants 6–11 months should consume at least 10 lg/day and possibly
up to 25 lg/day (Garabedian et al., 1991), and that most children aged 4 years and over, but maybe
not those aged 1–3 years, had enough sun exposure for an adequate vitamin D synthesis. Thus, the
SCF set a reference value of 10 lg/day for children 1–3 years, then ranges of 0–10 (4–10 years) and
0–15 (11–17 years) lg/day, the higher end of the ranges applying in case of minimal endogenous
synthesis.
The UK has revised the DRVs for vitamin D (DH, 1991) (Section 4.1). There were insufﬁcient data
to set RNI for infants and children aged 0–3 years (SACN, 2016). ‘Safe intakes’14 were set at
8.5–10 lg/day for all infants (including exclusively breastfed infants) and 10 lg/day for ages 1 to
< 4 years. A RNI of 10 lg/day was set for subjects aged 4 years and over (Section 4.1).
An overview of DRVS for vitamin D for infants and children is presented in Table 2.
Table 2: Overview of dietary reference values for vitamin D for children
SACN
(2016)(a)
D-A-CH
(2015)(b)
NCM
(2014)(c)
NL
(2012)(d),(k)
IOM
(2011)
WHO/FAO
(2004)(e)
Afssa
(2001)
SCF
(1993)
DH
(1991)(f)
Age (months) 0–11 0 to < 12 6–11 0 to < 12 0 to < 12 0 to < 12 0 to < 12 6–11 7 to < 12
DRV (lg/day) 8.5–10 10 10 10 10(g) 5 20–25(h) 10–25 7
Age (years) 1–17 1–18 1–18 1–18 1–18 1–18 1–3 1–3 1–3
DRV (lg/day) 10 20 10 10 15(i) 5 10 10 7
Age (years) 4–19 4–10 4–18
DRV (lg/day) 5 0–10(j) 0
Age (years) 11–17
DRV (lg/day) 0–15(j)
(a): ‘Safe intakes’ for the age 0 to < 4 years, RNI afterwards.
(b): AIs set considering a lack of endogenous vitamin D synthesis. Vitamin D supplementation of infants, and of children aged up to 2 years
during winter, was recommended.
(c): PRI assuming some endogenous vitamin D synthesis.
(d): AIs in case of lack of endogenous synthesis. Vitamin D supplementation (10 lg/day) of young children was recommended.
(e): PRI in case of no endogenous vitamin D synthesis.
(f): DRVs to be met by supplementation up to at least 2 years of age. DRVs revised by SACN (2016).
(g): AI.
(h): Based on the summary table of Afssa (2001). Supplementation of infants (10–20 lg/day), of children (18 months–5 years) during winter
(10–20 lg/day), and of adolescents during winter and with low sun exposure was advisable.
(i): PRI considering minimal sun exposure.
(j): Acceptable ranges of intake. Zero in case of adequate endogenous synthesis, the higher end of the range in case of minimal endogenous
synthesis.
(k): NL, Health Council of the Netherlands
14 Deﬁned as a value ‘judged to be a level or range of intake at which there is no risk of deﬁciency, and below a level where
there is a risk of undesirable effects’ (DH, 1991).
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4.3. Pregnancy and lactation
According to D-A-CH (2015), maternal serum 25(OH)D concentration inﬂuences that of the fetus
(Hollis and Wagner, 2004b; Wagner et al., 2008b). The vitamin D concentration in breast milk can be
inﬂuenced by intake (Hollis and Wagner, 2004a,b; Wagner et al., 2006) but with high doses up to
160 lg/day (Wagner et al., 2006; Hollis et al., 2011), which were not considered advisable by D-A-CH
(Wagner et al., 2008a). The same AI as that for non-pregnant non-lactating women was thus set, i.e.
20 lg/day in case of lack of endogenous vitamin D synthesis.
The Nordic Council of Ministers (2014) considered the marked increase in serum 1,25(OH)2D
concentration during pregnancy, a correlation between maternal and neonatal vitamin D status
(Markestad, 1983), and lower winter serum 25(OH)D concentrations in pregnant Nordic women (Bjorn
Jensen et al., 2013; Brembeck et al., 2013). The Council also considered the ‘normal’ serum 25(OH)D
concentrations in pregnant women supplemented with 10 lg/day vitamin D (Markestad et al., 1986),
the improved vitamin D status at term by supplementation during pregnancy (Cranney et al., 2007;
De-Regil et al., 2012; Lamberg-Allardt et al., 2013), and the limited data on health outcomes. Thus,
the previous RI for pregnant or lactating women, i.e. 10 lg/day, was maintained.
The Health Council of the Netherlands (2012) advised vitamin D supplementation particularly for
pregnant women with light skin and insufﬁcient sun exposure, or those with dark skin (10 lg/day,
maybe even prior to pregnancy) and noted the low vitamin D concentration in breast milk (IOM,
2011). The Council applied the same AI for pregnant or lactating women as for other young women.
IOM (2011) (Sections 5.1.2 and 5.1.3, Appendix B) found (i) insufﬁcient evidence on the
association between maternal serum 25(OH)D concentration and BMD during pregnancy, (ii) no effect
of maternal 25(OH)D concentration in pregnancy on fetal calcium homeostasis or skeletal outcomes,
(iii) negative skeletal outcomes in the newborn below the EAR-type value (40 nmol/L, Section 4.1) for
maternal 25(OH)D concentration and (iv) no reduced skeletal BMC in children above the RDA-type
value (50 nmol/L, Section 4.1) for maternal 25(OH)D concentration (Delvin et al., 1986; Javaid et al.,
2006; Cranney et al., 2007; Viljakainen et al., 2010). The IOM also considered that neither maternal
BMD nor maternal or fetal serum 25(OH)D concentrations could be used to set reference values for
vitamin D during lactation. IOM (2011) noted that there is no evidence that the vitamin D requirement
of lactating adolescents or women differs from that of non-lactating females in relation to maternal or
child outcomes. Thus, the same EAR and RDA were set for pregnant or lactating women as for non-
pregnant non-lactating women.
WHO/FAO (2004) considered the limited impact of changes in vitamin D metabolism during
pregnancy on maternal requirements, the vitamin D transfer from mother to fetus, and the use of
conventional prenatal vitamin D supplements to ensure adequate vitamin D status. The WHO/FAO
estimated that there was no direct role for vitamin D in lactation because of the regulation of
increased calcium needs by the PTH-related peptide (Sowers et al., 1996; Prentice, 1998) and the lack
of evidence of any change in vitamin D metabolites during lactation (Kovacs and Kronenberg, 1997;
Sowers et al., 1998). Vitamin D concentration in breast milk was considered as low (Specker et al.,
1985), and the rare cases of nutritional rickets were almost always observed in breast-fed infants not
exposed to the sun (Binet and Kooh, 1996; Brunvand and Nordshus, 1996; Gessner et al., 1997;
Pettifor and Daniels, 1997). Evidence was lacking for an increased calcium or vitamin D transfer in milk
after supplementation in lactating mothers (Sowers et al., 1998). Therefore, the same recommended
nutrient intake of 5 lg/day was applied for pregnant and lactating women and for other younger
women (19–50 years).
Afssa (2001) considered that pregnant women in France may have a deﬁcient vitamin D status at
the end of pregnancy, particularly in winter or early spring, even in the South of France. Vitamin D
supplementation (25 lg/day during the last trimester, or a single dose of 5 mg at the seventh month)
was also mentioned. The reference value of pregnant or lactating women was set at 10 lg/day.
The SCF (1993) considered that usual sun exposure in Europe may be insufﬁcient to cover vitamin
D needs, especially during the last trimester of pregnancy and at the end of winter, and that the
ensuing vitamin D deﬁciency would affect mother and newborn (as neonatal vitamin D stores depend
on maternal ones). The SCF (1993) recommended 10 lg/day to maintain 25(OH)D concentrations of
pregnant and lactating women (Cockburn et al., 1980; Greer et al., 1981).
The UK has revised the DRVs for vitamin D (DH, 1991). The RNI of 10 lg/day proposed for subjects
aged 4 years and over (Section 4.1) also applies to pregnant and lactating women (SACN, 2016).
An overview of DRVs for vitamin D for pregnant and lactating women is presented in Table 3.
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5. Criteria (endpoints) on which to base dietary reference values
The Panel considered serum 25(OH)D concentration as a useful biomarker of vitamin D intake (in a
population with low exposure to UV-B irradiation) and of vitamin D status in children and adults
(Section 2.4.6). The Panel also considered that serum 25(OH)D concentration represents total vitamin
D from exposure to both UV-irradiation (cutaneous synthesis) and dietary sources (Section 2.3.3). The
Panel considered that the association between vitamin D intake and status for the purpose of deriving
DRVs for vitamin D should be assessed under conditions of minimal endogenous vitamin D synthesis
(Section 2.3.1). As indicated previously (Sections 2.4.1 and 4), there is an ongoing debate about the
optimal range of serum 25(OH)D concentration and the cut-off values for deﬁning deﬁciency,
insufﬁciency and sufﬁciency.
Thus, the Panel reviewed data ﬁrst on serum 25(OH)D concentration and health outcomes
(Section 5.1), irrespective of the analytical method applied to measure serum 25(OH)D concentration
(Section 2.4.1). Then, the Panel reviewed data on vitamin D intake (from supplements) and health
outcomes (Section 5.2). Finally, the Panel reviewed and assessed data on the relationship between
vitamin D intake (from food and supplements) and serum 25(OH)D concentration under conditions of
minimal endogenous synthesis, and on factors potentially inﬂuencing this relationship (Section 5.3,
Appendices C and D).
5.1. Serum 25(OH)D concentration and health outcomes
5.1.1. Serum concentration
The active metabolite 1,25(OH)2D in association with VDR has a biological function not limited to
bone, intestine, kidneys and parathyroid glands, but throughout the body, regulating many functions
(Section 2.3.6). The Panel thus considered the relationships between vitamin D status, assessed by
serum 25(OH)D concentration, and the risk of various health outcomes (musculoskeletal or non-
musculoskeletal), to evaluate whether they might inform the setting of DRVs for vitamin D. This
assessment was undertaken irrespectively of the analytical method applied to measure serum 25(OH)D
concentration (Section 2.4.1).
The review of data on serum 25(OH)D concentration and musculoskeletal health outcomes in
(healthy) adults and children is ﬁrst described (Section 5.1.2). Then, the Panel reviewed data on
serum 25(OH)D concentration and health outcomes in pregnancy (Section 5.1.3) and lactation
(Section 5.1.4). Finally, an overview of available data on serum 25(OH)D and non-musculoskeletal
health outcomes is given (Section 5.1.5).
• For all of these outcomes, the Panel took as a starting point the results of the literature search
and conclusions from the report by IOM (2011) (Section 4, Appendix B). This report by the IOM
was based (i) on the systematic review (of RCTs (mainly), prospective cohort, case–control and
before-after studies published in 1966–2006) by Cranney et al. (2007) on effectiveness and
safety of vitamin D in relation to bone health, (ii) on another systematic review (of RCTs, non-
randomised comparative studies, cohort and nested case–control studies and systematic reviews)
by Chung et al. (2009) on vitamin D and/or calcium and various health outcomes, which focused,
Table 3: Overview of dietary reference values for vitamin D for pregnant and lactating women
SACN
(2016)(a)
D-A-CH
(2015)(b)
NCM
(2014)(c)
IOM
(2011)(d)
NL
(2012)(b),(g)
WHO/FAO
(2004)(e)
Afssa
(2001)
SCF
(1993)(a)
DH
(1991)(f)
Pregnancy
(lg/day)
10 20 10 15 10 5 10 10 10
Lactation
(lg/day)
10 20 10 15 10 5 10 10 10
(a): PRI.
(b): AI in case of lack of endogenous synthesis of vitamin D.
(c): PRI assuming some endogenous vitamin D synthesis.
(d): PRI considering minimal sun exposure.
(e): PRI in case of no endogenous vitamin D synthesis.
(f): DRVs to be met by supplementation. DRVs revised by SACN (2016).
(g): NL, Health Council of the Netherlands
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however, on RCTs published in 2006–2008 in relation to bone health outcomes to update the
review by Cranney et al. (2007), and (iii) on additional literature search.
• For all of these outcomes, the Panel also considered the report of the Agency for Healthcare
Research and Quality (AHRQ) by Newberry et al. (2014), which is an update of Chung et al.
(2009) for the period 2008–2013 with regard to data on vitamin D intake (and status) with or
without calcium. The Panel considered as well the report by SACN (2016) submitted for public
consultation in July–September 2015 and that served as a basis for updating the references
values for vitamin D in the UK. The report by SACN (2016) took as a starting point the results
of the literature search of the report by IOM (2011). It contains a review of human studies
published up to 2014 in the document published for public consultation, further updated up to
March 2016. For musculoskeletal health outcomes, the Panel also considered the systematic
literature review (of systematic reviews (mainly) and RCTs published in 2000–2012) by
Lamberg-Allardt et al. (2013) on vitamin D intake and status and health (including safety),
which tried to identify a serum 25(OH)D concentration that would reﬂect sufﬁcient vitamin D
status and served as a basis for updating the reference values for vitamin D for the Nordic
Nutrition Recommendations 2012 (Nordic Council of Ministers, 2014) (Section 4).
• For its literature search related to musculoskeletal health outcomes in adults and children, as well
as health outcomes in pregnancy and lactation, the Panel considered pertinent primary studies
published from 2010 (after the IOM report) onwards until March 2015 in PubMed and/or as
identiﬁed in Newberry et al. (2014) and/or SACN (2016), on the possible relationship between
vitamin D status and health outcomes, with the aim to identify a serum 25(OH)D concentration to
be used for deriving the DRVs for vitamin D (Also, using the same approach, the Panel considered
pertinent primary studies on vitamin D intake and health outcomes, see Section 5.2).
Regarding the design of the primary studies considered, the Panel focused on intervention studies
and prospective observational studies in healthy subjects, i.e. excluding cross-sectional studies (except
for osteomalacia), case reports and ecological studies. The Panel notes that, in observational studies,
positive, inverse, or lack of associations between 25(OH)D concentration and musculoskeletal health
outcomes might be biased because of uncertainties in the methodology for measuring serum 25(OH)D
concentration or confounded by factors that have not been properly addressed. In the following
sections, for each musculoskeletal health outcome in adults and children, as well as each health
outcome in pregnancy and lactation, ﬁrst the intervention studies and then the prospective
observational studies are described individually, and ﬁnally, an overall discussion and conclusion by
health outcome is provided.
With the aim of setting DRVs for vitamin D, the Panel considered studies on vitamin D intake from
food and/or daily or weekly supplementation using doses up to the UL for the respective population
group (e.g. for adults: 100 lg/day) (EFSA NDA Panel, 2012a), and excluded studies reporting on lower
frequency of consumption (e.g. monthly, once per trimester, or yearly administration).
5.1.2. Serum 25(OH)D concentration and musculoskeletal health outcomes
The Panel reviewed the available evidence on vitamin D status and musculoskeletal health
outcomes, with the aim of identifying a target serum 25(OH)D concentration associated with low risk
of compromised musculoskeletal health that can be used for the setting of DRVs for vitamin D.
The Panel considered musculoskeletal health outcomes to include BMD/BMC, risk of osteomalacia or
of rickets, fracture risk, risk of falls/falling, muscle strength/muscle function/physical performance, and
calcium absorption (Sections 2.2.1, 2.2.2.1 and 2.4.3). Markers of bone turnover (i.e. of bone
formation and resorption) were not considered (Section 2.4.5).
The Panel decided to consider available data on bone measurements (BMC, BMD) in children and
adults obtained via different techniques (e.g. dual-energy X-ray absorptiometry (DXA) or peripheral
quantitative computed tomography (pQCT) (Appendix A) and after an appropriate study duration (e.g.
at least 1 year (EFSA NDA Panel, 2012b)).
5.1.2.1. Adults
5.1.2.1.1. Bone mineral density/bone mineral content (BMD/BMC)
IOM (2011) (Section 4 and Appendix B) underlined that results from RCTs did not show an
association between serum 25(OH)D concentration and BMD or bone loss. The IOM considered,
however, that the majority of observational studies in post-menopausal women and older men
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supported an association between serum 25(OH)D concentration and BMD or change in BMD,
particularly at the hip sites, and that 25(OH)D concentrations that were associated with an increase of
bone loss at the hip ranged from < 30 to 80 nmol/L.
Lamberg-Allardt et al. (2013) based their conclusions about the possible relationship between 25
(OH)D concentration and BMD or BMC in older adults on Cranney et al. (2007) and Chung et al.
(2009) and their conclusions were in agreement with those derived by IOM (2011). Newberry et al.
(2014) did not speciﬁcally report on the relationship between 25(OH)D concentration and BMC/BMD in
adults beyond the conclusions of IOM (2011). With regard to bone health indices in adults aged
50 years and over, SACN (2016) additionally considered a systematic review by Reid et al. (2014) that
included 23 studies (most of which were published between 1991 and 2009; four of the seven more
recent studies were on patients or institutionalised subjects), two intervention studies (K€arkk€ainen
et al., 2010; Macdonald et al., 2013) and one prospective cohort study (Ensrud et al., 2009). However,
no overall conclusion was drawn on the association between serum 25(OH)D concentration and risk for
increase of bone loss.
The Panel retrieved 15 intervention and prospective observational studies in free-living adults,
reporting on BMD/BMC in relation to 25(OH)D concentration and that were published after the report
by IOM (2011). In the following section, the seven intervention studies and then the eight prospective
observational studies are described individually. The results are then summarised, and an overall
conclusion on BMD/BMC in adults is provided.
RCTs with vitamin D supplementation
In a double-blind 1-year RCT performed in Norway by Jorde et al. (2010), overweight men and
women (21–70 years) received 500 lg vitamin D3 per week (equivalent to 71 lg/day) (DP group
n = 132), or placebo (PP group, n = 142). All subjects were given 500 mg/day calcium and
202 subjects completed the study. Mean (standard deviation, SD) serum 25(OH)D concentration
increased from 58 (20) to 100 (20) nmol/L in the DP group and remained unchanged in the PP group
(58 (20) nmol/L). After 1 year, there were no signiﬁcant differences between the two groups regarding
change in BMD (lumbar spine and hip). The Panel notes that raising mean 25(OH)D concentration
from 58 to 100 nmol/L by weekly high dose supplementation with vitamin D for 1 year did not have
an effect on BMD in these healthy overweight and mostly vitamin D sufﬁcient subjects with an
adequate calcium supply and who covered a large age range.
In a 1-year RCT by Islam et al. (2010), 200 apparently healthy young female factory workers
(16–36 years) in Bangladesh received either: (1) daily 10 lg vitamin D15; (2) daily 10 lg vitamin
D + 600 mg calcium; (3) daily 10 lg vitamin D and other micronutrients + 600 mg calcium; or
(4) placebo. These women worked from dawn to dusk on all days of the week and wore concealing
clothing (hands and faces uncovered). Mean 25(OH)D concentration was between 35 and 38 nmol/L
among the groups at baseline, but was signiﬁcantly (p < 0.001) higher in the three supplemented
groups than in the placebo group (69 vs 36 nmol/L) at the end of the study. After adjustments for
potential confounders, BMD and BMC increased signiﬁcantly at the femoral neck (p < 0.001) and at
the greater trochanter and Ward’s triangle (for both, p < 0.05) in the supplemented groups compared
with placebo, but there was no signiﬁcant difference between groups at the lumbar spine (L2–L4).
The Panel notes that raising mean 25(OH)D concentration from 35–38 nmol/L up to 69 nmol/L in
these young Bangladeshi women with low sun exposure by vitamin D supplementation (with or
without calcium) for 1 year was associated with a signiﬁcant increase in BMD at the femoral neck,
greater trochanter and Ward’s triangle, but not at the lumbar spine.
In a randomly selected subsample of 593 subjects from a randomised population-based open trial
with a 3-year follow-up in 3,432 women (aged 66–71 years) in Finland (K€arkk€ainen et al., 2010), the
intervention group (n = 287 completers) received daily 20 lg vitamin D3 + 1,000 mg calcium for
3 years, while the control group (n = 306 completers) received neither supplementation nor placebo.
The respective mean calcium intakes were 988 and 965 mg/day at baseline. The respective mean (SD)
25(OH)D concentrations were 50.1 (18.8) and 49.2 (17.7) nmol/L at baseline. At the end of the trial,
serum 25(OH)D was signiﬁcantly higher in the intervention group as compared to the control group
(74.6 (21.9) vs 55.9 (21.8) nmol/L, p < 0.001). In the intention-to-treat (ITT) analysis, total body BMD
increased signiﬁcantly more in the intervention group than in the control group (0.84% vs 0.19%,
p = 0.011) and the BMD decrease at Ward’s triangle was lower in the intervention group (2.69% vs
2.83%, p = 0.003). BMD changes at the lumbar spine, femoral neck, trochanter, and total proximal
15 Personal communication from one author: vitamin D3.
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femur were not statistically different between groups. The women who were adherent (i.e. those who
took at least 80% of their supplementation) showed signiﬁcantly lower bone loss in femoral neck
(1.26% vs 1.73%, p = 0.002), Ward’s triangle (1.63% vs 2.83%, p < 0.0001), trochanter
(0.25% vs –0.88%, p = 0.001), and total proximal femur (0.84% vs 1.47%, p < 0.0001) than the
women in the control group. Further, total body BMD increased more in the intervention group (1.31%
vs 0.19%, p = 0.002). In contrast, the increase in lumbar spine BMD was lower in the intervention
group than in the control group (0.67% vs 0.76%, p = 0.033). The Panel notes that raising mean 25
(OH)D concentration from 50 nmol/L to 75 nmol/L by daily vitamin D and calcium supplementation for
3 years was associated with a signiﬁcantly higher increase in total BMD in these women and, in
subjects that adhered to the protocol, with a signiﬁcantly lower bone loss in femoral neck, Ward’s
triangle, trochanter and total proximal femur, but a signiﬁcantly lower increase in lumbar spine BMD
compared to the control group. The Panel also notes that all analyses were unadjusted.
In an 18-month RCT with a factorial design in Australia by Kukuljan et al. (2011), 180 Caucasian
men aged 50–79 years were randomised to: fortiﬁed milk (400 mL/day of milk containing 1,000 mg/day
calcium and 20 lg/day vitamin D3); exercise + fortiﬁed milk; exercise; or control (no milk, no
exercise). Mean baseline serum 25(OH)D concentrations averaged 86.3  36 nmol/L across the
groups, in which no, one and 17 participants had serum 25(OH)D concentrations below 12.5 nmol/L,
of 12.5–25 nmol/L and of 25–50 nmol/L, respectively. Serum 25(OH)D concentrations increased by an
average of 21 nmol/L in the fortiﬁed milk compared with the two non-fortiﬁed milk groups after
12 months (p < 0.001), with no further increases observed at 18 months. Changes in BMD, bone
structure, and strength at the lumbar spine, proximal femur (femoral neck), mid-femur, and mid-tibia
were measured. There were no exercise-by-fortiﬁed milk interactions at any skeletal site. Main effect
analysis showed that exercise led to a net gain in femoral neck section modulus (a measure for
bending strength) and lumbar spine trabecular BMD, but there were no main effects of the fortiﬁed
milk at any skeletal site. The Panel notes that raising mean 25(OH)D concentration from about 86 to
107 nmol/L by providing vitamin D3 (with calcium) to these mostly replete men for 18 months did not
enhance BMD. This suggests that other factors may confound the relationship between vitamin D
intake, serum 25(OH)D and BMD or that, above a certain 25(OH)D concentration, there is no effect of
additional calcium and vitamin D on BMD.
In a 2-year double-blind RCT in the US, Nieves et al. (2012) investigated the effect of 25 lg/day
vitamin D3 supplementation vs placebo on bone loss in post-menopausal African-American women
(mean age about 62 years) (ITT: n = 103) and the inﬂuence of polymorphisms in the gene encoding
VDR (Sections 2.2.1, 2.3.6 and 2.5). All women received calcium supplementation (to reach a total
intake of 1,000 mg/day). Mean ( SD) baseline 25(OH)D concentrations were 29  13 and
29  14 nmol/L in the intervention (n = 55) and placebo (n = 48) groups, respectively, and in 50% of
the subjects, 25(OH)D concentration was below 25 nmol/L. After 2 years, serum 25(OH)D signiﬁcantly
increased by 27.5 nmol/L in the intervention group (p < 0.001), but did not change in the placebo
group. Two-year changes in spine or hip BMD did not signiﬁcantly differ between groups at any
skeletal site. When the entire population was divided according to Fok1 polymorphism (that has been
associated with BMD in post-menopausal women), there were no signiﬁcant differences in the 25(OH)
D response to vitamin D supplementation by genotype. Despite similar elevations in 25(OH)D, femoral
neck BMD was only responsive to vitamin D supplementation in FF subjects (n = 47), not in Ff/ff
subjects (n = 31). The Panel notes that, in these post-menopausal African American women, raising
mean 25(OH)D concentration from about 29 to 56 nmol/L by vitamin D supplementation was not
associated with signiﬁcantly different 2-year changes in spine or hip BMD compared with the placebo
group, both groups having a mean baseline 25(OH)D concentration of 29 nmol/L and sufﬁcient calcium
supply. The Panel also notes that the possible relationship between baseline or follow-up 25(OH)D
concentration and BMD may depend, among other factors, on genetic predisposition. In this context,
the Panel notes that, with regard to the Fok1 polymorphism, the reported frequency of the FF
genotype among various populations was reported to be between 40% and 50% (Laaksonen et al.,
2004; Sanwalka et al., 2013).
In a 1-year double-blind RCT in Scotland, Macdonald et al. (2013) determined whether daily
vitamin D3 supplementation compared with placebo affects BMD change in healthy Caucasian post-
menopausal women aged 60–70 years (ITT: n = 264). Mean intakes of calcium and vitamin D from
food and other supplements amounted, respectively, to around 1.3 g/day and 5 lg/day at baseline in
all groups. Total mean vitamin D intake (i.e. with food and all supplements) amounted to about 5, 15,
and 30 lg/day in the placebo (n = 90), 10 lg supplemented (n = 84) and 25 lg supplemented
(n = 90) groups, respectively. Mean ( SD) baseline 25(OH)D was 33.8  14.6 nmol/L. The 25(OH)D
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changes were 4.1  11.5 nmol/L, +31.6  19.8 nmol/L, and +42.6  18.9 nmol/L in the placebo,
10 lg, and 25 lg groups, respectively. After adjustments for potential confounders, mean BMD loss at
the hip, but not lumbar spine, was signiﬁcantly less for the 25 lg vitamin D group (0.05  1.46%)
compared with the 10 lg vitamin D or placebo groups (0.57  1.33% and 0.60  1.67%,
respectively) (p < 0.05). Neither at baseline nor at the ﬁnal visit were signiﬁcant associations between
serum 25(OH)D and mean total hip BMD or lumbar spine BMD found. The Panel notes that raising
mean 25(OH)D concentration from about 34 to 65 and 76 nmol/L, respectively, by supplemental doses
of 10 or 25 lg/day of vitamin D for 1 year in these post-menopausal women did not result in
corresponding dose-dependent effects on BMD. This suggests that other factors may confound the
relationship between vitamin D intake, serum 25(OH)D and BMD, and that 25(OH)D concentrations
above 34 nmol/L were not associated with BMD in this study.
In a 2-year double-blind RCT in 409 home-dwelling women (70–80 years) in Finland, Uusi-Rasi
et al. (2015) (Sections 5.1.2.1.4, 5.1.2.1.5, 5.2.3 and 5.2.4) investigated the effect of daily vitamin D3
supplementation (20 lg) with or without exercise on BMD assessed as secondary outcome. The
subjects were randomly assigned to four groups, two vitamin D groups who received daily vitamin D3
supplementation, either with (n = 103) or without exercise (n = 102), and two placebo groups, either
with (n = 103) and without exercise (n = 102). Mean calcium and vitamin D intakes at baseline and at
the end of the study were 1,098 and 1,212 mg/day, respectively, for calcium, and 10.4 and 10.5 lg/
day, respectively, for vitamin D. The mean (SD) baseline serum 25(OH)D concentrations among groups
ranged between 65.5 (17.5) and 69.5 (18.0) nmol/L (not signiﬁcantly different). After 2 years, while
serum 25(OH)D concentrations remained stable in the placebo groups, concentrations increased in the
vitamin D groups to 92.5 (18.5) nmol/L. ITT analyses yielded that femoral neck BMD declined in all
groups, with the mean decline being greatest in the placebo without exercise group and differed
signiﬁcantly from that in all other study groups (p < 0.02, p < 0.01, p < 0.04). Lumbar spine BMD did
not change signiﬁcantly in any group, whereas trabecular bone density at the tibia was slightly but
signiﬁcantly increased in the vitamin D and exercise group compared to the placebo without exercise
group (p = 0.02). However, there was no difference between vitamin D without exercise group and the
placebo without exercise group. Also, in none of the intervention groups, changes in either tibial shaft
cortical or area density differed from the placebo without exercise group. The Panel notes that, in
this study, vitamin D supplementation of 20 lg/day (above the usual intake of 10 lg/day) leading to
an increase of mean serum 25(OH)D concentration from about 66 nmol/L up to 93 nmol/L, resulted in
a lower decrease in femoral neck BMD as compared to placebo. The Panel also notes that similar
effects were observed with exercise without vitamin D or with exercise and vitamin D and that vitamin
D alone had no effect on BMD at other sites.
Prospective observational studies
Bolland et al. (2010) examined the association between baseline serum 25(OH)D concentration and
multiple health outcomes (Sections 5.1.2.1.3, 5.1.2.1.4 and 5.1.2.1.5) in 1,471 community-dwelling
women (mean age 74 years) who took part in a 5-year calcium supplementation study in Australia.
Fifty per cent of women had a seasonally adjusted 25(OH)D concentration < 50 nmol/L and these
women were signiﬁcantly older, heavier, and less physically active and had more comorbidities than
women with a seasonally adjusted 25(OH)D concentration ≥ 50 nmol/L. After adjustments for potential
confounders (including treatment allocation to calcium or placebo), women with a seasonally adjusted
baseline 25(OH)D concentration < 50 nmol/L and those with 25(OH)D concentrations ≥ 50 nmol/L did
not show any difference in change in bone density (lumbar spine, total femur, total body). The
Panel notes that this study of community-dwelling older women showed no difference in BMD
change in those with a seasonally adjusted 25(OH)D concentration < 50 nmol/L compared with those
with 25(OH)D concentrations ≥ 50 nmol/L over a 5-year period.
In a cohort of 1,097 healthy peri- or post-menopausal Caucasian Danish women (45–57 years,
median: 51 years) with a 16-year follow-up, Rejnmark et al. (2011) (Section 5.1.2.1.3) investigated
the association of tertiles of PTH concentrations (upper tertile ≥ 4.5 pmol/L) with BMD (assessed at
the 10-year follow-up) stratiﬁed according to baseline 25(OH)D concentrations < 50 nmol/L, at
50–80 nmol/L, or > 80 nmol/L, after adjustments for potential confounders. Mean baseline plasma 25
(OH)D was 65  31 nmol/L. Within the group of women with plasma 25(OH)D < 50 nmol/L at
baseline, high (≥ 4.5 pmol/L) PTH concentration, compared to low PTH concentration (< 4.5 pmol/L),
was associated with a signiﬁcantly larger decrease in lumbar spine BMD between baseline and the 10-
year visit (5.6  7.0% vs 3.4  7.0%, p = 0.01) after adjustments for potential confounders. In
contrast, high (vs low) PTH concentration was not associated with bone loss rates at the lumbar spine
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in women with 25(OH)D concentrations of 50–80 nmol/L or in women with 25(OH)D concentrations
> 80 nmol/L. However, there was no inﬂuence of plasma 25(OH)D concentration on the relationships
of PTH with 10-year changes in BMD at the total hip, femoral neck, and whole body. The
Panel notes that this study indicates that, in these women, a greater 10-year BMD loss at the lumbar
spine was associated with a baseline plasma 25(OH)D concentration < 50 nmol/L at higher PTH
concentration and that the relationship between 25(OH)D concentration and BMD depends on PTH.
In a cohort of mobile community-dwelling Chinese men aged 65 years and over (n = 712) with a
4-year follow-up, Chan et al. (2011) (Section 5.1.2.1.3) examined serum 25(OH)D in relation to BMD.
Mean baseline 25(OH)D concentration was 78.2  20.5 nmol/L, and, respectively, 5.9%, 41.5%, and
52.6% had concentration below 50 nmol/L, of 50 to < 75 nmol/L, or 75 nmol/L or higher. After
adjustments for potential confounders, there was no association between serum 25(OH)D
concentration and 4-year percentage change in BMD at total hip, spine, and femoral neck. The results
remained unchanged when subjects were divided into quartiles of serum 25(OH)D, i.e. concentration
of the ﬁrst quartile ≤ 63 nmol/L vs concentration > 63 nmol/L. The Panel notes that, in this study in
men with a mean serum 25(OH)D concentration of about 78 nmol/L at baseline, no association was
found between baseline serum 25(OH)D concentration (continuous variable or over quartiles of
< 63 nmol/L up to > 91 nmol/L) and a lower 4-year bone loss at any site.
In a cohort study among 2,614 community-dwelling white and black women and men aged
≥ 70 years in the USA, secondary analyses were conducted by Barbour et al. (2012) (Section 5.1.2.1.3)
to determine the average annual change in hip areal BMD (aBMD) by quartiles of 25(OH)D concentration
(< 44.5 nmol/L, 44.5–61 nmol/L, 61–79.8 nmol/L, > 79.8 nmol/L; mean baseline value was not
reported). Blood samples were drawn at year 2, which formed the baseline for this analysis, and hip
aBMD was measured at baseline, years 3, 5 or 6, 8, and 10. After adjustments for potential confounders,
lower 25(OH)D was associated with greater aBMD loss (p trend = 0.024). Participants in the top 25(OH)D
quartile had signiﬁcantly lower annualised hip aBMD loss (0.55%, 95% conﬁdence interval (CI): 0.48
to 0.62%) compared with those in the lowest quartile (0.65%, 95% CI: 0.58 to 0.72%). The
Panel notes that, in this study, a baseline serum 25(OH)D concentration below 44.5 nmol/L (lowest
quartile) was associated with a 0.1% higher annual hip aBMD loss compared to serum 25(OH)
D > 79.8 nmol/L.
In a case-cohort study with a 4.6 year follow-up in the US, Barrett-Connor et al. (2012)
(Section 5.1.2.1.3) tested the hypothesis that combinations of ‘low’ serum 25(OH)D concentration
(< 50 nmol/L), ‘low’ sex hormones (SH) (bioavailable testosterone (BioT) < 163 ng/dL; bioavailable
estradiol (BioE) < 11 pg/mL), and ‘high’ sex hormone binding globulin (SHBG) (> 59 nmol/L) would
have a synergistic effect on total hip BMD loss. Participants were a random subsample of 1,468 men
(mean age: 74 years) from a larger prospective cohort study plus 278 men from this cohort with
incident non-spine fractures. One quarter of the men had baseline 25(OH)D < 50 nmol/L (mean
38.8 nmol/L). After adjustments for potential confounders, ‘low’ 25(OH)D in isolation, and ‘low’ BioT
with or without ‘low’ 25(OH)D, were not signiﬁcantly related to BMD loss. However, the combination of
25(OH)D < 50 nmol/L with ‘low’ BioE and/or ‘high’ SHBG was associated with signiﬁcantly lower
baseline total hip BMD (p = 0.03, p = 0.002) and higher annualised rates of hip bone loss (p = 0.007,
p = 0.0006), than SH abnormalities alone or no abnormality. The Panel notes that the adverse effect
of ‘low’ BioE and/or ‘high’ SHBG serum concentrations on total hip BMD was more pronounced in older
men with baseline serum 25(OH)D concentration < 50 nmol/L (lowest quartile, mean 38.8 nmol/L),
whereas 25(OH)D concentration < 50 nmol/L in isolation was not associated with BMD.
In a population-based cohort of 192 apparently healthy ambulatory older Lebanese men (n = 64)
and women (n = 128) aged 65–85 years, with a median 4-year follow-up, Arabi et al. (2012) analysed
the association of 25(OH)D, PTH and body composition with change in BMD at the lumbar spine, hip
(femoral neck, trochanter, total hip), and forearm and subtotal body BMC. For serum 25(OH)D and
PTH, average of baseline and follow-up concentrations were used in the analyses. Mean 25(OH)D
concentration was 36.8  16 nmol/L and BMD signiﬁcantly decreased at all skeletal sites except at the
spine. Multivariate analyses of per cent changes in BMD (at all skeletal sites) or subtotal body BMC
showed that 25(OH)D was not a signiﬁcant predictor, contrary to changes in body composition and
PTH. The Panel notes that this study showed no association between serum 25(OH)D and 4-year
bone loss at the lumbar spine, hip or forearm in a population with a mean serum 25(OH)D
concentration of about 37 nmol/L (average of baseline and follow-up).
In a cohort study in Japan, Kitamura et al. (2013) explored the association between serum 25(OH)
D concentration, PTH concentration and 5-year changes in BMD of the lumbar spine and femoral neck
in 482 independently living post-menopausal women (mean age, range: 63.1 years, 55–74 years).
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Their mean baseline serum 25(OH)D concentration was 56 nmol/L. In the serum 25(OH)D quartiles
(< 46.5, 46.5 to < 56.1, 56.1 to < 65.1, ≥ 65.1 nmol/L), mean concentrations were 37.5  7.5,
51.2  2.8, 60.3  2.4, and 74.7  7.7 nmol/L, respectively. Mean calcium intake was not signiﬁcantly
different between serum 25(OH)D quartiles (519–536 mg/day). After adjustment for potential
confounders, there was no signiﬁcant association between baseline serum 25(OH)D concentration (as
quartiles) and change in BMD (at either site). The Panel notes that this study indicates that, even at
a rather low calcium intake, the lowest baseline quartile serum 25(OH)D concentration (< 46.5 nmol/L,
mean of about 38 nmol/L) was not associated with a higher 5-year post-menopausal bone loss at the
lumbar spine or femoral neck.
In a cohort of 922 women during the menopausal transition (mean age 48.5  2.7 years) at ﬁve
US clinical centres and with an average follow-up of 9.5 years, Cauley et al. (2015)
(Section 5.1.2.1.3) determined if higher serum 25(OH)D baseline concentration is associated with
slower loss of BMD. BMD was measured at each annual visit. The mean 25(OH)D concentration was
54.5 nmol/L; 43% of the women had 25(OH)D concentrations < 50 nmol/L. Changes in lumbar spine
and femoral neck BMD across menopause were not signiﬁcantly associated with serum 25(OH)D
concentration. The Panel notes that, in this study, baseline serum 25(OH)D concentration (mean
54.5 nmol/L) was not associated with changes in lumbar spine and femoral neck BMD across
menopause.
Conclusions on BMD/BMC in adults
Among the 15 studies identiﬁed, most of which were in older free-living adults, the Panel notes the
heterogeneity of study designs, populations and skeletal sites investigated. The Panel considers that
the sensitivity of serum concentrations of 25(OH)D in predicting losses in BMD/BMC may be limited
because of confounding by a variety of factors (e.g. PTH, genetic factors, sex steroids, body
composition, age, sex, calcium intake, life-style factors, baseline values, season of assessment, and
possible other yet unknown factors) that have only been partly considered in these analyses.
Furthermore, observational studies mostly used single measurements of 25(OH)D concentration, thus
possible long-term changes in 25(OH)D concentration were not considered in the analyses of the
relationship with BMD/BMC changes.
Of the seven RCTs with vitamin D supplementation durations between 1 and 3 years, two RCTs in
women indicated that daily vitamin D and calcium supplementation that led to an increase in mean 25
(OH)D concentrations from 35–38 nmol/L to 69 nmol/L (Islam et al., 2010) and from 50 nmol/L to
75 nmol/L (K€arkk€ainen et al., 2010), respectively, was associated with a signiﬁcantly higher increase in
BMD compared to the control group. In subjects that adhered to the protocol, raising mean 25(OH)D
concentration from 50 nmol/L to 75 nmol/L was also associated with a signiﬁcantly lower bone loss in
femoral neck, Ward’s triangle, trochanter and total proximal femur (K€arkk€ainen et al., 2010). In one
RCT, vitamin D supplementation alone, which led to an increase of mean serum 25(OH)D
concentration from about 66 nmol/L up to 93 nmol/L, resulted in a lower decrease in femoral neck
BMD as compared to placebo, but had no effect on BMD at other sites (Uusi-Rasi et al., 2015).
However, in four RCTs, an increase in serum 25(OH)D concentration from a mean of 29 nmol/L
(Nieves et al., 2012), 34 nmol/L (Macdonald et al., 2013), 58 nmol/L (Jorde et al., 2010) and 86 nmol/L
(Kukuljan et al., 2011) up to 56 nmol/L, 76 nmol/L, 100 nmol/L and 107 nmol/L, respectively, after
vitamin D supplementation or consumption of vitamin D-fortiﬁed food (with or without calcium), did not
result in a change in BMD.
Of the eight prospective observational studies, one reported a 0.1% higher annual hip aBMD
loss associated with baseline 25(OH)D concentrations < 45 nmol/L (lowest quartile), as compared to 25
(OH)D concentrations above 80 nmol/L (highest quartile) (Barbour et al., 2012). One study found a
signiﬁcant relationship between PTH concentration and 10-year BMD loss at the lumbar spine at
baseline serum 25(OH)D concentrations of < 50 nmol/L (Rejnmark et al., 2011). A third study observed
an association between annual hip BMD loss and baseline 25(OH)D concentrations < 50 nmol/L (lowest
quartile, mean 39 nmol/L) only in subjects with ‘low’ sex steroid concentrations (Barrett-Connor et al.,
2012). However, three studies found no difference in (4- or 5-year) BMD changes at any sites between
baseline serum 25(OH)D concentrations in the lowest quartile (< 46.5 nmol/L, (Kitamura et al., 2013);
< 50 nmol/L (Bolland et al., 2010); < 63 nmol/L, (Chan et al., 2011)) and higher concentrations. Two
other studies also did not ﬁnd an association between BMD or BMC losses and serum concentrations of
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25(OH)D in populations with mean 25(OH)D of 37 nmol/L (average of baseline and 4-year-follow-up)
(Arabi et al., 2012) or 55 nmol/L (baseline) (Cauley et al., 2015).
The Panel notes that two RCTs (Islam et al., 2010; K€arkk€ainen et al., 2010) indicate that BMD
may increase when mean serum 25(OH)D concentration increases from about 35–38 to 69 nmol/L in
young women and from 50 to 75 nmol/L in older women and that BMD losses at subsites may be less
pronounced when mean serum 25(OH)D concentration is increased from about 50 to 75 nmol/L in
these older women. The Panel also notes that three observational studies (Rejnmark et al., 2011;
Barbour et al., 2012; Barrett-Connor et al., 2012) suggest that baseline serum 25(OH)D concentration
below 45–50 nmol/L (alone (Barbour et al., 2012) or in combination with high PTH concentration or
low’ BioE and/or ‘high’ SHBG (Rejnmark et al., 2011; Barrett-Connor et al., 2012)) may be associated
with increased BMD losses at various sites. However, the Panel considers that the majority of both
RCTs and observational studies do not report increased BMD/BMC losses at or below similar serum 25
(OH)D concentrations (baseline mean or lowest quartile). The Panel notes that other factors can
interfere with the association between 25(OH)D and BMD/BMC and thus may contribute to these
inconsistencies. The Panel concludes that, altogether, these 15 studies in apparently healthy adults,
published after the report by IOM (2011), do not provide sufﬁcient evidence for a conclusion on a
serum 25(OH)D concentration below which there is an increased risk of BMD/BMC loss.
The IOM had considered that results from RCTs did not show an association between serum 25
(OH)D concentration and BMD or bone loss, but that the majority of observational studies in post-
menopausal women and older men supported an association between serum 25(OH)D concentration
and BMD or change in BMD, particularly at the hip sites. IOM also considered that serum 25(OH)D
concentrations that were associated with an increase in bone loss at the hip ranged from below 30 to
80 nmol/L. Taking into account the conclusions of IOM (2011) and the studies published
thereafter, the Panel considers that there is some evidence, mostly from observational studies in
mainly older adults, that the risk of increased BMD/BMC loss in free-living adults is higher with a serum
25(OH)D concentration below 50 nmol/L.
5.1.2.1.2. Osteomalacia
Only one study (Priemel et al., 2010), considered by IOM (2011), in 675 subjects aged
20–100 years (mean age = 58.7 years in males (n = 401) and 68.3 years in females (n = 274)),
provides information on serum 25(OH)D concentration and osteomalacia (Section 2.2.2.1) assessed by
post mortem bone biopsies. These subjects had been residing in Germany and died for reasons not
related to cancer, metabolic disorders, or bone diseases. Priemel et al. (2010) assessed bone
undermineralisation by pathological accumulation of osteoid, and deﬁned osteomalacia as a ratio of
osteoid volume (OV, i.e. bone matrix that is not mineralised) to total bone volume (BV) greater or
equal to 2%. Only a few subjects had osteomalacia (OV/BV ≥ 2%) at serum 25(OH)D concentration
above 50 nmol/L and no subject had osteomalacia at serum concentration of at least 75 nmol/L. By
further inspecting the graphical presentation of the results of this study, IOM (2011) (Section 4. and
Appendix B) noted that about 1% of subjects with a serum 25(OH)D concentration above 50 nmol/L
had osteomalacia, while less than half of the subjects with serum 25(OH)D concentrations below 40 or
even 25 nmol/L had osteomalacia. IOM (2011) used this study to consider that a serum 25(OH)D
concentration of 50 nmol/L provides coverage for at least 97.5% of the population. The Panel notes
that some concerns with regard to limitations of the Priemel study have been raised, such as the
histomorphometric threshold used to deﬁne osteomalacia and the validity of post mortem 25(OH)D
measurements (Aspray and Francis, 2013). However, the Panel considers that the threshold of OV/BV
≥ 2% used to deﬁne osteomalacia by Priemel et al. (2010) is a conservative approach. The Panel also
notes that no studies are available showing whether post mortem 25(OH)D measurements are valid.
Lamberg-Allardt et al. (2013) referred to the conclusion of IOM (2011) regarding osteomalacia and
stated that no additional reduction in the risk of osteomalacia is to be expected at serum 25(OH)D
concentration above 50 nmol/L. Newberry et al. (2014) also did not address the relationship between
25(OH)D and osteomalacia beyond the report by IOM (2011). SACN (2016) considered two cross-
sectional studies (Preece et al., 1975; Gifre et al., 2011), as well as case reports, on patients with
osteomalacia from early 1940s to 2013 and concluded that evidence on vitamin D and osteomalacia is
limited and drawn mainly from case reports, that there is no clear serum 25(OH)D threshold
concentration below which the risk of osteomalacia is increased, but noted that mean concentrations
(in patients) were below about 20 nmol/L in all the studies considered. The Panel did not retrieve any
additional pertinent primary study published from 2010 onwards.
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The Panel notes that no recently published relevant data from RCTs or prospective observational
studies on the association between serum 25(OH)D concentration and ostemalacia are available.
The Panel takes into account the ﬁndings by SACN (2016), based mainly on case-reports and
two cross-sectional studies in patients with overt osteomalacia at mean serum 25(OH)D concentrations
below about 20 nmol/L. Based on the evidence available (Priemel et al., 2010) and in line with the
conclusion of IOM (2011), the Panel considers that the risk of vitamin D-deﬁciency osteomalacia
appears to be small with serum 25(OH)D concentration at or above 50 nmol/L.
5.1.2.1.3. Fracture risk
IOM (2011) (Section 4 and Appendix B) reported that there was a wide variation in serum 25
(OH)D concentrations below which fracture risk may be increased and that this was observed for
concentrations between 30 and 70 nmol/L.
Lamberg-Allardt et al. (2013) based their conclusions about risk of fractures in older adults on three
systematic reviews (Avenell et al., 2009; Chung et al., 2009; Vestergaard et al., 2011). The overall
conclusion in the NNR 2012 is that intervention with vitamin D alone has not been proven effective in
preventing fractures in older adults. Moreover, Lamberg-Allardt et al. (2013) concluded that, although
a threshold for serum 25(OH)D concentration of 74 nmol/L was considered to show a reduction in
total fracture incidence, the variability in analytical methods and the fact that serum 25(OH)D was
assayed only in subsamples, made this threshold unreliable. Newberry et al. (2014) did not identify
any recent RCTs that assessed the effect of interventions of vitamin D alone on fracture risk. They
reported on six recent observational studies that assessed the association between serum 25(OH)D
and fracture risk (Cauley et al., 2011; Barbour et al., 2012; Barrett-Connor et al., 2012; de Boer et al.,
2012; Holvik et al., 2013; Looker, 2013) and concluded that results were inconsistent among them.
SACN (2016) additionally reported that evidence from ﬁve studies (Cauley et al., 2010, 2011;
Nakamura et al., 2011; Barbour et al., 2012; Rouzi et al., 2012) is mixed. SACN (2016) also considered
studies (intervention and cohorts studies, systematic review of observational studies) about prevention
of stress fractures in younger adults (less than 50 years) that were military personnel. Such a
population was not considered by the Panel in this section (with the aim of setting DRVs for vitamin D
for the general population).
The Panel retrieved 15 relevant prospective observational studies in free-living adults (but no
RCTs), reporting on fractures in relation to 25(OH)D concentration and that were published after the
report by IOM (2011). In the following section, the 15 prospective observational studies are described
individually. The results are then summarised, and an overall conclusion on fracture risk is provided.
Prospective observational studies
In a case-cohort study in men aged 65 years and older, Cauley et al. (2010) followed 436 men with
incident non-spine fractures, including 81 hip fractures, and a random subcohort of 1,608 men over an
average of 5.3 years. The mean baseline total 25(OH)D concentration was 61.5  19.5 nmol/L in non-
spine fracture subjects, 53.8  19.8 nmol/L in hip fracture subjects and 63.0  19.5 nmol/L in
controls (non-spine fracture subjects versus non-patients, p = 0.14; hip fracture subjects versus
controls, p < 0.0001). Serum 25(OH)D concentration was unrelated to non-spine fractures. Compared
with men in the top quartile of total 25(OH)D concentration (≥ 70 nmol/L), the hazard ratio (HR) of
hip fracture was 2.36 (95% CI: 1.08–5.15) for men in the lowest quartile (< 50 nmol/L) (p = 0.009 for
trend), after adjustments for potential confounders.16 The results were not always statistically
signiﬁcant when other additional adjustments were considered.17 The Panel notes that, in these
older men, serum 25(OH)D concentration < 50 nmol/L (lowest quartile) was associated with an
increased risk for hip, but not for non-spine fractures.
Bolland et al. (2010) examined the association between baseline serum 25(OH)D concentration and
multiple health outcomes (Sections 5.1.2.1.1, 5.1.2.1.4 and 5.1.2.1.5) in 1,471 community-dwelling
women (mean age 74 years) who took part in a 5-year calcium supplementation study in Australia.
Fifty per cent of women had a seasonally adjusted 25(OH)D concentration < 50 nmol/L. After
adjustments for potential confounders (including treatment allocation to calcium or placebo), women
with a seasonally adjusted baseline 25(OH)D concentration < 50 nmol/L were not at increased risk of
fracture (hip, vertebral, distal forearm, or osteoporotic), compared with those with 25(OH)D
16 Age, race, clinic, season of blood draw, physical activity, weight, and height.
17 Per cent of body fat, or health status, or neuromuscular measures (unable to complete chair stand or narrow walk, grip
strength), or hip BMD, or falls.
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 35 EFSA Journal 2016;14(10):4547
concentration ≥ 50 nmol/L. The Panel notes that this study of community-dwelling older women with
a seasonally adjusted 25(OH)D concentration < 50 nmol/L compared with those with 25(OH)D
concentration ≥ 50 nmol/L showed no increased risk of fractures over a 5-year period.
In a nested case–control study in the USA in 400 white, 381 black, 193 Hispanic, 113 Asian and
46 Native American women (aged 50–79 years), Cauley et al. (2011) evaluated the incidence of
fractures (all types) over an average of 8.6 years. In multivariable models, compared with
concentrations < 50 nmol/L, higher baseline 25(OH)D concentrations ≥ 75 nmol/L were associated
with a lower risk of fracture in white women (for 50 to < 75 nmol/L, odds ratio (OR): 0.82; 95% CI:
0.58–1.16; for ≥ 75 nmol/L: OR: 0.56; 95% CI: 0.35–0.90, p trend = 0.02). In contrast, higher 25(OH)
D (≥ 50 nmol/L) compared with concentrations < 50 nmol/L were associated with a higher risk of
fracture in black women (OR: 1.45; 95% CI: 1.06–1.98, p trend = 0.043), after adjustment for
potential confounders. In Asian women, the OR for fracture at higher 25(OH)D concentrations
(≥ 75 nmol/L) compared with 25(OH)D < 50 nmol/L, was 2.78 (95% CI: 0.99–7.80, p trend = 0.04).
There was no association between 25(OH)D and fracture in Hispanic or Native American women. The
Panel notes that, in this study, associations between 25(OH)D and fracture by race/ethnicity were
divergent and that serum 25(OH)D were associated with signiﬁcantly lower fracture risk in white
women with baseline concentrations ≥ 75 nmol/L, but a higher fracture risk in black women with
baseline concentrations ≥ 50 nmol/L.
In a cohort study, Nakamura et al. (2011) followed-up 773 community-dwelling Japanese women
aged 69 years and older, for 6 years. Mean serum 25(OH)D concentration was 60.0  17.6 nmol/L
and mean calcium intake was 586  259 mg/day. The adjusted HRs of limb and vertebral fracture for
the ﬁrst quartile (< 47.7 nmol/L) and the third quartile (59.2–70.9 nmol/L) of baseline serum 25(OH)D
concentration, compared to the fourth quartile (≥ 71.0 nmol/L), were 2.82 (95% CI: 1.09–7.34) and
2.82 (95% CI: 1.09–7.27), respectively.18 The pooled adjusted HR was 0.42 (95% CI: 0.18–0.99)
when the incidence in the fourth quartile (≥ 71.0 nmol/L) was compared to the other three quartiles
combined (< 71.0 nmol/L). The Panel notes that, in this study in Japanese women with rather low
calcium intake, risk for limb and vertebral fracture was higher at baseline serum 25(OH)D
concentration < 71 nmol/L (quartiles Q1–Q3).
In a cohort study, Robinson-Cohen et al. (2011) followed-up 2,294 US Caucasian and African
American men and women (mean age: 74 years) for a median duration of 13 years. Baseline serum
25(OH)D was below 37.5 nmol/L for 382 participants. After adjustments for potential confounders,
serum 25(OH)D concentration less than 37.5 nmol/L was associated with a 61% greater risk of hip
fracture (95% CI: 12–132%). The Panel notes that this study in both Caucasian and African
American subjects indicated a greater risk for hip fractures at baseline serum 25(OH)D concentration
< 38 nmol/L.
In a cohort study in Danish women (median age: 51 years) followed-up for 16 years (assessment
after 10 years of follow-up) and with a mean baseline plasma 25(OH)D of about 65 nmol/L
(Section 5.1.2.1.1), Rejnmark et al. (2011) also examined the risk of (all) fractures according to
plasma 25(OH)D (below 50 nmol/L, at 50–80 nmol/L, and above 80 nmol/L) and tertiles of PTH
concentrations. Plasma 25(OH)D concentrations per se were not associated with the risk of any fracture.
High PTH concentrations (> 4.5 pmol/L) were associated with an increased fracture risk at 25(OH)D
concentrations < 50 nmol/L (HRadj = 1.71; 95% CI:
1.1–2.66, p < 0.01) and at 25(OH)D concentrations 50–80 nmol/L (HRadj = 1.60; 95% CI: 1.07–2.37,
p < 0.02). The Panel notes that this study in women indicated that baseline plasma 25(OH)D
concentrations per se were not associated with fracture risk, but were related to fracture risk at
concentrations < 80 nmol/L at high PTH concentrations. Thus, the relationship between 25(OH)D
concentration and fracture risk was shown to depend on PTH.
In a cohort study in mobile community-dwelling Chinese men aged at least 65 years whose mean
baseline 25(OH)D concentration was about 78  20 nmol/L (Section 5.1.2.1.1), Chan et al. (2011)
also found, in multivariate regression analyses, no association between baseline serum 25(OH)D
concentration (continuous variable or over quartiles of < 63 nmol/L up to > 91 nmol/L) and the 4-year
risk of non-vertebral or hip fractures. The Panel notes that this study in men with a mean serum 25
(OH)D concentration of about 78 nmol/L found no association between baseline serum 25(OH)D
concentrations and risk of non-vertebral or hip fractures.
18 Fracture risk in the second quartile was not statistically different from the one in fourth quartile.
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In a cohort study with a median follow-up time of 6.4 years in US community-dwelling white and
black men and women aged ≥ 70 years (Section 5.1.2.1.1), Barbour et al. (2012) also investigated
whether increasing serum 25(OH)D and decreasing PTH concentrations are associated with decreased
risk of hip and any non-spine fracture, assessed every 6 months after year 2 (‘baseline’). In multivariate
analyses, there was no signiﬁcant association between the risk of hip fracture and 25(OH)D
concentration assessed as quartiles (≤ 44.5 nmol/L, 44.5–60.9 nmol/L, 60.9–79.9 nmol/L, compared to
> 79.9 nmol/L). The Panel notes that this study in older subjects found no evidence of an association
between baseline serum 25(OH)D concentration ranging from < 45 nmol/L to ≥ 80 nmol/L (extreme
quartiles) and any non-spine fractures.
In a case-cohort study in older men (mean age: 74 years) in the USA, of which one quarter had 25
(OH)D concentration < 50 nmol/L with a mean of 38.8 nmol/L, Barrett-Connor et al. (2012)
(Section 5.1.2.1.1) also tested the hypothesis that combinations of low 25(OH)D (< 50 nmol/L), low
SH, and high SHBG would have a synergistic effect on non-spine fracture risk. Compared to men with 25
(OH)D > 50 nmol/L, BioT > 163 ng/dL, BioE > 11 pg/mL, SHBG < 59 nmol/L, multivariate analyses
showed no signiﬁcant association between risk for incident non-spine fractures and low 25(OH)D
(< 50 nmol/L) in isolation, or low BioE and/or high SHBG in isolation. The multivariate-adjusted HR
(95% CI) was 1.6 (1.1–2.5) for low BioE/high SHBG plus low 25(OH)D. Fracture risk for men with
isolated low serum 25(OH)D, or those with low BioT with 25(OH)D > 50 nmol/L, did not differ from
risk for men without low serum 25(OH)D or SH/SHBG abnormality. Signiﬁcantly higher fracture risk
was detected in the men with low BioE and/or high SHBG concurrent with a low 25(OH)D (adjusted
HR 1.62; 95% CI: 1.05–2.51). The Panel notes that, in these older men, the fracture risk associated
with baseline serum 25(OHD) concentration < 50 nmol/L (lowest quartile, mean 38.8 nmol/L) was
observed only in the presence of low BioE or high SHBG, whereas 25(OH)D concentration < 50 nmol/L
in isolation was not associated with fracture risk.
In a prospective cohort study, Rouzi et al. (2012) followed a cohort of 707 healthy Saudi post-
menopausal women (mean age  SD: 61.3  7.2 years) for a mean  SD of 5.2  1.3 years. Their
mean baseline serum 25(OH)D concentration was about 34 nmol/L. In multivariate logistic regression,
besides physical activity score, age, hand-grip strength, BMD of total hip, past year history of falls,
baseline serum 25(OH)D concentration and dietary calcium intake in the lowest quartiles were
identiﬁed as independent predictors of risk of all osteoporosis-related fractures. For the lowest quartile
(Q1) of serum 25(OH)D (≤ 17.9 nmol/L) vs higher values, the relative risk (RR) was 1.63 (95% CI:
1.06–2.51, p < 0.027) and for dietary calcium intake in Q1 (≤ 391 mg/day) vs higher values, RR was
1.66 (95% CI: 1.08–2.53, p < 0.020). The Panel notes that this study in post-menopausal women
indicated an increase in the risk for osteoporosis-related fractures at baseline serum 25(OH)D
concentration ≤ 17.9 nmol/L (lowest quartile).
In a pooled US cohort of 4,749 men and women aged 65 years and older from two surveys, Looker
(2013) found that baseline serum 25(OH)D concentration was a signiﬁcant linear predictor of risk of
major osteoporotic fracture (hip, spine, radius and humerus) and signiﬁcant quadratic predictor of hip
fracture in the total sample and among those with less than 10 years of follow-up. It was not related
to risk of either fracture type among those with 10 years of follow-up or more. After adjustments for
potential confounders, fracture risk was signiﬁcantly increased for serum 25(OH)D concentration
< 30 nmol/L (major osteoporotic fracture RR: 2.09; 95% CI: 1.32–3.32; hip fracture RR: 2.63; 95%
CI: 1.60–4.32), compared to serum 25(OH)D ≥ 30 nmol/L. Using other cut-off values, risk for either
fracture outcome among those with serum 25(OH)D concentration between 30 and 49 nmol/L and 50
and 74 nmol/L did not differ from that seen in those with serum 25(OH)D ≥ 75 nmol/L, whereas the
risk for either fracture was again signiﬁcantly higher for those with serum 25(OH)D < 30 nmol/L. The
Panel notes that this study in older subjects indicated an increase in the risk for fractures (major
osteoporotic or hip only) at baseline serum 25(OH)D concentration < 30 nmol/L.
Using a stratiﬁed case-cohort design in 21,774 men and women (65–79 years) who attended four
community-based health studies in Norway with a maximum follow-up of 10.7 years, Holvik et al.
(2013) found an inverse association between baseline serum 25(OH)D concentration and risk of hip
fracture. After adjustments for potential confounders, in the fully adjusted model (not adjusted for
sex), only subjects with 25(OH)D concentration in the lowest quartile (< 42.2 nmol/L) had a 34%
(95% CI: 5–70%) increased risk of hip fracture compared with the highest quartile (≥ 67.9 nmol/L).
Investigating possible sex differences, after a ﬁrst partial adjustment for age, sex, study centre and
BMI, the association was statistically signiﬁcant in men (HR 1.65; 95% CI: 1.04–2.61), but not in
women, but the association was not statistically signiﬁcant in either sexes in the fully adjusted model
(including also month of blood sample). The Panel notes that, in this study in older subjects, an
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increased risk of hip fracture with baseline 25(OH)D concentration < 42 nmol/L (lowest quartile) was
observed, when compared to 25(OH)D concentration ≥ 68 nmol/L (highest quartile).
In a population-based, prospective cohort study in Australia, Bleicher et al. (2014) followed
1,662 community-dwelling men (70–97 years) for a mean of 4.3 years (mean baseline serum 25(OH)
D: about 56 nmol/L). In multivariate analyses,19 the risk of incident fractures was greatest in men with
baseline 25(OH)D concentration in the lowest quintile (25(OH)D ≤ 36 nmol/L; mean 28.1  6.6 nmol/L;
HR: 3.5; 95% CI: 1.7–7.0) and in men in the highest quintile (25(OH)D > 72 nmol/L; HR: 2.7; 95%
CI: 1.3–5.4), compared with men in the fourth quintile (25(OH)D ≥ 60 to ≤ 72 nmol/L). The difference
in risk in quintiles 2 and 3 compared to 4 generally remained not statistically signiﬁcant after additional
adjustments20 or a sensitivity analysis. The Panel notes that this study in older men indicated an
increased risk for fractures in men at baseline serum 25(OH)D concentration < 36 nmol/L and
> 72 nmol/L (lowest and highest quintiles).
In a prospective study of 5,764 men and women, aged 66–96 years (either frail or healthy), based
on a representative sample of the population of Reykjavik, Iceland, HRs of incident hip fractures were
determined according to serum concentrations of 25(OH)D at baseline (Steingrimsdottir et al., 2014).
Mean follow-up was 5.4 years. Compared with serum 25(OH)D of 50–75 nmol/L, HRs for hip fractures
were 2.08 (95% CI 1.51–2.87) for serum 25(OH)D < 30 nmol/L in the fully adjusted model including
physical activity. No difference in risk was associated with 30–50 nmol/L or ≥ 75 nmol/L in either
model compared with the reference. This was also true when analysing men and women separately.
The Panel notes that, in this study in older subjects, at baseline 25(OH)D concentration of
< 30 nmol/L, the risk for hip fractures increased, whereas no difference in the risk was observed over
the range above 30–75 nmol/L.
In a US prospective cohort study in 922 women during the menopausal transition and with an
average follow-up of 9.5 years, Cauley et al. (2015) (Section 5.1.2.1.1) also determined if higher
baseline 25(OH)D concentration is associated with lower fracture risk. The mean 25(OH)D
concentration was 54.5 nmol/L; 43% of the women had 25(OH)D concentration < 50 nmol/L. There was
no signiﬁcant association between serum 25(OH)D and traumatic fractures. However, in multivariable
adjusted hazards models, the HR for non-traumatic fractures was 0.72 (95% CI: 0.54–0.95) for each
25 nmol/L increase in 25(OH)D, and was 0.54 (95% CI: 0.32–0.89) when comparing women whose 25
(OH)D concentration was ≥ 50 vs < 50 nmol/L. The Panel notes that, in this study, serum 25(OH)D
concentration < 50 nmol/L was associated with an increased risk for non-traumatic fracture in mid-life
women.
Conclusions on fracture risk in adults
Among the 15 recent prospective observational studies identiﬁed, most of which were in older free-
living adults, the Panel notes the heterogeneity of observational study designs, populations and
fracture sites investigated and considers that the relationship of serum 25(OH)D concentration and
fracture risk may be confounded by a variety of factors (see Section 5.1.2.1.1). Furthermore,
observational studies mostly used single measurements of 25(OH)D concentration, thus possible long-
term changes in 25(OH)D concentration were not considered in the analyses of the relationship with
fracture risk.
An increased risk of fractures was seen at baseline 25(OH)D concentrations < 18 nmol/L (Rouzi
et al., 2012) (lowest quartile), < 30 nmol/L (Looker, 2013; Steingrimsdottir et al., 2014), < 36 nmol/L
(Bleicher et al., 2014) (lowest quintile), < 38 nmol/L (Robinson-Cohen et al., 2011), < 42 nmol/L
(Holvik et al., 2013) (lowest quartile), < 50 nmol/L ((Cauley et al., 2015); lowest quartile in Cauley
et al. (2010), lowest quartile and only in case of low sex steroid concentrations for Barrett-Connor
et al. (2012)), and < 71 nmol/L (Nakamura et al., 2011) (quartiles Q1–Q3). One study observed a
signiﬁcant negative relationship between PTH concentration and fracture risk at serum 25(OH)D
concentrations < 50–80 nmol/L (Rejnmark et al., 2011). An increased fracture risk was also reported at
25(OH)D concentrations > 72 nmol/L (Bleicher et al., 2014) (highest quintile), > 50 nmol/L in black
women and > 75 nmol/L in Asian (non-statistically signiﬁcant) women but a lower fracture risk at 25
(OH)D < 75 nmol/L in white women (statistically signiﬁcant) (Cauley et al., 2011). However, three
studies found no difference in fracture risk between baseline serum 25(OH)D concentrations in the
19 Adjusted for age, country of birth, BMI, physical activity, season of blood draw, previous low-trauma fracture after age
50 years, calcium supplement, and vitamin D supplement.
20 Additional adjustments for falls or BMD or neuromuscular measures (chair stands and narrow walk test) or serum 1,25(OH)2D
or multivariate model excluding subjects taking vitamin D supplements.
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lowest quartile (< 45 nmol/L, (Barbour et al., 2012); < 50 nmol/L (Bolland et al., 2010); < 63 nmol/L,
(Chan et al., 2011)) and higher concentrations.
The Panel notes that 9 out of 15 observational studies reported an increased risk for fractures that
was associated with baseline 25(OH)D concentrations between < 18 nmol/L and < 50 nmol/L in free-
living adult populations (Cauley et al., 2010, 2015; Robinson-Cohen et al., 2011; Barrett-Connor et al.,
2012; Rouzi et al., 2012; Holvik et al., 2013; Looker, 2013; Bleicher et al., 2014; Steingrimsdottir et al.,
2014). One study observed a signiﬁcant negative relationship between PTH concentration and fracture
risk at serum 25(OH)D concentrations < 80 nmol/L (Rejnmark et al., 2011) and, in one study in
Japanese women (with low calcium intake), an increased fracture risk was reported at 25(OH)D
concentration < 71 nmol/L (Nakamura et al., 2011).
In contrast, an increased fracture risk was observed at ≥ 50 to ≥ 75 nmol/L in two studies: in
Bleicher et al. (2014), as well as in Cauley et al. (2011) only in black (signiﬁcant result) and Asian
(non-signiﬁcant result) women, respectively. This was not observed in other studies: in Cauley et al.
(2011) in white women, nor in Chan et al. (2011), Barbour et al. (2012) or Looker (2013).
The Panel notes the conclusions by IOM (2011) on a wide variation in serum 25(OH)D
concentration associated with an increased fracture risk. Taking into account also the
observational studies published thereafter (mainly on older adults), the Panel considers that,
overall, the majority of studies indicate an increased fracture risk associated with 25(OH)D
concentrations of < 18 nmol/L to < 50 nmol/L in free-living adults.
5.1.2.1.4. Muscle strength/function and physical performance
IOM (2011) (Section 4 and Appendix B) considered physical performance and falls as independent
health outcomes, but because of the joint consideration of these outcomes in the literature, the
available evidence was considered together. IOM (2011) reported some support, mainly from
observational studies, for an association between 25(OH)D concentrations and physical performance,
but concluded that high-quality observational evidence from larger cohort studies was lacking.
Lamberg-Allardt et al. (2013) identiﬁed two systematic reviews with meta-analyses of RCTs on
vitamin D and muscle strength in older subjects (Muir and Montero-Odasso, 2011; Stockton et al., 2011).
Based on a meta-analysis of 17 RCTs (n = 5,072, mean age 60 years in most studies), Stockton et al.
(2011) concluded that vitamin D supplementation does not have an effect on muscle strength in adults
with mean baseline serum 25(OH)D concentrations ≥ 25 nmol/L, and that two RCTs (in patients)
demonstrate an increase in hip muscle strength in adults with serum 25(OH)D concentrations < 25 nmol/L.
The systematic review on 13 RCTs (n = 2,268) by Muir and Montero-Odasso (2011) concluded that
vitamin D doses of 20–25 lg/day showed beneﬁcial effects on balance and muscle strength in older
adults (≥ 60 years of age). Mean baseline serum 25(OH)D concentrations were about 25–65 nmol/L in
12 RCTs that provided the information (mean baseline of 25–50 nmol/L in 10 of these RCTs). The
Panel notes that only three references among the studies considered in these two systematic reviews
were published in 2010 or afterwards, and that seven RCTs were in common in both systematic reviews.
Newberry et al. (2014) identiﬁed two new RCTs in older adults that examined the effects of one
year of vitamin D supplementation with calcium on muscle strength or function (Pfeifer et al., 2009;
Zhu et al., 2010). Newberry et al. (2014) also identiﬁed ﬁve prospective cohort studies on the
association between serum 25(OH)D concentrations and muscle strength, muscle function or physical
performance (Dam et al., 2009; Scott et al., 2010; Michael et al., 2011; Houston et al., 2012; Menant
et al., 2012). Newberry et al. (2014) concluded that the associations between serum 25(OH)D
concentrations and muscle strength, muscle function or physical performance in post-menopausal
women or older men were inconsistent.
SACN (2016) considered three systematic reviews with meta-analyses of RCTs (two already
mentioned above (Muir and Montero-Odasso, 2011; Stockton et al., 2011) and another one (Beaudart
et al., 2014)21 on 30 RCTs (n = 5,615). These systematic reviews reported a beneﬁcial effect of
vitamin D supplementation on muscle strength and function in adults aged > 50 years with mean
baseline serum 25(OH)D concentrations of 24–66 nmol/L (Muir and Montero-Odasso, 2011),
< 30 nmol/L (Beaudart et al., 2014), and < 25 nmol/L (institutionalised older adults (Stockton et al.,
2011)). The Panel notes that 14 RCTs out of the 30 RCTs included in (Beaudart et al., 2014) were
published in 2010 or afterwards,22 and 8 or 11 references were in common with the systematic review
21 Some studies also on vitamin D metabolites/analogues were considered in these systematic reviews.
22 Some of these studies are described below. Others were undertaken, e.g. with vitamin D metabolite or based on a frequency
of supplementation (e.g. once per 3 months) that did not match the inclusion criteria of the Panel (Section 5.1).
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by Muir and Montero-Odasso (2011) or by Stockton et al. (2011), respectively. SACN (2016) identiﬁed
three subsequent RCTs (Lips et al., 2010; Knutsen et al., 2014; Pirotta et al., 2015) and seven cohort
studies (Bolland et al., 2010; Scott et al., 2010; Houston et al., 2011, 2012; Michael et al., 2011; Chan
et al., 2012; Menant et al., 2012), which provided mixed results, and also noted that, in most of the
cohort studies, cut-offs were predeﬁned.
The Panel considered pertinent primary studies from 2010 onwards mostly on healthy adults and,
when excluding studies in populations during a resistance training intervention, retrieved
15 intervention and prospective observational studies, reporting on muscle strength or function,
physical performance or related outcomes (e.g. postural stability, muscle power, mobility), in relation to
25(OH)D concentrations. In the following section, the nine intervention studies and then the six
prospective observational studies are described individually. The results are then summarised, and an
overall conclusion on muscle strength/function and physical performance is provided.
RCTs with vitamin D supplementation
In a 16-week double-blind multicentre RCT in North America and Europe, Lips et al. (2010) studied
the effects of a dose of 210 lg vitamin D3 per week (~ 30 lg/day) or a placebo on postural
stability, measured as postural body sway, and physical performance, measured as short physical
performance battery (SPPB),23 in 246 older subjects (age 70 years and older). Baseline serum 25(OH)
D concentrations were between 15 and 50 nmol/L. Mean serum 25(OH)D concentration increased
signiﬁcantly from 35 to 65 nmol/L (p < 0.001) in supplemented subjects, with no change in the
placebo group. No differences in postural stability or physical performance were observed between
groups at the end of the study. In a post-hoc analysis of a subgroup of subjects with elevated sway at
baseline, supplementation with vitamin D3 signiﬁcantly reduced sway. The Panel notes that this
study in older subjects with weekly vitamin D3 supplementation, which increased their mean serum 25
(OH)D concentration from 35 to 65 nmol/L, found no effect on postural stability or physical
performance compared with placebo. The Panel also notes that the study found an increased postural
stability (i.e. signiﬁcantly reduced sway) in a subgroup of subjects with elevated body sway at
baseline.
In a 6-month double-blind RCT in the Netherlands, Janssen et al. (2010) compared the effects of a
daily supplementation of 10 lg vitamin D3 and 500 mg calcium with a placebo + 500 mg calcium
supplementation only, on muscle strength (knee extension or handgrip strength), power (leg
extension power) and mobility (Timed Up And Go (TUAG) test and Modiﬁed Cooper test24) in
70 female geriatric outpatients. Most participants lived in residential homes, all were above 65 years of
age with baseline serum 25(OH)D concentrations between 20 and 50 nmol/L (mean baseline of
33–34 nmol/L among groups). At 6 months, a signiﬁcant difference in mean serum 25(OH)D (77.2 vs
41.6 nmol/L, p < 0.001) and 1,25(OH)2D concentrations (94.1 vs 67.5 pmol/L, p < 0.001) was found
between the two groups, but no differences in muscle strength, power or mobility. The Panel notes
that, in this study, older subjects supplemented daily with vitamin D3 and calcium for 6 months,
compared with calcium alone, increased their mean serum 25(OH)D from 33 to 77 nmol/L compared
with increases from 34 to 42 nmol/L in the placebo + calcium group, and that no effect on muscle
strength, power or mobility was observed.
In a 1-year population-based double-blind RCT in Australia, Zhu et al. (2010) assessed the effects
of a daily 25 lg vitamin D2 supplement or placebo (both groups receiving 1 g calcium/day) on muscle
strength in different muscle groups and mobility using the TUAG test in 302 older community-
dwelling women aged 70–90 years. Mean baseline serum 25(OH)D was 44  10.5 nmol/L (with 66%
of subjects with 25(OH)D concentration lower than 50 nmol/L). In the vitamin D and calcium group
after 1 year, 25(OH)D concentration increased to 60  14 nmol/L (with 80% of subjects achieving a
serum 25(OH)D concentration higher than 50 nmol/L). For hip extensor and adductor strength and
TUAG, but not for other muscle groups, a signiﬁcant interaction between treatment group and baseline
values of 25(OH)D was noted. Only in subjects in the lowest tertile of baseline hip extensor and
adductor strength and TUAG test, muscle strength and TUAG test improved more with vitamin D and
calcium supplementation compared with calcium supplementation alone. Baseline 25(OH)D
concentration did not inﬂuence subject’s response to supplementation with regard to muscle strength
and mobility. The Panel notes that this study in older women supplemented daily with vitamin D2
together with calcium for 12 months increased mean serum 25(OH)D concentration from 44 to
23 The SPPB includes an assessment of standing balance, gait speed (4-m walking speed) and 5-time chair stand tests.
24 The Modiﬁed Cooper test is used as a measurement of overall mobility.
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60 nmol/L, compared with calcium alone, and that increased muscle strength and mobility were found
only in those who were the weakest and slowest at baseline.
In a 6-month double-blind, randomised exploratory clinical trial in the USA, Lagari et al. (2013)
investigated the effects of daily 10 or 50 lg vitamin D3 supplementation on physical performance
and muscle strength, in 86 community-dwelling subjects aged 65–95 years with a mean baseline
serum 25(OH)D concentration of 82.5 nmol/L. Physical performance was assessed as a four-metre
walk speed test to calculate gait speed, timed sit-to-stand test or chair stand test, single-leg balance
test and gallon-jug test, and muscle strength was measured as handgrip test. A mean decrease in
serum 25(OH)D concentration of 3 nmol/L in men (n = 6) and 8.5 nmol/L in women (n = 25) was
observed in the 10 lg/day supplement group and a mean increase was observed in the 50 lg/day
supplement group of 16 nmol/L in men (n = 9) and 13 nmol/L in women (n = 46). Overall, no
signiﬁcant changes in physical performance or muscle strength were found at the end of the
intervention period. However, subjects with the slowest gait speed at baseline improved their ability to
do chair-stand tests after vitamin D supplementation, after adjustments for potential confounders. The
Panel notes that, in this study in older subjects, two daily doses of vitamin D3 supplementation for
6 months decreased (3 to 8.5 nmol/L) or increased serum 25(OH)D concentrations (+13 to
+16 nmol/L) from a mean baseline of 82.5 nmol/L, and that no effect of dose on physical performance
or muscle strength was measured. The study showed that subjects with the slowest gait speed at
baseline showed an improvement in one of the physical performance tests.
In a 12-week RCT in the UK in 25 young athletes (mean age 21 years) receiving either placebo,
500 lg or 1,000 lg/week vitamin D3 (~ 71 lg/day and 142 lg/day), Close et al. (2013b) measured
serum 25(OH)D concentration and muscle function (bench press and leg press and vertical jump
height) before supplementation and at 6 and at 12 weeks post-supplementation. Baseline mean serum
25(OH)D concentration was 51  24 nmol/L, with 57% of subjects below 50 nmol/L. Following 6 and
12 weeks supplementation, serum 25(OH)D concentration increased above 50 nmol/L in all
participants (mean in each group: about 85–90 nmol/L (values read on ﬁgure)). In contrast, 25(OH)D
concentration in the placebo group decreased at 6 and 12 weeks to 37  18 and 41  22 nmol/L,
respectively. None of the muscle function parameters in these young athletes was signiﬁcantly affected
by an increase of serum 25(OH)D concentration. The Panel notes that, in younger subjects, weekly
vitamin D3 supplementation for 12 weeks increased their serum 25(OH)D concentration above
50 nmol/L, and that this study found no effect on muscle function compared with placebo.
In a parallel group double-blind RCT by Wood et al. (2014) (Sections 5.1.2.1.5, 5.2.3 and 5.2.4),
‘healthy’ post-menopausal women from North East Scotland aged 60–70 years, were assigned to daily
vitamin D3 of 10 lg (n = 102), of 25 lg (n = 101) or matching placebo (n = 102) for 1 year. Grip
strength (primary outcome), diet, physical activity and UV-B irradiation exposure were measured
bimonthly, as were serum 25(OH)D, phosphate and calcium and concentrations. Mean (SD) serum 25
(OH)D concentrations at baseline were 34.3 (14.7) nmol/L, 33.9 (14.3) nmol/L and 32.4 (16.3) nmol/L
in normal weight (BMI < 25 kg/m2; n = 113), overweight (BMI 25–25.99 kg/m2; n = 139) and obese
(BMI ≥ 30 kg/m2; n = 53) subjects, respectively. After 1 year of treatment with 10 and 25 lg of
vitamin D, serum 25(OH)D concentration increased among the various BMI groups by 31–33 lmol/L
and 39–48 nmol/L, respectively. In contrast, the change in 25(OH)D in the placebo groups was
between  1.7 to  6.6 lmol/L. Supplementation had no effect on grip strength. The Panel notes
that, in this study, two different daily doses of vitamin D3 supplementation for 1 year increased mean
serum 25(OH)D concentration, but had no effect on grip strength compared to placebo.
In a 16-week randomised, double-blind, placebo-controlled trial in Norway, Knutsen et al. (2014)
compared the effects of a daily vitamin D3 supplementation (10 or 25 lg vitamin D3) or placebo on
muscle power and strength measured as jump height and handgrip strength and chair-rising
differences between pre- and post-intervention in adults from ethnic minority groups (n = 215) with a
mean age of 37 years (range 18–50 years). Mean serum 25(OH)D3 concentration increased from 27 to
52 nmol/L and from 27 to 43 nmol/L in the groups receiving 25 and 10 lg/day, respectively, with no
changes in the placebo group. Vitamin D supplementation had no signiﬁcant effect on muscle power
or strength. The Panel notes that this 16-week study in younger adults from minority ethnic groups
with two daily supplemental doses of vitamin D3 increased mean 25(OH)D concentration from 27 to 52
or 43 nmol/L with no signiﬁcant effect on muscle power or muscle strength compared with placebo.
In a 10-week RCT in Australia, Pirotta et al. (2015) investigated the effects of a daily supplement
(50 lg vitamin D3 or a placebo) in 26 older adults (> 60 years) with baseline 25(OH)D concentrations
between 25 and 60 nmol/L on neuroplasticity as the primary outcome and muscle power and
function (mobility) measured as stair climbing power, gait (TUAG), dynamic balance (four square step
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test) as the secondary outcome. Mean serum 25(OH)D concentration increased from 46 to 81 nmol/L
in the vitamin D supplemented group with no changes in the placebo group. No signiﬁcantly different
changes in any of the outcome measures were observed between the vitamin D supplemented and
placebo groups at the end of the intervention period. The Panel notes that this was a relatively short
intervention study and that it showed that daily vitamin D supplementation increased mean serum 25
(OH)D concentration from 46 to 81 nmol/L with no effect on muscle power or function in older adults
compared with placebo.
In a 2-year double-blind RCT in 409 home-dwelling women (70–80 years) in Finland, Uusi-Rasi
et al. (2015) (Sections 5.1.2.1.1, 5.1.2.1.5, 5.2.3 and 5.2.4) also investigated the effect of daily
vitamin D3 supplementation (20 lg) with or without exercise (compared with placebo groups, with or
without exercise), on measures of physical functioning (secondary analysis). These measures were
physical performance (measured by SPPB), mobility (TUAG test), dynamic balance (backward
walking) and muscle strength (leg extensor strength). These subjects were at risk of falling (having
fallen at least once during the previous 12 months), and were not performing vigorous exercise more
than 2 h per week. Mean serum 25(OH)D concentrations were not signiﬁcantly different among groups
at baseline, between 65.5 and 69.5 nmol/L, and, after 2 years, they remained almost unchanged in
the two placebo groups (around 68.7 nmol/L), while, in the vitamin D groups, they increased up to
92.5 nmol/L. Vitamin D supplementation alone did not improve any measures of physical functioning
(which were improved by exercise). The Panel notes that, in this study in women at risk of falling,
daily vitamin D supplementation alone increased mean serum 25(OH)D concentration from about 66 to
92.5 nmol/L with no improvement in physical functioning.
Prospective observational studies
In a cohort of 686 community-dwelling older adults (mean age 62  7 years, 49% women) in
Australia, Scott et al. (2010) investigated associations between serum 25(OH)D concentration and leg
muscle strength and leg muscle quality (LMQ)25 at baseline and at a mean follow-up of
2.6  0.4 years. At baseline, 297 subjects had serum 25(OH)D concentration ≤ 50 nmol/L (mean  SD
of 37.1  8.4 nmol/L), and 389 had serum 25(OH)D > 50 nmol/L (mean  SD of 67.8  13.4 nmol/L).
After adjustments for potential confounders (including season of analysis), baseline 25(OH)D
concentration was positively associated with the change in leg muscle strength and LMQ over 2.6 years
(p = 0.027 and 0.003, respectively). The Panel notes that, in this study in older adults in which about
43% had baseline serum 25(OH)D below 50 nmol/L, baseline 25(OH)D concentration was positively
associated with the change in leg muscle strength and LMQ.
Bolland et al. (2010) (Section 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.5) examined the association between
baseline serum 25(OH)D concentration and multiple health outcomes in 1,471 community-dwelling
women (mean age 74 years) who took part in a 5-year calcium supplementation study in Australia.
Fifty per cent of women had a seasonally adjusted 25(OH)D concentration < 50 nmol/L. After
adjustments for potential confounders (including treatment allocation to calcium or placebo), women
with a seasonally adjusted baseline 25(OH)D concentration < 50 nmol/L and those with 25(OH)D
concentration ≥ 50 nmol/L did not show any difference in change (decline) in grip strength. The
Panel notes that this study of community-dwelling older adults showed no difference in change in
grip strength in women with a seasonally adjusted baseline 25(OH)D concentration < 50 nmol/L
compared with those with 25(OH)D concentration ≥ 50 nmol/L, over a 5-year period.
In a cohort of 534 US post-menopausal women (mean age: 70.3  3.9 years, mainly Caucasian),
Michael et al. (2011) evaluated the association between baseline serum 25(OH)D concentration
(48.2  21.4 nmol/L) and a physical summary score at baseline, at 1, 3 and 6 years. The physical
summary score was derived from data on timed walk test, chair-stand test and grip strength. In the
6 years of follow-up, participants with baseline serum 25(OH)D concentration ≥ 75 nmol/L (but not
those with 25(OH)D of 25–49 and 50–74 nmol/L) had signiﬁcantly higher scores for physical
performance compared with the reference category (< 25 nmol/L) after adjustments for potential
confounders (p < 0.001). Physical performance declined over the follow-up period as a result of
ageing, but higher baseline serum 25(OH)D concentration was not associated with a reduction in the
decline in physical performance over the 6-year period. The Panel notes that this study showed that
higher baseline serum 25(OH)D concentration (≥ 75 nmol/L) in older women was associated with
25 Leg muscle quality (LMQ) deﬁned as the level of force produced per unit of muscle mass.
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higher physical performance at follow-up compared with baseline concentration < 25 nmol/L, but was
not associated with the age-related decline in physical performance over a 6-year period.
In community-dwelling men and women aged 77–100 years in four different US settings, Houston
et al. (2011) examined the association between baseline serum 25(OH)D concentration and mobility
disability (difﬁculty walking half a mile or up 10 steps) and activities of daily living (ADL)
disability measured at baseline and every 6 months over 3 years of follow-up (longitudinal analysis).
Almost one-third (31%) of participants had serum 25(OH)D concentration < 50 nmol/L at baseline.
After adjustments for potential confounders, in participants free of mobility disability at baseline,
participants with baseline serum 25(OH)D concentration < 50 nmol/L (but not participants with serum
25(OH)D of 50–74 nmol/L) were at greater risk of incident mobility disability over 3 years of follow-up
(HR: 1.56; 95% CI: 1.06–2.30), compared with those with serum 25(OH)D concentration ≥ 75 nmol/L.
In participants free of ADL disability at baseline, there was no association between baseline serum 25
(OH)D concentration and risk of ADL disability. The Panel notes that, in this study in older
community-dwelling adults, participants with baseline serum 25(OH)D concentration < 50 nmol/L had
a greater risk of incident mobility disability (but not of ADL disability) after 3 years of follow-up
compared with those with serum 25(OH)D ≥ 75 nmol/L.
In a cohort of 2,641 men and women (age 71–80 years), 38% African American, in the USA,
Houston et al. (2012) investigated associations between serum 25(OH)D concentration measured at
baseline and physical performance, measured as SPPB and a second physical performance battery,
gait speed (20-m or 400-m), and muscle strength (knee extensor strength and grip strength),
measured at baseline and at 2 and 4 years follow-up. After full adjustments for potential confounders,
longitudinal associations between baseline 25(OH)D concentration and physical performance at 4-year
follow-up showed that participants with serum 25(OH)D < 50 nmol/L (but not those with serum 25
(OH)D of 50–74 nmol/L) had poorer physical performance than participants with 25(OH)D ≥ 75 nmol/L
(p < 0.01 for both battery scores) and lower 400-m gait speed (p < 0.001). Baseline serum 25(OH)D
was not associated with muscle strength at the 4-year follow-up. Physical performance and gait speed
declined over the 4 years of follow-up (p < 0.0001), and, except for SPPB, the rate of decline was not
associated with baseline 25(OH)D concentration. The Panel notes that this study in older subjects
showed a poorer physical performance at 4 years (but not muscle strength) in subjects with baseline
serum 25(OH)D concentration < 50 nmol/L compared with ≥ 75 nmol/L, but that serum 25(OH)D
concentration at baseline was not related to the age-related decline in physical performance and
strength over a 4-year follow-up.
In a longitudinal analysis of a prospective cohort study in China of community-dwelling men
(n = 714; age > 65 years), Chan et al. (2012) analysed the association between baseline serum 25
(OH)D concentration and 4-year physical performance measures (including grip strength, 6-m walking
speed, step length in a 6-m walk, time to complete ﬁve chair stands). Baseline mean  SD serum 25
(OH)D concentration was 77.9  20.5 nmol/L with 94% of participants having a concentration of
50 nmol/L or greater. After adjustment for potential confounding factors, serum 25(OH)D
concentration was not associated with baseline or 4-year absolute change in physical performance
measures. The Panel notes that this study in older community-dwelling men with relative high baseline
serum 25(OH)D concentration showed no association with physical performance after a 4-year period.
Conclusions on muscle strength/function and physical performance in adults
The Panel notes the heterogeneity in the design of the nine RCTs with respect to age proﬁle of
subjects, dose and length of administration of vitamin D with or without calcium, and measures of
muscle strength and physical performance or related outcomes. The Panel notes that seven RCTs were
carried out in older not-institutionalised subjects (Janssen et al., 2010; Lips et al., 2010; Zhu et al.,
2010; Lagari et al., 2013; Wood et al., 2014; Pirotta et al., 2015; Uusi-Rasi et al., 2015).
The Panel notes that, in the nine RCTs with vitamin D supplementation (with or without calcium)
between 10 weeks and 2 years, mean serum 25(OH)D concentrations increased from 27 nmol/L
(Knutsen et al., 2014), 33 nmol/L (Janssen et al., 2010), about 32–34 nmol/L (Wood et al., 2014),
35 nmol/L (Lips et al., 2010), 44 nmol/L (Zhu et al., 2010), 46 nmol/L (Pirotta et al., 2015), 51 nmol/L
(Close et al., 2013b), about 66 nmol/L (Uusi-Rasi et al., 2015) or 82.5 nmol/L (Lagari et al., 2013), up
to 52 nmol/L, 77 nmol/L, about 82 nmol/L, 65 nmol/L, 60 nmol/L, 81 nmol/L, about 90 nmol/L, about
92.5 nmol/L or about 98 nmol/L, respectively. These RCTs showed that increasing mean serum 25(OH)
D concentrations from these baseline to ﬁnal values by vitamin D supplementation did not result in a
change in measures of physical performance or muscle strength/function.
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The Panel notes that all six prospective observational studies identiﬁed on the association
between baseline serum 25(OH)D concentration and muscle strength/physical performance were on
older subjects, but otherwise were heterogeneous with respect to design, and that the studies may be
confounded by a variety of factors (Sections 5.1.2.1.1 and 5.1.2.1.3). Furthermore, as for other health
outcomes (Sections 5.1.2.1.1 and 5.1.2.1.3), observational studies used single measurements of 25
(OH)D concentration, thus possible long-term changes in 25(OH)D concentration were not considered
in the analyses of the relationship with muscle strength/physical performance.
In one study in older adults in which about 43% had baseline serum 25(OH)D below 50 nmol/L,
baseline 25(OH)D concentration was positively associated with the change in leg muscle strength and
LMQ (Scott et al., 2010). Three other observational studies (Houston et al., 2011, 2012; Michael et al.,
2011) used predeﬁned cut-off concentration for serum 25(OH)D, of < 25 nmol/L (versus 25–49, 50–74 and
≥ 75 nmol/L) (Michael et al., 2011), or > 75 nmol/L (versus < 50 or 50–74 nmol/L) (Houston et al.,
2011, 2012). Among these three studies, two studies showed a higher risk of mobility disability as well
as poorer physical performance in men and women with baseline serum 25(OH)D concentrations
below 50 nmol/L (versus ≥ 75 nmol/L) (Houston et al., 2011, 2012). A third study, in older women,
showed a better physical performance at 6-year follow-up with baseline serum 25(OH)D concentrations
≥ 75 nmol/L (versus < 25 nmol/L) (Michael et al., 2011). In contrast, one study showed no difference
in change in muscle strength (grip strength) in women with a seasonally adjusted baseline 25(OH)D
concentration < 50 nmol/L (predeﬁned cut-off) compared with those with 25(OH)D concentrations
≥ 50 nmol/L (Bolland et al., 2010). Finally, one study showed no association between serum 25(OH)D
(mean baseline: 78–94 nmol/L) and measures of physical performance (Chan et al., 2012). The
Panel notes that the observational studies were inconsistent in their ﬁndings.
In its conclusion, the Panel took into account the conclusions by IOM (2011) on some (mainly
observational) evidence supporting an association between serum 25(OH)D concentrations and
physical performance and on the lack of large high-quality observational evidence, the conclusions of
Lamberg-Allardt et al. (2013), Newberry et al. (2014) and SACN (2016). The Panel also took into
account the identiﬁed studies published thereafter, and notes that the evidence is inconsistent. The
Panel considers that, overall, the recent RCTs, all undertaken in populations with mean baseline serum
25(OH)D concentration of 27 nmol/L or higher, show no support for an association between serum 25
(OH)D concentration and physical performance in healthy older adults. Four of the six new prospective
observational studies used predeﬁned cut-off values for serum 25(OH)D concentration. The
Panel considers that four out of six observational studies reported a positive association between
baseline serum 25(OH)D and better muscle strength/quality, lower risk of mobility disability or of
poorer physical performance at follow-up. Overall, from the available evidence, the
Panel considers that no target value for serum 25(OH)D concentration with regard to muscle
strength/function and physical performance can be derived.
5.1.2.1.5. Risk of falls and falling
A fall is deﬁned as ‘the unintentional coming to rest on the ground, ﬂoor, or other lower level’ and
the number of falls in a population subgroup over a period of time can be recorded and results
expressed as, e.g. the number of falls per person per observation time (incidence), the total number of
falls or the number of subjects falling at least once (termed fallers) (EFSA NDA Panel, 2011)).
IOM (2011) (Section 4 and Appendix B) concluded that the greater part of RCTs found no effects
of vitamin D with or without calcium on reduction in the risk for falls. IOM (2011) also concluded that
the observational studies (mostly cross-sectional) suggested an association between a higher serum 25
(OH)D concentration and a reduced risk of falls in older adults.
Lamberg-Allardt et al. (2013) based their conclusions on seven systematic reviews (Cranney et al.,
2007; Chung et al., 2009; Kalyani et al., 2010; Michael et al., 2010; Murad et al., 2011; Cameron
et al., 2012; Gillespie et al., 2012). Lamberg-Allardt et al. (2013) noted that the systematic reviews
included many of the same studies, with some variation due to different inclusion and exclusion criteria
and timeframe, and that the deﬁnition of ‘falls’ and ‘falling’ varied among trials. Lamberg-Allardt et al.
(2013) concluded that there is probable evidence that supplementation with vitamin D in combination
with calcium is effective in preventing falls in older adults, especially in those with ‘low’ baseline serum
25(OH)D concentration either community-dwelling or in nursing care facilities. The threshold for a 25
(OH)D concentration below which the risk for falls or falling was increased was unclear.
Newberry et al. (2014) identiﬁed two RCTs, already cited in the IOM report, and that examined the
effect of supplementation with vitamin D and calcium on the risk of falls/falling among older adults
(Prince et al., 2008; Pfeifer et al., 2009), as well as one prospective cohort study (Menant et al., 2012)
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on serum 25(OH)D concentration and the risk of falls. Newberry et al. (2014) concluded that an
association was seen between lower serum 25(OH)D concentration and increased risk of falls.
SACN (2016) considered ﬁve systematic reviews and meta-analyses (Kalyani et al., 2010; Murad
et al., 2011; Cameron et al., 2012; Gillespie et al., 2012; Bolland et al., 2014a), two RCTs of which one
(Sanders et al., 2010) was considered by IOM (2011), and the other one (Bischoff-Ferrari et al., 2016)
used supplementation given monthly which did not correspond to the inclusion criteria deﬁned by the
Panel for its literature search (Section 5.1). SACN (2016) also considered one cohort study (Menant
et al., 2012), and two genetic studies (Onder et al., 2008; Barr et al., 2010).
SACN (2016) concluded that the evidence on vitamin D and falls is mixed but, on balance, that the
evidence is suggestive of beneﬁcial effects of vitamin D supplementation in reducing fall risk in adults
> 50 years with mean baseline serum 25(OH)D concentrations over a broad range of values (23–59,
24–28, 24–55, 23–82 nmol/L according to the systematic reviews considered).
In addition to the RCTs by Wood et al. (2014) and Uusi-Rasi et al. (2015) (Sections 5.1.2.1.1,
5.1.2.1.4, 5.2.3 and 5.2.4) and the observational study by Bolland et al. (2010) (Sections 5.1.2.1.1,
5.1.2.1.3 and 5.1.2.1.4), the Panel identiﬁed one prospective observational study in free-living older
adults published after the IOM report, that is described hereafter and followed by an overall conclusion
on risk of falls and falling.
RCTs with vitamin D supplementation
In the double-blind RCT in ‘healthy’ post-menopausal women from Scotland (60–70 years, BMI
18–45 kg/m2) assigned to daily vitamin D3 of 10 lg (n = 102), 25 lg (n = 101) or matching placebo
(n = 102) for 1 year (mean baseline serum 25(OH)D: about 32–34 nmol/L) (Sections 5.1.2.1.4, 5.2.3
and 5.2.4), Wood et al. (2014) also measured falls bimonthly (secondary outcome, self-reported at
study visit) among the various BMI groups. The Panel notes that, in this study, two different daily
doses of vitamin D3 supplementation for 1 year increased mean serum 25(OH)D concentration, but
had no effect on the number of ‘ever fallen’ falls compared to placebo.
In the 2-year double-blind RCT in 409 home-dwelling women in Finland (70–80 years, mean
baseline serum 25(OH)D concentrations among groups between 65.5 and 69.5 nmol/L) who were at
risk of falling, Uusi-Rasi et al. (2015) (Sections 5.1.2.1.1, 5.1.2.1.4, 5.2.3, and 5.2.4) also investigated
the effect of daily vitamin D3 supplementation (20 lg) with or without exercise on self registered falls
(primary outcome) obtained from prospective fall diaries returned monthly via mail as primary
outcome. There was no interaction between vitamin D and exercise. Fall incidence rate ratios
calculated as the total number of falls divided by the time over which falls were monitored (100
persons/year), and HRs for fallers were not different between the two vitamin D and the two placebo
groups. In a secondary analysis, HRs for injured fallers (faller requiring medical care) were signiﬁcantly
lower in both exercise groups compared with placebo without exercise, and the HR in the vitamin D
group without exercise was not different from those in the placebo without exercise. The
Panel notes that this study in home-dwelling older women found that daily vitamin D
supplementation for 2 years increased mean serum 25(OH)D concentration, but had no effect on the
rate or risk of falls or injurious falls.
Prospective observational studies
Bolland et al. (2010) examined the association between baseline serum 25(OH)D concentration and
multiple health outcomes (Sections 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.4) in 1,471 community-dwelling
women (mean age 74 years) who took part in a 5-year calcium supplementation study in Australia.
Fifty per cent of women had a seasonally adjusted 25(OH)D concentration < 50 nmol/L. After
adjustments for potential confounders (including treatment allocation to calcium or placebo), women
with a seasonally adjusted baseline 25(OH)D concentration < 50 nmol/L were not at increased risk of
falls (monitored with a diary), compared with those with 25(OH)D concentration ≥ 50 nmol/L. The
Panel notes that this study of community-dwelling older women with a seasonally adjusted 25(OH)D
concentration < 50 nmol/L compared with those with 25(OH)D concentration ≥ 50 nmol/L showed no
increased risk of falls over a 5-year period.
In a cohort of 463 older community-dwelling men and women (54%) (age 70–90 years) in
Australia, Menant et al. (2012) studied the relationship between baseline serum 25(OH)D
concentration and falls monitored with monthly diaries and assessed at 12-months follow-up. At
baseline, 21% of men and 44% of women had serum 25(OH)D concentration ≤ 50 nmol/L. After
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adjustments for potential confounders, baseline serum 25(OH)D concentration < 50 nmol/L
(predeﬁned cut-off) was associated with an increased rate of falls in men (incident rate ratio: 1.93;
95% CI: 1.19–3.15, p = 0.008), but not in women. The Panel notes that this study in older subjects
showed that serum 25(OH)D concentration < 50 nmol/L was associated with increased rate of falls in
men only.
Conclusions on risk of falls and falling in adults
The Panel considered two RCTs published after the IOM report, which showed that mean serum
25(OH)D concentrations increased after vitamin D3 supplementation for 1–2 years, while this
supplementation had no effect on the number of ‘ever fallen’ falls compared to placebo in one study,
or on the rate or risk of falls or injurious falls in the other. The Panel considered two prospective
observational study published after the IOM report, with inconsistent results. One study of
community-dwelling older women with a seasonally adjusted 25(OH)D concentration < 50 nmol/L
compared with those with 25(OH)D concentration ≥ 50 nmol/L showed no increased risk of falls over
a 5-year period (Bolland et al., 2010). The other study in older subjects showed that serum 25(OH)D
concentration < 50 nmol/L was associated with increased rate of falls in men only (Menant et al.,
2012). Furthermore, as for other health outcomes (Sections 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.4),
observational studies used single measurements of 25(OH)D concentration, thus possible long-term
changes in 25(OH)D concentration were not considered in the analyses of the relationship with rate/
risk of falls.
The Panel considered the conclusion by IOM (2011), by SACN (2016), Newberry et al. (2014),
Lamberg-Allardt et al. (2013), that took several systematic reviews (undertaken with different inclusion
criteria) into account. The Panel notes that the evidence on serum 25(OH)D is inconsistent, but
overall, is suggestive of beneﬁcial effects of vitamin D in reduction of the risk of falling in older adults
over a broad range of mean baseline serum 25(OH)D concentrations (23–82 nmol/L according to the
systematic reviews considered in previous reports). From the available evidence, the
Panel concludes that no target value for serum 25(OH)D concentration with regard to the risk of
falls or falling can be derived.
5.1.2.1.6. Calcium absorption
Regarding the physiological role of 1,25(OH)2D in the active transport regulation of calcium
absorption in the intestine (Section 2.2.1) (EFSA NDA Panel, 2015b), the Panel considered it pertinent
to review the possible relationship between 25(OH)D concentration and calcium absorption to try to
identify a possible threshold value for this relationship. Calcium absorption is usually measured as
fractional calcium absorption for which the dual calcium isotope technique is regarded as the gold
standard (Heaney, 2000; IOM, 2011), whereas single isotope methods, which are considered more
convenient to use, have also been developed (Lee et al., 2011).
IOM (2011) (Section 4 and Appendix B) considered both RCTs and cross-sectional studies in
relation to vitamin D status and calcium absorption and concluded that fractional calcium absorption
reaches a maximum at serum 25(OH)D concentrations between 30 and 50 nmol/L in adults, ‘with no
clear evidence of further beneﬁt above 50 nmol/L’. The Panel notes that the IOM included the study by
Need et al. (2008) in patients attending osteoporotic clinics, which found that ‘low’ vitamin D status
does not reduce serum 1,25(OH)2D concentration, and therefore calcium absorption, until the serum
25(OH)D concentration falls to around 10 nmol/L and suggested this concentration below which the
formation of 1,25(OH)2D is compromised. The Panel notes that neither Lamberg-Allardt et al. (2013),
nor Newberry et al. (2014) or SACN (2016) considered the relationship between serum 25(OH)D
concentration and calcium absorption.
For studies post-dating the IOM report, the Panel identiﬁed several studies, including two RCTs
(Shapses et al., 2013; Aloia et al., 2014) and one observational study (Shapses et al., 2012) using the
dual isotope technique to measure fractional calcium absorption. The Panel also identiﬁed two RCTs
(Gallagher et al., 2012, 2014) that used a single isotope technique. They were considered as
supportive evidence by the Panel and are described individually below, followed by a summary of the
results and an overall conclusion on calcium absorption in adults.
With regard to results obtained with the dual isotope technique, in a 6-week placebo-
controlled, double-blind RCT, Shapses et al. (2013) measured fractional calcium absorption in
83 post-menopausal women (mean age 57.8  0.7 years, mean BMI of 30.2  3.7 kg/m2, mean
baseline serum 25(OH)D concentration of 62.3  14.3 nmol/L), during either a weight loss or weight
maintenance period. All women were given 1.2 g calcium/day and 10 lg vitamin D3/day, and either
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weekly vitamin D3 (375 lg) or a placebo, equivalent to a total supplementation of 63 lg/day and
10 lg/day, respectively, both sufﬁcient to maintain calcium balance. The study showed that vitamin D
supplementation increases fractional calcium absorption. The Panel notes, however, that no
correlation was found between fractional calcium absorption and either serum 25(OH)D or 1,25(OH)2D
concentrations at baseline or after the intervention, in this study with mean baseline serum 25(OH)D
concentration of 62.3 nmol/L.
In an 8-week placebo-controlled, double-blind RCT, Aloia et al. (2014) determined fractional calcium
absorption in 71 healthy women (age 58.8  4.9 years; mean BMI of the groups of 26.0–27.6 kg/m2,
and mean baseline serum 25(OH)D concentration of 63  14 nmol/L, range: 30 to > 75 nmol/L), who
were assigned to placebo, 20, 50, or 100 lg/day of vitamin D3. After adjustment for potential
confounders, there was a statistically signiﬁcant linear relationship between an increase in 10-week
calcium absorption and increasing vitamin D3 doses (R
2 = 0.41, p = 0.03) and a marginally signiﬁcant
linear effect by 10-week serum 25(OH)D concentration (p = 0.05, R2 not reported). The changes
(follow-up minus baseline) in serum 25(OH)D concentration and in calcium absorption were not
signiﬁcantly correlated. The Panel notes that no threshold value for serum 25(OH)D concentration in
relation to calcium absorption was found in this study with ﬁnal serum 25(OH)D concentrations
between 40 and 130 nmol/L.
In a retrospective observational study, Shapses et al. (2012) examined the inﬂuence of body weight
and hormonal and dietary factors on fractional calcium absorption in 229 adult women (age
54  11 years, and BMI of 31.0  7.0 kg/m2). When categorised into tertiles of BMI, mean serum 25
(OH)D concentrations were signiﬁcantly lower (63 nmol/L) in the obese group (mean BMI
39.0  10.4 kg/m2) compared with the over- or normal weight groups (75 nmol/L) (p < 0.05),
whereas mean 1,25(OH)2D3 concentrations were similar. Fractional calcium absorption was signiﬁcantly
(p < 0.05) higher in obese women compared to non-obese women. After adjustment for multiple
confounders, 1,25(OH)2D3 was a signiﬁcant predictor of fractional calcium absorption (p = 0.042), but
not 25(OH)D. The Panel notes that no threshold value of 25(OH)D concentration in relation to
fractional calcium absorption was found in this study.
With regard to results obtained with the single isotope technique, in a 1-year double-blind
RCT, Gallagher et al. (2012) measured calcium absorption, expressed as percentage of the actual dose
per litre of plasma, at baseline and 12 months in 163 post-menopausal Caucasian women (age
57–90 years) with baseline serum 25(OH)D concentrations in the range of 12.5–50 nmol/L.
Participants received one of the vitamin D3 supplementation doses of 10, 20, 40, 60, 80, 100, or
120 lg/day or placebo and mean serum 25(OH)D increased from a mean value of 38 nmol/L at
baseline (all subjects) to 112 nmol/L in subjects with the highest dose of vitamin D. Calcium
absorption at 12 months was more related to 12-month serum 25(OH)D concentration (R2 = 0.51,
p < 0.001) than to dose (R2 = 0.48, p < 0.033), after adjustments for potential confounders. There
was, however, no evidence for a threshold value for a reduced calcium absorption in the 12-month
serum 25(OH)D concentration range of 25–165 nmol/L (values read on ﬁgure). In another 1-year
double-blind RCT, Gallagher et al. (2014) measured calcium absorption (% dose per litre of plasma) at
baseline and after 12 months in 198 Caucasian and African American women (age 25–45 years) with
initial serum 25(OH)D concentration ≤ 50 nmol/L. Participants received a vitamin D3 supplementation
dose of 10, 20, 40, 60 lg/day or placebo and were advised to take a calcium supplement (200 mg) to
maintain a calcium intake of approximately 1,000 mg/day. Mean serum 25(OH)D increased from
33.5 nmol/L (all subjects) at baseline to 100 nmol/L in the group receiving the highest dose of vitamin
D3. No changes in calcium absorption were observed over time on any dose in either Caucasians or
African Americans, and no signiﬁcant relationship was observed between 12-month calcium absorption
and baseline or ﬁnal serum 25(OH)D. No threshold value of serum 25(OH)D for calcium absorption
was found at baseline or in the longitudinal study. The Panel notes that these two studies do not to
identify a threshold for serum 25(OH)D concentration below which calcium absorption is impaired.
Conclusions on calcium absorption in adults
The Panel notes that all studies identiﬁed after the IOM report were conducted in women (mostly
post-menopausal women), but were otherwise quite heterogeneous with respect to study design (age
proﬁle of subjects, ethnicity, body weight, dose of vitamin D, calcium supplementation), which
contribute to the mixed ﬁndings and limit a conclusion. Duration of RCTs ranged between 6 weeks and
1 year.
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The Panel notes that the cross-sectional single isotope study by Need et al. (2008), included in the
review by the IOM, showed that calcium absorption was reduced at 25(OH)D concentrations around
10 nmol/L, below which the formation of 1,25(OH)2D was compromised.
The Panel also notes that the two recent RCTs (Shapses et al., 2013; Aloia et al., 2014) and the
one observational study (Shapses et al., 2012) using the dual isotope technique included subjects with
relatively high baseline serum 25(OH)D concentrations (mean above 60 nmol/L). The Panel notes that
these three studies showed no threshold value for serum 25(OH)D concentration in relation to
fractional calcium absorption, in particular no threshold value in the serum 25(OH)D range between 40
and 130 nmol/L (Aloia et al., 2014) or that fractional calcium absorption was higher in the group
(Shapses et al., 2012) with the lowest serum 25(OH)D concentration (mean 63 nmol/L). These results
are supported by ﬁndings of two RCTs (Gallagher et al., 2012, 2014) using the single isotope
technique and undertaken at lower baseline mean serum 25(OH)D concentrations (33.5 and 38 nmol/L).
Results of studies are inconsistent on whether serum 25(OH)D concentration was a statistically signiﬁcant
predictor of calcium absorption (Gallagher et al., 2012; Aloia et al., 2014) or not.
Overall, based on these studies, the Panel considers that calcium absorption was shown to be
compromised only in patients with vitamin D deﬁciency (with serum 25(OH)D concentration ≤ 10 nmol/L)
and that the recent studies provide no evidence of a threshold effect in relation to fractional calcium
absorption in adults, for serum 25(OH)D concentrations ranging between 33.5 and 75 nmol/L (mean
at baseline) or between 40 to 130 nmol/L (range of ﬁnal concentrations).
5.1.2.1.7. Summary of conclusions on serum 25(OH)D concentration as an indicator of musculoskeletal
health in adults
The Panel notes that the evidence on a possible threshold value for serum 25(OH)D concentration
with regard to the risk of adverse musculoskeletal health outcomes in adults shows a wide variability of
results. Several factors contribute to this (Sections 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.4) and also include
the large variation in the results from different laboratories and assays used for measuring serum 25
(OH)D concentration (Section 2.4.1). Furthermore (as indicated in the previous sections), observational
studies mostly used single measurements of 25(OH)D concentration, thus possible long-term changes in
25(OH)D concentration were not considered in the analyses of the relationship with health outcomes.
The Panel concludes that, regarding the relationship between serum 25(OH)D concentration and
• BMD/BMC in free-living adults, there is some evidence for a higher risk of increased BMD/BMC
loss with serum 25(OH)D concentrations below 50 nmol/L,
• osteomalacia, overt osteomalacia has been reported in studies on patients at mean serum 25
(OH)D concentration below about 20 nmol/L, while there is some evidence that the risk of
vitamin D-deﬁciency osteomalacia is small with serum 25(OH)D concentrations at or above
50 nmol/L,
• fracture risk in free-living adults, the majority of studies indicate an increased risk of fractures
associated with serum 25(OH)D concentrations of < 18 nmol/L to < 50 nmol/L,
• muscle strength/function and physical performance, the evidence is inconsistent, and no target
value for 25(OH)D concentration with regard to muscle strength/function and physical
performance can be derived,
• falls/falling, the evidence is mixed, but overall is suggestive of beneﬁcial effects of vitamin D
supplementation for reducing the risk of falls and falling in older adults over a range of serum
25(OH)D concentrations (means of 23–82 nmol/L according to the systematic reviews
considered). From the available evidence, no target value for 25(OH)D concentration with
regard to the risk of falls or falling can be derived,
• calcium absorption, a threshold below which fractional calcium absorption is compromised has
been shown in patients with serum 25(OH)D concentrations around 10 nmol/L, and that there
is no evidence of a threshold effect in relation to fractional calcium absorption in adults, for
serum 25(OH)D concentrations above about 30 nmol/L.
5.1.2.2. Infants and children
5.1.2.2.1. Bone mineral density/content
IOM (2011) (Section 4 and Appendix B) noted the lack of data relating serum 25(OH)D
concentration to bone accretion measures in infants, and that the evidence for an association between
serum 25(OH)D concentration and BMC measures in infants was inconsistent. IOM (2011) noted that,
in children above 1 year of age, serum 25(OH)D concentrations of 40–50 nmol/L ‘would ideally
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coincide with bone health beneﬁts such as positive effects on BMC and BMD’ (Viljakainen et al., 2006a;
Cranney et al., 2007; Chung et al., 2009). IOM (2011) also noted that the results of RCTs in children
are inconsistent when compared to results of observational studies. Overall, the IOM considered that
there was some evidence for a positive association between serum 25(OH)D concentration in children
and baseline BMD or change in BMD.
Lamberg-Allardt et al. (2013) based their conclusions about the possible relationship between
serum 25(OH)D concentration and BMC or BMD in infants and children on Cranney et al. (2007), and
their conclusions were in agreement with those derived by IOM (2011).
Newberry et al. (2014) examined the effect of vitamin D supplementation on 25(OH)D
concentration and BMC in infants or children (Molgaard et al., 2010; Holmlund-Suila et al., 2012;
Khadilkar et al., 2012), and considered that there was no reason to change previous conclusions
(Cranney et al., 2007; Chung et al., 2009).
In infants, SACN (2016) concluded that the evidence from four intervention studies (Kim et al.,
2010; Kumar et al., 2011; Abrams et al., 2012; Holmlund-Suila et al., 2012), is inconsistent with regard
to an effect of vitamin D supplementation on indices of bone health in infants. SACN (2016) also noted
some methodological limitations in one study (Kim et al., 2010), and the speciﬁc population of another
study (undernourished low birth-weight infants (Kumar et al., 2011). For bone health indices in
children aged 1–3 years, SACN (2016) identiﬁed a cross-sectional study (Hazell et al., 2015) on the
relationship between plasma 25(OH)D and BMC/BMD, that is not a type of study considered by the
Panel for this Section (Section 5.1.1). For children aged above 4 years, SACN (2016) concluded that a
systematic review and meta-analysis including six RCTs (Winzenberg et al., 2011)26 (mean age:
10–13 years) reported a beneﬁcial effect of vitamin D3 supplementation on total body BMC when
baseline serum 25(OH)D concentration was < 35 nmol/L. However, SACN (2016) noted that the
35 nmol/L cut-off value was arbitrarily selected based on the distribution of data (to have sufﬁcient
data for subgroup analyses). SACN (2016) also identiﬁed ﬁve trials on ‘bone health indices’, i.e. calcium
absorption (Park et al., 2010), BMC/BMD (Ward et al., 2010; Molgaard et al., 2010; Khadilkar et al.,
2012), marker of bone resorption (Ghazi et al., 2010) in children and adolescents. However, three of
these studies used supplementation given monthly, bimonthly, or every third month (Ghazi et al.,
2010; Ward et al., 2010; Khadilkar et al., 2012), which did not correspond to the inclusion criteria
deﬁned by the Panel for its literature search (Section 5.1.1).
The Panel retrieved ﬁve intervention and prospective observational studies, reporting on BMD/BMC
in infants/children in relation to 25(OH)D concentrations and that were published after the report by
IOM (2011). In the following section, the four intervention studies, ﬁrst in infants then in children, are
described individually, followed by the one prospective observational study in children. The results are
then summarised, and an overall conclusion on BMC/BMD in infants/children is provided.
Trials with vitamin D supplementation
In a trial in 38 breastfed healthy infants (Hispanic and non-Hispanic) in the USA, who all received
10 lg/day vitamin D3 supplementation for 3 months from 1 week after birth, Abrams et al. (2012)
investigated changes in 25(OH)D concentration (cord blood then infant blood), BMC and BMD between
baseline and follow-up. Mean 25(OH)D concentrations were 57.5 nmol/L (non-Hispanic) and 42 nmol/L
(Hispanic) in cord blood, and were 94 nmol/L and 78 nmol/L, respectively, at age 3 months. There
was no signiﬁcant linear relationship between change in 25(OH)D and change in BMC. After
adjustment for potential confounders, there was no signiﬁcant relationship between cord 25(OH)D and
BMC at 3 months. The Panel notes that, in this study of short duration (3 months), mean 25(OH)D
concentration rose from about 42–58 nmol/L (cord blood) to 78–94 nmol/L at follow-up after daily
vitamin D supplementation of all infants, but there was no relationship between cord 25(OH)D and
BMC at 3 months.
In a double-blind randomised trial in 113 healthy term newborns (107 included in the analyses,
among which 102 were breastfed infants) in Finland, Holmlund-Suila et al. (2012) investigated whether
vitamin D3 supplementation (10 lg/day or two other doses higher than the UL for infants, i.e. higher
than 25 lg/day) from age 2 weeks to 3 months could ensure a serum 25(OH)D concentration of at
least 80 nmol/L, without signs of excess. Samples of cord blood were collected at birth to measure
baseline serum 25(OH)D, and tibia total and trabecular bone density or area, cortical bone density or
area, and bone stress and strain index were assessed by pQCT (see Appendix A). Serum 25(OH)D
measured at birth in cord blood did not differ among groups (mean: 52–54 nmol/L according to
26 None of the included studies in this systematic review were published in 2010 or afterwards.
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groups, median: 53 nmol/L in the whole population) and was 88 nmol/L (mean) at 3 months in the
group receiving 10 lg/day, with a minimum value at 3 months of 46 nmol/L. After adjustment for
potential confounders, there was no signiﬁcant difference in bone parameters measured by pQCT
between the three vitamin D-supplemented groups. The Panel notes that, in this study of short
duration (2.5 months), mean serum 25(OH)D concentration rose from about 53 nmol/L (cord blood) to
88 nmol/L (in the group receiving the lowest dose) after vitamin D3 supplementation in infants, but
vitamin D3 doses of 10 lg/day or higher did not result in differences in BMD.
In a double-blind randomised trial in Canada, 132 (mostly breast-fed) infants aged ≤ 1 month
received, for 11 months, vitamin D3 supplementation at either 10, 20, 30 or 40 lg/day (two of these
doses being higher than the UL for infants, i.e. higher than 25 lg/day) (Gallo et al., 2013). The
primary outcome was to achieve a plasma 25(OH)D concentration of 75 nmol/L or greater in 97.5% of
infants at 3 months. Whole body and regional BMC were included among the secondary outcomes and
monitored at baseline, 3, 6, 9 and 12 months of age. Mean plasma 25(OH)D concentration was
59 nmol/L (95% CI, 55–63 nmol/L) across all groups at baseline and peaked in all groups at 3 months
(at 78 and 102 nmol/L in the two groups with the lowest dose). While authors reported a
dose–response relationship for vitamin D dosage and plasma 25(OH)D concentration, no such
relationship was observed between vitamin D dosage and BMC (lumbar spine, femur, whole body) or
BMD (lumbar spine) over time. The Panel notes that, in this study, mean plasma 25(OH)D
concentration rose from 59 nmol/L to at least 78 nmol/L (at 3 months) after vitamin D3
supplementation, but vitamin D3 doses of 10 or 20 lg/day or higher did not result in differences in
BMC/BMD over 1 year.
In a double-blind RCT (Molgaard et al., 2010), 225 Danish girls (221 completers) aged 11–12 years
were randomised to vitamin D3 (5 or 10 lg/day) or placebo over 1 year with the same study design as
in Viljakainen et al. (2006a) in Finnish girls (included in the review by the IOM). However, Molgaard
et al. (2010) recruited the subjects during all seasons, whereas Viljakainen et al. (2006a) recruited
between October and March. Whole-body and lumbar spine BMC, bone area (BA) and BMD were
measured by DXA at baseline and after 12 months. Mean serum 25(OH)D (about 42–44 nmol/L) or
bone measures did not differ between groups at baseline. Adjusting for baseline values, the 12-month
mean change in serum 25(OH)D concentration was signiﬁcantly different between groups
(p < 0.0001), the ﬁnal concentration being 39.7 nmol/L (3.1 nmol/L from baseline) in the placebo
group and 52.9 and 57.9 nmol/L (+11 and +13.3 nmol/L from baseline) in the 5 lg and 10 lg groups,
respectively. The intervention had no effect on total body and lumbar spine BMC, BMD or BA in the
whole population compared with placebo, except for the lumbar spine BA (p = 0.039, with the lowest
increase in the group supplemented with 10 lg/day). The Panel notes that, in this RCT in
prepubertal and pubertal girls, raising mean serum 25(OH)D concentration from 42–44 nmol/L to
53–58 nmol/L by two daily vitamin D3 supplementation (compared with placebo) did not result in
changes in BMD or BMC after 1 year.
Prospective observational study
In a UK prospective cohort study in Caucasian children (n = 2,247 in fully adjusted analyses), Sayers
et al. (2012) investigated the relationship between plasma 25(OH)D2 or 25(OH)D3 concentrations and a
number of pQCT measures (cortical BA, cortical BMC, cortical BMD, periosteal circumference, endosteal
circumference and cortical thickness) (Appendix A) of the mid-tibia at age 15.5 years. Plasma 25(OH)D
concentrations from samples collected at the age of 9.9 years were considered in the analysis, or at
the age of 11.8 or 7.6 years if measurement at age 9.9 years was not available. Mean baseline plasma
25(OH)D3 concentration was about 57–60 nmol/L in boys and girls, and mean 25(OH)D2 concentration
was about 4.5 nmol/L in both genders. Plasma 25(OH)D3 concentration at baseline was signiﬁcantly
associated (negatively) with endosteal circumference (adjusted for periosteal circumference) and was
signiﬁcantly associated (positively) with cortical BMC, cortical BA or cortical thickness, after adjustment
for potential confounders. The Panel notes that in this study in children with a mean baseline plasma
25(OH)D3 concentration of about 57–60 nmol/L, plasma 25(OH)D3 concentration was signiﬁcantly
associated with several bone measures.
Conclusions on BMC/BMD in infants/children
In infants, the Panel found three recent trials on BMD or BMC in (mostly) breastfed infants, two of
short duration (3 months of less) (Abrams et al., 2012; Holmlund-Suila et al., 2012) and one of
11 months (Gallo et al., 2013). One trial did not show any relationship between baseline or change in
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mean 25(OH)D concentration (from 42–58 nmol/L (cord) up to 78–94 nmol/L) after vitamin D
supplementation and BMC at 3 months (Abrams et al., 2012). After different daily doses of vitamin D
supplementation, the two others did not show that increasing mean serum 25(OH)D concentrations
from about 53 nmol/L (cord) (Holmlund-Suila et al., 2012) or 59 nmol/L (≤ 1 month) (Gallo et al.,
2013), up to means at 3 months of at least 88 nmol/L or at least 78 nmol/L, respectively, resulted in
differences in BMD/BMC (at age 3 (Holmlund-Suila et al., 2012) or 12 (Gallo et al., 2013) months).
For children, the only RCT, undertaken in prepubertal and pubertal girls, showed that raising mean
serum 25(OH)D concentration from 42–44 nmol/L to 53–58 nmol/L by two daily doses of vitamin D3
supplementation (compared with placebo) did not result in changes in BMD or BMC after 1 year
(Molgaard et al., 2010). In one prospective cohort study in children with a mean baseline plasma 25
(OH)D3 concentration of about 57–60 nmol/L, plasma 25(OH)D3 concentration was signiﬁcantly
associated with several bone measures (Sayers et al., 2012).
The Panel takes into account the conclusions by IOM on the relationship between serum 25(OH)D
concentrations and BMC/BMD in infants (inconsistent results) and children (evidence for a positive
association), and the studies published thereafter. Overall, the Panel considers that there is some
evidence that, in infants and children, increasing mean serum 25(OH)D from about 40–60 nmol/L to
higher values is not associated with further beneﬁt on BMC/BMD.
5.1.2.2.2. Rickets
IOM (2011) (Section 4 and Appendix B) considered, that in the presence of an adequate calcium
intake, there was evidence for an association between low mean serum 25(OH)D concentration
(< 30 nmol/L) and conﬁrmed rickets (Section 2.2.2.1) and that the risk of rickets was ‘minimal when
serum 25(OH)D levels range between 30 and 50 nmol/L’.
Based on Cranney et al. (2007), Lamberg-Allardt et al. (2013) concluded that there was an
increased risk of rickets below a serum 25(OH)D concentration of 27.5 nmol/L, i.e. about 30 nmol/L.
No new data on rickets were identiﬁed by Newberry et al. (2014). SACN (2016) concluded that the
evidence from a total of 44 studies (including several case reports that is not a type of study
considered by the Panel for this Section), on vitamin D and rickets is mainly observational and
therefore subject to confounding. SACN (2016) notes that most studies did not report on calcium
intake, thus it was unclear if rickets was caused by vitamin D deﬁciency or by low calcium intake or
both, and that most studies did not provide information on the time of year in which the blood sample
was drawn. SACN (2016) reported that serum 25(OH)D concentration in case reports ranged from
< 2.5 to < 50 nmol/L and that mean/median concentrations ranged between 5 and 50 nmol/L in other
study types in patients. Individual and mean serum 25(OH)D concentrations were < 25 nmol/L in the
majority of studies examined.
The Panel did not ﬁnd any relevant primary study on serum 25(OH)D and the risk of rickets in
infants and children, providing information on their calcium intake and published after the IOM report.
The Panel takes into account the conclusions by IOM (2011) and Lamberg-Allardt et al. (2013)
on evidence of overt rickets at mean serum 25(OH)D concentrations below 30 nmol/L with adequate
calcium intake. Based on conclusions by IOM that the risk of rickets was minimal when serum 25(OH)D
concentration ranges between 30 and 50 nmol/L, the Panel concludes that there is no risk of
vitamin D-deﬁciency rickets with serum 25(OH)D concentrations at or above 50 nmol/L and
adequate calcium intake.
5.1.2.2.3. Calcium absorption
IOM (2011) reviewed together data on calcium absorption in adults or children (Sections 4 and
5.1.2.1.6, Appendix B). The IOM concluded that, in life stages of bone accretion, maximal calcium
absorption is associated with serum 25(OH)D concentrations of at least 30 nmol/L, and closer to 40–
50 nmol/L, and that fractional calcium absorption does not appear to increase with serum 25(OH)D
concentration above 50 nmol/L. The Panel notes that the IOM included the study by Abrams et al.
(2009), which pooled studies in 251 children (about 5–17 years) using the dual isotope technique. This
study found that, when serum 25(OH)D concentration was studied as a categorical variable in the
whole population, fractional calcium absorption adjusted (in particular) for calcium intake was slightly
but signiﬁcantly higher at serum 25(OH)D concentration of 28–50 nmol/L (0.344  0.019), compared
with concentrations of 50–80 nmol/L (0.280  0.014, p < 0.001) or greater than 80 nmol/L
(0.297  0.015, p < 0.007). Calcium absorption was not considered ‘as such’ by Lamberg-Allardt et al.
(2013), Newberry et al. (2014) or SACN (2016). However, SACN (2016) considered the trial by Park
et al. (2010) on fractional calcium absorption (described below).
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 51 EFSA Journal 2016;14(10):4547
The Panel identiﬁed one additional RCT (Abrams et al., 2013) using the dual-stable isotope
technique for measuring fractional calcium absorption. As for studies on calcium absorption in adults
(Section 5.1.2.1.6), the Panel also described two studies (Park et al., 2010; Lewis et al., 2013) using
the single isotope technique (considered as supportive evidence by the Panel).
With regard to results obtained with the dual isotope technique, in an 8-week RCT in
63 prepubertal children aged 4–8.9 years consuming 600 to 1,200 mg/day calcium at baseline and
who received 25 lg/day vitamin D3 or a placebo (Abrams et al., 2013), mean 25(OH)D concentration
was about 70 nmol/L in both groups at baseline and was signiﬁcantly lower (mean  SD:
75  12 nmol/L) in the placebo than in the supplemented group (90  6 nmol/L) (p = 0.01) at the
end of the study period. No signiﬁcant difference in fractional calcium absorption was measured at
baseline and at the end of the study between the placebo group and the vitamin D3 supplemented
group. The Panel notes that, in this study, increasing mean serum 25(OH)D from 70 to 90 nmol/L by
vitamin D supplementation (compared with placebo) did not result in any difference in fractional
calcium absorption.
With regard to results obtained with the single isotope technique, Park et al. (2010) used
a two-period metabolic balance study to investigate the effect of vitamin D supplementation on
calcium absorption and retention in 11 adolescent girls aged 12–14 years with a mean baseline serum
25(OH)D concentration of 35.1 nmol/L. Subjects consumed a controlled intake (providing 5 lg vitamin
D and 1,117 mg calcium/day) for two 3-week metabolic balance periods separated by a 1-week
washout period. After the ﬁrst metabolic balance period, participants received 25 lg/day vitamin D3
supplementation for 4 weeks. Fractional calcium absorption was measured in each metabolic balance
period using a stable calcium isotope method. All urine and faecal samples were collected and
analysed to measure net calcium absorption and calcium retention. Daily supplementation with 25 lg
vitamin D resulted in a mean increase in serum 25(OH)D of 13.3 nmol/L (p < 0.01) but a decrease in
fractional calcium absorption of 8.3% (p < 0.05) and no signiﬁcant change in fasting serum 1,25
(OH)2D, PTH, net calcium absorption, or calcium skeletal retention. The Panel notes that, in this
study in pubertal girls, increasing mean serum 25(OH)D from 35.1 nmol/L to 48.4 nmol/L did not
improve fractional or net calcium absorption.
In a 12-week double-blind RCT in children aged 9–13 years (165 African American and
158 Caucasian) with a mean baseline calcium intake of about 900 mg/day, Lewis et al. (2013)
evaluated the effects of daily vitamin D3 supplementation (10 lg, 25 lg, 50 lg, 100 lg) or placebo on
25(OH)D concentration and other parameters including fractional calcium absorption. Compared with a
mean baseline 25(OH)D concentration of 70 nmol/L in the whole population, the mean change in 25
(OH)D was 10 nmol/L for the placebo group, and ranged from +5.5 nmol/L to +76.1 nmol/L in the
supplemented groups. In the whole population, 25(OH)D concentration at baseline or after 12 weeks
was not related to changes in fractional calcium absorption, even after adjustment for potential
confounders. There was no effect of vitamin D3 supplementation on change in fractional calcium
absorption. The Panel notes that, in this study, 25(OH)D concentration at baseline (mean: 70 nmol/L)
or after 12 weeks of vitamin D supplementations compared with placebo was not related to changes in
fractional calcium absorption.
Conclusions on calcium absorption in children
The Panel notes that few data are available on the relationship between serum 25(OH)D
concentration and fractional calcium absorption in children.
The Panel notes that the dual isotope study by Abrams et al. (2009), included in the review by the
IOM, showed that fractional calcium absorption was slightly but signiﬁcantly higher at serum 25(OH)D
concentration of 28–50 nmol/L (0.344  0.019), compared with concentrations of 50–80 nmol/L
(0.280  0.014, p < 0.001) or greater than 80 nmol/L (0.297  0.015, p < 0.007), among children of
5–17 years of age. The Panel also took into account a metabolic balance study in adolescent girls
(Park et al., 2010) showing that increasing mean serum 25(OH)D from 35 nmol/L to 48 nmol/L did not
improve fractional or net calcium absorption. In addition, the Panel notes that the two recent RCTs
using the dual isotope technique (Abrams et al., 2013) or the single isotope technique (Lewis et al.,
2013) in children with relatively high baseline serum 25(OH)D concentrations (mean about 70 nmol/L)
did not ﬁnd any relationship between fractional calcium absorption and serum 25(OH)D concentration
(or any threshold value for this concentration).
Overall, based on these studies, the Panel considers that there is no relationship between fractional
calcium absorption in children and serum 25(OH)D concentration above about 30–50 nmol/L.
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5.1.2.2.4. Summary of conclusions on serum 25(OH)D concentration as an indicator of
musculoskeletal health in infants and children
The Panel notes the paucity of data on serum 25(OH)D concentrations and musculoskeletal health
outcomes in infants and children.
In spite of the large variation in the results from different laboratories and assays used for
measuring serum 25(OH)D concentrations (Section 2.4.1), the Panel concludes that, regarding the
relationship between serum 25(OH)D concentration and
• BMD/BMC in infants and children, there is some evidence that increasing mean serum 25(OH)D
from about 40–60 nmol/L to higher values is not associated with further beneﬁt on BMC/BMD,
• rickets, there is evidence of overt rickets at mean serum 25(OH)D concentrations below
30 nmol/L with adequate calcium intake, but no risk of vitamin D-deﬁciency rickets with serum
25(OH)D concentrations at or above 50 nmol/L and adequate calcium intake,
• calcium absorption, there is no relationship between fractional calcium absorption in children
and serum 25(OH)D concentration above about 30–50 nmol/L.
The Panel considers that the evidence on associations between serum 25(OH)D and
musculoskeletal health outcomes is not adequate to set a different target value for serum 25(OH)D
concentration in children compared to adults.
5.1.3. Serum 25(OH)D concentration and health outcomes in pregnancy
IOM (2011) (Section 4 and Appendix B) considered the following outcomes for pregnancy:
calcium absorption, maternal/fetal/neonatal/childhood bone health and related outcomes (e.g. PTH),
neonatal rickets, and maternal blood 25(OH)D. Separately, the IOM also considered pre-eclampsia (i.e.
hypertension with proteinuria) and pregnancy-induced hypertension (i.e. transient hypertension
without proteinuria). IOM (2011) concluded that calcium absorption, maternal bone health, neonatal
rickets, risk of pre-eclampsia or pregnancy-induced hypertension, or non-skeletal (maternal or infant)
outcomes could not be used to set DRVs for vitamin D for pregnant women. IOM concluded that fetal
and childhood bone-related health outcomes were informative for the development of reference values
for vitamin D in pregnancy, which in the end did not differ from that for non-pregnant women.
Newberry et al. (2014) identiﬁed one article in relation to pre-eclampsia that reported on two
combined RCTs assessing the effect of supplemental vitamin D (Wagner et al., 2013b). They also refer
to ﬁve nested case–control studies (Baker et al., 2010; Powe et al., 2010; Shand et al., 2010; Woodham
et al., 2011; Wei et al., 2012) and two prospective cohort studies (Scholl et al., 2013; Wei et al., 2013).
Newberry et al. (2014) noted that some recent studies suggest a possible relationship between vitamin
D supplementation or status and the risk of preeclampsia. Newberry et al. (2014) identiﬁed two cohort
studies (Bodnar et al., 2010; Burris et al., 2012) published after the report by IOM, that assessed the
association between maternal serum 25(OH)D concentrations and the risk of giving birth to a small-for-
gestational-age (SGA) infant (Bodnar et al. (2010) being already included in the IOM report). Newberry
et al. (2014) also identiﬁed one nested case–control study and one prospective cohort study that
assessed the association with preterm birth (Baker et al., 2011; Bodnar et al., 2013), of which one
study was conducted in pregnant women expecting twins (Bodnar et al., 2013).
SACN (2016) identiﬁed one cohort study (Haliloglu et al., 2011) on a marker of bone turnover in
pregnancy and post partum and ﬁve cohort studies (Prentice et al., 2009; Mahon et al., 2010;
Viljakainen et al., 2010; Dror et al., 2012; Young et al., 2012) (some of them included in the IOM
report, and some of them using predetermined cut-offs for serum 25(OH)D)). SACN (2016) reported
that four of the cohort studies showed a positive association between maternal serum 25(OH)D
concentration and various ‘indices of bone health’ in the fetus (Mahon et al., 2010; Young et al., 2012)
or newborn (tibia BMC and cross-sectional area (CSA) (Viljakainen et al., 2010), or cord serum bone
speciﬁc ALP and cord serum 25(OH)D (Dror et al., 2012)). SACN (2016) also reported on one
multicentre double-blind randomised placebo controlled trial (Cooper et al., 2016) on maternal vitamin
D3 supplementation during pregnancy and neonatal whole body BMC (EFSA, 2016) (Section 5.2.6).
SACN (2016) also considered maternal serum 25(OH)D concentration in relation to non-skeletal
outcomes in the mother as well as in the newborn (risk of pre-eclampsia, neonatal hypocalcaemia,
birth weight and length, risk of SGA, cognitive and psychological development in the offspring, growth
and respiratory disease in the offspring). In particular, SACN (2016) considered evidence from a
systematic review (Harvey et al., 2014), which reported that the association between maternal serum
25(OH)D concentration during pregnancy and pre-eclampsia and gestational diabetes is inconsistent.
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The Panel undertook a literature search and also reviewed recent primary studies identiﬁed in two
systematic reviews of intervention and observational studies (Harvey et al., 2014; Newberry et al.,
2014). As for men and non-pregnant women and children, markers of bone formation and turnover
(e.g. Haliloglu et al., 2011; Dror et al., 2012) were not an outcome considered by the Panel in view of
setting DRVs for vitamin D (Section 5.1.1).
Regarding the review health outcomes in pregnancy,with the aim of setting DRVs for vitamin D:
• The Panel considered available primary studies (RCTs and prospective observational studies)
on serum 25(OH)D during pregnancy and maternal outcomes (bone health, for which no
new data were found, pre-eclampsia or pregnancy-induced hypertension). The Panel also
considered the relationship between serum 25(OH)D during pregnancy and the following
outcomes in the newborn or child (but not in the fetus): bone health at birth,
gestational length, anthropometry at birth in relation to the risk of SGA infant, risk of preterm
birth, bone health/anthropometry/body composition after about the ﬁrst year of life.
• In addition, the Panel did not consider studies providing risk estimates in speciﬁc
populations like women with type 1 diabetes (Azar et al., 2011), patients already with
pre-eclampsia or women all recruited for being at high risk of pre-eclampsia (Shand et al.,
2010; Robinson et al., 2011), or studies with supplementation of other nutrients besides
vitamin D but without measurement of 25(OH)D concentration (Watson and McDonald, 2010).
In addition, the Panel did not consider data on adolescent or twin pregnancies (Bodnar et al.,
2013). The Panel also did not consider further investigations (Woodham et al., 2011; Wei
et al., 2013) of studies described below, as these further investigations dealt with the
combined association of angiogenesis and endothelial dysfunction indicators, in addition to
serum 25(OH)D concentration, with the risk of preeclampsia.
The Panel identiﬁed a total of 12 references on maternal 25(OH)D concentration and: risk of
pre-eclampsia, risk of being born SGA, risk of preterm birth, and bone health of the offspring.
Some studies identiﬁed considered several of these outcomes. In the following section, for each of
these outcomes (Sections 5.1.3.1–5.1.3.4), the studies are described individually below; the results are
then summarised, and a conclusion on maternal 25(OH)D concentration and the considered outcome is
proposed. Finally, an overall conclusion for health outcomes in pregnancy is provided (Section 5.1.3.5).
5.1.3.1. Risk of pre-eclampsia
The Panel identiﬁed only two intervention studies with vitamin D during pregnancy and several
outcomes including birth weight and the risk of preterm birth or pre-eclampsia, reported in one
reference (Wagner et al., 2013b). The other six pertinent references on the risk of pre-eclampsia
identiﬁed were observational studies and are described afterwards.
RCTs with vitamin D supplementation
Wagner et al. (2013b) combined data sets from two double-blind RCTs (Hollis et al., 2011; Wagner
et al., 2013a) on healthy women (total n = 504, age ≥ 16 years) at 12 to 16 weeks of pregnancy and
followed until delivery. All subjects received a prenatal 10 lg/day vitamin D3 supplement, and were
randomised to receive either a placebo, or daily doses of vitamin D3 supplements (to reach a total
intake of 50 or 100 lg/day). Serum 25(OH)D concentrations were not signiﬁcantly different between
groups (means between 57 and 65 nmol/L) at baseline (during pregnancy), but were higher in the
supplemented groups compared to control in maternal blood within 6 weeks of delivery or in neonatal/
cord blood, after adjustments for potential confounders. Four main Comorbidities Of Pregnancy
(COPs), including pre-eclampsia and related hypertensive disorders as well as preterm birth without
pre-eclampsia, were investigated as secondary outcomes. The study showed that the OR of any COP
per 25 nmol/L increment of ﬁnal maternal 25(OH)D concentration did not reach statistical signiﬁcance
(but the risk was signiﬁcantly reduced when all COPs were considered together). Neonatal birth weight
did not signiﬁcantly differ between supplemented groups and controls. The Panel notes that there
was no effect of daily supplementation with vitamin D3 during pregnancy on neonatal birth weight,
and risk of pre-eclampsia or preterm birth in this population with mean serum 25(OH)D concentrations
of 57–65 nmol/L at baseline.
Prospective observational studies
In the following observational studies, pre-eclampsia was deﬁned as the occurrence of gestational
hypertension in previously normotensive women accompanied by new-onset proteinuria after 20 weeks
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of gestation. Deﬁnition of pre-eclampsia based on values of systolic and/or diastolic blood pressure and
proteinuria, although close, differed between studies, and severe pre-eclampsia was deﬁned based on
higher values of systolic blood pressure/diastolic blood pressure or proteinuria.
In a nested case–control study in the USA, Powe et al. (2010) assessed the association between
ﬁrst trimester total serum 25(OH)D concentrations and development of pre-eclampsia in 39 cases (with
a signiﬁcantly higher ﬁrst trimester systolic and diastolic blood pressure), and 131 normotensive
control women (who remained normotensive in pregnancy, did not have gestational diabetes mellitus
or did not give birth to SGA infants). Baseline serum 25(OH)D concentrations did not differ signiﬁcantly
between cases and controls (mean about 68 and 72 nmol/L, respectively, measured at (mean  SD)
11.2  3.6 versus 11.6  3.0 weeks of gestation) and were not associated with baseline systolic or
diastolic blood pressure. No association was found between ﬁrst trimester serum 25(OH)D
concentration (per 25 nmol/L increase, across quartiles, or for those < or > 37.5 nmol/L) and risk of
subsequent pre-eclampsia, after full adjustments for potential confounders. The Panel notes that this
study did not report an association between serum 25(OH)D concentration during the ﬁrst trimester of
pregnancy and incidence of pre-eclampsia.
One nested case–control study by Baker et al. (2010) was conducted in the USA in a population
selected from a cohort of 3,992 healthy women, who had previously given blood in the framework of
routine prenatal care. The study analysed maternal 25(OH)D status during mid-gestation (15–20 weeks
of gestation) and risk of development of severe pre-eclampsia. From the cohort, a case group of
51 women was identiﬁed who developed severe pre-eclampsia (median age 28 years), out of which
41 women were included in the analysis. The control group was composed of 198 randomly selected
ethnicity-matched healthy women delivering at term. Median serum 25(OH)D concentration in the case
group was 75 nmol/L, which was signiﬁcantly lower than that in the control group, i.e. 98 nmol/L.
After adjustment for potential confounders, the risk of severe pre-eclampsia in women with
mid-gestation 25(OH)D concentration of less than 50 nmol/L (n = 19 controls and 11 women with
severe pre-eclampsia) was ﬁvefold higher (OR: 5.41; 95% CI: 2.02–14.52) than in women with mid-
gestation 25(OH)D of at least 75 nmol/L (n = 138 controls and 22 women with severe pre-eclampsia).
There was no signiﬁcant difference in risk in women with 25(OH)D between 50 and 74.9 nmol/L
(n = 41 controls, and 10 with severe pre-eclampsia) compared with 25(OH)D of at least 75 nmol/L.
The Panel notes that this study found that the risk for severe pre-eclampsia was higher in women
with a 25(OH)D concentration at 15–20 weeks of gestation less than 50 nmol/L in comparison to those
with concentrations higher than 75 nmol/L.
In a case–control study in the USA, Robinson et al. (2010) investigated maternal plasma 25(OH)D
concentration in 50 women with diagnosed early onset severe pre-eclampsia (EOSP, diagnosed before
34 weeks of gestation) compared to 100 ethnicity- and gestational age-matched healthy controls
followed throughout their normal singleton pregnancy. Plasma 25(OH)D concentration (median,
interquartile range (IQR)), was obtained in the cases at time of diagnosis (45, 32.5–77.5 nmol/L) and was
signiﬁcantly lower than in controls (80, 50–110 nmol/L; p < 0.001), both at a mean gestational age of
29 weeks (28–31 weeks in cases, 26–31 weeks in controls). Birth weight and gestational age at delivery
were signiﬁcantly lower in cases than in controls, while mean arterial pressure at sample collection and
incidence of intrauterine growth restriction (i.e. less than 10th percentile birth weight for gestational age)
were signiﬁcantly higher. After adjustment for potential confounders, there was a signiﬁcant association
between a 25 nmol/L increase in maternal plasma 25(OH)D and a reduced risk of EOSP (OR: 0.37;
95% CI: 0.22–0.62, p < 0.001). Women with plasma 25(OH)D concentration ≤ 49 nmol/L (lowest
quartile) had a 3.6-fold increased risk of EOSP compared to women with higher concentrations (OR: 3.60;
95% CI: 1.71–7.58, p < 0.001). The Panel notes that this study indicates that the risk for EOSP was 3.6
times higher in women with a plasma 25(OH)D concentration less than 50 nmol/L at about 34 weeks of
gestation in comparison with women with higher plasma 25(OH)D concentrations.
In a Spanish prospective cohort study in unsupplemented women followed from pregnancy to
delivery (n = 466 at delivery), Fernandez-Alonso et al. (2012) investigated the relationship between
ﬁrst-trimester serum 25(OH)D concentration and obstetric and neonatal pregnancy outcomes. These
included pre-eclampsia, gestational hypertension, preterm birth (i.e. birth at 21–37 weeks of
pregnancy), and number of SGA infants (i.e. with birth weights below the 10th percentile for
gestational age). Serum 25(OH)D concentration at 11–14 weeks of pregnancy was below 50 nmol/L,
between 50 and 74 nmol/L or at least 75 nmol/L for, respectively, 109, 191 and 166 women. No
signiﬁcant non-parametric correlations were found between the ﬁrst-trimester 25(OH)D levels and
several numeric obstetric or neonatal outcome variables. The Panel notes that this study only
assessed correlations between 25(OH)D concentrations and obstetric or neonatal outcomes.
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In post-hoc analyses on a group of 697 Canadian women, who had previously participated during
pregnancy in a multicentre trial of vitamin C and E supplementation and prevention of pre-eclampsia,
Wei et al. (2012) measured plasma 25(OH)D concentration in maternal blood samples collected during
that previous trial at visit 1 (baseline, 12–18 weeks of gestation) and visit 2 (24–26 weeks of
gestation). The purpose of these new analyses was to investigate the association between maternal 25
(OH)D concentrations and risk of pre-eclampsia. In the previous trial, the subjects had been stratiﬁed
in the ‘high-risk’ group (n = 229, with at least one of four risk factors for pre-eclampsia identiﬁed by
the authors) or in the ‘low-risk’ group (n = 468, women who had been nulliparous without risk factors
for pre-eclampsia). The difference between maternal mean 25(OH)D concentrations in pre-eclamptic
(n = 32) and non-pre-eclamptic (n = 665) women was not statistically signiﬁcant at visit 1 (about
51–56.0 nmol/L), but signiﬁcant at visit 2 (mean  SD: 48.9  16.8 nmol/L versus 57.0  19.1 nmol/L,
p = 0.03), in particular in the low-risk group. After adjustments for potential confounders (including
the risk group), the risk of pre-eclampsia associated with maternal 25(OH)D < 50 nmol/L at
24–26 weeks of gestation (n = 236, including 19 pre-eclamptic) was 3.2-fold higher (OR: 3.24; 95%
CI: 1.37–7.69) compared with maternal 25(OH)D ≥ 50 nmol/L (n = 368, 9 pre-eclamptic). This
relationship was not observed for maternal 25(OH)D < 50 nmol/L (n = 272, 15 pre-eclamptic) or
≥ 50 nmol/L (n = 425, 17 pre-eclamptic) earlier in pregnancy, i.e. at 12–18 weeks of gestation. The
Panel notes that according to these study ﬁndings, the risk of pre-eclampsia associated with
maternal 25(OH)D concentration < 50 nmol/L at 24–26 weeks of gestation (but not at 12–18 weeks)
was signiﬁcantly higher compared with maternal 25(OH)D ≥ 50 nmol/L.
In a prospective cohort study on 1,141 US healthy pregnant women (mainly Hispanic and African
American), Scholl et al. (2013) analysed the association of serum 25(OH)D concentration < 50 nmol/L
(with or without PTH > 6.82 pmol/L) and the risk of pre-eclampsia. Maternal serum 25(OH)D
concentration was measured at (mean  SD) 13.7  5.7 weeks of gestation, as 25(OH)D3 and 25(OH)
D2, but mean baseline value was not reported. About 6% of women developed pre-eclampsia. After
adjustment for potential confounders, and compared with women with 25(OH)D concentration of at
least 50 nmol/L (n = 750), the risk of pre-eclampsia was signiﬁcantly twofold higher in pregnant women
with concentrations lower than 30 nmol/L or between 30 and 39 nmol/L (n = 121 and 116,
respectively, e.g. adjusted OR for 25(OH)D < 30 nmol/L: 2.13; 95% CI: 1.07–4.26, p for trend = 0.027)
(but the risk was not signiﬁcantly reduced in the 154 women with 25(OH)D of 40–50 nmol/L). Women
with secondary hyperparathyroidism (n = 72, PTH > 6.82 pmol/L and serum 25(OH)D < 50 nmol/L) had
a 2.8-fold increase in risk (95% CI: 1.28–6.41) compared to women with similar 25(OH)D concentration
without ‘high’ PTH. The Panel notes that, according to this cohort study in mainly Hispanic and
African American women, the risk of pre-eclampsia was about twofold higher when the 25(OH)D
concentration of the mother at 13.7  5.7 weeks of gestation was < 40 nmol/L compared to those with
a concentration ≥ 50 nmol/L.
Conclusions on risk of pre-eclampsia
The Panel notes that an increase in serum 25(OH)D concentration from a mean baseline of
57–65 nmol/L (after vitamin D supplementation in the second trimester of pregnancy compared with
placebo) did not result in a change in the risk of pre-eclampsia (Wagner et al., 2013b). Out of six
observational studies, two (Powe et al., 2010; Fernandez-Alonso et al., 2012) found no association
between serum 25(OH)D during pregnancy (at time points of about 11–14 weeks of gestation), and
risk of pre-eclampsia. In these two studies, investigated (predeﬁned) cut-offs for 25(OH)D were < 37.5
and 50 nmol/L (versus > 37.5 or > 75 nmol/L). In contrast, four observational studies (Baker et al.,
2010; Robinson et al., 2010; Wei et al., 2012; Scholl et al., 2013) found a signiﬁcant association
between low maternal serum 25(OH)D concentration (measured between about 13 to 31 weeks of
gestation) and risk of pre-eclampsia or severe pre-eclampsia. In these studies, the investigated
cut-offs, often predeﬁned, were < 30 nmol/L, 30–39 nmol/L or < 50 nmol/L, compared most often
with > 50 nmol/L (or ≥ 75 nmol/L). Overall, the Panel considers that the evidence of an
association between maternal serum 25(OH)D concentration and risk of pre-eclampsia is inconsistent,
although there is some evidence suggestive of an increase in the risk of pre-eclampsia at 25(OH)D
concentrations below about 50 nmol/L.
5.1.3.2. Risk of being born small-for-gestational-age
With regard to the risk of being born SGA, the Panel considered four observational studies,
including the study by Fernandez-Alonso et al. (2012) mentioned above.
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Prospective observational studies
In a prospective population-based cohort study on healthy Danish Caucasian women (Moller et al.,
2012), the association between preconception 25(OH)D concentration and several outcomes was
investigated. Outcomes included incidence of miscarriage and birth outcomes, i.e. birth weight and
length, head circumference, number of SGA infants, in 153 women with immediate pregnancy plans
(whose vitamin D status was compared to 75 women (50 completers) who had no pregnancy plans for
the next 21 months as age-matched controls). Plasma 25(OH)D concentration was measured in both
groups on four occasions (at baseline, and once at each of the follow-up visits every trimester).
Median (IQR) baseline plasma 25(OH)D concentration (70 (56–92) nmol/L) was signiﬁcantly
(p < 0.001) higher in the control group compared to women with pregnancy plans (59 (46–71) nmol/L).
Baseline mean plasma 25(OH)D concentrations did not differ between those who experienced
miscarriage (n = 8, out of 92 who conceived) and those who did not. Plasma 25(OH)D concentration
(at baseline, at each visit, or on average during pregnancy) was not associated with gestational length,
birth weight, birth length, head circumference, incidence of SGA infants, even after adjustments for
potential confounders. The Panel notes that this study, in a population with baseline median plasma
25(OH)D concentration of about 50–70 nmol/L, did not ﬁnd an association between maternal 25(OH)D
concentration during pregnancy and anthropometric outcomes in the newborn or SGA incidence.
In a prospective cohort study of pregnant women in the US, Burris et al. (2012) assessed the
association between second trimester maternal plasma 25(OH)D concentration (947 Caucasians,
186 African Americans) or cord plasma 25(OH)D concentration (606 Caucasians, 128 African
Americans) and the risk of being born SGA. Women were included at less than 22 weeks of singleton
pregnancies. Mean  SD maternal and cord 25(OH)D concentrations were 60  21 (at 26–28 weeks
of gestation) and 47  19 nmol/L, respectively, and there were 53 SGA infants. After adjustments for
potential confounders, maternal or cord plasma 25(OH)D < 25 nmol/L was associated with a
signiﬁcantly increased risk of being born SGA, compared with plasma 25(OH)D of 25 nmol/L or greater.
Indeed, the adjusted OR of being born SGA was 3.17 (95% CI: 1.16–8.63) for maternal plasma
< 25 nmol/L (7 SGA infants from mothers in this category), and 4.64 (95% CI: 1.61–13.36) for cord
plasma < 25 nmol/L (9 SGA infants in this category). The Panel notes that this study in second
trimester pregnant women showed that maternal or cord plasma/serum 25(OH)D concentrations below
25 nmol/L (versus at least 25 nmol/L) were associated with increased risk of being born SGA.
In a US prospective cohort study, Gernand et al. (2013) studied 2,146 pairs of singleton term newborns
and mothers (52% Caucasian, with no pre-existing diabetes or hypertension) who had participated in a
large multicentre observational study (63% study sites at latitude ≥ 41° North). The aim of the study was to
investigate the association between maternal 25(OH)D concentration and several outcomes, including the
risk of being born SGA. Maternal serum 25(OH)D concentration was measured at 26 weeks of gestation or
less, and every 8 weeks afterwards (mean baseline: 51.3  28.0 nmol/L). There were 395 SGA infants.
After adjustments for potential confounders, the risk of being born SGA was half in infants whose
mothers had ﬁrst trimester 25(OH)D of ≥ 37.5 nmol/L, compared to < 37.5 nmol/L (OR: 0.50; 95% CI:
0.27–0.91) (11.8 and 23.8% of SGA infants from mothers in each category). This association was not
observed in the second trimester. The Panel notes that this study showed that maternal serum 25(OH)
D concentrations above 37.5 nmol/L in the ﬁrst trimester of pregnancy, but not the second trimester,
were associated with half the risk of SGA compared with serum concentrations below 37.5 nmol/L.
Conclusions on risk of being born SGA
The Panel notes that, in contrast to Fernandez-Alonso et al. (2012) and Moller et al. (2012) (which
measured frequency), two larger observational studies (Burris et al., 2012; Gernand et al., 2013) using
predeﬁned 25(OH)D cut-off values found an association of maternal 25(OH)D < 25 nmol/L (at
26–28 weeks of gestation) or < 37.5 nmol/L (in the ﬁrst trimester, but not the second) with an
increased risk of being born SGA (versus higher values). The Panel concludes that the evidence of an
association between maternal serum 25(OH)D concentration and risk of being born SGA is
inconsistent, although there is some evidence suggestive of an increase in the risk at 25(OH)D
concentrations below about 25–37.5 nmol/L.
5.1.3.3. Risk of preterm birth
With regard to the risk of preterm birth, in addition to the two intervention studies reported in one
reference (Wagner et al., 2013b) already described above (Section 5.1.3.1), the Panel identiﬁed one
nested case–control study.
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Baker et al. (2011) assessed the relationship between maternal 25(OH)D concentration during
pregnancy and the risk of preterm birth in a US nested case–control study of 4,225 women with
singleton pregnancies, from whom blood had been collected at 11–14 weeks of gestation for the
screening of trisomy 21. Preterm birth was deﬁned as spontaneous delivery between 23 and 35 weeks
of gestation. Fourty women with preterm birth were compared to ethnicity-matched randomly selected
healthy controls who delivered at term (n = 120) and gave blood at a similar gestational age. Median
(IQR) serum 25(OH)D concentration for the whole study group was 89 (73–106) nmol/L. After
adjustment for potential confounders, there was no association between maternal serum 25(OH)D
concentration (< 50 nmol/L or 50–74.9 nmol/L, compared with ≥ 75 nmol/L) and the risk of preterm
birth. The Panel notes that this study found no association between 25(OH)D concentration during
pregnancy and the risk for preterm birth in this population with high baseline median 25(OH)D value
(about 90 nmol/L).
5.1.3.4. Bone health of the offspring
With regard to bone health of the offspring, the Panel considered one observational study.
Viljakainen et al. (2011) evaluated in a Finnish prospective cohort study, whether there was a
catch-up in tibia BMC or CSA in children (n = 87) at 14 months, from a group of 125 children
previously assessed at birth (Viljakainen et al., 2010). These infants had been categorised according to
maternal vitamin D status during pregnancy (deﬁned as the mean of the ﬁrst-trimester and of the
2-day post-partum serum 25(OH)D concentrations below or above the median of 42.6 nmol/L). BMD,
BMC and CSA of the left tibia were measured in the newborns and at 14 months by pQCT
(Appendix A). Complete baseline and follow-up data were available for 29 and 26 children whose
mothers had, respectively, lower or higher vitamin D status during pregnancy. Whereas tibia BMC at
birth was signiﬁcantly higher in children whose mothers had a high (i.e. above median) vitamin D
status during pregnancy (Viljakainen et al., 2010), the mean total BMC gain over 14 months was
signiﬁcantly higher in the children whose mothers had a low vitamin D status (0.062 g/cm2, p = 0.032)
resulting in similar BMC in both groups of children at 14 months (Viljakainen et al., 2011). Although
tibia CSA at birth was signiﬁcantly larger in children whose mothers had a high vitamin D status during
pregnancy (Viljakainen et al., 2010), the differences between groups in mean CSA change over
14 months or in ﬁnal CSA at 14 months did not reach statistical signiﬁcance (Viljakainen et al., 2011).
The Panel notes that maternal 25(OH)D at or below about 43 nmol/L during pregnancy was
associated with bone outcomes in the child at birth, which did not persist at the age of about 1 year
possibly due to infant vitamin D supplementation starting at 2 weeks of age.
5.1.3.5. Summary of conclusions on serum 25(OH)D concentration and health outcomes
in pregnancy
The Panel notes that the evidence on a possible threshold value for serum 25(OH)D concentration
with regard to the risk of adverse pregnancy-related health outcomes shows a variability of results.
Several factors contribute to this (as also discussed in Sections 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.4 for
musculoskeletal health outcomes in adults) and also include the large variation in the results from
different laboratories and assays used for measuring serum 25(OH)D concentrations (Section 2.4.1).
Furthermore, observational studies often used single measurements of 25(OH)D concentration, thus
possible changes in 25(OH)D concentration throughout pregnancy were not considered in the analyses
of the relationship with health outcomes.
The Panel concludes that, regarding the relationship between maternal serum 25(OH)D
concentration and
• pre-eclampsia, there is inconsistent evidence of an association between maternal serum 25
(OH)D concentration and risk of pre-eclampsia or severe pre-eclampsia, but that there is some
evidence suggesting an increase in the risk at 25(OH)D concentrations below about 50 nmol/L.
• risk of SGA, there is inconsistent evidence of an association of maternal 25(OH)D concentration
with an increased risk of SGA, but that there is some evidence suggesting an increase in the
risk at 25(OH)D concentrations below about 25–37.5 nmol/L.
• risk of preterm birth, there is no evidence of an association.
• indicators of bone health in the child after birth, although maternal 25(OH)D at or below about
43 nmol/L during pregnancy was associated with bone outcomes in the child at birth, there is
no evidence of an association persisting at the age of about 1 year.
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5.1.4. Serum 25(OH)D concentration and health outcomes in lactation
IOM (2011) (Section 4 and Appendix B) noted that maternal serum 25(OH)D concentrations
increased after vitamin D supplementation of lactating mothers, but that this supplementation had no
signiﬁcant effect on either infant serum 25(OH)D concentrations (for supplementation below 100 lg/day)
or infant weight or height. The IOM also noted that there was a lack of association between maternal
25(OH)D concentration and maternal post partum changes in BMD, or breast milk calcium content.
The IOM considered that neither maternal BMD nor maternal or fetal serum 25(OH)D concentrations
could be used to set reference values for vitamin D during lactation.
SACN (2016) considered one review on vitamin D supplementation during lactation in relation to
breast milk vitamin D concentration and serum 25(OH)D concentration in exclusively breast-fed infants
(Thiele et al., 2013) and stated that the vitamin D concentration of breast milk increased signiﬁcantly
following supplemental vitamin D of ≥ 50 lg/day but not of 10 lg/day. SACN (2016) also discussed
data on plasma 25(OH)D concentration and vitamin D and 25(OH)D concentration in breast milk from
lactating mothers (við Streym et al., 2016).
The Panel undertook a literature search to identify primary studies (RCTs and prospective or
case–control observational studies) on the relationship between maternal serum 25(OH)D and health
outcomes of mothers during lactation, published after the evidence reviewed by IOM (2011). The
Panel also considered the systematic review by Newberry et al. (2014). In its search, as for
pregnancy-related outcomes (Section 5.1.3), the Panel did not consider data on lactating adolescent.
The Panel identiﬁed one study published in 2010 on the relationship between maternal serum 25(OH)D
and health outcomes of lactating women that is described hereafter.
Salama and El-Sakka (2010) assessed vitamin D in a cohort of 32 breastfed infants (exclusively
(n = 20) or partially) with rickets (including nine with hypocalcaemic seizures) and their lactating
mothers, in Egypt. Subjects were identiﬁed based on clinical presentation, biochemical results and
radiological ﬁndings, and serum concentrations of calcium, phosphorus, ALP, 25(OH)D and PTH were
measured (calcium intake was not reported). Neither infants or their mothers received calcium or
vitamin D supplementation and all had limited sun exposure. Infants were aged (mean  SD)
3.7  1.6 months or 12.4  4.3 months, in the groups with or without hypocalcaemic seizures,
respectively. Median (IQR) serum 25(OH)D concentration was 40 (45) nmol/L in mothers (range
10–175 nmol/L), and was 37.5 (32.5) nmol/L in infants (range 7.5–95 nmol/L), with median (IQR) of
17 (25) and 45 (25) nmol/L in the groups with or without hypocalcaemic seizures, respectively. The
correlation between serum 25(OH)D concentrations in rachitic infants and serum 25(OH)D
concentrations in their mothers (r = 0.326) was not statistically signiﬁcant. The Panel notes that this
study found no signiﬁcant association between serum 25(OH)D concentrations in infants with rickets
and in their lactating mothers.
Conclusions on serum 25(OH)D concentration and health outcomes in lactation
The Panel notes that the only recent study identiﬁed by the Panel found no signiﬁcant association
between serum 25(OH)D concentrations in infants with rickets and serum 25(OH)D concentrations in
their mothers. Data on the low concentration of vitamin D in breast milk, and on vitamin D intake and
status of lactating women were discussed by the Panel previously (Section 2.3.7.2).
The Panel concludes that there is no evidence for a relationship between serum 25(OH)D
concentration and health outcomes of lactating women that may be used to set a DRV for vitamin D.
5.1.5. Serum 25(OH)D concentration and non-musculoskeletal health outcomes
For non-musculoskeletal health outcomes, as indicated in Section 5.1.1, the Panel considered the
evidence collated in and conclusions of the report by IOM (2011), the systematic review by Newberry
et al. (2014) and the report by SACN (2016). The Panel’s main objective in this section was to
investigate whether data on serum 25(OH)D concentration and non-musculoskeletal health outcomes
may be used to set a target value for serum 25(OH)D in order to derive DRVs for vitamin D. As the
three reports the Panel considered may have had different objectives (e.g. without always drawing
separate conclusions for vitamin D intake and vitamin D status), the overall conclusions of these
reports with regard to the relationship between vitamin D intake (either alone or with calcium) or
status (i.e. serum 25(OH)D concentration) and several health outcomes are brieﬂy summarised below.
The three reports covered often the same health outcomes (cancer, cardiovascular diseases (CVD),
markers of immune function, function of the nervous system and risk of related disorders, non-skeletal
obstetric outcomes), with some exceptions. For example, all-cause mortality and pancreatic cancer
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were covered by Newberry et al. (2014) and not by IOM (2011). Type 2 diabetes and metabolic
syndrome, functions of the nervous system and risk of related disorders (e.g. cognition, mood,
depression, autism) and non-skeletal obstetric outcomes were covered by IOM (2011) (Appendix B)
and not by Newberry et al. (2014). Other cancers (such as oesophagus, stomach, larynx, oropharynx,
lung, endometrium, ovary, kidney, non-Hodgkin, liver, bladder, melanoma and basal cell skin cancer),
maternal serum 25(OH)D concentration in pregnancy and later cognitive and psychological
development of the offspring, neonatal hypocalcaemia, oral health and age-related macular
degeneration (AMD) were only covered by SACN (2016).
According to these reports, there is no or an inconsistent relationship between vitamin D intake
(with or without calcium) or status and all-cause mortality or total cancer risk and mortality, although
SACN (2016) reported conclusion from a systematic review that vitamin D supplementation in
combination with calcium reduces mortality risk and that this is not seen with vitamin D
supplementation alone. Most of the evidence on breast cancer, colorectal cancer and prostate cancer,
was of observational nature and was considered of limited value or inconsistent or insufﬁcient to
conclude on a dose–response relationship. However, Newberry et al. (2014) concluded that the only
observational evidence identiﬁed in their update for pancreatic cancer found an increase in the risk
with increased serum 25(OH)D concentration.
For total CVD/cardiovascular events and hypertension, IOM (2011), Newberry et al. (2014) and
SACN (2016) concluded that no or an inconsistent relationship was found between vitamin D intake
(with or without calcium) or status and the risk of these outcomes, based on evidence which was
considered limited, not statistically signiﬁcant or not supported by intervention studies. However, when
addressing CVD mortality separately, Newberry et al. (2014) concluded that 8 observational studies
(prospective cohort or nested case–control studies, no RCTs) showed a higher risk for cardiovascular
death for subjects with the lowest serum 25(OH)D concentrations (lower bounds throughout all the
studies ranged between 8 and 40 nmol/L) compared with those with the highest (higher bounds
ranged between 45 and > 100 nmol/L).
The evidence on type 2 diabetes and metabolic syndrome was considered not conclusive by the
IOM for the purpose of setting DRVs. In addition, limited or inconsistent evidence of mostly
observational nature was also found on the relationship between vitamin D intake (either alone or with
calcium) or status and functions of the nervous system and the risk of related disorders.
For markers of immune function, IOM (2011), Newberry et al. (2014) and SACN (2016) considered
a variety of outcomes including asthma, autoimmune diseases, wheeze, atopy and various infectious
diseases and IOM (2011) and SACN (2016) concluded that the evidence for a cause and effect
relationship was insufﬁcient for setting DRVs for vitamin D.
For non-skeletal obstetric outcomes (caesarean section, obstructed labour in the mother, and
immune-related outcomes in the offspring such as type 1 diabetes mellitus, asthma and atopic
disorders, or other outcomes in the offspring, e.g. Apgar score assessed by one and/or the other
report), IOM (2011) and SACN (2016) concluded that the evidence is limited and not conclusive, as
conﬂicting results are shown in observational studies and RCTs.
For all the health outcomes (other cancers, maternal serum 25(OH)D concentration in pregnancy
and later cognitive and psychological development of the offspring, neonatal hypocalcaemia, oral
health, AMD) assessed only by SACN (2016), the evidence from observational studies is not supported
by robust clinical trials or evidence is lacking, or inconsistent, or only weak.
The Panel also noted the large systematic review of prospective cohort studies and randomised
trials by Autier et al. (2014) whose conclusions are in line with those from IOM (2011), Newberry et al.
(2014) and SACN (2016), in that many prospective studies have shown associations between low 25
(OH)D concentrations and a wide range of health disorders, but that a similar number of RCTs did not
provide evidence for a causal relationship between serum 25(OH)D concentrations and the occurrence
or the course of such disorders.
The Panel notes the consistency of the overall conclusions of the systematic reviews and reports
discussed in this Section with regard to non-musculoskeletal health outcomes, thus did not undertake
a speciﬁc literature search for these outcomes in view of setting DRVs for vitamin D. The
Panel considers that the available evidence on these non-musculoskeletal health outcomes is
insufﬁcient to be used as criterion for setting DRVs for vitamin D.
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5.1.6. Overall conclusions on serum 25(OH)D concentration and various health
outcomes, in relation to the setting of DRVs for vitamin D
The Panel notes that most evidence on the relationship between serum 25(OH)D concentration and
health outcomes is related to musculoskeletal health outcomes (Section 5.1.1). The Panel notes that
the evidence on a possible threshold value for serum 25(OH)D concentration with regard to adverse
musculoskeletal or pregnancy-related health outcomes, that may be used to inform the setting of
DRVs for vitamin D, shows a wide variability of results (Sections 5.1.2.1.7, 5.1.2.2.4 and 5.1.3).
Several factors contribute to this (Sections 5.1.2.1.1, 5.1.2.1.3 and 5.1.2.1.4) and also include the
large variation in the results from different laboratories and assays used for measuring serum 25(OH)D
concentrations (Section 2.4.1). Furthermore, observational studies mostly used single measurements of
25(OH)D concentration, thus possible long-term changes in 25(OH)D concentration were not
considered in the analyses of the relationship with health outcomes.
Taking into account the overall evidence and uncertainties for adults (Section 5.1.2.1.7) and infants
and children (Section 5.1.2.2.4), the Panel considers that there is sufﬁcient evidence for an increased
risk of adverse musculoskeletal health outcomes at 25(OH)D concentration below 50 nmol/L. Taking
into account the overall evidence and uncertainties for pregnancy (Section 5.1.3), the Panel considers
that there is also evidence for an increased risk of adverse pregnancy-related health outcomes at 25
(OH)D concentration below 50 nmol/L. The Panel concludes that this concentration can be
used as a target value to derive a DRV for vitamin D intake for adults, infants, children
and pregnant women. The setting and analyses of the available studies do not allow a conclusion to
be drawn as to whether this concentration should be achieved by about half of or most subjects in the
population.
The Panel notes that there is no evidence for a relationship between serum 25(OH)D concentration
and health outcomes of lactating women that may be used to set a DRV for vitamin D.
5.2. Vitamin D intake from supplements and musculoskeletal health
outcomes, pregnancy and lactation
Following a similar approach as in Section 5.1 for serum 25(OH)D concentration and health
outcomes, the Panel considered studies (here, preferably RCTs) on vitamin D intake (mostly as
supplements, with or without calcium) and various health outcomes (several musculoskeletal health
outcomes in children and adults (including free-living older adults), health outcomes in pregnancy and
lactation, as deﬁned in Section 5.1), to evaluate whether they might inform the setting of DRVs for
vitamin D.
5.2.1. Bone mineral density/content in adults
IOM (2011) (Sections 4 and 5.1.2.1.1, Appendix B) reported that most of the studies (all expect
one of the 18 RCTs cited) evaluated the effect of vitamin D supplementation in combination with
calcium supplementation, often without information on the habitual dietary intake from foods (eight
RCTs). These RCTs were predominantly conducted in post-menopausal women, using supplemental
vitamin D at doses of 7.5–25 lg/day (all except two RCTs), along with 377–1,450 mg/day of calcium.
From these RCTs, the IOM concluded that there was evidence that supplementation of vitamin D plus
calcium (compared with placebo) resulted in small increases in BMD of the spine, total body, femoral
neck and total hip, but that the evidence on vitamin D supplementation alone and BMD was limited.
SACN (2016) (Section 5.1.2.1.1) concluded that the evidence was suggestive of a beneﬁcial effect of
vitamin D supplementation on bone health indices at some skeletal sites in adults aged ≥ 50 years, but
that the evidence for adults < 50 years was insufﬁcient to draw conclusions.
The Panel takes into account the same seven RCTs that were considered in relation to associations
between serum 25(OH)D concentrations and BMD/BMC, from which only two (Macdonald et al., 2013;
Uusi-Rasi et al., 2015) provided data on vitamin D intake from food (and possible supplements other
than that of the intervention) in the study population (Section 5.1.2.1.1). The Panel notes that two of
the seven RCTs found no effect on BMD of vitamin D plus calcium, from supplements or fortiﬁed foods,
at doses of about 71 lg/day (Jorde et al., 2010) or 20 lg/day (Kukuljan et al., 2011), in subjects with
mean baseline 25(OH)D concentrations of 58 and 86 nmol/L, respectively.
In contrast, three RCTs (Section 5.1.2.1.1) in subjects with mean baseline concentrations of 25(OH)
D of 34–50 nmol/L reported an increase in BMD or a decrease in BMD loss following vitamin D
supplementation at doses of 10–25 lg/day (with or without calcium) (Islam et al., 2010; K€arkk€ainen
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et al., 2010; Macdonald et al., 2013) (results from unadjusted analyses in (K€arkk€ainen et al., 2010)).
One RCT (Nieves et al., 2012) in subjects with mean baseline concentration of 29 nmol/L found an
increase in BMD following vitamin D supplementation with 25 lg/day plus calcium only in subjects with
the FF genotype (but not in subjects with the Ff/ff Fok1 genotypes). One RCT (Uusi-Rasi et al., 2015)
in subjects with mean baseline concentration of 66 nmol/L found that vitamin D supplementation of
20 lg/day alone (above the usual intake of 10 lg/day) resulted in a lower decrease in femoral neck BMD
as compared to placebo, but had no effect on BMD at other sites. The controls (to which the
intervention was compared to) in these studies were of various nature (Section 5.1.2.1.1).
For the present Section, the Panel also identiﬁed one prospective observational study in
9,382 women and men in Canada aged 25 years to more than 71 years and followed for 10 years,
that investigated changes over time in calcium and vitamin D intakes (from foods and supplements,
assessed repeatedly by food frequency questionnaires (FFQs)), and their longitudinal associations with
BMD (Zhou et al., 2013). The Panel notes that, in this study, after adjustments for potential
confounders, vitamin D intakes ≥ 10 lg/day (mean 10-year intake) were positively associated with
10-year BMD change at total hip or femoral neck, compared with intakes of vitamin D < 5 lg/day, in
women (but not in men) (e.g. for total hip: 0.008 g/cm2; 95% CI: 0.003–0.013).
The Panel notes that the results of these studies with heterogeneous designs are not consistent.
In line with the conclusions of the report by IOM (2011), altogether, the Panel notes that there is some
evidence suggesting that beneﬁcial effects of vitamin D supplementation on BMD/BMC may be
achieved with doses of about 10 to 25 lg/day in free-living subjects with mean 25(OH)D
concentrations between 29 and 50 nmol/L, and that the effects may depend on calcium intake.
5.2.2. Fracture risk in adults
IOM (2011) (Sections 4 and 5.1.2.1.3, Appendix B) reviewed a total of 19 RCTs identiﬁed by
Cranney et al. (2007) (15 RCTs), Chung et al. (2009) (two RCTs) or by additional literature searches
(2 RCTs). These RCTs provided vitamin D2 or D3 (with or without calcium), with various doses (e.g. out
of the 15 RCTs identiﬁed by Cranney et al. (2007), 11 used vitamin D3 doses of 7.5–20 lg/day), at
various frequency (e.g. daily, every 4 months, once per year), and often with no information on the
habitual dietary intake of vitamin D from foods. The IOM concluded that vitamin D supplementation
with calcium was effective in reducing fracture risk (total or hip) in institutionalised older populations
only (considering a limited number of studies out of the 15 RCTs identiﬁed by Cranney et al. (2007)),
but that the evidence for a beneﬁt of vitamin D and calcium supplementation on fracture risk in
community-dwelling individuals was inconsistent across trials.
Newberry et al. (2014) identiﬁed one RCT using vitamin D and calcium, that assessed fracture risk,
and that was not already considered by the IOM. This RCT (Prentice et al., 2013) was a re-analysis of
data from a previous trial that attempted to assess the effects of daily supplementation with 10 lg
vitamin D and 1,000 mg calcium, consumed over an average intervention period of 7 years (habitual
dietary intake not reported). Results were provided for the whole study group as well as for those that
were not using personal supplements at baseline. The study found no signiﬁcant effect of the
intervention on overall total fracture risk.
SACN (2016) identiﬁed one RCT already considered by the IOM and that used a single high annual
dose of vitamin D (Sanders et al., 2010), reported mixed evidence from three meta-analyses on
vitamin D supplementation and fracture prevention, and concluded that RCTs do not show an effect of
vitamin D supplements on fracture risk in older men and women (≥ 50 years). One meta-analysis of 19
RCTs (12 on vitamin D, 7 on a vitamin D metabolite, assessed separately) was supportive of a
beneﬁcial effect of vitamin D supplementation (D2 or D3, with or without calcium) of doses above
10 lg/day in reducing the risk of non-vertebral fractures (9 RCTs) and hip fractures (5 RCTs) (Bischoff-
Ferrari et al., 2009b). In contrast, the two other meta-analyses (of 53 and 22 RCTs, respectively)
showed that ‘vitamin D’ alone had no effect on fracture risk (Avenell et al., 2014; Bolland et al.,
2014b). Avenell et al. (2014) did not exclude studies using supplementation with vitamin D metabolites
and only Bischoff-Ferrari et al. (2009b) included exclusively studies based on oral vitamin D
supplementation (12 on oral vitamin D2 or D3, out of 19 RCTs included). All three systematic reviews
included studies on institutionalised subjects; few included studies were published in 2010 or
afterwards, i.e. after the IOM report; and several studies were in common in these three reviews. The
systematic review by Avenell et al. (2014) included a subgroup analysis on community-dwelling
subjects receiving vitamin D plus calcium (versus placebo or no treatment), indicating that hip fracture
incidence was not signiﬁcantly reduced with vitamin D supplementation of 10–20 lg/day. A similar
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ﬁnding on the lack of effect on the risk of total or hip fracture of vitamin D plus calcium in community-
dwelling subjects was reported by Bolland et al. (2014b). The Panel considers that no conclusion can
be drawn from these systematic reviews for the setting of DRVs for vitamin D.
For the present Section, the Panel considered a population-based Swedish cohort, which included
61,433 women (born between 1917 and 1948, mean age between 56 and 59 years of subjects in
quintiles of vitamin D intake) followed for 19 years (Snellman et al., 2014). Total dietary intakes (from
foods and supplements) were assessed repeatedly by several FFQs. Women with a total intake higher
than 12.5 lg/day did not have a lower rate of fracture of any type, compared with those with a total
vitamin D intake below 3.5 lg/day. Calcium intake (higher or less than 800 mg/day) did not modify
these results. The Panel notes that, in this study, dietary intakes of vitamin D, from foods and
supplements, was not associated with the rate of fractures in community-dwelling middle-aged
women.
The Panel notes that the available evidence does not indicate that vitamin D supplementation up
to 20 lg/day has a signiﬁcant positive effect on fracture risk in community-dwelling adults with
adequate calcium intakes.
5.2.3. Muscle strength/function and physical performance in adults
IOM (2011) (Sections 4, 5.1.2.1.4 and Appendix B) noted that randomised trials suggest that
vitamin D dosages of at least 20 lg/day, with or without calcium, may improve physical performance
measures, but that the evidence was insufﬁcient to deﬁne the shape of the dose–response curve. The
ﬁndings by Lamberg-Allardt et al. (2013), Newberry et al. (2014) and SACN (2016) have been
described previously (Section 5.1.2.1.4).
The Panel takes into account the same nine RCTs with heterogeneous designs, which were
considered in relation to associations between serum 25(OH)D concentrations and muscle strength/
function and physical performance (Section 5.1.2.1.4). From these, only three provided data on
habitual dietary intake of vitamin D: means at baseline of 1.6 and 4.1 lg/day in the placebo and
intervention groups, respectively (Pirotta et al., 2015); median habitual dietary intake of vitamin D of
about 4.3–4.8 lg/day (Wood et al., 2014); means of 10.4 and 10.5 lg/day at baseline and end of study
(Uusi-Rasi et al., 2015).
Overall, these nine RCTs do not provide evidence for an effect of vitamin D supplementation (10 to
about 71 lg/day), with or without calcium, on these outcomes. However, one study showed a
beneﬁcial effect of vitamin D supplementation (vs placebo) on postural stability in the subgroup of
subjects with elevated baseline body sway (Lips et al., 2010). Another one showed a beneﬁcial effect
of vitamin D supplementation with calcium (vs calcium alone) on muscle strength and mobility in those
who were the weakest and slowest at baseline (Zhu et al., 2010). A third one found a beneﬁcial effect
of vitamin D supplementation (two different doses compared) on the ability to do chair-stand tests in
subjects with the slowest gait speed at baseline (Lagari et al., 2013). These three studies used doses
ranging between 10 and 50 lg/day.
The Panel notes that these studies suggest that vitamin D supplementation does not generally
affect muscle strength/function and indices of physical performance. However, subgroup analyses on
small numbers of older subjects, with impaired indices of physical performance at baseline, indicated
beneﬁcial effects of vitamin D supplementation doses (ranging between 10 and 50 lg/day) in three of
these studies.
5.2.4. Risk of falls and falling in adults
IOM (2011) (Sections 4, 5.1.2.1.5 and Appendix B) concluded, based on Cranney et al. (2007)
and Chung et al. (2009) and an additional literature search, that, some RCTs found a signiﬁcant effect
of vitamin D supplementation on fall incidence or risk or number of fallers, but the greater part of the
20 RCTs considered found no effect of supplemental vitamin D (usually with doses of 10–20 lg/day
and 50 lg/day in one), with or without supplemental calcium, on the risk of falls. A number of RCTs
analysed falls rather than fallers.
Newberry et al. (2014) identiﬁed two RCTs that examined the effect of supplementation with
vitamin D and calcium on the risk of falls/falling among community-dwelling older adults (Prince et al.,
2008; Pfeifer et al., 2009) considered by IOM (2011). Prince et al. (2008) supplemented older women
daily with 25 lg vitamin D2 and 1,000 mg calcium or only 1,000 mg calcium in a 1-year RCT and found
a signiﬁcantly decreased risk of falling at least once, and a decreased risk for ﬁrst falls, especially in
winter/spring, in the group that received vitamin D2. In the 1-year RCT performed by Pfeifer et al.
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(2009), older individuals received daily either 20 lg vitamin D3 and 1,000 mg calcium or only 1,000
mg calcium and found a reduction in the number of ﬁrst fallers in the group that received vitamin D3.
The Panel notes the above-mentioned RCTs in populations with different mean baseline serum 25
(OH)D concentration (Sections 5.1.2.1.4, 5.1.2.1.5 and 5.2.3). The RCT by Wood et al. (2014) showed
no effect of vitamin D3 supplementation (10 or 25 lg/day versus placebo) on the number of ‘ever
fallen’ falls in healthy post-menopausal women. The RCT by Uusi-Rasi et al. (2015), that investigated
the effect of daily vitamin D3 supplementation (20 lg) with or without exercise (versus placebo with or
without exercise) on falls in women at risk of falling, showed no effect of vitamin D3 on the rate or risk
of falls or injurious falls.
The Panel considers that, among studies identiﬁed by IOM (2011) and Newberry et al. (2014),
some provide evidence of an effect on falls or the number of fallers with daily 20–25 lg vitamin D2/D3
with calcium in comparison with calcium alone in community-dwelling older adults, whereas two RCTs
retrieved by the Panel thereafter in healthy post-menopausal women did not ﬁnd such effect of vitamin
D3 compared with placebo.
5.2.5. Bone mineral density/content in infants and children
For infants, IOM (2011) identiﬁed two RCTs (Greer et al., 1982; Greer and Marshall, 1989), using
supplemental doses of 10 lg/day vitamin D, and which found inconsistent effects on BMC (Sections 4,
5.1.2.2.1 and Appendix B).
The Panel takes into account the same two randomised trials (Holmlund-Suila et al., 2012; Gallo
et al., 2013) that were considered in relation to associations between serum 25(OH)D concentrations
and BMD/BMC (Section 5.1.2.2.1), and that used various doses of vitamin D3 supplementation, without
a placebo group, in (mostly) breastfed infants. Only one provided data on the vitamin D intake
through breast milk between ages 1 and 12 months (1–6 lg/day) (Gallo et al., 2013). They showed
that a supplementation with 10 lg/day vitamin D3 was sufﬁcient to reach a plasma/serum 25(OH)D of
at least 50 nmol/L in (almost) all subjects, and that there was no signiﬁcant differences in several
bone measurements between groups.
For children, IOM (2011) considered ﬁve RCTs (Ala-Houhala et al., 1988b; Cheng et al., 2005;
El-Hajj Fuleihan et al., 2006; Viljakainen et al., 2006a; Andersen et al., 2008) performed in children of
various ages and receiving doses of vitamin D between 5 and about 50 lg/day (Sections 4, 5.1.2.2.1
and Appendix B). Only three of them provided data on habitual dietary intake of vitamin D. Three
studies did not ﬁnd an effect of these doses on BMC/BMD, while one study found an effect with 5 and
10 lg/day only in subjects with compliance above 80% (but not in the ITT analysis) and another with
50 lg/day.
The Panel takes into account the same RCT that was considered in relation to associations between
serum 25(OH)D concentrations and BMD/BMC (Section 5.1.2.2.1). Molgaard et al. (2010)
supplemented 12-year-old girls with either placebo, 5 or 10 lg vitamin D/day for 1 year, in addition to
the habitual dietary intake of vitamin D (mean intakes of 2.6, 2.8 and 2.5 lg/day, respectively) and
found no effect on BMC/BMD.
The Panel notes that the data available on vitamin D supplementation in infants (10 lg/day or
higher) and children (5–50 lg/day) and BMD/BMC are inconsistent. The Panel, however, notes that
two recent trials showed that a supplementation with 10 lg/day vitamin D3 in (mostly) breastfed
infants was sufﬁcient to reach a plasma/serum 25(OH)D of at least 50 nmol/L in (almost) all subjects.
5.2.6. Pregnancy, lactation and related outcomes in mothers and infants
For pregnancy, IOM (2011) (Sections 4, 5.1.3, 5.1.4 and Appendix B) considered one RCT that
found no effect of maternal vitamin D supplementation in combination with calcium on the incidence
of preeclampsia (Marya et al., 1987), and reported on four RCTs that found no effect of maternal
vitamin D supplementation on birth weight or length of the children (Brooke et al., 1980; Maxwell
et al., 1981; Mallet et al., 1986; Marya et al., 1988). In these studies, the supplementation was
generally based on doses of 25–30 lg/day, and started at various time points in pregnancy.
SACN (2016) identiﬁed one RCT (Cooper et al., 2016) (Section 5.1.3), which did not show any
signiﬁcant difference in neonatal whole body BMC (primary outcome) between intervention group
(maternal supplementation of 25 lg/day vitamin D3 from about 14–17 weeks of gestation and until
delivery) and placebo (EFSA, 2016).
The Panel takes into account the same paper by Wagner et al. (2013b) that was considered in
relation to associations between serum 25(OH)D concentrations and health outcomes in pregnancy
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(Section 5.1.3). This paper reported on pooled data from two RCTs in which daily supplementation
doses of 50 and 100 lg vitamin D3 during pregnancy had no effect on neonatal birth weight, and risk
of pre-eclampsia or preterm birth in pregnant women with mean serum 25(OH)D concentrations of
57–65 nmol/L at baseline. The Panel did not retrieve any relevant RCT on vitamin D intake/
supplementation during lactation and relevant outcomes in mother or child.
The Panel notes that the number of RCTs that focused on effects of supplementation during
pregnancy or lactation on outcomes related to, e.g. bone, pre-eclampsia and birth weight, is small.
The doses used in the few studies reported varies between 25 and 100 lg/day, with no effect on the
variables studied. In addition, the amount of vitamin D in human milk is modestly correlated with
maternal vitamin D intake (unless ‘high’ supplemental doses are used, Section 2.3.7.2).
5.2.7. Overall conclusions on vitamin D intake from supplements and
musculoskeletal health outcomes, pregnancy and lactation, in relation to
the setting of DRVs for vitamin D
The Panel concludes that:
• there is some evidence suggesting that beneﬁcial effects of vitamin D supplementation on
BMD/BMC may be achieved with doses of about 10 to 25 lg/day in free-living subjects with 25
(OH)D concentrations between 29 and 50 nmol/L, and that the effects may depend on calcium
intake,
• available studies suggest that vitamin D supplementation does not generally affect muscle
strength/function and indices of physical performance. However, subgroup analyses on small
numbers of older subjects, with impaired indices of physical performance at baseline, indicated
beneﬁcial effects of vitamin D supplementation doses (ranging between 10 and 50 lg/day) in
three studies,
• although results of available studies on vitamin D supplementation with or without calcium are
not entirely consistent, there is some evidence for an effect on the risk of falls/falling with daily
20–25 lg vitamin D supplementation with calcium in comparison with calcium alone, in
community-dwelling older subjects,
• available studies provide no evidence for an effect of vitamin D supplementation on fracture
risk,
• the available data do not allow conclusion to be drawn on an effect of vitamin D
supplementation on BMD/BMC in infants and children. However, two recent trials showed that
a supplementation with 10 lg/day vitamin D3 in (mostly) breastfed infants was sufﬁcient to
reach a plasma/serum 25(OH)D of at least 50 nmol/L in (almost) all subjects,
• available studies provide no evidence for an effect of vitamin D supplementation on a number
of outcomes in pregnancy or lactation.
Overall, the Panel notes that there may be beneﬁcial effect of vitamin D supplementation above
10 lg/day (in addition to the habitual dietary intake of vitamin D) on some musculoskeletal health
outcomes, particularly in subjects with compromised musculoskeletal health or ‘low’ 25(OH)D
concentration. Habitual dietary intake of vitamin D is generally low (Section 3); however, the Panel notes
that, in these supplementation studies with heterogeneous designs, vitamin D intake from foods was
reported only in a limited number of trials. In addition, the extent to which cutaneous vitamin D synthesis
has contributed to the vitamin D supply, and thus may have confounded the relationship between vitamin
D intake and reported outcomes, is not known. The Panel concludes that these data are not useful as such
for setting DRVs for vitamin D. For the purpose of deriving DRVs for vitamin D, these data may only be
used to support the outcome of the characterisation of the vitamin D intake-status relationship undertaken
by the Panel under conditions of assumed minimal endogenous vitamin D synthesis (Section 5.3).
5.3. Vitamin D intake and serum 25(OH)D concentration
The relationship between vitamin D intake and serum 25(OH)D concentrations has been
investigated in numerous intervention studies in all age groups including different doses of vitamin D
provided as supplements or as foods or fortiﬁed foods.
The systematic reviews by Cranney et al. (2007) and Chung et al. (2009), which were used by
IOM (2011), included RCTs using supplements or fortiﬁed foods. Focusing on 28 RCTs (26 on adults),
Chung et al. (2009) concluded that a relationship between increasing supplementation doses of
vitamin D3 and increasing net change in serum 25(OH)D concentration was evident in both adults and
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children, that the dose–response relationships differed depending on serum 25(OH)D concentration of
the participants at baseline (< 40 nmol/L vs > 40 nmol/L), and depending on the duration of
supplementation (< 3 months vs > 3 months). The range of supplementation doses was large
(5–125 lg/day), the baseline serum 25(OH)D concentrations varied and the assays used for measuring
serum 25(OH)D concentrations were heterogeneous. Supplementation with vitamin D2 was more
commonly used than supplementation with vitamin D3 in RCTs in infants and pregnant or lactating
women, with a resulting signiﬁcant increase in serum 25(OH)D concentrations in infants or lactating
mothers and in cord blood. Based on Cranney et al. (2007) and Chung et al. (2009) and some new
RCTs, IOM (2011) undertook speciﬁc meta-regression analyses to obtain a dose–response curve, in
order to set DRVs for vitamin D (Section 5.3.1).
Lamberg-Allardt et al. (2013) considered the results from four systematic reviews (Cranney et al.,
2007; Chung et al., 2009; Cashman et al., 2011a; Black et al., 2012) (Section 5.3.1 for Cashman et al.
(2011a)) on the relationship between vitamin D supplementation/fortiﬁcation and serum 25(OH)D
concentrations, and underlined the important issue of the heterogeneity in the results according to the
assays used to measure serum 25(OH)D concentrations (Section 2.4.1). Lamberg-Allardt et al. (2013)
concluded that the systematic reviews indicated a clear effect of supplementation and fortiﬁed foods
on the serum 25(OH)D concentration, but the doses needed to achieve speciﬁc concentrations of 25
(OH)D are difﬁcult to determine. One systematic review (Black et al., 2012) estimated that 1 lg
vitamin D ingested only from fortiﬁed foods increased the serum 25(OH)D concentration by 1.2 nmol/L
(heterogeneity index (I2) = 89%, adjusted R2 = 0.67). Habitual dietary intake of vitamin D was usually
not reported in the 16 RCTs included in this review thus was not added to the content of the fortiﬁed
foods for the data analysis.
Newberry et al. (2014) identiﬁed one systematic review (Autier et al., 2012) that included
76 placebo-controlled and open-label trials published from 1984 through 2011 and addressed the
relationship between supplementation with vitamin D2 or D3 (oral or injection, with or without calcium,
with vitamin D doses ranging from 5 to 250 lg/day (median: 20 lg/day)) and net change in serum 25
(OH)D concentrations. The meta-regression analysis by Autier et al. (2012) of serum 25(OH)D
concentration on (log-transformed) vitamin D doses (< 100 lg/day) showed that serum 25(OH)D
concentrations increased by an average of 1.95 nmol/L for each 1 lg per day vitamin D3
supplementation (without calcium). In this analysis, vitamin D2 supplementation resulted in smaller
increases compared with vitamin D3 supplementation, and simultaneous supplementation with calcium
resulted in non-signiﬁcantly smaller increases in serum 25(OH)D concentrations. As the number of
trials that used higher doses of vitamin D was small (n = 3 with doses of 100 lg/day or more),
whether the dose–response relationship reaches a plateau at higher doses could not be assessed.
Newberry et al. (2014) noted that most studies included in Autier et al. (2012) did not stratify ﬁndings
by sex, and the review itself did not stratify ﬁndings by assay method. In addition to the systematic
review by Autier et al. (2012), Newberry et al. (2014) identiﬁed eighteen new RCTs (in addition to
those included by Chung et al. (2009)) (two of them using fortiﬁed foods, the others using vitamin D
supplements with or without calcium, one study using a vitamin D2 supplement). Overall, all studies
reported an increase in serum 25(OH)D with vitamin D supplementation. Newberry et al. (2014) also
provided plots showing the relationship between vitamin D3 supplementation doses and net changes in
serum 25(OH)D concentrations in 44 RCTs, according to populations (adults and children), baseline
serum 25(OH)D concentrations, duration of supplementation, and assay used to assess serum 25(OH)D
concentration.
The Panel notes that studies based on vitamin D supplementation and/or food and food
fortiﬁcation suggest a relationship between vitamin D intake and serum 25(OH)D concentrations in all
ages and that this relationship depends on several factors, including baseline serum 25(OH)D
concentrations, supplementation dose, study duration, and assay used to assess serum 25(OH)D
concentration.
5.3.1. Characterisation of the intake-status relationship in previous approaches
One approach to assess the intake-status relationship could be to rely on a sample of individual
data from a particular study (e.g. regression analysis on individual data). The Panel did not have
access to a sufﬁciently large and representative sample of individual data from a study considered
relevant for the aim of setting DRVs at the European level.
Several bodies have characterised the intake-status relationship through meta-regression
approaches, which has also been the target of various authors (e.g. Cashman et al. (2011a); Autier
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et al. (2012)). In a meta-regression approach, a quantitative synthesis of the dose–response
relationship between mean results at group level from studies is usually carried out (taking into
account potential confounders by relevant adjustments). Once the methodological heterogeneity is
characterised, the remaining variation reﬂects a real phenomenon that describes the extent to which
different populations behave differently. One advantage of the meta-regression approach is the
representativity, by considering several studies from various populations in different contexts, instead
of relying on speciﬁc data from one speciﬁc study undertaken in a particular context. However, by
using group means from studies, the information on the variability between individuals is diminished,
which may complicate the setting of, e.g. a reference value that would correspond to the intake
needed to cover the requirements of 97.5% of individuals. The CI in meta-regression analyses
provides an estimate of the uncertainty about the ﬁtted response line due to sampling, but does not
provide an estimate of the variability between individuals (Section 5.3.2).
IOM (2011) carried out meta-regression analyses of the relationship between serum 25(OH)D
concentrations and log-transformed (ln) total intake of vitamin D (from food and supplements)
during winter at latitudes above 49.5°N in Europe or Antarctica, separately for children/
adolescents, young/middle-aged adults, and older adults (Ala-Houhala et al., 1988b; Van Der
Klis et al., 1996; Schou et al., 2003; Larsen et al., 2004; Viljakainen et al., 2006a, 2009; Cashman
et al., 2008, 2009; Smith et al., 2009).27 The IOM considered that the response of serum 25(OH)D
concentration to vitamin D intake is non-linear, the rise being steeper below 25 lg/day and ﬂattening
above 25 lg/day. Baseline serum 25(OH)D concentrations and age did not have a signiﬁcant effect in
the response of serum 25(OH)D concentration to total vitamin D intake. The IOM performed also a
meta-regression analysis on all age-groups (6 to more than 60 years) at latitudes above 49.5°N
using the CI around the mean. The IOM performed as well a separate analysis for latitudes 40–49°N
during winter. In particular, this analysis (i) showed that the achieved serum 25(OH)D concentration at
these lower latitudes was greater (24%) for a given total intake compared to that achieved in the
previous analysis at higher latitudes, and (ii) explained less variability than the model at higher
latitudes. Thus, the IOM decided to focus on latitude above 49.5°N to set DRVs for vitamin D. The
IOM noted that, at a total intake of 10 lg/day, the predicted mean serum 25(OH)D concentration was
59 nmol/L in children and adolescents, young and middle-aged adults, and older adults (with a lower
limit of the CI of about 52 nmol/L). The IOM also noted that, at a total intake of 15 lg/day, the
predicted mean serum 25(OH)D concentration was 63 nmol/L (lower limit of the CI of 56 nmol/L).
These results were used to set the EAR and RDA for vitamin D, which take into account the
uncertainties in these analyses (Section 4).
Cashman et al. (2011a) applied a meta-regression approach using different model constructs
(curvilinear as in the approach by the IOM, or linear) to explore the most appropriate model of the
relationship between total vitamin D intake (from food and supplements) and serum 25(OH)D
concentration. Priority was given to data from winter-based RCTs performed at latitudes 49.5–78°N,
using vitamin D3 supplementation (not vitamin D2) in children and adults (i.e. excluding infants,
pregnant and lactating women) and with a duration of at least 6 weeks (Harris and Dawson-Hughes,
2002). Thus, 12 RCTs in 11 references were included (Ala-Houhala et al., 1988b; Honkanen et al.,
1990; Pfeifer et al., 2001; Meier et al., 2004; Barnes et al., 2006; Viljakainen et al., 2006b, 2009;
Cashman et al., 2008, 2009, 2011b; Smith et al., 2009). When the included RCTs did not assess
and/or did not report the habitual vitamin D intake (Ala-Houhala et al., 1988b; Honkanen et al., 1990;
Pfeifer et al., 2001; Meier et al., 2004), the authors considered the mean intake of the relevant age
and sex group, from the national nutrition survey preferably from the country in which the RCT was
performed. A combined weighted linear model meta-regression analysis of log-transformed (ln)
total vitamin D intake (maximum 50 lg/day) versus achieved serum 25(OH)D in winter produced a
curvilinear relationship. Use of non-transformed total vitamin D intake data (maximum 35 lg/day,
Section 2.4.1 and Aloia et al. (2008)) provided a linear relationship. At an intake of 15 lg/day (i.e. the
RDA set by the IOM for vitamin D for adults aged 19–70 years, Section 4), the predicted serum 25
(OH)D concentration at the lower limit of the 95% CI of the log-transformed and the linear models
was 54.4 and 55.2 nmol/L, respectively. The total vitamin D intake estimated to achieve the ‘RDA-type’
and ‘EAR-type’ values for 25(OH)D concentrations set by the IOM (50 and 40 nmol/L, Section 4) was
9 lg/day for 50 nmol/L (and 2.7 lg/day for 40 nmol/L) in the log-transformed model. In the linear
model, this intake was 12 lg/day for 50 nmol/L (and 6.5 lg/day for 40 nmol/L), respectively. In
further publications of the same author, use of a 95% prediction interval (PI) in meta-regression
27 All these studies used vitamin D3 supplementation.
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analyses was considered to allow for estimation of the requirement of 97.5% of the population
(Cashman and Kiely, 2014; Cashman, 2015).
The Nordic Council of Ministers (2014) performed two meta-regression analyses of log10 (serum 25
(OH)D) versus total vitamin D intake. The included studies were selected mainly from the systematic
review by Cashman et al. (2011a) and the previous Nordic recommendations (NNR, 2004), and studies
using doses of vitamin D higher than 30 lg/day were excluded. The ﬁrst meta-regression analysis
included six supplementation studies pertinent to the Nordic countries, undertaken in adults
(≤ 60 years) (Barnes et al., 2006; Cashman et al., 2008; Viljakainen et al., 2009) and children
(Ala-Houhala et al., 1988b; Molgaard et al., 2010; Cashman et al., 2011b), during winter, at latitudes
50–61°N. The response to intake was found to be limited or absent for baseline concentrations above
50 nmol/L. It was considered that an intake of 7.2 lg/day would maintain a mean serum
concentration during winter of about 50 nmol/L for 50% of subjects. Using the lower limit of the 95%
CI, it was considered that about 10 lg/day would be sufﬁcient for most of the population. The
second meta-regression analysis was based on supplementation studies in mainly older adults
(> 65 years) (Sem et al., 1987; Pfeifer et al., 2001; Meier et al., 2004; Viljakainen et al., 2006b;
Cashman et al., 2009) during winter at latitudes 51–61°N. It was considered that an intake of about
5 lg/day would maintain a mean serum 25(OH)D concentration of about 50 nmol/L during wintertime.
This estimate was lower than for younger adults, but the 95% CI was wider and, based on its lower
bound, it was considered that an intake of about 10–11 lg/day is sufﬁcient for most of this population.
These results were used to set the reference values for vitamin D in the Nordic Countries (Section 4).
The Panel applied the meta-regression approach to assess the intake-status relationship with the
aim to set DRVs for vitamin D.
5.3.2. Characterisation of the intake-status relationship by EFSA in adults and
children
As indicated previously (Section 2.3.1), the Panel considered that the association between vitamin
D intake and status for the purpose of deriving DRVs for vitamin D should be assessed under
conditions of minimal endogenous vitamin D synthesis.
5.3.2.1. Methods
As preparatory work for the setting of DRVs for vitamin D, a comprehensive literature search and
review was performed to identify and summarise studies that could be used to assess the dose–
response relationship between vitamin D2 or vitamin D3 intake (i.e. oral exposure) and plasma/serum
25(OH)D concentration (Brouwer-Brolsma et al., 2016).
Prospective studies (that primarily aimed to investigate the dose–response association of vitamin D
intake and status) and trials that investigated vitamin D intake and 25(OH)D concentration, published
through July 2014 were systematically searched and reviewed (Brouwer-Brolsma et al., 2016). Studies
were eligible for inclusion if they:
• were conducted in humans of all ages,
• investigated oral exposure to vitamin D2 or vitamin D3 at least twice a week via diet, supplements
or fortiﬁed foods and its subsequent effect/association on/with 25(OH)D concentration,
• were performed in a period of assumed minimal endogenous vitamin D synthesis, i.e.
at latitudes above 40°N from October through April (or below 40°S from April through
October).28 Additional further selections were also proposed (Brouwer-Brolsma et al., 2016),
based on the UV-index (UV-index < 3) or a simulation model (Webb, 2006; Webb and
Engelsen, 2006) (Section 2.3.1), but in the end were not applied in this analysis, as it would
have led to a substantial reduction in the number of arms (53% and 86% of the 83 arms
would have been excluded, respectively),
• and lasted for at least 6 weeks (Sections 2.4.1 and 5.3.1).
More information on the inclusion/exclusion criteria and the selection process can be found in
Brouwer-Brolsma et al. (2016).
Finally, 56 articles matched the eligibility criteria, reporting on data of 65 relevant studies (e.g. one
article reporting data in children and in adults was considered as one article reporting data on two
studies). The majority of the included studies were trials (n = 57), investigating the effects of
28 Based on the protocol by Brouwer-Brolsma et al. (2016).
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supplements, fortiﬁed foods or foods naturally rich in vitamin D (ﬁsh). Only eight prospective cohort
studies fulﬁlled the inclusion criteria.
Using a meta-analytic approach, EFSA performed quantitative syntheses of the summary data
extracted by Brouwer-Brolsma et al. (2016) from the included studies (Appendix C). Data from
prospective observational studies identiﬁed were analysed but were not included in the
meta-regression dose–response model by EFSA, which was based solely on randomised
trials data.
The 57 trials included in the preparatory literature review represented 141 arms. Of these 141
arms, EFSA excluded a total of 58 arms from the analysis (25 arms excluded from the preliminary data
set of 116 arms, and 33 arms further excluded from the ﬁnal data set of 83 arms, Table 8,
Appendix D.A), in particular:
• arms from trials on population groups other than children and adults (i.e. infants, pregnant
women, lactating women, as these populations represent particular age and/or physiological
conditions and the number of arms were low29),
• arms resulting in total intakes exceeding the UL set for adults (EFSA NDA Panel, 2012a)
(Section 2.2.2.2),
• arms in which vitamin D2 was administered. In view of the conﬂicting results regarding the
potential differences in the biological potencies and catabolism of vitamin D2 and D3
(Sections 2.3.2 and 2.3.6), and the low number of arms using vitamin D2 (six), this exclusion
was considered appropriate by the Panel.
• arms for which methodological and/or statistical inconsistencies were identiﬁed.
This left 83 arms from 35 trials in the analysis (Appendix D.B), of which nine arms were on
children (age range: 2–17 years) and the other arms were on adults (mean age between 22 and
86 years).
The continuous outcome, i.e. plasma/serum 25(OH)D concentration, was analysed by EFSA
using the summary data extracted for each arm in each individual study. Background intake was
added by EFSA to the supplemental vitamin D dose to generate total vitamin D intake
estimates. If the habitual vitamin D intake of the cohort(s) within a study was not
reported in the papers, surrogates were imputed using the appropriate age- and
sex- speciﬁc mean vitamin D intake values (from food) from the national nutrition survey
relevant to the country in which the study was performed (17 trials) (Appendix C and
Table 11 of Appendix D.B).
Two different models of the dose–response relationship between total vitamin D intake and plasma/
serum 25(OH)D concentration were explored (Appendix C): a linear model and a non-linear model (i.e.
with the natural logarithm transformation of the total intake). Finally, the Panel decided to retain the
non-linear model to better describe the dose–response shape and to be able to include results from
trials using higher supplemental doses (i.e. up to 50 lg/day).
A number of factors potentially inﬂuencing the dose–response relationship (Section 2)
were investigated, in order to select factors to be included in the ﬁnal model to characterise the high
heterogeneity of results across individual trials. These were: total vitamin D intake, baseline serum
concentration, study duration (≤ 3 months versus > 3 months; or ≤ 3 months, versus 3–6 months
versus 1–2 years), latitude (as different categories), assay method (HPLC and LC–MS versus
immunoassays; or each analytical method as an individual category), BMI (Section 2.3.5),
co-supplementation with calcium, funding source, age, sex, risk of bias (RoB), assessment of
compliance, period of study publication (before/after 2000) or study start period (as a ‘proxy’ to the
temporal trends in assay method use, Section 2.4.1), and ethnicity (as a ‘proxy’ for skin pigmentation,
possible effects of genotypes and some lifestyle habits (Sections 2.3.1 and 2.5) that were usually not
reported in the included trials). In particular for ethnicity, the data were missing for almost half of the
studies, as this information was not reported in the papers (Appendix C).
5.3.2.2. Results
The meta-regression analysis carried out on the selected arms resulted in two predictive equations
of achieved serum 25(OH)D concentration:
y = 23.2 ln (total vitamin D intake in lg/day) (equation 1, unadjusted model)
and
29 Two arms on pregnant women, three arms on lactating women, three arms on infants.
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y = 16.3 ln (total vitamin D intake) + 0.5 mean baseline 25(OH)D  0.5 latitude + 0.9
study start year  2.0 HPLC  4.7 LC–MS + 0.6 CPBA  6.4 ELISA/nr + 1.3 Other assay +
7.8 compliance not assessed (equation 2, adjusted model)
The model corresponding to equation 2 was adjusted for baseline concentration (continuous),
latitude (continuous), study start year (continuous), type of analytical method applied (RIA as
‘reference’ category for the model, HPLC, LC-MS, CPBA, ELISA/not reported (nr), other30), assessment
of compliance (yes as ‘reference’ category for the model, no/unknown). No interaction terms were
introduced.
The 95% CI around the coefﬁcient mentioned above for each variable are given in Table 5,
Section 8.8 of Appendix C (e.g. about 14.4–18.2 for the coefﬁcient of about 16.3 obtained for ln (total
vitamin D intake)). The summary data of the included studies are given in Appendix D.B, in particular
the mean and SD baseline and achieved serum 25(OH)D concentrations per included arm are given in
Table 11 of this Appendix.
After the inclusion of the ﬁnal set of covariates, the adjusted R2 (proportion of between-study
variance explained) of the ﬁnal model was 85%, meaning that the ﬁtted factors were able to
characterise most of the across-trials variability in response.
The two equations above were used to predict the achieved mean serum 25(OH)D
concentrations corresponding to total vitamin D intakes of 5, 10, 15, 20, 50, 100 lg/day (Appendix C,
Table 6) and to estimate the total vitamin D intakes that would achieve serum 25(OH)D
concentrations of 50, 40, 30, 25 nmol/L (Appendix C, Table 7).
In the adjusted multivariable models, all covariates were set to their mean values:
mean baseline serum 25(OH)D concentration: 50.7 nmol/L; mean latitude: 53°N; study start year:
2005; assay – HPLC: 10%; LC–MS: 18%; CPBA: 13%; ELISA: 20%; Other: 8%; compliance not
assessed/unknown: 27%. As such the adjusted model predictions can be interpreted as referring to an
average ideal population in which the major factors inﬂuencing the heterogeneity across different
populations have been ruled out. Such a reduction in heterogeneity is reﬂected in the narrower PI as
compared to the unadjusted model.
Lower and upper limits of the 95% CI and of the 95% PI were calculated for both the adjusted and
the unadjusted model. In the meta-regression context, where a random-effects approach is applied:
• the CI illustrates the uncertainty about the position of the regression line (i.e. across-study
conditional means);
• the PI illustrates the uncertainty about the true mean effect that would be predicted in a
future study.
The 95% PI refers to the population of mean responses (not individual responses) as analysed in
the random-effects model, while DRVs are set for healthy individuals and populations, if possible
taking into account the distribution of requirements in the population (EFSA NDA Panel, 2010). As
such, it is possible to think of the 95% PI of the meta-regression only as an approximation of the
interval that would allow for estimation of the requirements for 95% of individuals in the overall
population.
The role of BMI (Section 2.3.5) was tested and it was not included in the ﬁnal model as a
covariate, as it did not reach statistical signiﬁcance and in consideration of potential ecological fallacy
(Appendices C and D.C). Sex and age were also not included in the ﬁnal model, as they did not
further explain between-study variability once mutually adjusted for all other factors (Appendices C
and D.C). However, regarding the role of age, a stratiﬁed analysis was carried out (Tables 14 and 15 of
Appendix D.G), to quantify the impact of the exclusions of the four trials on children (age range:
2–17 years, nine arms) on the predicted achieved mean serum 25(OH)D concentrations (Appendix C,
Table 6) and estimated total vitamin D intakes (Appendix C, Table 7).
• In the restricted data set of 74 arms on adults only, there was an overall small decrease in all
serum estimates (and consequently a small increase in total intakes that would achieve target
values). Overall estimates (Tables 14 and 15 of Appendix D.G) did not substantially change as
compared to the full data set including children (Tables 6 and 7 of Appendix C). Thus, the
Panel decided to retain the data on children and on adults in the dose–response
analysis (Section 6).
30 Based on the data reported by the contractor. ‘Other’ covers methods presented as ‘enzyme immunoassays’, Nichols method,
‘chemoluminescence immunoassays’, ‘immunoenzymetric assay’ in the references included by the contractor.
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• Children tended to achieve the same mean serum 25(OH)D concentrations as adults at a lower
total intake (Table 14 of Appendix D.G). It was not possible to apply a full adjustment to
estimate the values based only on the four children trials, as it would have required a much
higher minimum number of ‘points’ per covariate (at least 10 arms for each included factor).
Instead, values from a model adjusted for mean baseline 25(OH)D concentration
were provided. As such these estimates are not directly comparable to the ones in the
adjusted model in adults, as they are not adjusted for the same set of covariates.
The unadjusted model showed lower average intakes, but estimates were less precise; also the
highest dose investigated in the included arms was 10 lg/day, so predictions at higher intakes
are extrapolations from the model. For these reasons results from the models on children data
could only be evaluated qualitatively.
A number of sensitivity analyses were also carried out by EFSA to evaluate whether the ﬁndings
were robust to the assumptions made in the systematic review protocol and the analyses
(Appendix C), in particular, on the background intake imputation process, on eligibility criteria (e.g.
fortiﬁed food trials versus supplement trials, cf. Section 2.3.2); characteristics of participants (e.g.
exclusion of trials that did not explicitly exclude supplement users, persons on speciﬁc medications,
persons using sunbeds/artiﬁcial UV-B sources or going on sunny holidays, Table 16 of Appendix D.H).
None of these sensitivity analyses raised serious concerns about the robustness of the overall analysis.
In addition, there was no particular indication of publication bias as explored on the subset of trials for
which the mean difference in response could be estimated (Appendices C and D.J).
The Panel considers that the results of this meta-regression analysis can be used to set DRVs for
vitamin D. The meta-regression model of serum 25(OH)D response to ln of total vitamin D intake from
the adjusted model (n = 83 arms) is shown in Figure 3, as well as in Appendix D.F (for comparison
with the unadjusted model).
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Circles represent mean achieved 25(OH)D in all included arms, either control or intervention arms. Mean achieved
values are modelled against total vitamin D intake and adjusted in the multivariable approach by mean baseline
values, latitude, study start year, analytical method for measuring serum 25(OH)D and compliance (Appendix C).
The conﬁdence interval (CI) illustrates the uncertainty about the position of the regression line (blue). The
prediction interval (PI) illustrates the uncertainty about the true mean effect that would be predicted in a future
study.
Figure 3: Meta-regression model of serum 25(OH)D response to ln of total vitamin D intake (adjusted
model) (n = 83 arms)
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5.3.3. Qualitative overview of available data on infants, children, pregnant or
lactating women
Only two studies (Ala-Houhala et al., 1986; Atas et al., 2013) that were conducted in breastfed
infants met the eligibility criteria of the comprehensive literature search (Brouwer-Brolsma et al., 2016)
mentioned previously (Section 5.3.2.1) (in situation of assumed minimal endogenous vitamin D
synthesis). Both studies included an intervention group that was allocated to 10 lg/day vitamin D. Atas
et al. (2013) also included a study group that was allocated to 5 lg/day. Ala-Houhala et al. (1986)
supplemented with vitamin D2 from birth for the duration of 15 weeks. At baseline, mean serum 25(OH)
D concentrations were approximately 20 nmol/L, which rose to roughly 80 nmol/L after 15 weeks
(values estimated from ﬁgures). Atas et al. (2013) supplemented with vitamin D3 from birth for the
duration of 17 weeks, but did not measure baseline serum 25(OH)D concentration. Follow-up
measurements at 4 months of age showed, however, higher serum 25(OH)D concentrations than in the
study by Ala-Houhala et al. (1986): serum 25(OH)D reached a median (min–max) concentration of
99 (43–265) nmol/L in the 5 lg group, and 141 (80–375) nmol/L in the 10 lg group (Atas et al., 2013).
Three prospective studies (Sullivan et al., 2005; Lehtonen-Veromaa et al., 2008; Andersen et al.,
2013) met the eligibility criteria of the comprehensive literature search (Brouwer-Brolsma et al., 2016)
mentioned previously (Section 5.3.2.1). Two of these studies reported on dietary vitamin D intake
(food only; Sullivan et al., 2005; Lehtonen-Veromaa et al., 2008); one study measured vitamin D
intake covering both dietary as well as supplemental intake (Andersen et al., 2013). Vitamin D intakes
ranged from median (IQR) 3.9 (1.9–7.0) lg/day ((Andersen et al., 2013), dietary and supplemental
intake) to mean of 5.4  1.4 ((Sullivan et al., 2005), dietary intake only). Follow-up time ranged from
one (Andersen et al., 2013) to 4 years (Lehtonen-Veromaa et al., 2008). Mean ( SD) age at baseline
ranged from 11  1 (Sullivan et al., 2005) to 16  2 (Lehtonen-Veromaa et al., 2008) years old. All
three studies performed the baseline and follow-up 25(OH)D measurements in February/March. In one
study (Andersen et al., 2013), baseline vitamin D intake was (median (IQR)) 3.9 (1.9–7.0) lg/day,
food and supplements) and serum 25(OH)D concentrations at follow-up were (median (IQR)) 23
(17–36) nmol/L. For the two others (Sullivan et al., 2005; Lehtonen-Veromaa et al., 2008), baseline
vitamin D intakes (food only) were (mean  SD) 5.4  1.4 and 4.0  2.2 lg/day, while serum 25(OH)
D concentrations at follow-up were 50  14 and 48  17 nmol/L, respectively.
Two RCTs on pregnant or lactating women met the eligibility criteria of the comprehensive literature
search (Brouwer-Brolsma et al., 2016) mentioned previously (Section 5.3.2.1).
In an open-label trial, Ala-Houhala et al. (1986) examined the effect of vitamin D supplementation
on serum 25(OH)D concentration in pregnant women (41 starters, 39 completers) living in Finland
(61°N), delivering in January, and whose age was not reported. Eight women were supplemented with
12.5 lg vitamin D3 per day throughout the pregnancy; 33 others did not receive any supplementation.
31
Background dietary vitamin D and calcium intakes were not assessed. Serum 25(OH)D was measured
only at the delivery (thus at the end of the supplementation period). At delivery, there was a
pronounced difference in mean ( SEM) serum 25(OH)D concentrations between women that received
vitamin D supplementation (57  11 nmol/L) and those that did not (25  2 nmol/L) (p < 0.01).
In the same open-label trial, Ala-Houhala et al. (1986) also studied the effect of vitamin D
supplementation in lactating women (49 starters, 49 completers)32 (whose age was not reported) from
January through March. Mothers received either no treatment (n = 16), 25 lg (n = 16) or 50 lg
(n = 17) vitamin D3 per day from delivery until 15 weeks post partum. Background dietary vitamin D
and calcium intakes were not assessed. At baseline, there were no signiﬁcant differences in serum 25
(OH)D concentrations across the three groups, showing mean concentrations around 32 nmol/L
(concentration is estimated from ﬁgure in original article). However, after 15 weeks, serum 25(OH)D
concentration signiﬁcantly increased in the treatment groups (p < 0.01). That is, up to about 75 nmol/L
in the 25 lg/day group and 100 nmol/L in the 50 lg/day group (concentrations are estimated from
ﬁgure in original article).
31 The study by Ala-Houhala et al. (1986) also included a third study group, including women that were supplemented during
the second trimester of the pregnancy. As 25(OH)D measurements were only conducted at delivery, the data of this group
that was supplemented in the second trimester were not considered relevant to the review by Brouwer-Brolsma et al. (2016).
(i.e. supplementation was terminated several months before the 25(OH)D measurements were conducted).
32 Researchers already followed these lactating women during pregnancy, during which women were distributed over three
groups: i.e. eight women were supplemented with 12.5 µg vitamin D3 per day throughout the pregnancy; eight women were
supplemented with 12.5 µg vitamin D3 per day during the second trimester of pregnancy; 33 others did not receive any
supplementation. After delivery, the women were redistributed into three ‘new’ groups, as explained in the paragraph above.
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The Panel considers that the two infant studies may be used to set DRVs for vitamin D in infants
(Section 6.2), while the other available studies on children, and pregnant or lactating women are not
informative for the setting of DRVs for vitamin D for these population groups. The Panel also notes
that the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
(Braegger et al., 2013) recommends the ‘pragmatic use’ of a serum 25(OH)D concentration of
> 50 nmol/L to indicate sufﬁciency and a daily supplement of 10 lg to all infants. The Panel notes that
mean vitamin D concentrations in breast milk of healthy lactating women, unsupplemented or
supplemented with vitamin D, are low (0.25–2.0 lg/L) (Section 2.3.7.2), that maternal vitamin D
intake during lactation inﬂuences maternal serum 25(OH)D concentration, but is only modestly
correlated with the amount of vitamin D in human milk, unless high supplemental doses are used.
Thus, the Panel considers that the derivation of a DRV for infants in the second half of the ﬁrst year of
life by extrapolation from the vitamin D intake of exclusively breastfed infants (in the ﬁrst half year of
life) is not possible, and that the derivation of DRVs for vitamin D for lactating women based on the
compensation of the vitamin D loss in breast milk is not justiﬁed.
6. Data on which to base dietary reference values
In spite of the high variability in serum 25(OH)D measurements obtained with different analytical
methods, the Panel concludes that serum 25(OH)D concentration, which reﬂects the amount of vitamin
D attained from both cutaneous synthesis and dietary sources, can be used as a biomarker of vitamin
D status in adult and children populations. Serum 25(OH)D concentration can also be used as a
biomarker of vitamin D intake in a population with low exposure to UV-B irradiation.
The Panel considers some musculoskeletal health outcomes as suitable to set DRVs for vitamin D
for (healthy) adults, infants and children (Sections 5.1.1–5.1.5). Taking into account the overall
evidence and uncertainties on the relationship between serum 25(OH)D concentration and the risk of
these health outcomes, the Panel concludes that a serum 25(OH)D concentration of 50 nmol/L is a
suitable target value for all age and sex groups (Section 5.1.6). For setting DRVs for vitamin D,
the Panel considers the dietary intake of vitamin D necessary to achieve this serum 25(OH)D
concentration. As for other nutrients, DRVs for vitamin D are set assuming that intakes of interacting
nutrients, such as calcium (EFSA NDA Panel, 2015b) (Section 2.3.8), are adequate.
The Panel considers that the available evidence (Sections 5.1.6, 5.2.7 and 5.3.2) does not allow the
setting of ARs and PRIs and chooses to set AIs instead, for all population groups.
6.1. Adults
The Panel used information obtained from characterising the intake-status relationship for vitamin D
(meta-regression described in Section 5.3.2 and related Appendices C and D) to derive the vitamin D
intake to achieve a target serum 25(OH)D concentration of 50 nmol/L. For the purpose of deriving
AIs for vitamin D, the Panel decided to focus on the adjusted model of achieved mean serum
25(OH)D according to ln (total vitamin D intake) (i.e. total intake from habitual diet, fortiﬁed foods or
supplements). As indicated in Section 5.3.2, this adjusted model was obtained with data mostly on
adults (74 arms out of 83 included arms) in randomised trials using vitamin D3 (not vitamin D2)
(Sections 2.3.2, 2.3.6, 5.3.2 and Appendix C), and the estimates from this adjusted model were
derived based on all covariates set to their mean values.
In the adjusted model, the total intake estimated to achieve a serum 25(OH)D concentration of
50 nmol/L, as identiﬁed by the lower limit of the 95% PI, is 16.1 lg/day (Appendix C, Table 7).
Equally, at a vitamin D intake of 15 lg/day, the predicted mean serum 25(OH)D concentration is
63 nmol/L (95% CI: 58–69 nmol/L), with a predicted value at the lower limit of the 95% PI of
49 nmol/L (Appendix C, Table 6).
The Panel supports the use of the prediction interval (and not only the conﬁdence interval) in the
context of the meta-regression analysis and notes that the PI in the context of a meta-regression
analysis illustrates the uncertainty about the true mean response predicted in a future study
(Section 5.3). The Panel also considers that the 95% PI of the mean responses can provide useful
indications on the interval that would include true individual responses from the populations of interest
(PI of the individual responses). The extent to which it can cover the 95% PI of individual responses
can vary quite signiﬁcantly depending on speciﬁc conditions and assumptions, such as the distribution
that can be assumed for the biomarker within each study and how much the available studies are
representative of the target population. In the current case, an empirical analysis has shown that the
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use of the 95% PI lower limit of the mean response (serum 25(OH)D) concentration) can support the
statement that the majority of the adult population will achieve the target serum concentration.
The Panel therefore sets an AI for vitamin D for adults at 15 lg/day, considering that, at this
intake, the majority of the adult population will achieve the target serum 25(OH)D concentration near
or above 50 nmol/L. The Panel notes that this value for total intake of vitamin D is above the
supplementation dose identiﬁed in Section 5.2.7 in relation to beneﬁcial effect on musculoskeletal
health outcomes. The Panel decided not to set speciﬁc AIs for ‘younger’ or ‘older’ adults, because
there was no evidence of a signiﬁcant difference in absorption capacity of vitamin D between ‘younger’
and ‘older’ healthy adults (Section 2.3.2) and the majority of the studies used to set the target value
for 25(OH)D concentration were carried out in ‘older’ free-living healthy adults (Section 5.1).
The unadjusted model (Appendix C, Table 6) can be also taken into account as it encompasses the
whole heterogeneity across trials. In this unadjusted model, considering a vitamin D intake of
15 lg/day, (i) the lower limit of the 95% PI is 34 nmol/L and (ii) the upper limit of the 95% PI is
91 nmol/L (while 78 nmol/L in the adjusted model). The Panel notes that the value of 34 nmol/L is
above the concentrations that have been observed in relation to overt adverse health outcomes
(Sections 5.1.2.1.2 and 5.1.2.1.6) and that the value of 91 nmol/L (or 78 nmol/L) is in the
physiological range.
The Panel underlines that the meta-regression was done on data collected under conditions of
assumed minimal cutaneous vitamin D synthesis. In the presence of endogenous cutaneous
vitamin D synthesis (Section 2.3.1), the requirement for dietary vitamin D is lower or may even be zero.
6.2. Infants aged 7–11 months
The Panel notes that there are few data on the relationship between serum 25(OH)D concentration
and the risk of adverse musculoskeletal health outcomes available in infants (Section 5.1.2.2). The
Panel notes that there are no data to suggest a different target value for serum 25(OH)D
concentration for infants compared to the adult age group (Section 5.1.6). The Panel also notes that
there is a general agreement that human milk does not contain sufﬁcient vitamin D to prevent rickets
in the breastfed infant (Olafsdottir et al., 2001), that a vitamin D intake of 10 lg/day was considered
adequate for the majority of infants in the ﬁrst half year of life (EFSA NDA Panel, 2013) and that
ESPGHAN Committee on Nutrition recommends a daily oral supplementation of 10 lg vitamin D for all
infants during the ﬁrst year of life starting from birth onwards (Braegger et al., 2013). The
Panel considers that, since breast milk does not supply adequate amounts of vitamin D to the
breastfed infant (Section 2.3.7.2), the derivation of an AI for infants in the second half of the ﬁrst year
of life by extrapolation from the vitamin D intake of exclusively breastfed infants (in the ﬁrst half year)
is not possible (Section 5.3.3).
In line with conclusions by the IOM (Section 4), the Panel notes that two recent trials (Holmlund-
Suila et al., 2012; Gallo et al., 2013) (Sections 5.1.2.2 and 5.2.6) showed that a supplementation with
10 lg/day vitamin D3 in (mostly) breastfed infants was sufﬁcient to reach a plasma/serum 25(OH)D of
at least 50 nmol/L in (almost) all subjects. Only two studies (Ala-Houhala et al., 1986; Atas et al.,
2013) that were conducted in breastfed infants in situation of assumed minimal endogenous vitamin D
synthesis met the eligibility criteria of the comprehensive literature search (Brouwer-Brolsma et al.,
2016) mentioned previously (Sections 5.3.2 and 5.3.3). Giving vitamin D supplementation of 10 lg/day
to breastfed infants for at least 15 weeks led to an achieved mean/median serum 25(OH)D
concentration of at least 80 nmol/L in both studies.
The Panel sets an AI for vitamin D for infants aged 7–11 months at 10 lg/day.
6.3. Children
The Panel notes that there are few data on the relationship between serum 25(OH)D concentration
and the risk of adverse musculoskeletal health outcomes available in children (Section 5.1.2.2). The
Panel notes that there are no data to suggest a different target value for serum 25(OH)D
concentration for children compared to the adult age group (Section 5.1.6).
The Panel sets an AI for vitamin D for adults at 15 lg/day, based on the analysis of the adjusted
and unadjusted models of the meta-regression analysis (Sections 5.3.2 and 6.1, and Appendix C) that
were obtained from data collected mostly on adults, but also on children. Thus, this value of 15 lg/day
may also apply to children.
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From Appendices C and D.G, a further stratiﬁed analysis by age group (adults versus children)
(Section 5.3.2) showed that children tended to achieve the same mean serum 25(OH)D concentrations
as the adults at a lower total intake (Appendix D.G). In addition, in the analysis based only on the four
trials in children (age range: 2–17 years, nine arms), taking into account the limitations previously
described in details (Section 5.3.2):
• In the adjusted model (adjusted only for baseline serum 25(OH)D concentration), the total
intake estimated to achieve a serum 25(OH)D concentration of 50 nmol/L (Appendix D.G,
Table 15), at the lower limit of the 95% CI, is 7.9 lg/day and at the lower limit of the 95% PI
is 10.9 lg/day. In the unadjusted model, the total intake estimated to achieve a serum 25(OH)
D concentration of 50 nmol/L, at the lower limit of the 95% CI, is 11.5 lg/day and, at the
lower limit of the 95% PI, is 27.6 lg/day.
• Equally, at a vitamin D intake of 15 lg/day (Appendix D.G, Table 14), in the adjusted model
(adjusted only for baseline mean serum 25(OH)D), the predicted mean serum 25(OH)D
concentration is 67 nmol/L (95% CI: 61–73 nmol/L), with a predicted value at the lower limit
of the 95% PI of 55 nmol/L. In the unadjusted model, at a vitamin D intake of 15 lg/day, the
predicted mean serum 25(OH)D concentration is 73 nmol/L (95% CI: 56–91 nmol/L), with a
predicted value at the lower limit of the 95% PI of 35 nmol/L. The Panel notes that this value
of 35 nmol/L is above the concentrations that have been observed in relation to overt adverse
health outcomes (Section 5.1.2.2.2).
The Panel sets an AI for vitamin D for all children (1–17 years) at 15 lg/day. The Panel underlines
that the meta-regression was done on data collected under conditions of assumed minimal
cutaneous vitamin D synthesis. In the presence of endogenous cutaneous vitamin D synthesis
(Section 2.3.1), the requirement for dietary vitamin D is lower or may even be zero.
6.4. Pregnancy
The Panel notes that there are no data to suggest a different target value for 25(OH)D
concentration for pregnant women compared to non-pregnant women (Sections 5.1.3 and 5.1.6).
The Panel considers that the AI for pregnant women is the same as for non-pregnant women
(15 lg/day). The Panel underlines that the meta-regression on adults (Sections 5.3.2 and 6.1) was
done on data collected under conditions of assumed minimal cutaneous vitamin D synthesis.
In the presence of endogenous cutaneous vitamin D synthesis (Section 2.3.1), the requirement for
dietary vitamin D is lower or may even be zero.
6.5. Lactation
The Panel notes that no studies were available for setting an AI for lactating women (Sections 5.1.4
and 5.1.6). The Panel notes that mean vitamin D concentrations in breast milk of healthy lactating
women, unsupplemented or supplemented with vitamin D, are low (0.25–2.0 lg/L), that maternal
vitamin D intake during lactation inﬂuences maternal serum 25(OH)D concentration, but is only modestly
correlated with the amount of vitamin D in human milk, unless high supplemental doses are used. The
Panel considers that the derivation of DRVs for vitamin D for lactating women based on the
compensation of the vitamin D loss in breast milk is not justiﬁed (Sections 2.3.7 and 5.3.3).
The Panel considers that the AI for lactating women is the same as for non-lactating women
(15 lg/day). The Panel underlines that the meta-regression on adults (Sections 5.3.2 and 6.1) was
done on data collected under conditions of assumed minimal cutaneous vitamin D synthesis.
In the presence of endogenous cutaneous vitamin D synthesis (Section 2.3.1), the requirement for
dietary vitamin D is lower or may even be zero.
Conclusions
The Panel concludes that ARs and PRIs for vitamin D cannot be derived for adults, infants and
children, and therefore deﬁnes AIs, for all population groups. The Panel considers that serum 25(OH)D
concentration, which reﬂects the amount of vitamin D attained from both cutaneous synthesis and
dietary sources, can be used as a biomarker of vitamin D intake in adult and children populations with low
exposure to UV-B irradiation and as a biomarker of vitamin D status. The Panel notes that the evidence on
the relationship between serum 25(OH)D concentration and the risk of musculoskeletal health outcomes
in (healthy) adults, infants and children, and some adverse pregnancy-related health outcomes, is widely
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variable. Several factors contribute to this, and also include the large variation in the results from different
laboratories and assays used for measuring serum 25(OH)D concentrations. Taking into account the
overall evidence and uncertainties, the Panel considers that a serum 25(OH)D concentration of 50 nmol/L
is a suitable target value for all population groups, in view of setting the AIs for vitamin D.
For adults, the Panel sets an AI for vitamin D at 15 lg/day. This is based on an adjusted model of the
meta-regression analysis of serum 25(OH)D concentration according to total vitamin D intake (natural log
of the sum of habitual diet, and fortiﬁed foods or supplements using vitamin D3). The Panel considers
that, at this intake, the majority of the adult population will achieve a serum 25(OH)D concentration near
or above the target of 50 nmol/L. For children aged 1–17 years, the Panel sets an AI for vitamin D at
15 lg/day, based on the meta-regression analysis. For infants aged 7–11 months, the Panel sets an AI
for vitamin D at 10 lg/day, based on four recent trials on the effect of vitamin D supplementation on
serum 25(OH)D concentration in (mostly) breastfed infants. For pregnant and lactating women, the
Panel considers that the AI is the same as for non-pregnant non-lactating women, i.e. 15 lg/day. The
Panel underlines that the meta-regression in adults and children was done on data collected under
conditions of assumed minimal cutaneous vitamin D synthesis. In the presence of endogenous cutaneous
vitamin D synthesis, the requirement for dietary vitamin D is lower or may even be zero (Table 4).
Recommendations for Research
There is a need for further research to study the respective impact of vitamin D dietary intake and
sunlight exposure on serum 25(OH)D concentrations. Future studies should investigate food-based
strategies to ensure adequate vitamin D intakes accounting for latitude, sunlight exposure and diet.
Studies are needed that are speciﬁcally designed to identify cut-off values for serum 25(OH)D
concentration or other suitable biomarkers for vitamin D status to derive DRVs for vitamin D for
infants, children, adults, pregnant and lactating women.
Standardised investigations are needed to assess changes in musculoskeletal health outcomes (and
surrogate markers) in response to vitamin D2 and D3 intake, and in relation to serum 25(OH)D
concentrations.
The potential mechanisms of the cause and effect relationships between vitamin D and non-
musculoskeletal health outcomes should be further explored.
There is a need for studies that assess the different diets of infants, in particular those consuming
infant or follow-on formulas and processed cereal-based foods fortiﬁed with vitamin D in addition to
vitamin D supplements.
More data on the effects of genotype and body fat mass on vitamin D metabolism and the
requirements for vitamin D are warranted.
More precise data on total vitamin D concentration in foods would also be useful. Studies
investigating the effect of 25(OH)D naturally occurring in foods on serum 25(OH)D concentration are
also suggested.
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aBMD areal bone mineral density
ADL activities of daily living
Afssa Agence francaise de securite sanitaire des aliments
AHRQ Agency for Healthcare Research and Quality
AI adequate intake
ALP alkaline phosphatase
AMD age-related macular degeneration
AR average requirement
BA bone area
BioE bioavailable estradiol
BioT bioavailable testosterone
BMC bone mineral content
BMD bone mineral density
BMI body mass index
BV bone volume
CI conﬁdence interval
CPBA competitive protein binding assay
CSA cross-sectional area
CVD cardiovascular disease
CYP cytochrome P450
CYP24A1 24-hydroxylase
CYP27B1 1a-hydroxylase
CYP2R1, CYP27A1, CYP3A4, CYP2J3 25-hydroxylase
D-A-CH Deutschland-Austria-Confoederatio Helvetica
DBP Vitamin D-binding protein
DEQAS Vitamin D External Quality Assessment Scheme
DHCR7 7-dehydrocholesterol reductase
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DRV dietary reference value
DXA dual-energy X-ray absorptiometry
EAR estimated average requirement
ELISA enzyme-linked immunosorbent assay
EOSP early onset severe pre-eclampsia
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology
and Nutrition
FAO Food and Agriculture Organisation
FGF-23 ﬁbroblast growth factor 23
GC group speciﬁc component gene
HPLC high-performance liquid chromatography
HR hazard ratio
HRadj HR adjusted
I2 heterogeneity index
IOM US Institute of Medicine of the National Academy of Sciences
IQR interquartile range
ITT intention-to-treat
IU International unit
LC–MS liquid chromatography–mass spectroscopy
LC–MS/MS liquid chromatography-tandem mass spectroscopy
LMQ leg muscle quality
NCM Nordic Council of Ministers
NIST National Institute of Standards and Technology
NNR Nordic Nutrition Recommendations
NOAEL No Observed Adverse Effect Level
OR odds ratio
OV osteoid volume
PI prediction interval
pQCT peripheral quantitative computed tomography
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PRI population reference intake
PTH parathyroid hormone
Q1 ﬁrst quartile
QCT quantitative computed tomography
QUS quantitative ultrasound
RCT randomised controlled trial
RDA recommended dietary allowance
RI Recommended Intake
RIA radioimmunoassay
RMP Reference measurement procedure
RNI Reference Nutrient Intake
RoB risk of bias
RR relative risk
SACN Scientiﬁc Advisory Committee on Nutrition
SCF Scientiﬁc Committee for Food
SD standard deviation
SGA small-for-gestational-age
SH sex hormones
SHBG sex hormone binding globulin
SNP single nucleotide polymorphism
SPPB short physical performance battery
TUAG Timed Up And Go
UHT ultra-high temperature
UL tolerable upper intake level
UV ultraviolet
VDR Vitamin D receptor
VDSP Vitamin D standardization program
Vitamin D2 ergocalciferol
Vitamin D3 cholecalciferol
WHO World Health Organization
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Appendix A – Measurements for the assessment of bone health
Bone measurements in children and adults may be obtained using different techniques of bone
densitometry, e.g. dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT),
peripheral quantitative computed tomography (pQCT) or quantitative ultrasound (QUS). Assessments of
the advantages, precision, speciﬁcity and sensitivity of these methods in different populations (for
example: Baroncelli, 2008; Brunner et al., 2011; Edelmann-Schafer et al., 2011) and recommendations
on their use (e.g. from the International Society for Clinical Densitometry) have been published.
DXA is the most commonly used method of measuring bone mass. DXA measurements may include
lumbar spine, hip, forearm and whole body. The DXA scans provide a number of outcomes: bone area,
bone mineral content (BMC) and bone mineral density (BMD) in the above-mentioned anatomical
areas. BMD is a two-dimensional measurement of the bone, i.e. areal BMD (aBMD, g/cm2). The
calibration of the different DXA densitometers may differ between studies, resulting in different BMD
and BMC values.
In contrast, QCT, which also involves X-ray radiation, is used to measure three-dimensional
(volumetric) BMD (g/cm3) in the spine or hip, and to assess bone structure, i.e. separately analyse
BMD for the compact (or cortical) bone or for the trabecular (or cancellous) bone. Moreover, pQCT
measures bone characteristics in ‘peripheral’ body sites, such as the forearms or legs, and provides a
number of outcomes, e.g. volumetric BMD, the stress–strain index and measures of the geometry of
the bone (i.e. spatial distribution of the bone mass) (Section 5.1.2). QUS methods have been
developed to give estimates of bone health, without the use of ionising radiation. Measurements are
usually performed at the heel (calcaneus). In its review, the Panel did not identify any recent relevant
study on bone-related outcomes using this technique.
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Appendix B – Summary of the evidence considered by the IOM to set DRVs
for vitamin D
1. Adults
IOM (2011) used mostly the systematic reviews by Cranney et al. (2007) and by Chung et al.
(2009) to draw conclusions on 25(OH)D concentrations and bone-related health outcomes.
Cranney et al. (2007) considered 19 studies on the association between serum 25(OH)D
concentrations and BMD in older adults. They comprised six randomised controlled trial (RCTs)
on vitamin D supplementation with calcium (Dawson-Hughes et al., 1995; Storm et al., 1998;
Schaafsma et al., 2002; Cooper et al., 2003; Aloia et al., 2005) or without calcium (Ooms et al., 1995).
These RCTs and two cohort studies (Dennison et al., 1999; Gerdhem et al., 2005) reported no
signiﬁcant association between serum 25(OH)D concentrations and BMD or bone loss. However, ﬁve
other cohort studies reported a signiﬁcant association, particularly at the hip sites (Rosen et al., 1994;
Stone et al., 1998; Melin et al., 2001; del Puente et al., 2002; Bischoff-Ferrari et al., 2005), and only
one at the lumbar spine (Rosen et al., 1994). Six case–control studies (Villareal et al., 1991; Thiebaud
et al., 1997; Boonen et al., 1999; Landin-Wilhelmsen et al., 1999; Yan et al., 2003; Al-oanzi et al.,
2006) reported an association between 25(OH)D concentrations and BMD, most consistently at the
femoral neck. Chung et al. (2009) included two additional RCTs (Andersen et al., 2008, Zhu et al.,
2008b). Zhu et al. (2008b) showed that vitamin D2 supplementation over 1 year provided no extra
beneﬁt in older Caucasian women (mean baseline serum 25(OH)D concentration: 44.3 nmol/L) on total
hip BMD compared to calcium supplementation alone. Andersen et al. (2008) reported no effect of the
vitamin D3 supplementation on BMC/BMD and no differences in 1-year BMD changes at the lumbar
spine between the intervention and placebo groups, either in female or in male Pakistani immigrants in
Denmark (mean baseline serum 25(OH)D concentration: 12 (women) and 21 (men) nmol/L).
With regard to vitamin D supplementation with or without calcium in older adults and
BMD, Cranney et al. (2007) identiﬁed 17 RCTs (Dawson-Hughes et al., 1991, 1995, 1997; Chapuy
et al., 1992, 2002; Ooms et al., 1995; Baeksgaard et al., 1998; Komulainen et al., 1998; Hunter et al.,
2000; Patel et al., 2001; Jensen et al., 2002; Cooper et al., 2003; Grados et al., 2003; Harwood et al.,
2004; Meier et al., 2004; Aloia et al., 2005; Jackson et al., 2006), mostly in post-menopausal women
and older men (a few references (Patel et al., 2001; Meier et al., 2004) also included younger
subjects). Combining results of individual studies to calculate weighted mean differences, Cranney
et al. (2007) concluded that vitamin D3 plus calcium supplementation compared with placebo resulted
in ‘small’ signiﬁcant increases in BMD of the lumbar spine, total body and femoral neck (but not of the
forearm). However, they concluded that vitamin D3 plus calcium compared with calcium did not have a
signiﬁcant effect on BMD of the lumbar spine, total hip, forearm or total body (but the effect for
femoral neck was signiﬁcant). They also concluded that vitamin D3 supplementation alone versus
placebo had a signiﬁcant effect on BMD at the femoral neck but not at the forearm. Chung et al.
(2009) identiﬁed three additional RCTs in older adults (Moschonis and Manios, 2006; Bolton-Smith
et al., 2007; Zhu et al., 2008a), only two of which (Moschonis and Manios, 2006; Zhu et al., 2008a)
found a signiﬁcant increase in hip or total BMD in post-menopausal women receiving vitamin D2 or D3
plus calcium compared with placebo.
For osteomalacia, the IOM used a study on post-mortem biopsies (Priemel et al., 2010)
(Section 5.1.2.1.2).
For fracture risk in older adults, with regard to serum 25(OH)D concentrations, Cranney
et al. (2007) identiﬁed only observational studies. They took into account three prospective cohort
studies in independently living older adults (Woo et al., 1990; Cummings et al., 1998; Gerdhem et al.,
2005). They also considered case–control studies (Lund et al., 1975; Lips et al., 1983, 1987; Punnonen
et al., 1986; Cooper et al., 1989; Lau et al., 1989; Boonen et al., 1997, 1999; Thiebaud et al., 1997;
Diamond et al., 1998; Landin-Wilhelmsen et al., 1999; LeBoff et al., 1999; Erem et al., 2002;
Bakhtiyarova et al., 2006). Cranney et al. (2007) concluded that there was inconsistent evidence for an
association between a lower serum 25(OH)D concentration and an increased risk of fracture. IOM
(2011) identiﬁed six additional observational studies (Cauley et al., 2008, 2010; Looker and Mussolino,
2008; van Schoor et al., 2008; Ensrud et al., 2009; Melhus et al., 2010). These showed inconsistent
results on 25(OH)D concentrations below which there may be an increased risk of fracture, which
varied between 30 and 70 nmol/L.
With regard to vitamin D supplementation and risk of fractures, Cranney et al. (2007)
assessed 15 RCTs (Chapuy et al., 1992, 2002; Lips et al., 1996; Dawson-Hughes et al., 1997;
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Komulainen et al., 1998; Pfeifer et al., 2000; Trivedi et al., 2003; Anderson et al., 2004; Harwood
et al., 2004; Larsen et al., 2004; Flicker et al., 2005; Grant et al., 2005; Porthouse et al., 2005;
Jackson et al., 2006; Law et al., 2006). These RCTs investigated the effect of vitamin D (with or
without calcium) on fractures in post-menopausal women and older men with baseline 25(OH)D
concentrations ranging from 22 to 82.7 nmol/L. Eleven of these RCTs used vitamin D3 preparations
(7.5–20 lg/day), and the others vitamin D2 (Anderson et al., 2004; Larsen et al., 2004; Flicker et al.,
2005; Law et al., 2006). Cranney et al. (2007) conducted a meta-analysis of 13 of these RCTs,
omitting the abstract by Anderson et al. (2004) and the study by Larsen et al. (2004) with no placebo
control. Cranney et al. (2007) calculated combined ORs that indicated non-signiﬁcant effect of the
interventions for total fractures,33 non-vertebral fractures,34 hip fractures,35 vertebral fractures,36 and
total or hip fractures in community-dwelling older adults. Combined ORs also indicated signiﬁcant
reduction in the risk of fractures for end of study 25(OH)D concentration ≥ 74 nmol/L (compared to 25
(OH)D < 74 nmol/L),37 and for total or hip fractures in institutionalised older adults.38 Chung et al.
(2009) identiﬁed three additional RCTs on bone health (Bunout et al., 2006; Burleigh et al., 2007;
Lyons et al., 2007), two of which investigated fracture risk. These did not show signiﬁcant effects of
either vitamin D2 (four-monthly dose equivalent to 20.6 lg/day) compared with placebo, or of vitamin
D3 (20 lg/day) plus calcium compared with calcium, in reducing the risk of total fractures, in a cohort
of hospital inpatients (Burleigh et al., 2007) and in older adults living in residential or care homes
(Lyons et al., 2007). IOM (2011) identiﬁed two additional RCTs (Salovaara et al., 2010; Sanders et al.,
2010). In both studies, there was no statistically signiﬁcant effect of the combination of calcium and
vitamin D3 on incident fractures compared to no treatment.
Based on Cranney et al. (2007) and Chung et al. (2009) and observational data outside of these
reviews (four other cross-sectional (Bischoff-Ferrari et al., 2004; Boxer et al., 2008; Stewart, 2009) or
longitudinal (Wicherts et al., 2007) observational studies), IOM (2011) found that there was some
support for an association between 25(OH)D concentrations and physical performance (data for
this outcome were considered together with that for the risk of falls mentioned below). However,
IOM (2011) found that high-quality and large observational cohort studies were lacking, and that
randomised trials suggest that vitamin D dosages of at least 20 lg/day, with or without calcium,
may improve physical performance measures. Although the IOM considered that high doses of
vitamin D (i.e. ≥ 20 lg/day) may provide greater beneﬁt for physical performance than low doses
(i.e. 10 lg/day), the IOM found that the evidence was insufﬁcient to deﬁne the shape of the dose–
response curve for higher levels of intake.
Based on Cranney et al. (2007) and Chung et al. (2009) and two RCTs (Bischoff-Ferrari et al.,
2010; Sanders et al., 2010) published afterwards, IOM (2011) considered that no consistent result was
found from randomised trials that tested for effects of vitamin D with and without calcium on
reduction in risk for falls. IOM considered 20 randomised trials on oral doses (Graafmans et al.,
1996; Pfeifer et al., 2000, 2009; Chapuy et al., 2002; Bischoff-Ferrari et al., 2003, 2006, 2010; Trivedi
et al., 2003; Flicker et al., 2005; Grant et al., 2005; Larsen et al., 2005; Law et al., 2006; Broe et al.,
2007; Burleigh et al., 2007; Prince et al., 2008) or injected doses (Latham et al., 2003; Dhesi et al.,
2004; Harwood et al., 2004; Smith et al., 2007; Sanders et al., 2010). These RCTs had heterogeneous
designs, e.g. subjects were either free-living or institutionalised older subjects, and supplemented with
vitamin D with or without calcium and compared to calcium or placebo. From these, IOM noted that
only four (Pfeifer et al., 2000; Harwood et al., 2004; Flicker et al., 2005; Broe et al., 2007) found a
signiﬁcant effect of vitamin D on fall incidence, and that there were only two signiﬁcant studies for
fallers (Pfeifer et al., 2000, 2009).39 The IOM (2011) noted that a number of the RCTs analysed falls
rather than fallers. The IOM concluded that the greater part of the causal evidence indicated no
signiﬁcant reduction in fall risk related to vitamin D intake or achieved concentration in blood. IOM
33 Vitamin D2 or D3 +/ calcium compared with calcium or placebo, vitamin D3 compared with placebo, vitamin D3 + calcium
compared with calcium.
34 Vitamin D3 compared with placebo, vitamin D3 + calcium compared placebo.
35 Vitamin D3 compared with placebo, vitamin D3 + calcium compared with calcium, vitamin D3 + calcium compared placebo.
36 Vitamin D2 or D3 +/ calcium compared with calcium or placebo.
37 In four trials using vitamin D3 with end of study 25(OH)D concentrations of > 74 nmol/L, out of 10 trials reporting follow-up
or change in mean 25(OH)D concentrations.
38 Older adults receiving vitamin D2 or D3 with calcium, compared to calcium or placebo (three trials on total fractures), or
vitamin D3 with calcium, compared to placebo (two trials on hip fractures, combined OR: 0.69; 95 % CI: 0.53–0.90).
39 In a sensitivity analysis, Cranney et al. (2007) found that combining the results from eight trials on oral vitamin D2 or D3 with
calcium, compared to placebo or calcium alone, showed a signiﬁcant reduction in the risk of falls (OR: 0.84 ; 95% CI:
0.76–0.93), heterogeneity I2 = 0%).
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(2011) noted that Cranney et al. (2007)40 and Chung et al. (2009) found no consistency between
study ﬁndings. With regard to the evidence from observational studies, the IOM noted one longitudinal
Dutch study (Snijder et al., 2006) (which was not part of Cranney et al. (2007) or Chung et al. (2009))
that found that a serum 25(OH)D concentration < 25 nmol/L was independently associated with an
increased risk of falling for subjects who experienced two or more falls compared with those who did
not fall or fell once. IOM (2011) summarised that observational studies suggested an association
between a higher serum 25(OH)D concentration and a lower risk of falls in older adults.
In relation to calcium absorption in adults, IOM (2011) considered RCTs in mainly post-
menopausal women with vitamin D supplementation (Francis et al., 1996; Patel et al., 2001; Zhu et al.,
2008a,b), using the dual isotope technique. The RCTs varied considerably in design and, overall,
showed no effect of increasing the serum 25(OH)D concentrations on intestinal calcium absorption
compared with placebo. In a short-term RCT in post-menopausal women using the dual isotope
technique, Hansen et al. (2008) showed a 3% increase in absorption after raising the serum 25(OH)D
concentration from 55 to 160 nmol/L. IOM also considered cross-sectional studies using the single
isotope technique (Kinyamu et al., 1998; Devine et al., 2002; Heaney et al., 2003a; Need et al., 2008;
Aloia et al., 2010). In particular, in 319 patients (mostly men) attending osteoporosis clinics and with
serum 25(OH)D concentrations less than 40 nmol/L, Need et al. (2008) found no increase in fractional
calcium absorption in subjects with serum 25(OH)D concentrations above 10 nmol/L. The studies by
Heaney et al. (2003a) and Kinyamu et al. (1998) indicated no changes in fractional calcium absorption
across ranges of serum 25(OH)D concentrations of 60–154 nmol/L and 50–116 nmol/L, respectively. In
the study by Aloia et al. (2010) in 492 African American and 262 Caucasian women (20–80 years), no
relationship was found between calcium absorption and serum 25(OH)D concentrations ranging from
30 to 150 nmol/L. The relationship between calcium absorption and 1,25(OH)2D concentration was
positive and stronger for lower than for higher 25(OH)D concentrations.
IOM (2011) concluded that serum 25(OH)D concentrations of 40 nmol/L, 50 nmol L or higher
were sufﬁcient to meet bone health requirements for most adults in RCTs, and to provide maximal
population coverage in observational studies on adults and bone health.
2. Infants and children
For infants, Cranney et al. (2007) reported on the inconsistent results of two RCTs with vitamin D2
supplementation examining serum 25(OH)D concentrations and BMC (Greer et al., 1982; Greer and
Marshall, 1989), and on the inconsistent results of three case–control studies (Bougle et al., 1998;
Namgung et al., 1998; Park et al., 1998) examining serum 25(OH)D concentrations and BMD and/or
BMC. Chung et al. (2009) found no additional RCTs in infants.
For children, Cranney et al. (2007) identiﬁed three RCTs (Ala-Houhala et al., 1988b; El-Hajj Fuleihan
et al., 2006; Viljakainen et al., 2006a), two prospective cohort studies (Lehtonen-Veromaa et al., 2002;
Javaid et al., 2006), and one case–control study (Marwaha et al., 2005). In children (8–10 years)
receiving vitamin D2 supplementation or placebo for more than 1 year (Ala-Houhala et al., 1988b), the
change in serum 25(OH)D concentrations after supplementation was not accompanied by a change in
distal radial BMC. However, Cranney et al. (2007) reported, in girls (10–17 years) receiving two doses of
vitamin D3 supplementation or a placebo for 1 year (El-Hajj Fuleihan et al., 2006), that baseline serum
25(OH)D concentrations were signiﬁcantly related to baseline BMD (positively) or per cent change in
BMC (negatively), at the lumbar spine, femoral neck, and radius. They also reported for this study a
signiﬁcant increase in BMC only of the total hip in girls receiving the highest dose of supplementation,
compared with placebo (El-Hajj Fuleihan et al., 2006). In girls (11–12 years) with ‘adequate’ calcium
intake and who received one of two doses of daily vitamin D3 supplementation or a placebo for 1 year,
mean achieved serum 25(OH)D was above 50 nmol/L in both intervention groups (Viljakainen et al.,
2006a). A signiﬁcant increase in BMC of the femur (for both doses) or lumbar spine (for the highest
dose) was reported in subjects with compliance above 80 %, but this was not statistically signiﬁcant in
the ITT analysis. Cranney et al. (2007) reported a positive association between baseline serum 25(OH)D
concentrations of girls (9–15 years) followed for 3 years and change in BMD (Lehtonen-Veromaa et al.,
40 In total, Cranney et al. (2007) identiﬁed one RCT, three cohort studies and one case–control study on the association between
serum 25(OH)D concentrations and risk of falls, as well as three RCTs and four cohort studies on the association between 25
(OH)D concentrations and measures of performance (among these, one cohort investigated both risk of falls and measures of
performance). Chung et al. (2009) identiﬁed three additional RCTs on vitamin D supplementation and the risk of falls,
including one which also investigated measures of performance, and one additional RCTs on vitamin D with calcium and
measures of performance.
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2002), and between maternal serum 25(OH)D during pregnancy and BMC of the children (8–9 years)
(Javaid et al., 2006). However, there was no signiﬁcant correlation between serum 25(OH)D and BMD of
children (10–18 years) in either group of the case–control study (Marwaha et al., 2005).
Cranney et al. (2007) concluded that there was evidence of an association between serum 25(OH)
D concentrations and baseline BMD and change in BMD or related variables, but that the results of
RCTs were not consistent with regard to the effect of vitamin D supplementation on BMD or BMC
across skeletal sites and age groups. Chung et al. (2009) identiﬁed one RCT in 26 healthy Pakistani
immigrant girls (10–17 years) living near Copenhagen (mean baseline 25(OH)D concentration:
11 nmol/L), and receiving one of two doses of vitamin D3 supplementation alone or a placebo
(Andersen et al., 2008). There were no signiﬁcant differences in whole-body BMC changes between
the supplemented groups and the placebo group. Chung et al. (2009) identiﬁed another RCT (Cheng
et al., 2005) in healthy girls (10–12 years) (mean baseline 25(OH)D concentration: 35 nmol/L)
receiving supplementation with vitamin D3 and calcium or a placebo, which showed no signiﬁcant
difference in BMC changes between groups after 2 years.
According to IOM (2011) and Cranney et al. (2007), among 13 studies on rickets, six (including
one RCT (Cesur et al., 2003)) reported mean or median serum 25(OH)D concentrations below
27.5 nmol/L, and expressed as about 30 nmol/L, in children with rickets (Garabedian et al., 1983;
Markestad et al., 1984; Bhimma et al., 1995; Majid Molla et al., 2000; Cesur et al., 2003; Dawodu
et al., 2005). The others (before-after or case–control) studies were reported as showing mean/
median serum 25(OH)D concentrations higher than 30 nmol/L and up to 50 nmol/L in children with
rickets (Arnaud et al., 1976; Elzouki et al., 1989; Oginni et al., 1996; Thacher, 1997; Thacher et al.,
2000; Balasubramanian et al., 2003; Graff et al., 2004). Seven case–control studies showed lower
serum 25(OH)D concentrations in cases than in controls (Arnaud et al., 1976; Oginni et al., 1996;
Majid Molla et al., 2000; Thacher et al., 2000; Balasubramanian et al., 2003; Graff et al., 2004;
Dawodu et al., 2005). Three studies were conducted in Western countries (Arnaud et al., 1976;
Garabedian et al., 1983; Markestad et al., 1984), while most were conducted in non-Western countries
with low calcium intake. Cranney et al. (2007) noted that low calcium intake can inﬂuence the
relationship between serum 25(OH)D and rickets and that the 25(OH)D cut-off value for rickets in
populations with high calcium intake is unclear. Chung et al. (2009) did not identify any additional
study on rickets.
For children, IOM (2011) identiﬁed two dual isotope studies (an observational study (Abrams et al.,
2009) or a randomised trial (Thacher et al., 2009)) on fractional calcium absorption, and a pooled
analysis of several 3-week calcium-balance metabolic studies in 105 girls (11–15 years) (Weaver et al.,
2008), in which serum 25(OH)D concentration was not related to net calcium absorption or retention.
However, in this last study, calcium balance or retention was calculated by subtracting calcium
excretion through urine and faeces from dietary calcium intake. Pooling studies in 251 children (about
5–17 years) and assessing the relationship of 25(OH)D concentration (as a continuous variable) with
either fractional or total calcium absorption, according to pubertal status and/or calcium intake,
Abrams et al. (2009) found inconsistent results. However, when 25(OH)D was studied as a categorical
variable in the whole population, fractional calcium absorption adjusted (in particular) for calcium
intake was slightly, but signiﬁcantly (p < 0.05), higher at 25(OH)D concentration of 28–50 nmol/L,
compared with ranges of 50–80 nmol/L or greater than 80 nmol/L. In Nigeria, 17 prepubertal children,
with rickets, ‘low’ calcium intake and mean baseline 25(OH)D concentration of 50 nmol/L, were
randomised to receive single oral supplementation of vitamin D2 or D3 (Thacher et al., 2009). An
increase in serum 25(OH)D concentrations was reported in both groups, but at ‘low’ calcium intake
and with no signiﬁcant increase in fractional calcium absorption between baseline and 3 days after
supplementation (Thacher et al., 2009).
3. Pregnancy
For IOM (2011), during pregnancy, maternal 1,25(OH)2D increases, while 25(OH)D is generally
unaffected in unsupplemented women. Animal data reviewed by IOM (2011) suggested that the
increased calcium absorption during pregnancy is independent from vitamin D or 1,25(OH)2D, and
observational data showed that vitamin D-deﬁciency rickets may develop weeks or months after birth.
For maternal bone health during pregnancy, Cranney et al. (2007) identiﬁed two prospective
observational studies (Ardawi et al., 1997; Morley et al., 2006) and one before-and-after study (Datta
et al., 2002), which found either a negative or no correlation between maternal serum 25(OH)D and
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parathyroid hormone (PTH) concentrations. Maternal BMD/BMC was not investigated in these studies.
Chung et al. (2009) or IOM (2011) identiﬁed no RCTs for this outcome.
For the prevention of pre-eclampsia, the IOM noted the absence of placebo-controlled
randomised trials in favour of an effect of vitamin D. One RCT (Marya et al., 1987) (identiﬁed by
Chung et al. (2009)) found no effect of vitamin D and calcium supplementation on the incidence of
pre-eclampsia and the results of a non-randomised trial on vitamin D3 and calcium supplementation
(Ito et al., 1994) were found unclear. Two observational studies showed inverse associations between
vitamin D intake from supplements and risk of pre-eclampsia (Hypponen et al., 2007; Haugen et al.,
2009). For the IOM, case–control or nested case–control studies (including one (Bodnar et al., 2007)
found by Chung et al. (2009)), investigating serum 25(OH)D concentration and the risk of
pre-eclampsia or comparing serum 25(OH)D concentration in women with or without pre-eclampsia,
found contradictory results (Frolich et al., 1992; Seely et al., 1992; Bodnar et al., 2007). However, one
case–control study (Lalau et al., 1993) showed lower total or free serum 1,25(OH)2D in women with
pregnancy-induced hypertension.
The IOM noted the limited observational evidence on non-skeletal maternal outcomes
(caesarean section, obstructed labour, vaginosis), reviewed neither in Cranney et al. (2007) nor in
Chung et al. (2009). In RCTs (most identiﬁed by Chung et al. (2009)) on maternal vitamin D
supplementation and birth weight or length (Brooke et al., 1980; Maxwell et al., 1981; Mallet et al.,
1986; Marya et al., 1988), no effect was observed. IOM also reported on observational studies with
conﬂicting results on vitamin D intake/status during pregnancy and infant birth size or small-for-
gestational age measurements (Brunvand et al., 1998; Morley et al., 2006; Gale et al., 2008;
Farrant et al., 2009; Scholl and Chen, 2009; Bodnar et al., 2010; Leffelaar et al., 2010).
For fetal/newborn bone health, an RCT (Delvin et al., 1986) was reported as showing no effect
of maternal vitamin D supplementation on fetal calcium homeostasis. The IOM also considered
observational studies (Maxwell and Miles, 1925; Brooke et al., 1980; Congdon et al., 1983; Silver et al.,
1985; Pereira and Zucker, 1986; Campbell and Fleischman, 1988; Specker et al., 1992; Specker, 1994;
Takeda et al., 1997; Teotia and Teotia, 1997; Kitanaka et al., 1998; Akcakus et al., 2006; Bouillon
et al., 2006; Beck-Nielsen et al., 2009). From them, the IOM concluded that there was no relationship
between maternal 25(OH)D concentration and fetal BMC or BMD, as well as normal fetal skeletal
development and no radiological evidence of rickets at birth in case of maternal vitamin D ‘deﬁciency’
or the absence of 1a-hydroxylase or the vitamin D receptor (VDR). Other observational studies were
reported as showing lower maternal and neonatal serum 25(OH)D concentrations in infants with
craniotabes (Reif et al., 1988) and an inverse association between fetal femur metaphyseal cross-
sectional area or splaying index and maternal 25(OH)D during pregnancy (Mahon et al., 2010). From
another observational study (Viljakainen et al., 2010), the IOM noted the lower newborn tibia BMC and
cross-sectional area with maternal serum 25(OH)D concentration below 42.6 nmol/L (mean of ﬁrst
trimester and two-day post-partum values, close to the ‘EAR-type value’ proposed by the IOM),
compared to higher serum 25(OH)D, after adjustments for potential confounders.
Regarding the relationship between maternal 25(OH)D during pregnancy and childhood bone
health, the IOM refers to a study providing follow-up data on 33% of the children included in a
mother-infant cohort (n = 596 initially) (Javaid et al., 2006). This observational study reported a
positive association between whole-body and lumbar spine BMC and aBMD in children (9 years) and
maternal serum 25(OH)D concentrations in pregnancy (mean: 34 weeks) after adjustments for
potential confounders. Children of mothers whose serum 25(OH)D concentrations in pregnancy were
less than 27.5 nmol/L (compared to above 50 nmol/L) had a signiﬁcantly lower whole-body BMC
(p = 0.002).
4. Lactation
IOM (2011) stated that breast milk is not a signiﬁcant source of vitamin D for breastfed infants, and
that the maternal skeleton recovers BMC after the end of lactation. IOM (2011) considered
observational studies (Cancela et al., 1986; Okonofua et al., 1987; Kent et al., 1990; Alfaham et al.,
1995; Cross et al., 1995; Sowers et al., 1998; Ghannam et al., 1999) and intervention studies (Greer
et al., 1982; Rothberg et al., 1982; Ala-Houhala, 1985; Ala-Houhala et al., 1988b; Greer and Marshall,
1989; Takeuchi et al., 1989; Kalkwarf et al., 1996; Hollis and Wagner, 2004a; Basile et al., 2006;
Wagner et al., 2006; Saadi et al., 2007). Some of these had been identiﬁed by Cranney et al. (2007)
and Chung et al. (2009). From these studies, the IOM reported no major change in serum 25(OH)D
concentration during lactation compared to non-lactating women, and that providing vitamin D to
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lactating mothers increased their serum 25(OH)D concentrations, without signiﬁcant effect on either
infant serum 25(OH)D concentrations (for supplementation below 100 lg/day) or infant weight or
height. The IOM also noted the lack of association between maternal 25(OH)D concentration and
maternal post partum changes in BMD (e.g. lumbar spine or femoral neck), or breast milk calcium
content (Prentice et al., 1997). IOM (2011) noticed that no RCTs had investigated the inﬂuence of
maternal vitamin D intake or status on the recovery of maternal skeletal mineral content after the end
of lactation.
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Appendix C – Dose–response analysis undertaken by EFSA of serum 25
(OH)D to total vitamin D intake: methods and key results
The speciﬁc objective of the quantitative analysis was to estimate the dose–response relationship
between vitamin D total intake and plasma/serum 25(OH)D concentration in situations of assumed
minimal endogenous vitamin D synthesis through exposure to the sun or artiﬁcial ultraviolet (UV)
irradiation in the healthy population.
The analysis as detailed in the present Appendix was developed based on the related analysis plan,
which has been informed by the systematic review protocol drafted by the contractor (Brouwer-
Brolsma et al., 2016) in agreement with EFSA and by speciﬁc input from the NDA WG on dietary
reference values for Vitamins.
Data synthesis: meta-analyses, meta-regression, dose–response models
1. Criteria under which study data were quantitatively synthesised
In a meta-analytic approach, quantitative synthesis is usually carried out if included studies are
sufﬁciently homogeneous to allow for meaningful combined estimates.
In the context of the current analysis, a high statistical heterogeneity across included studies was
expected; the relative contributions of methodological heterogeneity and/or ‘clinical’ heterogeneity
were evaluated by analysing the relevant data extracted at the study level (e.g. dimensions of
methodological quality, intake-status inﬂuencing factors).
In recognition of such heterogeneity, prospective observational studies were analysed separately
from randomised trials, the latter being the basis for the dose–response modelling.
Once the methodological heterogeneity possibly due to differences in the internal validity of the
results from individual studies is characterised, the remaining variation is likely to reﬂect a real
phenomenon that describes the extent to which different populations behave differently.
Independently of the extent to which identiﬁed ‘clinical’ covariates could explain it, heterogeneity was
incorporated in the derivation of DRVs, in the idea that they are being applied to different populations
in different contexts.
The very high heterogeneity was taken into account in meta-analyses and meta-regressions
applying a random-effects model. A random-effects model assumes that true effects follow a
normal distribution around a pooled weighted mean (or around the conditional linear
predictor for models) and allows for the residual heterogeneity among responses not
characterised by subgroups analyses (or not modelled by the explanatory variables
included in the multivariable models).
All statistical analyses were performed with STATA version 13.1 (Stata-Corp, College Station, TX,
USA). Unless otherwise speciﬁed, all estimates were presented with 95% conﬁdence intervals (CIs)
and all analyses were carried out at the level of statistical signiﬁcance of 0.05.
2. Summary measures
The continuous outcome (i.e. plasma/serum 25(OH)D as a marker of vitamin D status) was
analysed using the summary data extracted by the contractor (Brouwer-Brolsma et al., 2016) for each
arm in each individual study: the number of participants included (and assessed); the mean values
and SDs of the baseline and ﬁnal values of 25(OH)D (as reported in the original paper or as
converted by the contractor to nmol/L) at each relevant time point (i.e. ﬁnal concentrations measured
in a period of assumed minimal endogenous vitamin D synthesis) and for each vitamin D dose/intake
(up to 50 lg/day dose).
Summary measures and related standard errors were either calculated or imputed based on the
type of summary data available (e.g. means were estimated from medians when these were available).
Absolute achieved means and their standard errors were meta-analysed and used in the dose–
response meta-regression models. Weighted mean differences (with 95% CI) as calculated by pooling
study-speciﬁc estimates (when a control arm was available) in random-effects meta-analyses were
used for comparative purposes. Net changes from baseline to achieved means by arm were calculated
to check for consistency of results and to identify heterogeneity potentially due to methodological
issues.
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3. Unit of analysis issues
All included trials were assessed in order to check whether the unit of randomisation was consistent
with the unit of analysis in the trial (i.e. per individual randomised).
Only one cross-over trial was initially included (Patel et al., 2001), which was treated according to
the contractor’s criteria (i.e. only the two periods from November through February were considered
eligible and extracted as two different studies: Patel et al., 2001a and Patel et al., 2001b). The trial
was subsequently excluded based on its design and net change values (Table 8 of Appendix D.A).
4. Dealing with missing data
The contractor contacted the original authors of the individual studies to obtain relevant missing
data; imputation was used in the current analysis (e.g. mean age derived from age range) to deal with
key summary information that could not be retrieved despite the contractor’s efforts.
Speciﬁc formulae (Higgins and Green, 2011) were applied to derive summary data where not directly
extracted/available in the format of the statistics mentioned in Section 2 of this Appendix (e.g. SDs
were calculated from standard errors and group size or CIs). If no calculation/estimation was possible,
the missing data were imputed according to the approach proposed by Wan et al. (2014).
Information for all relevant study-level characteristics was complete with the exceptions of funding
source (6% missing), ethnicity (47%) and mean Body Mass Index (28%) (Appendix D.B, Tables 9–11).
Availability of BMI mean values in the ﬁnal data set was maximised by calculating it from mean weight
and mean height (BMI = body weight (kg)/height2 (meters)) when available; missing data proportion
dropped to 16%. While developing the ﬁnal model, BMI missing data were included in a speciﬁc category
as ‘not reported’, to be able to compare models with and without BMI as covariate (i.e. assuring same
number of arms in all models). Funding and ethnicity were analysed likewise, although the high proportion
of missing values for ethnicity prevented it from being included in the ﬁnal model.
Background intake estimates were added to the supplemental vitamin D dose to
generate total vitamin D intake estimates. If the habitual vitamin D intake of the cohort(s)
within a study was not reported, surrogates were imputed using the appropriate age- and
sex- speciﬁc mean vitamin D intake values (from food) from the national nutrition survey
relevant to the country in which the study was performed (17 studies – Appendix D.B,
Table 11); values were weighted for the arm-speciﬁc sex proportions and age ranges.
Only for one trial (Rich-Edwards et al., 2011) on children from Mongolia values were
imputed from another included trial (Madsen et al., 2013) on children from Denmark, as
participants were of comparable age.
Sensitivity analyses to assess the impact of summary data and background intake imputations on
the overall analyses were performed; the intake coefﬁcient estimated in the dose–response model with
no covariates on the revised data did not change substantially from the intake coefﬁcient on the
original values, showing an overall minor impact of imputation on the crude dose–response
relationship.
5. Assessment of heterogeneity
Statistical heterogeneity was tested using the v2 test (Cochran’s Q test; signiﬁcance level: 0.10) and
quantiﬁed by calculating the I2 statistic (Higgins and Thompson, 2002).
I2 ranges between 0 and 100 per cent and quantiﬁes the proportion of the variability
in effect estimates that can be attributed to heterogeneity rather than chance. As a
reference, 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; 75% to 100% represents considerable
heterogeneity (Higgins and Green, 2011).
I2 was 99% in the overall meta-analysis of achieved mean values and did not drop below 94% in
any subgroups except when intervention doses were investigated (85% in trials with dose = 2 lg/day,
76% in trials with dose = 50 lg/day). Given the very high level of heterogeneity between trials,
possible sources were explored by subgroup analysis, meta-regression and/or sensitivity analysis.
6. Data checking
For each variable, the proportion of missing observations was calculated and range checks carried
out to ensure that all values were plausible. The distributions of continuous variables were explored
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graphically and the frequency distributions of categorical variables tabulated. Key variables were cross-
tabulated or scattered against each other to check for consistency. Summary data were double
checked against original publications whenever deemed necessary and unit conversions of all included
25(OH)D and vitamin D dose/intake values were veriﬁed (ng/mL converted to nmol/L by multiplying by
2.496; IU/day converted to lg/day by dividing by 40).
7. Meta-analyses
Random-effects meta-analyses of summary response measures were carried out using the
DerSimonian and Laird approach (DerSimonian and Laird, 1986), which encompasses both variability
due to chance (i.e. the within-study variance component in the denominator of the individual study
weight) and variability due to heterogeneity (i.e. the between-study variance component added in the
denominator of the individual study weight – T2 statistic).
Studies included in the meta-analyses
The mean responses measured as achieved 25(OH)D serum concentration in trial arms (both
placebo/control and intervention groups) in a period of assumed minimal endogenous vitamin D
synthesis were included in the preliminary analyses as long as the related individual trial arms met the
following inclusion criteria:
• Young and older adults as well as children – no pregnant women, no lactating women, no
infants (following discussion with WG members, as these represent particular age/physiological
conditions),
• Vitamin D3 only (as discussion with WG members suggested that intake of vitamin D2 may
have a different impact on 25(OH)D concentration),
• Summary data available or possible to estimate/impute,
• Dose of supplemented vitamin D ≤ 100 lg/day (Tolerable Upper Intake Level set by EFSA for
adults (EFSA NDA Panel, 2012a)).
The inclusion criteria were applied at the arm level, as individual arms were considered the unit of
analysis (except when mean differences were analysed).
After applying the inclusion criteria, 116 arms (49 trials) out of the 141 available in the contractor’s
data set (57 trials from 49 articles41) were left for the preliminary analyses (Appendix D.A, Table 8,
third column showing the 25 excluded arms).
Upon evaluation of inconsistencies and outliers, a further 33 arms were excluded from the
preliminary data set (Appendix D.A, Table 8  fourth column). The ﬁnal data set included 83
arms from 35 trials (Appendix D.B), of which four studies (nine arms) were carried out on children
(overall age range: 2–17 years).
Absolute achieved mean values and mean differences were analysed to check for the inclusion of
trials/arms in the dose–response analysis (preliminary meta-analyses) and to complement the results
from the dose–response models (ﬁnal meta-analyses; results reported below).
Achieved means from 83 arms (35 trials), also included in the ﬁnal dose–response analysis, were
displayed in forest plots with their 95% CIs and pooled weighted values estimated, both overall
(pooled estimate: 57.9 nmol/L; 95% CI: 54.6–61.3) and by relevant subgroups (Appendix D.C,
Figures 8–15).
Mean differences in achieved mean serum 25(OH)D concentration were calculated for 30 RCTs,
out of the ﬁnal 35 studies included in the dose–response analysis, where a control/placebo group and
at least one intervention group were available (i.e. 5 trials out of 35 did not have a control group42).
In case of multiple intervention groups, the achieved mean serum 25(OH)D of the ﬁrst intervention
arm (with the lowest dose) was selected to be compared to the achieved mean serum 25(OH)D of the
control group. The pooled weighted mean difference across the 30 trials was 29.3 nmol/L (95% CI:
26.4–32.3) (Appendix D.D, Figure 16), with average achieved means of 41.3 nmol/L (SD = 10.3) and
70.8 nmol/L (SD = 14.1) in the control and intervention groups, respectively, and very close average
baseline means (50.4 and 51.1 nmol/L, SD = 16). Analysis of weighted pooled estimate of mean
differences in achieved mean serum 25(OH)D by 5 lg increase in total vitamin D intake (between
5 and 50 lg/day) is also reported in Appendix D.D (Figure 17).
41 Indicated as ‘ﬁrst author date a’ or ‘ﬁrst author date b’ or ‘ﬁrst author date c’ in case two (or three) different populations were
included in the same study, e.g. normal weight, overweight and obese people.
42 Barger-Lux et al., 1998; DeLappe et al., 2006; Goussous et al., 2005; Pekkarinen et al., 2010; and Vieth et al., 2001.
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Results from studies on speciﬁc populations (infants, lactating and pregnant women) were not
included in separated meta-analyses (Table 8 of Appendix D.A) because their number (two arms on
pregnant women, three arms on lactating women, three arms on infants) and characteristics were not
deemed suitable (a minimum of three per subpopulation is requested); their results are addressed
narratively in the contractor’s report (Brouwer-Brolsma et al., 2016).
8. Meta-regression of the response of serum 25-hydroxyvitamin D to
total vitamin D intake
Weighted linear meta-regression analyses of total vitamin D intake (i.e. habitual intake of the
vitamin plus the supplemental dose) versus mean achieved serum or plasma 25(OH)D concentration
measured at the end of the winter sampling points were performed.
The models were developed applying a random-effects approach (‘random-effects meta-
regression’), in which the extra variability due to heterogeneity is incorporated in the same way as in a
random-effects meta-analysis, where the inﬂuence of more precise studies on the relationship is
mitigated by the consideration of variability across studies. The approach allowed for extra residual
heterogeneity among dose–response estimates not modelled by the explanatory variables identiﬁed
and tested.
8.1. Studies included in the dose–response analysis
Meta-regression analyses were performed on the ﬁnal data set (83 arms, 35 trials), as identiﬁed in
Section 7 of this Appendix.
Most of the exclusions from the preliminary data set were based on inconsistencies in achieved
means, mean differences (between intervention and control in the same trial) and net mean changes
(between baseline and achieved mean in the same arm) of serum 25(OH)D (in the same trial across
intervention groups and/or across trials in the same dose group). Careful reconsideration of study
characteristics (e.g. design, type of participants, supplementation scheme, reporting issues, and
summary data type) was the basis as to whether conﬁrm exclusion of the identiﬁed arms (or entire
related trial) (Appendix D.A, Table 8 – fourth column).
In addition, four arms were excluded based on model checking results (statistical outliers), after
revision of all standardised residuals that were found to be either smaller than 2 or larger than +2.
Two further exclusions were applied after reconsideration of the maximum supplemented vitamin D
dose to be included, i.e. 50 lg/day, in order to model total vitamin D intakes that were not exceeding
100 lg/day (the UL set by EFSA) (Appendix D.A, Table 8 – fourth column).
8.2. Model construct
Two different model constructs of the dose–response relationship between plasma/serum 25(OH)D
and total vitamin D intake were explored:
Log-linear: total vitamin D intake was transformed to the natural log (ln) before regression
analysis; the regression intercept was set to 0 nmol of mean achieved 25(OH)D serum level to prevent
negative values (which are biologically implausible). The intercept of the ﬁnal adjusted model was not
statistically signiﬁcantly different from zero.
Linear: mean achieved serum 25(OH)D concentrations were regressed to total vitamin D intake on
its original scale; the total vitamin D intake data points modelled were limited by a maximum intake
dose of 35 lg/day, on the basis of evidence showing that the slope response of serum 25(OH)D to
increasing dose becomes constant at such dose, as suggested by others (Aloia et al., 2008).
A non-linear response of serum 25(OH)D to vitamin D intake was expected due to metabolic
kinetics (Heaney et al., 2008); in fact, the response of serum 25(OH)D is not best described by a linear
ﬁt model at doses above 35 lg/day.
The interest in exploring the linear model construct as an alternative to the curvilinear one was that
the latter has a steep decline in achieved serum 25(OH)D concentrations particularly at the lower end
of the range of total vitamin D intakes, and at zero intake the achieved serum 25(OH)D is forced to be
0 nmol/L to avoid a negative predicted value.
The WG decided to retain the log linear construct to better describe the dose–response shape and
to be able to include results from higher dose trials (i.e. up to 50 lg/day).
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8.3. Model ﬁtting
For each random-effects meta-regression model, the statistics T2 (tau-squared, between-study
variance) and Adjusted R2 were calculated. T2 was estimated using the restricted maximum likelihood
method (Thompson and Sharp, 1999) with Knapp–Hartung modiﬁcation of the estimates of the
variance–covariance matrices of the regression coefﬁcients (Knapp and Hartung, 2003) to reduce false-
positive rates.
The change in T2 after inclusion of each covariate gives the amount of heterogeneity
explained by the ﬁtted model, and this value over the T2 from the null model gives the
proportion of between-study variance explained (Adjusted R2).
T2 decreased from 312 to 46 in the ﬁnal model, with included factors explaining up to 85% of
heterogeneity (Appendix D.E, Table 13), i.e. ((312  46)/312) 9 100 = 85% (Adjusted R2) of
between-study variance explained and 15% of unexplained heterogeneity.
The residual I2 statistics gives a measure of the percentage of the residual variation
(the one not explained by the covariates) that is attributable to between-study
heterogeneity.
Residual I2 also decreased after inclusion of the ﬁnal set of covariates, yet remaining quite high
(87%) (Appendix D.E, Table 13).
In addition to the evaluation of the relative reduction of T2 and of the joint testing (using the F
distribution) of covariates as introduced in the model, a backward elimination process was used to
check the set of explanatory variables identiﬁed, by manual ﬁtting in the ﬁnal model, as signiﬁcant
predictors of the mean achieved serum concentrations.
8.4. Baseline measurements
The inﬂuence of the mean baseline 25(OH)D concentration on the dose–response relationship was
described by plotting its values against the corresponding achieved mean values and explored in
subgroup analyses (Appendix D.C, Figure 6; ≤ versus > 50 nmol/L) and meta-regression models
(continuous covariate, Table 5 of this Appendix C). Bubble plots of net values (achieved 25(OH)D
concentrations minus baseline values) were also considered to complement the dose–response analysis
(not shown in this report).
After total vitamin D intake, the mean baseline 25(OH)D concentration was the factor explaining
the highest proportion of between-study variability (17% in the simple meta-regression model – not
shown in this report).
This is not surprising as it is likely that baseline values can serve as a surrogate for many
inﬂuencing factors, potentially including some of those that could not be measured in the analysed
trials. In fact, in the ﬁnal adjusted model, the regression coefﬁcient for the mean baseline was only
marginally changed by the mutual adjustment for all the other included covariates (0.53 vs 0.48,
(Appendix D.E, Table 13)).
8.5. Inter-individual variability on dietary intake
Previous analyses on vitamin D intake-status have encountered difﬁculties in taking into account
the inter-individual variability on intake required to reach a chosen serum 25(OH)D cut-off.
The CI in meta-regression analyses provides an estimate of the uncertainty about the
ﬁtted response line due to sampling, but does not provide any estimate of the variability
between individuals in terms of dietary intake of vitamin D needed to achieve a serum 25
(OH)D concentration.
Attempts have been made to augment the meta-analytic approach by using individual data from
vitamin D RCTs (Cashman et al., 2011a), which was not possible in the case of the current analysis as
no individual data were available (Section 5.3.1 of the Scientiﬁc Opinion).
8.6. Model checking diagnostics
Outliers and inﬂuential studies were detected and tests for normality and homoscedasticity carried
out to check for model assumptions (e.g. normality of the random effects).
The normal probability plot of the standardised predicted random effects did not show substantial
departure from normality; outliers were identiﬁed by evaluation of standardised residual values smaller
than 2 or larger than +2 (Appendix D.A, Table 8, fourth column) as estimated from the ﬁnal models.
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When several covariates are used in meta-regression, either in several separate simple meta-
regressions or in one multiple meta-regression, there is an increased chance of at least one false-
positive ﬁnding (type I error). The statistics obtained from the random permutations can be used to
adjust for such multiple testing by comparing the observed t statistic for every covariate with the
largest t statistic for any covariate in each random permutation (Higgins and Thompson, 2004).
Permutation-based p-values were calculated by running a Monte Carlo permutation test.
8.7. Dose–response inﬂuencing factors, investigation of heterogeneity
between studies
A number of factors potentially inﬂuencing the dose–response relationship were identiﬁed a priori
both from the relevant literature and upon feedback from the WG.
The following list was prioritised based on the outcome of WG’s discussions; a selection of priority
study-level characteristics was tested in independent subgroup analyses and incorporated in the meta-
regression models one at a time and in the ﬁnal multivariable model:
• Total vitamin D intake: as continuous, as categorical (cut-offs determined by an increment of
5 lg/day; Appendix D.C, Figure 7),
• Baseline serum concentration: as continuous, as dichotomous (cut-offs: 30 nmol/L (not shown
in this report) and 50 nmol/L (Appendix D.C, Figure 6),
• Study duration: ≤ 3 months vs > 3 months,
• Latitude: as categorical, stratiﬁed by > 40°N to < 50°N and ≥ 50°N and 78°S,43
• Assay method used: HPLC and LC–MS versus immunoassays (i.e. RIA, CBPA, ELISA),
• Period of study publication: also related to trends in analytical methods (cut-off: year 2000)
(not shown in this report),
• Body Mass Index: a ‘proxy’ for body composition (which is not reported in the included trials);
as continuous (study-level mean BMI), as per four categories: ‘Normal weight’, ‘Overweight’,
‘Obese’, ‘Not reported’ (Appendix D.C, Figure 14),
• Ethnicity: a ‘proxy’ for skin pigmentation and some lifestyle habits that were usually not
reported in the included trials; as per four categories: ‘Caucasian’, ‘African’, ‘Mixed’, ‘Not
Reported’,
• Co-supplemented calcium: as categorical (Yes, No/Unknown) (not shown in this report)
• Funding source: as categorical (‘Non-proﬁt’, ‘Proﬁt’, ‘Mixed’, ‘Not reported’) (not shown in this
report),
• Age: as continuous (study-level mean age), as categorised according to three population
groups (children, adults, older adults; the latter from trials where the reported or estimated
mean age was ≥ 60 years) (Appendix D.C, Figure 14)
• Sex: as categorical based on percentage of males (‘Both’ for studies on mixed populations,
‘Women’ for studies on women only, ‘Men’ for studies on men only) (Appendix D.C, Figure 15)
• Risk of bias (RoB) dimensions: all individually categorised as ‘Yes’, ‘No/Unknown’ (adequate
randomisation, adequate allocation concealment, adequate blinding description, compliance
assessed, drop-outs addressed, dose check reported); as combined by the contractor
(Brouwer-Brolsma et al., 2016) in an overall RoB assessment (‘High’, ‘Moderate’, ‘Low’ RoB)
(Appendix D.B, Table 12).
The following further categorisations were also applied and tested a posteriori:
• Duration: ≤ 3 months vs > 3 months & < 6 months vs 1–2 years (Appendix D.C, Figure 8),
• Latitude: < 50°N, 50–55°N, > 55°N (Appendix D.C, Figure 9). For 76% of arms, latitude was
> 50°N (Table 9 in Appendix D.B),
• Assay method used: RIA versus HPLC versus LC–MS versus CPBA versus ELISA & Not Reported
versus Other30 (Appendix D.C, Figure 11). In the ﬁnal model (Section 8.8), each analytical
method was retained as an individual category to be able to estimate the speciﬁc effects,
• Ethnicity: ‘Caucasian’, ‘Mixed’, ‘Not Reported’. ‘African’ was grouped to the ‘Mixed’ category, as
it included three arms only (Appendix D.C, Figure 12).
43 Only one trial (four arms) was undertaken in the Southern hemisphere (at 78°S) (Smith et al., 2009). All the other trials
included were undertaken in the Northern hemisphere (41°N – 63°N) (Table 9 in Appendix D.B).
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Study start period was subsequently considered instead of publication year as a better proxy to the
temporal trends in assay method use (as continuous  since year of ﬁrst study in analysis, i.e. 1985;
as dichotomous -before or after 2000) (Appendix D.C, Figure 10).
Pooled estimates in the placebo/control arms and intervention arms were also reported for
descriptive purposes (Appendix D.C, Figure 5).
All results (Appendix D.C, Figures 4–15) were interpreted only qualitatively and group summary
estimates compared by visual inspection; subgroup comparisons are observational in nature and
results from statistical testing should not be used to infer that estimates differ from one stratum to
another.
8.8. Derivation of DRVs
The meta-regression analysis carried out on the selected arms resulted in two predictive equations
of achieved serum 25(OH)D:
y = 23.2 ln (total vitamin D intake) (unadjusted model) (Appendix D.F, Figure 18) and
y = 16.3 ln (total vitamin D intake) adjusted for baseline concentration (continuous; lg/day),
latitude (continuous; °N), study start year (continuous; years since ﬁrst study in analysis – 1985), type
of analytical method applied (RIA, HPLC, LC-MS, CPBA, ELISA/not reported, Other), assessment of
compliance (yes, no/unknown) (Table 5 of this Appendix C, and Figure 19 of Appendix D.F).
Age and sex were not included in the ﬁnal model as they did not explained further neither
the within- nor the between- study variability. The role of BMI was also tested in the subset of arms
for which such information was available (83%); overweight and obese subgroups from the study
populations showed on average higher achieved means when compared to the normal weight group
(Appendix D.C, Figure 13), but lower values once adjusted for all other covariates. BMI was not
included in the ﬁnal model as it did not reach statistical signiﬁcance in the preliminary analyses
from the preliminary data set (116 arms) and in consideration of potential ecological fallacy (i.e.
associations with mean BMI values when available or calculated from mean height and mean weight at
study-level are not necessarily consistent with associations with individual-level BMI values).
The same equations were used both to predict the achieved mean serum 25(OH)D levels
conditional to total vitamin D intakes of 5, 10, 15, 20, 50, 100 lg/day (Table 6 of this Appendix C) and
to estimate the total vitamin D intakes that would achieve serum 25(OH)D concentrations of 50, 40,
30, 25 nmol/L (Table 7 of this Appendix C).
Table 5: Adjusted meta-regression model (outcome variable: mean achieved 25(OH)D in nmol/L;
n = 83 arms)
Covariate b coefﬁcient SE P > t 95% CI
Ln of total vitamin D intake – lg/day 16.33 0.94 < 0.001 14.45–18.21
Mean Baseline 25(OH)D – nmol/L 0.50 0.05 < 0.001 0.39–0.61
Latitude – °N  0.46 0.09 < 0.001 0.63 to 0.29
Study start year (years since 1985) 0.93 0.21 < 0.001 0.51–1.35
Assay
RIA* 0.00
HPLC 1.93 3.29 0.56 8.49 to 4.62
LC-MS 4.72 3.00 0.12 10.69 to 1.26
CPBA 0.63 3.86 0.87 7.07 to 8.33
ELISA/nr 6.40 2.68 0.02  11.73 to 1.06
Other 1.30 3.61 0.72 5.89 to 8.49
Compliance assessed
Yes* 0.00
No/unknown 7.79 2.97 0.01 1.86–13.71
CI: conﬁdence interval; nr: not reported; SE: standard error.
P > t: indicates the probability of the hypothesis that the beta-coefﬁcient = 0 (since p = 0.05 is conventionally assumed as the
cut-off for statistical signiﬁcance in the analysis, a p value lower than 0.05 provides good evidence that the beta-coefﬁcient is
signiﬁcantly different from 0).
*Reference category.
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All values were calculated by using the regression equations of the predicted mean, of the lower
and upper limits of the 95% CI of the predicted mean and of the lower and upper limits of the 95%
prediction interval (PI) of the predicted mean. In the adjusted multivariable models, all
covariates were set to their mean values (mean baseline 25(OH)D: 50.7 nmol/L; latitude: 53°N;
study start year: 2005; assay – HPLC: 10%; LC-MS: 18%; CPBA: 13%; ELISA: 20%; other: 8%;
compliance not assessed/unknown: 27%).
A stratiﬁed analysis was carried out to quantify the impact of the exclusions of the four trials on
children (nine arms) on the predicted achieved mean serum 25(OH)D levels (Appendix D.G, Table 14,
ADULTS estimates) and estimated total vitamin D intakes (Appendix D.G, Table 15, ADULTS estimates).
In the restricted data set (74 arms), there was an overall small decrease in all serum estimates (and
consequently a small increase in total intakes that would achieve target values); this is possibly due both
to the fact that ‘children’ arms were just 9 and that children tend to achieve the same concentrations as
the adults at a lower total intake (Appendix D.G, Table 14, CHILDREN estimates). Overall estimates did
not substantially change as compared to the full data set including children.
Values based only on the four children trials were not calculated in the fully adjusted meta-
regressions, as they would have required a much higher minimum number of ‘points’ per covariate (at
least 10 arms for each included factor); instead, values from a model adjusted by mean baseline 25
(OH)D were provided. As such, these estimates are not directly comparable to the adults’
ones, as they are not adjusted for the same set of covariates. The unadjusted model showed
lower average intakes, but estimates were much less precise (with 95% CI overlapping with those
from the adults data), and could only be evaluated qualitatively (Appendix D.G, Table 15, CHILDREN
estimates).
In the meta-analytic context, when a random-effects approach is applied, the CI
reﬂects the precision with which we estimate the pooled (across studies) mean effect size
(via the available sample of studies), while the PI reﬂects the actual dispersion of the
true effects around the mean effect size.
If, for instance, there is an estimated mean response of 50 with a CI of 40 to 60, the range of 40
to 60 includes with a certain frequency (conventionally 95% of the times) the true mean response in
the population of studies from which the sample was drawn.
From a related PI of 30 to 70, it can be considered that probably (conventionally 95% of the times)
such range will include the true effect in a new study from the same population of studies. If the
number of studies were inﬁnite, then the CI width would approach zero but the PI would show little
change.
When interpreting the intervals drawn around the meta-regression lines, the CI illustrates the
uncertainty about the position of the line (i.e. across-study conditional means), while the PI
illustrates the uncertainty about the true mean effect that would be predicted in a future
study (i.e. the dispersion of the true effects around their mean).
As such, it is possible to think of the latter only as an approximation of the interval that would allow
for estimation of the requirements for 95% of the population, as it refers to the population of mean
responses (not individual responses) as analysed in the random-effects model.
Table 6: Predicted achieved serum 25(OH)D at selected values of total vitamin D intake
Regression equations used to predict serum
25(OH)D
Predicted serum 25(OH)D at selected values of total
vitamin D intake
100
lg/day
50
lg/day
20
lg/day
15
lg/day
10
lg/day
5
lg/day
Unadjusted models
y = 23.2 Ln (total vitamin D intake)(a)
Predicted mean 107 91 69 63 53 37
95% CI lower limit 101 86 66 59 50 35
95% CI upper limit 113 96 73 66 56 39
95% PI lower limit 78 62 41 34 25 9
95% PI upper limit 136 119 98 91 82 66
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9. Quality of the body of evidence: addressing risk of bias
The rating by the contractor of individual trials in terms of RoB (individual dimensions and overall
assessment) (Brouwer-Brolsma et al., 2016) was used to evaluate whether heterogeneity of results
could be attributed to differences in internal validity, both in the meta-analyses and meta-regression
models (Appendix D.B, Table 12). The following approaches were discussed and applied accordingly:
• To run the analysis on low-moderate-risk trials only (restriction): this option could not be
applied as the proportion of low-risk arms was only 16% (plus moderate-risk ones accounting
for an additional 18%). The trade-off between bias and precision would have been too much
towards (possibly) more valid but less precise estimates;
Regression equations used to predict serum
25(OH)D
Predicted serum 25(OH)D at selected values of total
vitamin D intake
100
lg/day
50
lg/day
20
lg/day
15
lg/day
10
lg/day
5
lg/day
Adjusted models(b)
y= 16.3 Ln (total vitamin D intake) + 0.5 mean baseline 25(OH)D  0.5 latitude + 0.9 start year  2.0
HPLC  4.7 LC-MS + 0.6 CPBA  6.4 ELISA/nr + 1.3 Other assay + 7.8 compliance not assessed(a)
Predicted mean 94 83 68 63 57 45
95% CI lower limit 89 78 63 58 52 40
95% CI upper limit 100 88 73 69 62 51
95% PI lower limit 80 69 54 49 42 31
95% PI upper limit 109 98 83 78 71 60
CI: conﬁdence interval; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay; HPLC: high-
performance liquid chromatography; LC-MS: liquid chromatography-mass spectroscopy; nr: not reported; PI: prediction interval;
RIA: radioimmunoassay.
(a): Predicted mean regression equations are reported (y = mean achieved serum 25-hydroxyvitamin D).
(b): Estimates from the adjusted models are based on all covariates set to their mean values.
Table 7: Estimated vitamin D intakes at selected serum 25(OH)D cut-off values
Regression equations used to estimate vitamin D
intake
Estimated vitamin D intake at selected serum
25(OH)D cut-off values
50 nmol/L 40 nmol/L 30 nmol/L 25 nmol/L
Unadjusted model
y = 23.2 ln (total vitamin D intake)(a)
Predicted mean 8.7 5.6 3.6 2.9
95% CI lower limit 9.8 6.2 3.9 3.1
95% CI upper limit 7.7 5.1 3.4 2.8
95% PI lower limit 29.9 19.4 12.6 10.1
95% PI upper limit 2.5 1.7 1.1 0.9
Adjusted model(b)
y = 16.3 ln (total vitamin D intake) + 0.5 mean baseline 25(OH)D  0.5 latitude + 0.9 start year 
2.0 HPLC  4.6 LC-MS + 0.5 CPBA  6.9 ELISA/nr + 1.3 Other assay + 7.8 compliance not
assessed(a)
Predicted mean 6.6 3.6 1.9 1.4
95% CI lower limit 9.1 4.9 2.7 2.0
95% CI upper limit 4.8 2.6 1.4 1.0
95% PI lower limit 16.1 8.7 4.7 3.5
95% PI upper limit 2.7 1.5 0.8 0.6
CI: conﬁdence interval; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay;
HPLC: high-performance liquid chromatography; LC-MS: liquid chromatography-mass spectroscopy; nr: not reported;
PI: prediction interval; RIA: radioimmunoassay.
(a): Predicted mean regression equations are reported (y = mean achieved serum 25-hydroxyvitamin D).
(b): Estimates from the adjusted model are based on all covariates set to their mean values.
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• To run a sensitivity analysis and see how the response changes if high-risk studies are
excluded: this was not carried out considering that the majority of trials were rated high-RoB;
• To run a subgroup analysis (or meta-regression) re-grouping the RoB variable into a dichotomous
one: this was considered but the covariate was tested as originally coded (low, moderate, high
risk). The lack of a statistically signiﬁcant difference between studies at high and low RoB (data
not shown in this report) should be interpreted cautiously as meta-regression analyses are
observational in nature;
• To use individual dimensions as recorded by the contractor (Brouwer-Brolsma et al., 2016): each
RoB dimension was evaluated in univariate and multivariable analyses. Assessed compliance
(categorised as yes versus no/unknown and independently of its deﬁnition across trials) was
found to play a role in further explaining the variability between studies (Appendix D.E,
Table 13); all other dimensions (randomisation appropriate, allocation concealment, etc.) were
not statistically signiﬁcantly impacting on the estimates (not shown in this report);
• To integrate a qualitative (narrative) evaluation of RoB in the discussion of the analysis results.
10. Sensitivity analyses
A number of sensitivity analyses were carried out to evaluate whether the ﬁndings were robust to
the assumptions made in the systematic review protocol and the analyses (e.g. meta-regression
models).
When sensitivity analyses show that the overall result and conclusions are not substantially affected
by the different decisions that could be made during the review process, the results of the review can
be regarded with a higher degree of certainty.
There were a number of assumptions/decisions/issues provisionally identiﬁed that could potentially
be tested in sensitivity analyses by comparing the results obtained with alternative input parameters to
those from the default model or by restricting to speciﬁc subsets; none of them raised serious
concerns about the robustness of the overall analysis (the most substantial departures were detected
in the smallest, then less representative, subsets of the ﬁnal data set).
The following analysis were considered:
• On data cleaning issues: implausible values, missing data,
• On quality dimensions: compliance assessment,
• On analytical approaches: data imputation; cut-off points, choice of categories,
• On eligibility criteria: fortiﬁed food trials; range of doses (exclusion of doses higher than
100 lg/day); characteristics of participants (exclusion of non-healthy volunteers, of
supplement users, etc.; Appendix D.H, Table 16).
11. Observational studies: contribution of their results to the analysis
Meta-analyses were performed separately for RCTs and observational studies (prospective cohort
studies) on the basis that, in principle, evidence from randomised and non-randomised studies is not
considered comparable. Eight prospective observational studies from seven articles were included.
(Appendix D.I, Table 17). They represented 11 study groups (e.g. children versus adults in Andersen
2013, Caucasian group versus Asian group in Darling et al. (2013), Caucasian from one study centre
versus a group of Caucasian and a group of Asian people in another study centre in MacDonald et al.
(2011)), three of which were on children (mean age between 11 and 16 years).
Achieved mean serum 25(OH)D concentration (and 95% CI) was investigated by study group
(Appendix D.I, Figure 20), as well as by relevant subgroups: age (children versus adults; Appendix D.I,
Figure 21), baseline mean serum 25(OH)D concentrations (≤ versus > 50 nmol/L; Appendix D.I,
Figure 22) and latitude (< 50°N versus ≥ 50°N; Appendix D.I, Figure 23).
12. Publication bias
Several systematic reviews of empirical studies have found that studies with statistically signiﬁcant
or positive results are more likely to be published than those with non-signiﬁcant or negative results.
Investigators’ decisions not to submit papers with negative results for publication, rather than editors’
rejection of such papers, tend to be the main source of publication bias. Studies with statistically
signiﬁcant results also tend to be published earlier than studies with non-signiﬁcant results. If studies
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 119 EFSA Journal 2016;14(10):4547
are missing from a systematic review for these reasons, effects may be over-estimated (Higgins and
Green, 2011).
Publication bias was examined by inspecting funnel plots (Sterne and Egger, 2001) and by
performing the Egger’s test for funnel plot asymmetry (Egger et al., 1997) on mean differences in
achieved mean serum 25(OH)D from the 30 RCTs included in the meta-analyses (see Section 8).
Egger’s test performs a linear regression of the intervention effect estimates on their standard
errors, weighting by 1/(variance of the intervention effect estimate) (Appendix D.J, Figure 24); the test
was not statistically signiﬁcant (p = 0.149).
Funnel plots investigate the association between study size and effect size; there was no particular
indication of funnel plot asymmetry, as trials testing a dose of 5 to < 10 lg/day were missing in the
right-hand side of the funnel while trials testing 45 lg/day and more were missing in the left-hand side
(Appendix D.J, Figure 25).
13. Uncertainty analysis
Sources of uncertainty and their potential impact on the ﬁnal estimates, where possible, were
identiﬁed and discussed:
• General interpretation of meta-regression results – the associations derived from meta-
regressions are observational and have a weaker interpretation than those derived from
randomised comparisons; this applies especially when population characteristics are included
as means at study level,
• Inter-individual variability on intake – failure to account for it may lead to underestimation of
the predicted intake of vitamin D needed to maintain a speciﬁed serum 25(OH)D concentration
(Cashman et al., 2011a),
• Predicted achieved mean serum 25(OH)D concentrations and estimated total vitamin D intakes
calculated based on the 95% CI of the predicted mean from the adjusted models were less
accurate than those from the unadjusted ones, due to the approximation of the ﬁtting on the
pair wise limits,
• Predictions from the lower range of the total vitamin D intakes are less accurate than those for
higher values because of the log-linear construct (not optimal ﬁtting in that intake range),
• Ecological fallacy – key risk factors that vary across populations and that can be measured only
as aggregate values, such as age, gender and BMI, are difﬁcult to address adequately by
meta-regression. One reason for this is that aggregated values tend to exhibit little between-
study variation, thus providing minimal information across the potential range of the factor.
Use of aggregated values may also introduce bias because of the failure to account for the
within-study variation (Thompson and Higgins, 2002),
• Selection of RCTs/arms – the main objective of the additional exclusion of arms from the ﬁnal
data set (Appendix D.A, Table 8) was to try to ‘remove’ as much heterogeneity as possible that
could be attributable to differences in design, bias, and/or methods, so that only ‘clinical’
heterogeneity (i.e. between-study variability due to population’s features) would be left to be
modelled and characterised. It is difﬁcult to quantify the potential relative misclassiﬁcation due
to such a selection; the proportion of heterogeneity explained by the inﬂuencing factors in the
ﬁnal subset was higher than that in the preliminary data set (85% vs 56%), but the regression
coefﬁcients of all covariates were almost unchanged. This could be interpreted as a relative
reduction of heterogeneity more in its methodological component across included studies, due
to the nature of the criteria applied for the additional exclusions.
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Appendix D – Dose–response analysis undertaken by EFSA of serum25(OH)D
to total vitamin D intake: appendices
A. List of trials arms not included in the meta-analyses and dose–
response analysis
Table 8: Reasons for exclusions from preliminary data set and ﬁnal data set (total: 58 arms
excluded out of 141)
RCT arms
Suppl.
vitamin D
dose
(lg/day)
Reasons for exclusion
from preliminary data
set (25 arms excluded
out of 141)
Reasons for exclusion from ﬁnal
data set (33 additional arms
excluded)
Ala-Houhala et al. (1986)a(a) 12.5 Study on pregnant women –
Ala-Houhala et al. (1986)a 0 Study on pregnant women –
Ala-Houhala et al. (1986)b(a) 50 Study on lactating women –
Ala-Houhala et al. (1986)b 25 Study on lactating women –
Ala-Houhala et al. (1986)b 0 Study on lactating women –
Ala-Houhala et al. (1986)c(a) 10 Study on infants –
Ala-Houhala et al. (1988b) 10 Study with supplemented
vitamin D2
–
Ala-Houhala et al. (1988b) 0 Study with supplemented
vitamin D2
–
Atas et al. (2013) 10 Study on infants –
Atas et al. (2013) 5 Study on infants –
Barger-Lux et al. (1998) 1,250 Arm with supplemented
dose > 100 lg/day
–
Barger-Lux et al. (1998) 250 Arm with supplemented
dose > 100 lg/day
–
Brazier et al. (2002) 20 – Methodological considerations(c)
applicable to whole study
Brazier et al. (2002) 0 – Inconsistent net mean change +
methodological considerations
Close et al. (2013a) 125 Arm with supplemented
dose > 100 lg/day
–
Close et al. (2013a) 0 – Inconsistent net mean change and
achieved mean + methodological
considerations
Forman et al. (2013) 100 – Arm with supplemented dose
≥ 100 lg/day
Heaney et al. (2003b) 250 Arm with supplemented
dose > 100 lg/day
–
Heaney et al. (2003b) 125 Arm with supplemented
dose > 100 lg/day
–
Holick et al. (2008) 25 Arm with supplemented
vitamin D2
–
Holick et al. (2008) 25 Arm with supplemented
vitamin D2
–
Holm et al. (2008) 5 – Supplementation scheme was
5 lg/3 days + inconsistent mean
difference
Holm et al. (2008) 0 – Control group only left from study
Honkanen et al. (1990)b 45 – Methodological considerations
applicable to whole study
Honkanen et al. (1990)b 0 – Statistical outlier
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RCT arms
Suppl.
vitamin D
dose
(lg/day)
Reasons for exclusion
from preliminary data
set (25 arms excluded
out of 141)
Reasons for exclusion from ﬁnal
data set (33 additional arms
excluded)
Johnson et al. (2005) 15 – Inconsistent achieved mean +
methodological considerations
Johnson et al. (2005) 0 – Methodological considerations
applicable to whole study
Johnson et al. (2005) 0 – Methodological considerations
applicable to whole study
Larsen et al. (2012) 25 – Statistical outlier
Larsen et al. (2012) 0 – Control group only left from study
Lehmann et al. (2013) 50 Arm with supplemented
vitamin D2
–
Mocanu et al. (2009) 125 Study with supplemented
dose > 100 lg/day
–
Nelson et al. (2009) 20 – Methodological considerations
applicable to whole study
Nelson et al. (2009) 0 – Inconsistent net mean change +
methodological considerations
Patel et al. (2001)a 20 – Inconsistent achieved mean +
methodological considerations
Patel et al. (2001)a 0 – Methodological considerations
applicable to whole study
Patel et al. (2001)b 20 – Inconsistent achieved mean +
methodological considerations
Porojnicu et al. (2008) 5 Quantitative data on
response not available
–
Porojnicu et al. (2008) 0 Quantitative data on
response not available
–
Rich-Edwards et al. (2011) 7.5 – Statistical outlier (fortiﬁed UHT milk
arm)
Schmidt and Zirkler (2011) 5 – Inconsistent mean difference +
methodological considerations
Schmidt and Zirkler (2011) 0 – Control group only left from study
Sorva et al. (1994) 25 Arm with supplemented
vitamin D2
–
Sorva et al. (1994) 25 – Statistical outlier
Sorva et al. (1994) 0 – Control group only left from study
Vieth et al. (2001) 100 – Arm with supplemented dose
≥ 100 lg/day
White et al. (2009) 3 Mixed intervention(b), very
high baseline values
–
White et al. (2009) 0 Mixed intervention(b), very
high baseline values
–
White et al. (2009) 0 Mixed intervention(b), very
high baseline values
–
Wood et al. (2014)_nw 25 – Methodological considerations
applicable to whole study
Wood et al. (2014)_nw 10 – Methodological considerations
applicable to whole study
Wood et al. (2014)_nw 0 – Inconsistent baseline mean value +
methodological considerations
Wood et al. (2014)_ow 25 – Methodological considerations
applicable to whole study
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B. Trials included in the dose–response analysis (35 trials) – main
study characteristics
RCT arms
Suppl.
vitamin D
dose
(lg/day)
Reasons for exclusion
from preliminary data
set (25 arms excluded
out of 141)
Reasons for exclusion from ﬁnal
data set (33 additional arms
excluded)
Wood et al. (2014)_ow 10 – Methodological considerations
applicable to whole study
Wood et al. (2014)_ow 0 – Inconsistent baseline mean value +
methodological considerations
Wood et al. (2014)_ob 25 – Methodological considerations
applicable to whole study
Wood et al. (2014)_ob 10 – Methodological considerations
applicable to whole study
Wood et al. (2014)_ob 0 – Inconsistent baseline mean value +
methodological considerations
nw: normal weight; ob: obese; ow: overweight; UHT: Ultra-high temperature.
Initial data set: 141 arms, preliminary data set: 116 arms (after exclusion if 25 arms), ﬁnal data set: 83 arms (after additional
exclusion of 33 arms), total of excluded arms: 58 (i.e. 25 + 33).
(a): e.g. (Ala-Houhala et al., 1986)a, (Ala-Houhala et al., 1986)b and (Ala-Houhala et al., 1986)c (as cited in Brouwer-Brolsma
et al. (2016)) refer to the same study, but different population groups (e.g. in this case: pregnant women, lactating women
and infants).
(b): Food fortiﬁed with vitamin D + training exercise, compared to supplements without vitamin D +training exercise.
(c): ‘Methodological considerations’ in this table: design, type of participants, supplementation scheme, reporting issues, and
summary data type (see Appendix C).
Table 9: Country, latitude, age, sex, duration (35 trials)
Source Country
Latitude
(°N)
Mean age
(years)
Age range
(years)
Males
(%)
Duration
(weeks)
Barger-Lux et al. (1998) USA 41.2 28 20–37 100 8
Barnes et al. (2006) IE 54.8 22 18–27 50 8
Bischoff-Ferrari et al.
(2003)
CH 47.3 85 – 0 12
Bolton-Smith et al.
(2007)
UK 56.3 70 60+ 0 104
Bonjour et al. (2013) FR 50.7 86 60+ 0 8
Braam et al. (2003) NL 50.9 55 50–60 0 156
Cashman et al. (2008) IE 51 30 20–40 50 22
Cashman et al. (2009) IE 51 71 64+ 40 22
Cashman et al. (2012) IE 51 57 50+ 38 10
Cashman et al. (2014) IE 51 60 50+ 28 15
de Gruijl and Pavel
(2012)
NL 52.2 24 18–30 9 8
DeLappe et al. (2006) IE 53.2 80 – 0 13
Forman et al. (2013) USA 42.2 51 30–79 35 13
Goussous et al. (2005) USA 42.2 65 50+ 27 13
Hansen et al. (2010) NO 60.4 35 20–60 100 23
Harris and Dawson-
Hughes (2002)a
USA 42 26 18–35 100 8
Harris and Dawson-
Hughes (2002)b
USA 42 70 62–79 100 8
Heaney et al. (2003b) USA 41.2 39 – 100 20
Heikkinen et al. (1998) FI 62.9 51 47–56 0 52
Holick et al. (2008) USA 42.3 60 18–84 31 6
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Source Country
Latitude
(°N)
Mean age
(years)
Age range
(years)
Males
(%)
Duration
(weeks)
Honkanen et al. (1990)a FI 63 70 67–72 0 11
Hower et al. (2013) DE 51.2 4 2–6 56 20
Keane et al. (1998) IE 53.2 78 65–92 24 47
Lehmann et al. (2013) DE 51.47 43 19–67 33 8
Madsen et al. (2013)a DK 55.7 10 4–17 48 26
Madsen et al. (2013)b DK 55.7 36 18–60 50 26
Meier et al. (2004) DE 50 54 33–78 33 25
O’Connor et al. (2010) DK 55.4 11 11–12 0 52
Pekkarinen et al. (2010) FI 61 74 69–79 0 52
Rich-Edwards et al.
(2011)
MN 48 10 9–11 53 7
Smith et al. (2009) AQ 78(a) 43 – 75 22
Trautvetter et al. (2014) DE 50.6 42 – 40 8
Vieth et al. (2001) CA 43 41 – 33 8
Viljakainen et al. (2006b) FI 61 71 65–85 0 12
Viljakainen et al. (2009) FI 61 29 21–49 100 26
AQ: Antarctica; CA: Canada; CH: Switzerland; DE: Germany; DK, Denmark; FI: Finland; FR: France; IE: Ireland; MN: Mongolia;
NL: the Netherlands; NO: Norway; UK: United Kingdom; USA: United States of America.
e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the same study, but
different population groups (e.g. in this case: children and adults).
(a): Latitude of 78°S.
Table 10: Start year, funding, ethnicity, analytical method, Ca co-supplementation (35 trials)
Source
Start
year
Funding Ethnicity
Analytical
method
Ca co-suppl.
Barger-Lux et al. (1998) 1997 Mixed Mixed HPLC No/unknown
Barnes et al. (2006) 2005 – – ELISA Yes
Bischoff-Ferrari et al. (2003) 1999 Mixed – RIA Yes
Bolton-Smith et al. (2007) 2003 Mixed – RIA Yes
Bonjour et al. (2013) 2010 Proﬁt – ELISA Yes
Braam et al. (2003) 1997 Mixed Caucasian RIA Yes
Cashman et al. (2008) 2006 Non-proﬁt Caucasian ELISA No/unknown
Cashman et al. (2009) 2007 Non-proﬁt Caucasian ELISA No/unknown
Cashman et al. (2012) 2011 Mixed Caucasian ELISA No/unknown
Cashman et al. (2014) 2012 Non-proﬁt Caucasian LC-MS No/unknown
de Gruijl and Pavel (2012) 2010 Mixed Mixed RIA No/unknown
DeLappe et al. (2006) 2003 – – RIA Yes
Forman et al. (2013) 2007 Mixed African RIA Yes
Goussous et al. (2005) 2003 Mixed Mixed RIA Yes
Hansen et al. (2010) 2008 Non-proﬁt Mixed RIA No/unknown
Harris and Dawson-Hughes (2002)a 2000 Mixed – CPBA No/unknown
Harris and Dawson-Hughes (2002)b 2000 Mixed – CPBA No/unknown
Heaney et al. (2003b) 2001 Non-proﬁt – Other No/unknown
Heikkinen et al. (1998) 1990 Mixed – CPBA Yes
Holick et al. (2008) 2007 Mixed Mixed LC-MS No/unknown
Honkanen et al. (1990)a 1985 Mixed – CPBA Yes
Hower et al. (2013) 2010 Proﬁt Caucasian Other No/unknown
Keane et al. (1998) 1993 Proﬁt – CPBA No/unknown
Lehmann et al. (2013) 2012 Non-proﬁt – LC-MS No/unknown
Madsen et al. (2013)a 2010 Mixed – LC-MS No/unknown
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Source
Start
year
Funding Ethnicity
Analytical
method
Ca co-suppl.
Madsen et al. (2013)b 2010 Mixed – LC-MS No/unknown
Meier et al. (2004) 2002 – – RIA Yes
O’Connor et al. (2010) 2008 Non-proﬁt Mixed HPLC No/unknown
Pekkarinen et al. (2010) 2006 Non-proﬁt Caucasian HPLC Yes
Rich-Edwards et al. (2011) 2009 Mixed Mixed LC-MS No/unknown
Smith et al. (2009) 2007 Non-proﬁt Caucasian RIA No/unknown
Trautvetter et al. (2014) 2011 Proﬁt – ELISA Yes
Vieth et al. (2001) 2000 Proﬁt Mixed RIA No/unknown
Viljakainen et al. (2006b) 2002 Non-proﬁt – HPLC No/unknown
Viljakainen et al. (2009) 2007 Non-proﬁt Caucasian Other No/unknown
Ca co-suppl: calcium co-supplementation; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay;
HPLC: high-performance liquid chromatography; LC-MS: liquid chromatography-mass spectroscopy; RIA: radioimmunoassay.
e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the same study, but
different population groups (e.g. in this case: children and adults).
Table 11: Vitamin D intakes, summary data (mean response with standard deviation) and body mass index (BMI)
(35 trials, 83 arms)
Source
Habitual
vitamin D
intake
(lg/day)
Supplemental
Vitamin D dose
(lg/day)
Total
vitamin D
intake
(lg/day)
Participants
per arm (n)
Baseline
Mean 25
(OH)D
(nmol/L)
Baseline
25(OH)D
SD
(nmol/L)
Achieved
Mean 25
(OH)D
(nmol/L)
Achieved
25(OH)D
SD
(nmol/L)
Mean
BMI
(kg/m2)
Barger-Lux
et al. (1998)(a)
5 25 30.0 13 67 25 96 18 25.7
Barnes et al.
(2006)
1.6 15 16.6 12 48 16 87 25 24.8
Barnes et al.
(2006)
2.4 0 2.4 15 56 19 48 17 22.9
Bischoff-Ferrari
et al. (2003)(a)
3.3 20 23.3 62 36 24 66 25 24.7
Bischoff-Ferrari
et al. (2003)
3.3 0 3.3 60 35 24 32 12 24.7
Bolton-Smith
et al. (2007)
5.9 10 15.9 49 62 17 71 16 26.1
Bolton-Smith
et al. (2007)
5.6 10 15.6 50 62 15 74 15 25.8
Bolton-Smith
et al. (2007)
5 0 5.0 56 57 15 49 13 26.2
Bonjour et al.
(2013)(a)
2.8 10 12.8 29 19 5 45 16 26.2
Bonjour et al.
(2013)
2.8 0 2.8 27 16 5 21 16 26.6
Braam et al.
(2003)(a)
3.2 8 11.2 56 57 18 62 15 25.1
Braam et al.
(2003)
3.2 8 11.2 46 56 14 62 11 25.5
Braam et al.
(2003)
3.2 0 3.2 60 51 14 56 13 26.1
Cashman et al.
(2008)
3.6 15 18.6 53 74 25 71 19 26.1
Cashman et al.
(2008)
3.5 10 13.5 57 73 27 60 14 26.1
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Source
Habitual
vitamin D
intake
(lg/day)
Supplemental
Vitamin D dose
(lg/day)
Total
vitamin D
intake
(lg/day)
Participants
per arm (n)
Baseline
Mean 25
(OH)D
(nmol/L)
Baseline
25(OH)D
SD
(nmol/L)
Achieved
Mean 25
(OH)D
(nmol/L)
Achieved
25(OH)D
SD
(nmol/L)
Mean
BMI
(kg/m2)
Cashman et al.
(2008)
4.3 5 9.3 48 67 31 52 11 26.1
Cashman et al.
(2008)
3.4 0 3.4 57 73 27 39 13 26.1
Cashman et al.
(2009)
4.8 15 19.8 48 55 23 75 21 28.9
Cashman et al.
(2009)
4.2 10 14.2 53 56 22 70 18 28.9
Cashman et al.
(2009)
4.1 5 9.1 48 55 23 56 18 28.9
Cashman et al.
(2009)
4.7 0 4.7 55 61 27 42 21 28.9
Cashman et al.
(2012)
7.6 20 27.6 13 50 16 69 9 28.3
Cashman et al.
(2012)
6.5 0 6.5 16 43 13 41 11 28.3
Cashman et al.
(2014)
4.4 20 24.4 27 54 25 80 19 26.7
Cashman et al.
(2014)
4.4 0 4.4 28 58 17 42 15 26.7
Cashman et al.
(2014)
4.4 20 24.4 34 54 22 74 15 26.7
Cashman et al.
(2014)
4.4 0 4.4 32 54 17 41 16 26.7
de Gruijl and
Pavel (2012)(a)
2.7 25 27.7 37 58 18 93 20 22.4
de Gruijl and
Pavel (2012)
2.7 0 2.7 33 62 24 55 21 22.3
DeLappe et al.
(2006)(a)
3.4 20 23.4 51 42 27 60 27 –
Forman et al.
(2013)(a)
4.5 50 54.5 65 36 24 87 24 31
Forman et al.
(2013)
4.5 25 29.5 56 41 22 74 22 31
Forman et al.
(2013)
4.5 0 4.5 64 41 24 38 24 31
Goussous et al.
(2005)
3.8 20 23.8 23 49 17 66 15 26.7
Goussous et al.
(2005)
4.6 20 24.6 29 48 16 64 16 30.9
Hansen et al.
(2010)(a)
6.7 7 13.7 15 48 15 60 16 –
Hansen et al.
(2010)
6.7 1 7.7 14 48 25 49 20 –
Harris and
Dawson-
Hughes
(2002)a
1.8 20 21.8 13 60 16 82 12 25
Harris and
Dawson-
Hughes
(2002)a
3.3 0 3.3 12 49 17 44 17 25.1
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Source
Habitual
vitamin D
intake
(lg/day)
Supplemental
Vitamin D dose
(lg/day)
Total
vitamin D
intake
(lg/day)
Participants
per arm (n)
Baseline
Mean 25
(OH)D
(nmol/L)
Baseline
25(OH)D
SD
(nmol/L)
Achieved
Mean 25
(OH)D
(nmol/L)
Achieved
25(OH)D
SD
(nmol/L)
Mean
BMI
(kg/m2)
Harris and
Dawson-
Hughes
(2002)b
3.5 20 23.5 14 62 16 84 19 29
Harris and
Dawson-
Hughes
(2002)b
1.5 0 1.5 11 54 18 49 18 30
Heaney et al.
(2003b)(a)
5.4 25 30.4 17 72 16 80 16 26.2
Heaney et al.
(2003b)
5.4 0 5.4 16 70 24 60 24 26.2
Heikkinen et al.
(1998)(a)
8.2 7.5 15.7 17 28 12 38 8 24.8
Heikkinen et al.
(1998)
8.2 7.5 15.7 18 24 8 33 8 25.7
Heikkinen et al.
(1998)
8.2 0 8.2 18 28 13 25 8 24.7
Holick et al.
(2008)(a)
4.4 25 29.4 20 49 28 65 28 30
Holick et al.
(2008)
4.4 0 4.4 10 47 22 45 22 29.3
Honkanen
et al.
(1990)a(a)
8.7 45 53.7 25 43 17 81 13 –
Honkanen
et al. (1990)a
8.7 0 8.7 26 36 12 23 12 –
Hower et al.
(2013)
1.9 7.1 9.0 39 67 25 65 24 –
Hower et al.
(2013)
1.9 0.1 2.0 24 58 22 44 19 –
Keane et al.
(1998)(a)
3.6 5 8.6 24 24 5 46 11 –
Keane et al.
(1998)
3.6 0.1 3.7 18 25 5 32 14 –
Lehmann et al.
(2013)(a)
3.2 50 53.2 42 44 23 89 22 23.7
Lehmann et al.
(2013)
3.2 0 3.2 19 41 15 32 13 23.7
Madsen et al.
(2013)a
2.3 7.9 10.2 154 75 17 68 4 –
Madsen et al.
(2013)a
2.2 0 2.2 167 76 20 43 5 –
Madsen et al.
(2013)b
2.4 5.4 7.8 201 76 20 66 4 –
Madsen et al.
(2013)b
2.2 0 2.2 204 73 22 41 6 –
Meier et al.
(2004)
3.2 12.5 15.7 27 75 29 88 20 26.1
Meier et al.
(2004)
3.2 0 3.2 16 77 23 51 21 26.2
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Source
Habitual
vitamin D
intake
(lg/day)
Supplemental
Vitamin D dose
(lg/day)
Total
vitamin D
intake
(lg/day)
Participants
per arm (n)
Baseline
Mean 25
(OH)D
(nmol/L)
Baseline
25(OH)D
SD
(nmol/L)
Achieved
Mean 25
(OH)D
(nmol/L)
Achieved
25(OH)D
SD
(nmol/L)
Mean
BMI
(kg/m2)
O’Connor et al.
(2010)(a)
2.3 10 12.3 33 48 16 58 14 18.1
O’Connor et al.
(2010)
2.3 0 2.3 34 48 18 40 18 18.1
Pekkarinen
et al. (2010)
6.4 20 26.4 20 58 10 74 10 26.9
Rich-Edwards
et al. (2011)(b)
2.2 7.5 9.7 140 20 10 50 15 16.4
Rich-Edwards
et al. (2011)
2.2 7.5 9.7 109 17 7 52 15 16.5
Rich-Edwards
et al. (2011)
2.2 0 2.2 101 20 10 20 10 17
Smith et al.
(2009)
8.9 50 58.9 18 45 14 71 23 28
Smith et al.
(2009)
8.2 25 33.2 19 44 19 63 25 31
Smith et al.
(2009)
7.6 10 17.6 18 44 18 57 15 29
Smith et al.
(2009)
15.7 0 15.7 7 36 17 34 12 28
Trautvetter
et al. (2014)
6.2 10 16.2 20 46 20 70 20 25
Trautvetter
et al. (2014)
6.5 10 16.5 17 50 16 67 16 25
Trautvetter
et al. (2014)
6.5 0 6.5 19 59 30 48 30 24
Vieth et al.
(2001)(a)
5.4 25 30.4 33 43 17 65 17 –
Viljakainen
et al. (2006b)
9.7 20 29.7 13 44 14 68 14 27.2
Viljakainen
et al. (2006b)
10.6 10 20.6 11 47 10 61 10 25.8
Viljakainen
et al. (2006b)
9.7 5 14.7 13 46 14 57 14 25.7
Viljakainen
et al. (2006b)
10.9 0 10.9 12 52 20 44 20 25.6
Viljakainen
et al. (2009)
8.6 20 28.6 16 62 14 90 14 24.4
Viljakainen
et al. (2009)
7.6 10 17.6 16 60 12 76 12 24.9
Viljakainen
et al. (2009)
6.6 0 6.6 16 65 19 52 19 24.8
BMI: body mass index; SD: standard deviation.
NB: e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the same study, but different
population groups (e.g. in this case: children and adults).
(a): Trials for which habitual dietary intake was imputed from national survey data (age-, sex-speciﬁc).
(b): Values for Rich-Edwards et al. (2011) were imputed from Madsen et al. (2013) (children with same mean age).
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Table 12: Risk of bias (RoB) dimensions – adequacy of randomisation, compliance assessment,
dose check, overall RoB classiﬁcation (35 trials)
Source
Randomisation
adequate
Compliance
assessed
Dose check
Overall risk
of bias
Barger-Lux et al. (1998) Yes Yes Yes High
Barnes et al. (2006) No/unknown No/unknown No/unknown High
Bischoff-Ferrari et al. (2003) Yes Yes No/unknown Moderate
Bolton-Smith et al. (2007) Yes Yes No/unknown Moderate
Bonjour et al. (2013) Yes Yes Yes Moderate
Braam et al. (2003) Yes No/unknown No/unknown Moderate
Cashman et al. (2008) Yes Yes Yes Low
Cashman et al. (2009) Yes Yes Yes Low
Cashman et al. (2012) Yes Yes Yes Moderate
Cashman et al. (2014) Yes Yes Yes Low
de Gruijl and Pavel (2012) Yes Yes No/unknown High
DeLappe et al. (2006) No/unknown Yes No/unknown High
Forman et al. (2013) Yes Yes No/unknown High
Goussous et al. (2005) No/unknown Yes No/unknown High
Hansen et al. (2010) No/unknown No/unknown No/unknown High
Harris and Dawson-Hughes (2002)a No/unknown No/unknown No/unknown High
Harris and Dawson-Hughes (2002)b No/unknown No/unknown No/unknown High
Heaney et al. (2003b) No/unknown Yes Yes High
Heikkinen et al. (1998) Yes No/unknown No/unknown High
Holick et al. (2008) No/unknown Yes Yes High
Honkanen et al. (1990)a No/unknown No/unknown No/unknown High
Hower et al. (2013) Yes Yes Yes High
Keane et al. (1998) No/unknown No/unknown Yes High
Lehmann et al. (2013) Yes Yes Yes Low
Madsen et al. (2013)a Yes Yes Yes High
Madsen et al. (2013)b Yes Yes Yes High
Meier et al. (2004) No/unknown Yes No/unknown High
O’Connor et al. (2010) No/unknown Yes No/unknown High
Pekkarinen et al. (2010) No/unknown Yes No/unknown High
Rich-Edwards et al. (2011) Yes Yes No/unknown Moderate
Smith et al. (2009) No/unknown Yes Yes High
Trautvetter et al. (2014) No/unknown Yes Yes High
Vieth et al. (2001) Yes Yes No/unknown High
Viljakainen et al. (2006b) No/unknown No/unknown No/unknown High
Viljakainen et al. (2009) No/unknown Yes Yes High
e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the same study, but
different population groups (e.g. in this case: children and adults).
Risk of bias dimensions and overall risk of bias as assessed by Brouwer-Brolsma et al. (2016).
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C. Forest plots of achieved mean serum 25(OH)D concentrations by
relevant factors explored in the dose–response models
(random-effects meta-analyses) (35 trials, 83 arms)
NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.1%, p = 0.000)
Trautvetter 2014
Madsen 2013a
Cashman 2014
Heikkinen 1998
Viljakainen 2009
Goussous 2005
Cashman 2009
Source
Smith 2009
Braam 2003
Smith 2009
O'Connor 2010
Viljakainen 2006
Trautvetter 2014
Viljakainen 2006
Meier 2004
Viljakainen 2009
Barnes 2006
Viljakainen 2009
Hansen 2010
Bonjour 2013
Cashman 2014
Cashman 2009
Meier 2004
Bischoff-Ferrari 2003
Braam 2003
Forman 2013
Harris 2002a
Heikkinen 1998
Rich-Edwards 2011
Hansen 2010
O'Connor 2010
Trautvetter 2014
Lehman 2013
Hower 2013
Heaney 2003
Honkanen 1990a
Holick 2008
Holick 2008
Cashman 2008
Cashman 2008
Madsen 2013a
Forman 2013
Heaney 2003
Forman 2013
Braam 2003
Cashman 2009
Honkanen 1990a
Bonjour 2013
Bischoff-Ferrari 2003
Pekkarinen 2010
Goussous 2005
Cashman 2012
Harris 2002b
Rich-Edwards 2011
Cashman 2014
Vieth 2001
De Gruijl 2012
Smith 2009
Cashman 2014
Harris 2002a
Smith 2009
Viljakainen 2006
Cashman 2012
Barnes 2006
Lehman 2013
Keane 1998
Hower 2013
Cashman 2008
Rich-Edwards 2011
Cashman 2008
Bolton-Smith 2007
Madsen 2013b
Viljakainen 2006
Bolton-Smith 2007
DeLappe 2006
De Gruijl 2012
Madsen 2013b
Bolton-Smith 2007
Keane 1998
Cashman 2009
Barger-Lux 1998
Heikkinen 1998
Harris 2002b
57.93 (54.53, 61.32)
70.00 (61.23, 78.77)
68.00 (67.37, 68.63)
74.00 (68.96, 79.04)
33.00 (29.30, 36.70)
52.00 (42.69, 61.31)
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ES (95% CI)
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e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the
same study, but different population groups (e.g. in this case: children and adults). CI: conﬁdence interval;
ES: estimate.
Figure 4: Achieved mean serum 25(OH)D (and 95% CI) by RCT and sorted by intervention arm
(n = 83 arms)
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NOTE: Weights are from random effects analysis.
Overall
Vitamin D Supplement
Subtotal
Study
ID
Placebo/Control
Subtotal
57.93 (54.53, 61.32)
40.60 (37.46, 43.73)
ES (95% CI)
67.51 (65.05, 69.98)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate.
Figure 5: Weighted pooled estimates of achieved mean serum 25(OH)D by INTERVENTION ARM
NOTE: Weights are from random effects analysis.
Overall
ID
Study
> 50 nmol/L
<= 50–nmol/L
Subtotal
Subtotal
57.93 (54.53, 61.32)
ES (95% CI)
53.27 (47.38, 59.17)
62.75 (58.42, 67.08)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate.
Figure 6: Weighted pooled estimates of achieved mean serum 25(OH)D by BASELINE MEAN serum
25(OH)D (nmol/L)
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NOTE: Weights are from random effects analysis
Overall
Subtotal
Subtotal
Subtotal
Subtotal
20-
25-
5-
ID
Subtotal
10-
Subtotal
45-
0-
Study
57.93 (54.53, 61.32)
70.50 (64.92, 76.08)
82.95 (76.79, 89.11)
61.90 (56.86, 66.94)
48.82 (40.99, 56.66)
ES (95% CI)
76.23 (69.96, 82.51)
40.24 (36.63, 43.85)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate.
Figure 7: Weighted pooled estimates of achieved mean serum 25(OH)D by TOTAL VITAMIN D
INTAKE (lg/day)
NOTE: Weights are from random effects analysis
Overall
ID
Study
<= 3 months
1–2 years
Subtotal
3–6 months
Subtotal
Subtotal
57.93 (54.53, 61.32)
ES (95% CI)
58.81 (51.64, 65.99)
51.46 (43.14, 59.78)
59.95 (54.93, 64.98)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate; mo: months.
Figure 8: Weighted pooled estimates of achieved mean serum 25(OH)D by STUDY DURATION
NOTE: Weights are from random effects analysis
Overall
ID
< 50°N
Subtotal
> 55°N
Subtotal
Subtotal
50–55°N
Study
57.93 (54.53, 61.32)
ES (95% CI)
55.88 (50.36, 61.40)
60.87 (50.92, 70.83)
57.95 (52.83, 63.07)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate.
Figure 9: Weighted pooled estimates of achieved mean serum 25(OH)D by LATITUDE
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NOTE: Weights are from random effects analysis
Overall
Study
Up to 2000
Subtotal
ID
Subtotal
After 2000
57.93 (54.53, 61.32)
59.05 (55.30, 62.80)
ES (95% CI)
54.01 (45.16, 62.86)
0 25 50 75 100
CI: conﬁdence interval; ES: estimate.
Figure 10: Weighted pooled estimates of achieved mean serum 25(OH)D by STUDY START PERIOD
NOTE: Weights are from random effects analysis
Overall
CPBA
Other
Subtotal
HPLC
Study
Subtotal
Subtotal
ELISA
Not Reported
Subtotal
LC–MS
Subtotal
Subtotal
Subtotal
RIA
ID
57.93 (54.53, 61.32)
48.64 (36.27, 61.01)
53.74 (45.86, 61.61)
62.22 (51.91, 72.52)
62.94 (52.07, 73.81)
55.07 (47.35, 62.80)
66.90 (54.58, 79.22)
61.91 (55.71, 68.10)
ES (95% CI)
0 25 50 75 100
CI: conﬁdence interval; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay; ES:
estimate; HPLC: high-performance liquid chromatography; LC-MS: liquid chromatography-mass spectroscopy;
RIA:, radioimmunoassay
Figure 11: Weighted pooled estimates of achieved mean serum 25(OH)D by ANALYTICAL METHOD
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NOTE: Weights are from random effects analysis
Overall
Not Reported
Subtotal
ID
Subtotal
Study
Caucasian
Mixed
Subtotal
57.93 (54.53, 61.32)
59.79 (49.26, 70.31)
ES (95% CI)
59.90 (54.93, 64.88)
55.64 (50.73, 60.54)
0 25 50 75 100
‘African’ was grouped to the ‘Mixed’ category, as this ethnicity included three arms only. CI: conﬁdence interval;
ES: estimate.
Figure 12: Weighted pooled estimates of achieved mean serum 25(OH)D by ETHNICITY
NOTE: Weights are from random effects analysis
Overall
Subtotal
Not reported
Obese
Study
Overweight
Subtotal
Subtotal
Subtotal
ID
Normal weight
57.93 (54.53, 61.32)
53.07 (45.48, 60.66)
60.05 (55.56, 64.55)
55.09 (45.53, 64.66)
62.95 (49.04, 76.86)
ES (95% CI)
0 25 50 75 100
Normal weight: 18.5–24.9 kg/m2, overweight: 25–29.9 kg/m2, obese: 30 kg/m2 and above. BMI: body mass
index; CI: conﬁdence interval; ES: estimate.
Figure 13: Weighted pooled estimates of achieved mean serum 25(OH)D by mean BMI of the study
population
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NOTE: Weights are from random effects analysis
Overall
ID
Both
Women
Study
Men
Subtotal
Subtotal
Subtotal
57.93 (54.53, 61.32)
ES (95% CI)
52.16 (44.88, 59.45)
58.12 (53.75, 62.48)
68.74 (59.20, 78.27)
0 25 50 75 100
‘Both’: for studies on mixed populations. CI: conﬁdence interval; ES: estimate.
Figure 15: Weighted pooled estimates of achieved mean serum 25(OH)D by SEX
NOTE: Weights are from random effects analysis
Overall
Children
Subtotal
Older adults
Subtotal
Adults
Subtotal
ID
Study
57.93 (54.53, 61.32)
60.82 (55.81, 65.83)
56.67 (50.24, 63.11)
48.85 (36.73, 60.97)
ES (95% CI)
0 25 50 75 100
‘Older adults’: from trials where the reported or estimated mean age was ≥ 60 years. CI: conﬁdence interval; ES:
estimate.
Figure 14: Weighted pooled estimates of achieved mean serum 25(OH)D by AGE
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D. Forest plots of mean differences in achieved serum 25(OH)D
concentrations (intervention arm versus control arm) by relevant
factors explored in the dose–response models (30 trials)
NOTE: Weights are from random effects analysis
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e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the
same study, but different population groups (e.g. in this case: children and adults).
As indicated in Appendix C, mean differences in achieved mean serum 25(OH)D concentration were calculated
for 30 RCTs, out of the ﬁnal 35 studies included in the dose–response analysis, where a control/placebo group
and at least one intervention group were available (i.e. 5 trials out of 35 did not have a control group).
CI: conﬁdence interval; ES: estimate.
Figure 16: Mean differences in achieved serum 25(OH)D by RCT (n = 30 trials) – random-effects
meta-analysis
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NOTE: Weights are from random effects analysis
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e.g. (Madsen et al., 2013)a and (Madsen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to the
same study, but different population groups (e.g. in this case: children and adults).
As indicated in Appendix C, mean differences in achieved mean serum 25(OH)D concentration were calculated
for 30 RCTs, out of the ﬁnal 35 studies included in the dose–response analysis, where a control/placebo group
and at least one intervention group were available (i.e. 5 trials out of 35 did not have a control group).
CI: conﬁdence interval; ES: estimate.
Figure 17: Weighted pooled estimates of mean differences in achieved serum 25(OH)D by TOTAL
VITAMIN D INTAKE (n = 30 trials)
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E. Model ﬁtting
F. Meta-regression dose–response models; predicted mean serum 25
(OH)D, 95% Conﬁdence interval and 95% prediction interval
Table 13: Regression coefﬁcients from meta-regression models as covariates are ﬁtted (ﬁrst row:
null model; second row: ln of total vitamin D intake; last row: fully adjusted model) and
related Tau2, Adjusted R2 and residual I2 value changes
Ln of total
vitamin D
intake
Mean
baseline
25(OH)D
Latitude
Start
year
Assay
(ELISA vs
RIA)
Compliance
assessed
Intercept Tau2
Adj R2
(%)
I2res
(%)
57.95*** 312 0 99
14.59*** 23.28*** 137 56 98
15.15*** 0.531*** 4.98 69 78 92
15.74*** 0.507*** 0.478*** 20.16** 55 82 91
15.93*** 0.481*** 0.460*** 0.268 14.85 53 83 90
15.67*** 0.477*** 0.501*** 0.598* 6.308* 13.22 50 84 88
16.02*** 0.477*** 0.535*** 0.783** 6.300* 7.155* 9.23 46 85 87
Adj R2: adjusted R2; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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Circles represent mean achieved 25(OH)D in all included arms, either control or intervention arms. Mean
achieved values are modelled against total vitamin D intake with no adjustments (i.e. no covariates)
(Appendix C). The conﬁdence interval (CI) illustrates the uncertainty about the position of the regression line.
The prediction interval (PI) illustrates the uncertainty about the true mean effect that would be predicted in a
future study.
Figure 18: Meta-regression model of serum 25(OH)D response to ln of total vitamin D intake
(unadjusted model) (n = 83 arms)
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G. Predicted achieved serum 25(OH)D and estimated total vitamin D
intakes by AGE (adults, children) (74, 9 arms)
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Circles represent mean achieved 25(OH)D in all included arms, either control or intervention arms. Mean
achieved values are modelled against total vitamin D intake and adjusted in the multivariable approach by mean
baseline values, latitude, study start year, analytical method for measuring serum 25(OH)D and compliance
(Appendix C). The conﬁdence interval (CI) illustrates the uncertainty about the position of the regression line.
The prediction interval (PI) illustrates the uncertainty about the true mean effect that would be predicted in a
future study.
Figure 19: Meta-regression model of serum 25(OH)D response to ln of total vitamin D intake
(adjusted model) (n = 83 arms)
Table 14: Predicted achieved serum 25(OH)D (nmol/L) at selected values of total vitamin D intake
(lg/day) by AGE
Regression
equations used
to predict serum
25(OH)D
Adults (74 arms) Children (9 arms)
Predicted serum 25(OH)D (nmol/L)
at selected values of total vitamin
D intake (lg/day)
Predicted serum 25(OH)D (nmol/L)
at selected values of total vitamin
D intake (lg/day)
100 50 20 15 10 5 100 50 20 15 10 5
Unadjusted models y = ln (total vitamin D intake)(a) y = ln (total vitamin D intake)(a)
Predicted mean 106 90 69 62 53 37 124 106 81 73 62 43
95% CI lower limit 100 85 65 59 50 35 94 80 61 56 47 33
95% CI upper limit 112 95 73 66 56 39 154 131 100 91 77 54
95% PI lower limit 77 61 40 34 24 9 82 65 42 35 24 7
95% PI upper limit 134 118 97 91 81 65 166 146 120 112 100 80
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Regression
equations used
to predict serum
25(OH)D
Adults (74 arms) Children (9 arms)
Predicted serum 25(OH)D (nmol/L)
at selected values of total vitamin
D intake (lg/day)
Predicted serum 25(OH)D (nmol/L)
at selected values of total vitamin
D intake (lg/day)
100 50 20 15 10 5 100 50 20 15 10 5
Adjusted models(b)
y = ln (total vitamin D intake) +
mean baseline 25(OH)D + latitude +
start year + HPLC + LC-MS + CPBA
+ ELISA/nr + Other assay +
compliance not assessed(a)
y = ln (total vitamin D intake) + mean
baseline 25(OH)D(a)
Predicted mean 95 83 68 63 56 45 101 88 72 67 60 47
95% CI lower limit 89 77 62 57 51 39 93 81 66 61 54 42
95% CI upper limit 100 89 74 69 62 51 108 95 78 73 65 53
95% PI lower limit 80 68 53 48 41 30 89 77 61 55 48 36
95% PI upper limit 110 98 83 78 71 60 113 100 84 78 71 59
CI: Conﬁdence interval; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay; HPLC: high-
performance liquid chromatography; LC–MS: liquid chromatography–mass spectroscopy; nr: not reported; PI: prediction interval;
RIA: radioimmunoassay.
(a): General predictive regression equations are reported.
(b): Estimates from the adjusted models are based on all covariates set to their mean values. Values for the adjusted
model using children data are in italics: as it was not possible to apply a full adjustment to estimate the values based only on
the four children trials, as it would have required a much higher minimum number of ‘points’ per covariate (at least 10 arms
for each included factor). Instead, values from a model adjusted for mean baseline 25(OH)D concentration are provided.
Table 15: Estimated vitamin D intakes (lg/day) at selected serum25(OH)D cut-off values (nmol/L) by AGE
Regression
equations used to
estimate vitamin
D intake
Adults (74 arms) Children (9 arms)
Estimated vitamin D intake at
selected serum 25(OH)D cut-off
values (nmol/L)
Estimated vitamin D intake at
selected serum 25(OH)D cut-off
values (nmol/L)
50 40 30 25 50 40 30 25
Unadjusted
models
y = ln (total vitamin D intake)(a) y = ln (total vitamin D intake)(a)
Predicted mean 8.8 5.7 3.7 3.0 6.4 4.4 3.0 2.5
95% CI lower limit 10.1 6.3 4.0 3.2 11.5 7.0 4.3 3.4
95% CI upper limit 7.9 5.2 3.4 2.8 4.4 3.3 2.4 2.1
95% PI lower limit 30.6 19.7 12.7 10.2 27.6 18.5 12.5 10.2
95% PI upper limit 2.6 1.7 1.1 0.9 1.8 1.3 0.9 0.7
Adjusted
models(b)
y = ln (total vitamin D intake) + mean
baseline 25(OH)D + latitude + start
year + HPLC + LC-MS + CPBA +
ELISA/nr + Other assay + compliance
not assessed(a)
y = ln (total vitamin D intake) + mean
baseline 25(OH)D(a)
Predicted mean 6.8 3.7 2.0 1.5 5.8 3.3 1.9 1.4
95% CI lower limit 9.6 5.2 2.9 2.1 7.9 4.4 2.4 1.8
95% CI upper limit 4.8 2.6 1.4 1.1 4.3 2.5 1.5 1.1
95% PI lower limit 16.9 9.2 5.0 3.7 10.9 6.2 3.5 2.6
95% PI upper limit 2.7 1.5 0.8 0.6 3.1 1.8 1.0 0.8
CI: conﬁdence interval; CPBA: competitive protein binding assay; ELISA: enzyme-linked immunosorbent assay; HPLC: high-
performance liquid chromatography; LC–MS: liquid chromatography–mass spectroscopy; nr: not reported; PI: prediction interval;
RIA: radioimmunoassay.
(a): General predictive regression equations are reported.
(b): Estimates from the adjusted models are based on all covariates set to their mean values. Values for the adjusted
model using children data are in italics: as it was not possible to apply a full adjustment to estimate the values based only on
the four children trials, as it would have required a much higher minimum number of ‘points’ per covariate (at least 10 arms
for each included factor). Instead, values from a model adjusted for mean baseline 25(OH)D concentration are provided.
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H. Sensitivity analyses
I. Prospective observational studies
Table 16: Adjusted meta-regression models on subsets of the ﬁnal data set after exclusions of trials
with speciﬁc characteristics
Adjusted Ln of total vitamin D
intake – lg/day (covariates coefﬁcients
not reported)
Coefﬁcient 95% CI
Number of
observations
Residual
I-squared (%)
Final model 16.3 14.5 18.2 83 87
Models restricted to trials without
Recruitment of patient groups 16.4 14.4 18.4 78 87
Vitamin D supplement users 16.8 14.5 19.1 52 86
Persons with sun holiday during trial 18.0 14.9 21.2 41 85
Persons using sunbeds/artiﬁcial UV-B 16.5 13.3 19.8 31 78
Users of medication 16.0 13.8 18.1 42 85
Participants with diseases known to
interfere with vitamin D metabolism
17.5 15.3 19.8 43 84
CI: conﬁdence interval; UV: ultraviolet.
For detailed information on the concerned trials, see Brouwer-Brolsma et al. (2016).
Table 17: Prospective observational studies – main study characteristics (n = 11 study groups)
Source
Publication
year
Country Latitude
Age
Mean
Male %
Ethnicity
(whole
study)
Duration
Andersen et al. (2013)a 2013 DK 55.4 13 0 – 52
Andersen et al. (2013)b 2013 DK 55.4 72 0 – 52
Darling et al. (2013) 2013 UK 51 34 0 Mixed 13
Darling et al. (2013) 2013 UK 51 38 0 Mixed 13
Hill et al. (2005) 2005 IE 51 60 0 – 52
Kift et al. (2013) 2013 UK 53.5 24 67 Asian 13
Lehtonen-Veromaa et al.
(2008)
2008 FI 60.3 16 0 Caucasian 208
MacDonald et al. (2011) 2011 UK 57 62 0 Mixed 65
MacDonald et al. (2011) 2011 UK 57 62 0 Mixed 65
MacDonald et al. (2011) 2011 UK 57 61 0 Mixed 65
Sullivan et al. (2005) 2005 USA 44 11 0 – 104
Source
Total
vitamin D
intake
Participants
per group
Baseline
Mean
25(OH)D
Baseline
25(OH)D
SD
Achieved
Mean
25(OH)D
Achieved
25(OH)D SD
Andersen et al.
(2013a)
3.9 54 23 14 30 13
Andersen et al.
(2013b)
8.1 52 47 25 51 24
Darling et al. (2013) 2.6 80 45 18 53 24
Darling et al. (2013) 2.0 26 20 11 22 11
Hill et al. (2005) 5.8 47 55 28 69 35
Kift et al. (2013) 1.4 86 20 7 15 7
Lehtonen-Veromaa
et al. (2008)
4.0 142 48 20 48 17
MacDonald et al.
(2011)
3.6 308 32 14 33 14
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Source
Total
vitamin D
intake
Participants
per group
Baseline
Mean
25(OH)D
Baseline
25(OH)D
SD
Achieved
Mean
25(OH)D
Achieved
25(OH)D SD
MacDonald et al.
(2011)
3.1 114 44 18 46 18
MacDonald et al.
(2011)
2.0 28 24 12 25 12
Sullivan et al. (2005) 5.4 20 56 17 51 14
DK: Denmark; FI: Finland; IE: Ireland; SD: standard deviation; UK: United Kingdom; USA: United States of America.
Eight prospective observational studies from seven articles were included, representing 11 study groups: (Andersen et al., 2013)a
and (Andersen et al., 2013)b, as cited in Brouwer-Brolsma et al. (2016), refer to the same article, but different study groups
(e.g. in this case: children and adults); a Caucasian group versus a Asian group were studied in Darling et al. (2013); a
Caucasian from one study centre versus a group of Caucasian and a group of Asian people in another study centre were studied
in MacDonald et al. (2011) (Appendix C).
NOTE: Weights are from random effects analysis
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e.g. (Andersen et al., 2013)a and (Andersen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to
the same article, but different study groups (e.g. in this case: children and adults). CI: conﬁdence interval;
ES: estimate.
Figure 20: Achieved mean serum 25(OH)D (and 95% CI) by STUDY GROUP
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NOTE: Weights are from random effects analysis
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e.g. (Andersen et al., 2013)a and (Andersen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to
the same article, but different study groups (e.g. in this case: children and adults). CI: conﬁdence interval;
ES: estimate.
Figure 21: Achieved mean serum 25(OH)D (and 95% CI) by AGE GROUP
NOTE: Weights are from random effects analysis
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e.g. (Andersen et al., 2013)a and (Andersen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016)) refer to
the same article, but different study groups (e.g. in this case: children and adults). CI: conﬁdence interval;
ES: estimate.
Figure 22: Achieved mean serum 25(OH)D (and 95% CI) by BASELINE MEAN serum 25(OH)D
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J. Funnel plots of mean differences in achieved serum 25(OH)D from
30 RCTs (studies included in the meta-analyses) and Egger’s test for
small-study effects
NOTE: Weights are from random effects analysis
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e.g. (Andersen et al., 2013)a and (Andersen et al., 2013)b (as cited in Brouwer-Brolsma et al. (2016) refer to the
same article, but different study groups (e.g. in this case: children and adults). CI: conﬁdence interval;
ES: estimate.
Figure 23: Achieved mean serum 25(OH)D (and 95% CI) by LATITUDE
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As indicated in Appendix C, mean differences in achieved mean serum 25(OH)D concentration were calculated
for 30 RCTs, out of the ﬁnal 35 studies included in the dose–response analysis, where a control/placebo group
and at least one intervention group were available (i.e. 5 trials out of 35 did not have a control group).
CI: conﬁdence interval; SE of MD: standard error of mean difference.
Figure 24: Funnel plot of mean differences and Egger’s regression line
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Funnel plot with pseudo 95% confidence limits
As indicated in Appendix C, mean differences in achieved mean serum 25(OH)D concentration were calculated
for 30 RCTs, out of the ﬁnal 35 studies included in the dose–response analysis, where a control/placebo group
and at least one intervention group were available (i.e. 5 trials out of 35 did not have a control group).e.g.
‘5-’ means 5 to < 10 lg/day. CI: conﬁdence interval; SE of MD: standard error of mean difference.
Figure 25: Funnel plot of mean differences by vitamin D dose categories
Dietary reference values for vitamin D
www.efsa.europa.eu/efsajournal 145 EFSA Journal 2016;14(10):4547
